gsk unite science technology talent ahead disease aim positively impact health billion people end decade successful grow company people thrive content strategic report corporate governance investor information ahead board gsk leadership financial record performance key team product development pipeline performance indicator chair governance statement product competition chair statement corporate governance architecture intellectual property ceo statement ahead board oversight principal risk uncertaintie business model continuous engagement key share capital control external environment decision dividend prevention board committee report financial calendar culture people remuneration committee chair annual general meeting research development annual statement tax information shareholder commercial operation annual report remuneration shareholder service contact performance vaccine director report law regulation performance specialty medicine group company performance general medicine financial statement glossary term operation manufacture director statement supply responsibilitie responsible business independent auditor report risk management disclosure financial statement statement note financial statement principal risk summary financial statement gsk plc climaterelate financial prepare uk gaap disclosure naturerelate financial disclosure nonfinancial sustainability information statement employee gender viability statement group financial review cautionary statement inside cover document cautionary statement forwardlooke statement nonifrs measure use number adjust noninternational financial reporting standard ifrs measure report performance business total report result represent group overall performance ifrs adjust result nonifrs measure consider addition substitute superior information present accordance ifrs adjust result nonifrs measure define page reconciliation near ifrs measure page strategic report governance remuneration financial statement investor information gsk annual report focus biopharma company strong momentum big ambition prevent treat disease vaccine commit get ahead specialty general medicine focus issue matter society science immune system sustainability company use new platform data technology include access healthcare diversity invest core therapeutic area equity inclusion health infectious disease hiv respiratory planet sector leader esg immunology oncology ahead performance make impact strategy mean intervene early societys urgent challenge prevent change course disease help protect people support purpose put people heart healthcare system success core ahead ambition gsk place confident future talented people thrive culture strong momentum improve outlook ambitious patient accountable sustained growth decade impact right thing confident ability deliver foundation deliver human health impact scale worldwide patient shareholder gsk people strategic report governance remuneration financial statement investor information gsk annual report performance key performance indicator financial deliver strong performance upgrade growth outlook broadbase performance drive sale profit earning growth group turnover bn turnover product area bn l vaccine bn aer bn aer cer cer l specialty medicine bn aer cer l general medicine bn growth exclude covid solution aer cer aer cer total operating profit bn adjust operating profit bn bn bn aer aer cer cer growth exclude covid solution aer cer total continue earning share p adjust earning share p p p aer aer cer cer p p p p p p growth exclude covid solution aer cer cash generate operation bn free cash flow bn bn bn use number adjust nonifrs measure report performance business adjust result nonifrs measure consider addition substitute superior information present accordance ifrs adjust result nonifrs measure define page aer actual exchange rate cer constant exchange rate exclude covid solution define adjusted operate profit positive impact exclude covid solution cer adjust eps positive impact exclude covid solution cer key performance indicator attributable continue operation link executive remuneration page detail strategic report governance remuneration financial statement investor information gsk annual report performance key performance indicator continue research development continue strengthen latestage pipeline organic rd delivery target business development support future growth bn innovation sale product major approval include infectious asset phase iiiregistration launch major lifecycle disease hiv oncology innovation expansion year asset pipeline major business development deal major product launch plan pipeline value progress report externally commercial sensitivity responsible business continue recognise environmental sustainability leadership esg performance rating track base performance metric meet exceed metric cover focus area access healthcare global health health security environment diversity equity inclusion ethical standard product governance page st pharmaceutical industry global health pipeline asset reduction operational sp global corporate sustainability progress address priority world carbon emission scope assessment score health organization disease november culture culture progress ambitious patient accountable impact right thing measure employee survey employee engagement score remain high read plan launch product nonrisk adjust peak year sale billion guidance outlook assumption basis preparation relate guidance outlook inside cover fy result slide gskcom strategic report governance remuneration financial statement investor information gsk annual report chair statement gsk continue significant progress strategic transformation programme change emma growth drive strong rd progress team deliver performance area execute company latestage fundamentally improve gsk business especially vaccine pipeline strengthen early competitiveness sharpen specialty medicine include hiv stage rd technological operational execution cost respiratory company capability remain company discipline strengthen pipeline build significant leadership number priority continue enhance group capital position competitive advantage receive significant attention allocation capacity shift exceptional launch world board include science gsk culture combine high integrity rsv vaccine arexvy committee undertake detailed performance clear stand achievement review year research area include vaccine clear report gsk rna technology antimicrobial develop distinctive role voice cost discipline group resistance amr oligonucleotides prevention disease offer clear continue improve follow antibodydrug conjugates adcs benefit patient healthcare period necessary investment liver disease nash system wide society product launch management focus deliver improve rd productivity strategic progress improvement operating margin inevitably longterm programme see evidence come year please good success transformation progress year operationally gsk perform previously discuss organically target well crucially demerger haleon business development total consistently competitively fundamentally reset strengthen deploy approximately billion point year gsk balance sheet rd business development include monetise billion holding group sale operating profit acquisition partnership haleon enable investment grow strongly ahead year pipeline future growth outlook company emma set letter cagr exclude covid page gsk significant solution previously set confirm potentially valuable late period gsk progress commitment shareholder return stage rd programme vaccine momentum progressive dividend policy infectious disease hiv respiratory upgrade outlooks board agree pay shareholder specific area oncology respectively increase dividend p share p share successful progression comparable basis programme vital support group growth outlook second half decade guidance outlook assumption basis preparation relate guidance outlook inside cover fy result slide gskcom gsk group dividend p gsk relate exclude dividend relate consumer healthcare h strategic report governance remuneration financial statement investor information gsk annual report chair statement continue culture responsibility clear extensive meeting please welcome julie believe strong discussion brown chief financial officer driver gsk longterm shareholder year cfo year julie bring performance culture shift recognise significant performance huge experience life sciences emma team drive improvement cfo large ukbased company deliver emphasis move see significant change gsk board excellent shorterterm outlook focus develop clear case worldleade experience medium term purpose strengthen leadership expertise include human upgrade outlook give embed businessrelevant genetic vaccine respiratory period confidence value behaviour infectious disease advanced board management technology include ai ml ensure environmental social gsk future biopharma commercial financial governance consideration uncertainty zantac expertise payer hcp properly embed strategy ranitidine litigation clearly patient understanding remain important impact gsk share price delight company gsk perform well performance month rank sector sps year continue vigorously defend assessment corporate increasingly positive outlook remain sustainability energy commitment claim include leadership emma team gsk continue lead ongoing proceeding delaware support company ambitious approach ensure global access hope great clarity programme change product develop litigation new medicine vaccine finally like thank board evolution disease malaria tb people partner customer composition maturity disproportionately affect shareholder support board continue improve ensure poor country world commitment year relevant skill look forward year second year experience provide good oversight progress gsk operation new remuneration support constructively policy design support challenge management gsk achievement outperformance business develop pure strategic financial esg biopharma company goal believe help please welcome wendy drive strong performance becker board october culture deep commitment sir jonathan symonds wendy highly experienced responsibility evident gsk chair nonexecutive director bring shareholder return excellent business technology board remain focused life science experience deliver strong shareholder return succeed urs rohner valuation gsk long chair remuneration term committee step agm like thank urs contribution gsk board particularly development new remuneration policy approve incentivise reward management performance consistent determined supporter gsk provide huge support emma strategic report governance remuneration financial statement investor information gsk annual report ceo statement gsk deliver commitment perform new standard excellent performance add shingles vaccine shingrix deliver provide multiple new opportunity deliver strong clear momentum expect target business development performance billion deliver year meaningful secure acquisition sale specialty medicine growth continue alliance innovative asset hiv business grow strongly focus prevention change new technology cer driven acceleration oral course disease twodrug longacte injectable achieve whilst regimen treatment deliver commitment maintain continue sharp focus prevention see good set series operating margin cash flow progress respiratory commitment shareholder mindful need invest marketleade il nucala include stepchange future deliver attractive cer lupus treatment benlysta performance follow significant return shareholder major contributor cer transformation gsk structure strong performance overall sale new product strategy capital allocation set page launch contribute culture performance demonstrate billion deliver progress sale exclude level performance help quarter consecutive sale growth covid solution total generate free cash flow billion exclude covid solution adjust profit grow double consequence performance twothird sale digit level cer momentum please generate vaccine clear highlight year increase dividend year specialty medicine key strategic exceptional launch arexvy penny share priority world vaccine rsv pipeline strengthen time continue contribute billion sale rd continue strengthen pipeline year american progress organically vaccine medicine adult age year old business development set clinical development majority vaccinate rsv page deliver latestage asset highlight twothird major product approval move forward positively vaccinate arexvy year arexvy apretude hiv time expect arexvy generate prevention ojjarra myelofibrosis annual sale billion jemperli firstline endometrial sale drive cancer asset phase iii penetration initial roll registrational study look vaccine europe japan forward significant late expansion arexvys indication stage rd milestone risk individual aged year strategic report governance remuneration financial statement investor information gsk annual report ceo statement continue target business development upgrade outlook longterm goal key continued strengthen pipeline sale grow metric place area support future growth activity adjust profit overall performance rating include acquisition cagr basis track base bellus health aiolos bio believe deliver metric meet exceed strengthen respiratory billion sale increase highlight year include pipeline signing licence billion versus estimate moving phase iii development agreement janssen hansoh give billion lowcarbon ventolin inhaler pharma infectious disease represent mark acceleration programme achieve leadership oncology effect expect reach diversity aspiration year early original goal gavi confirm roll upgrading outlook year early malaria vaccine mosquirix expect year country africa detail meaningful growth sale adjust continue focus strongly set page operate profit eps margin improvement retain publish standalone esg upgrade outlook flexibility invest growth performance report previously give period work deliver important emphasise clear momentum look ahead forecast include anticipate conclusion gsk strong progress business development progress momentum improve outlook develop portfolio earlystage pipeline standalone biopharma company pipeline additional productivity improvement expertise develop innovative alongside current growth driver vaccine medicine point strong outlook planning enormous opportunity prevent gsk sustain growth major product launch change course disease decade hundred million people year build trust bode equally commit make gsk include new potential know place talented people vaccine meningitis influenza remain focused deliver thrive culture pneumococcal disease herpe potential continue ambitious patient accountable simplex virus hsv potential pace patient shareholder impact right thing medicine longacte hiv people positive engagement score treatment prevention potential remain high late finally people functional cure hepatitis b employee engagement survey fuel momentum want bepirovirsen new portfolio thank achieve potential antiinfective treatment operate responsibly remain core optimistic include gepotidacin gsk aim continue deliver future excite potential new medicine respiratory sectorleading esg performance achieve ahead disease disease high burden unmet recognise late rank need depemokimab camlipixant sector leader sps global finally oncology corporate sustainability assessment potential indication reflect strong progress jemperli potentially cd core esg area access target variety cancer type healthcare global health health emma walmsley security environment diversity equity chief executive officer inclusion ethical standard product governance close early guidance outlook assumption basis preparation relate guidance outlook inside cover fy result slide gskcom strategic report governance remuneration financial statement investor information gsk annual report business model unite science technology talent ahead disease health impact shareholder return thrive people central success people expert science technology manufacturing regulation intellectual property commercialisation gsk people country worldwide supplier work directly gsk bn rd investment manufacturing site global rd centre aer cer uk belgium italy identify research develop testing groundbreake discovery manufacture commercialise vaccine specialty medicine general medicine broad vaccine portfolio target specialty medicine prevent portfolio infectious disease stage treat disease hiv primary care medicine include life help protect people respiratory disease immune inhaled medicine asthma meningitis shingle rsv flu polio inflammation disease like lupus copd antibiotic infection cancer bestinclass product prevent treat disease improve health million people world core therapeutic area infectious disease hiv respiratory oncology infectious disease leader hiv immunology emerge portfolio broadest focus end push frontier portfolio focus blood industry include global epidemic respiratory science woman cancer hiv account third industryleade harness science seek pipeline pipeline drive patient immune system transformative insight transform patient outcome breakthrough area unmet need immunooncology base decade innovative research total rd expenditure include intangible asset amortisation impairment plus immaterial amount major restructuring cost strategic report governance remuneration financial statement investor information gsk annual report business model continue power technology pipeline performance people productivity leverage new platform use technology enable technology core datum technology step productive efficient work ensure people rd process fast manufacturing process supply chain tool analytical capability effective predictive reliability return investment resource datadriven discovering develop innovative decision well work new medicine vaccine steer longterm priority innovation performance trust develop launch new bold ambition patient focus issue medicine vaccine reflect upgrade growth great impact reduce need well outlook pressure health system include fast rd tackle health challenge inequity protect environment take action diversity equity inclusion create value patient shareholder society bn p bn pack medicine share dividend corporate income tax pay dose vaccine deliver addition pay duty levy transactional employment taxis economy disease prevention early intervention improve health lessen pressure health system support economic productivity people support people grow work matter reinvestment return enable reinvest discover develop new vaccine medicine continue get ahead disease company director require law promote success organisation benefit shareholder wide stakeholder include employee supplier community information issue factor stakeholder board consider relevant complying section f company act section statement corporate governance section business model support esg strategy describe strategy support robust framework monitoring manage risk strategic report governance remuneration financial statement investor information gsk annual report external environment major theme influence external environment set mean respond economic growth show resilience pressure continue public finance global economy prove notable pocket public spending include health resilient expect strength america economy grow remain strain government recovery remain relatively buoy sustained consumer face unprecedented pressure fragile uneven prospect spend robust government finance string economic diverging region spend associate shock sustain sluggish growth infrastructure investment legislation high debt high interest rate country continue grapple pass make challenge persistent inflation drive resilience mirror service debt compelling factor include tight labour market example forecast government tough choice major central bank eurozone revise downwards direct spending respond increase interest rate region continue feel add burden rise cost impact weak demand consumer business despite high cost sticky inflation consequent tighten monetary policy amid rise level debt political global economy continue expand volatility global growth prospect albeit slow rate remain tepid global growth forecast slow geopolitical tension fuel shift alliance fragmentation regionalisation country look diversify de continue grow risk supply chain strategic ongoing conflict ukraine sector include biopharmaceutical middle east focus look india attention political alliance alternative supplier china august backdrop activity country invite join tension china china biopharmaceutical sector bric group remain new export control resilient recognise acceleration combine economy investment screen mechanism chinese innovation growth enlarge group emerge side particularly potential worth trillion focus critical mineral ai quarter semiconductor biotechnologie low middleincome world economy sign relation country capitalise global policy improve nation forum un general president meet assembly set agenda issue time year sideline relate health new technology asiapacific economic industrial development cooperation summit diverse voice global platform inequality see critical issue new alliance emerge government collectively potentially shift weight progress healthcare influence blocs summit debate good measure august see bric group widen access attention country widen membership equitable distribution time invite infrastructure capability know country include saudi arabia health product iran join protect intellectual property right efficient supply chain httpswwwimforgenblogsarticlesresilientglobaleconomystilllimpingalongwithgrowingdivergence httpswwwbbccouknewsworld strategic report governance remuneration financial statement investor information gsk annual report external environment continue change demographic create opportunity innovation prevention pressure health system continue saving health system look biopharma industry amid ongoing effort progress implementation driver innovation economic recover rebuild aftermath inflation reduction act ira growth president state covid pandemic population include select drug union address underline age bring complex potential price cut new appetite well health need chronic disease programme enable medicare treatment particularly cancer take increase toll infectious negotiate price highlight potential disease remain significant threat costly medicine biopharma industry partner potentially limit future innovation recovery harness science individual impact change access currently available technology provide solution demographic disease pattern medicine ira bring help prevent change course extend society economy meaningful benefit certain disease bring value individual large poor health significant drag medicare patient access health system society economic growth year poor vaccine bear health cost global real cost gdp premature death lose bn productive potential work eu take forward legislation age people uk test pharmaceutical million working day estimate innovation competitiveness society age bring lose year illness uk agree fiveyear different health challenge deal aim reduce medicine cost number people age despite potential improve nhs set annual limit year old worldwide individual outcome boost allow growth sale value project double economic productivity brand medicine rise million investing health particularly billion prevention early intervention government seek way government continue look cost cut medicine cost continue balance potential tech datum appropriate use rapid advance science revolution datum technological consider contextspecific use ai technology continue shape life capability open new possibility healthcare uk sciences sector rd establish patient advance drug continue consider place technology small molecule discovery enhance appropriate guardrail use vaccine remain key emerge manufacture supply ai support innovation technology map medicine possibility consider implication specific dnarna therapeutic include improve health outcome need sector landmark summit oligonucleotide gain ground balance appropriate regulation november uk eu build market share major support innovation ensure australia china agree work biopharma company continue responsible use develop ai safety research increase focus artificial technology intelligence machine learning ai use apply year ml accelerate drug discovery debate regulation ai bn progress hinge diverse patient gather pace government datum available step effort examine computational research particular technologys promise risk year biopharma genomic datum link health enter collaboration legislation kind eu information hold clinical record ai company pass ai act june take estimate worth stringent approach billion wwwmckinseycomindustrieshealthcareourinsightshowprioritizinghealthcouldhelprebuildeconomie wwwcbiorgukmediacentrearticlesboostingworkforcehealthcanhelptheukachieveeconomicgrowthambitionssayscbi wwwunorgdevelopmentdesadspdwpcontentuploadssiteswsrchapterkeymessagespdf chapter key messageswsr unorg wwwaccenturecomcontentdamaccenturefinalaccenturecomdocumentaccenturetechvisionbiopharmaaccenturemerging atomsandbitsinlifesciencesvpdf strategic report governance remuneration financial statement investor information gsk annual report external environment continue pressure increase climate nature action economic pressure political international climate grow focus realignment influence conference cop dubai country limit nature loss taskforce country approach global challenge commit transition away naturerelate financial disclosure need collective action include fossil fuel triple renewable release final recommendation climate change nature loss energy capacity see provide risk management intergovernmental panel climate climatehealth agenda give disclosure framework change issue final warning prominence organisation report act march c degree government endorse cop evolve naturerelate risk target reach set declaration climate health responsible business section urgency sufficient swift climate company continue action naturerelate action region need reduce climate impact protect financial disclosure climate action opportunity business model take step use green policy lever ensure product supply chain growth example european remain resilient consequence commission set green deal climate change scientific evidence industrial plan europe link climate change centre clean technology human health mean continue evidence innovation high expectation healthcare grow investor interest policy maker tackle rise sector reduce carbon emission nature nature action inflation increase living cost respond health impact aim mobilise institutional climate target come pressure climate change year investor establish uk soften net zero policy biopharma company step common agenda eu environment minister commitment include strengthen corporate action nature increase target reduce locally lead adaptation health focus sector greenhouse gas emission resilience programme vulnerable include biotechnology opposition member community affect climate pharmaceutical country change position challenge economic include example advocating population age infectious political landscape critical appropriate ip protection disease spread invest pipeline vaccine balance regulatory framework chronic disease take great medicine prevent support discovery delivery toll create unsustainable change course disease vaccine medicine develop pressure health system meet change unmet healthcare emerge technology believe get ahead need time reinforce importance global disease good investment work government regulator diversify supply chain patient carer community health industry partner sure system economy price environment medicine vaccine reach tough believe place continue work patient scale bringing value offer differentiate highvalue government payer partner people need pipeline prevention new model care payer treatment disease build enable early action prevent scientific innovation critical lever transformational new technology diagnose treat disease improve health boost productivity technique rd opportunity rethink economic growth ease fast smart demand datum health treat sickness strain health system continue realworld evidence support invest keep people work peer continue reimbursement new government sure product likely increase policy regulatory environment prevention continue work payer stimulate sustain innovation underpin purpose ahead design innovative solution disease manage risk uncertainty recognise health social economic value httpssciencebasedtargetsorgblog ipccreleasesfinalwarningtokeep innovative medicine vaccine cwithinreach strategic report governance remuneration financial statement investor information gsk annual report gsk believe prevention good medicine prevention heart get ahead disease prevent ill health place stop disease track prevention prevention mean important prevent change course opportunity prevent disease disease heart place change course health system stretch mean get ahead disease disease help prevent health need evolve harness science slow progression illness limit demographic disease technology longterm complication pattern change prevention focus pipeline portfolio include million vaccine premature death ve build broad vaccine portfolio people industry help protect people stage life avoid well childhood old age wide range prevention healthcare vaccine technology like map mrna adjuvant intervention oecd targeted approach allow develop country amount tailor vaccine different disease individual quarter death source oecd hiv trillion decade ve transform life people live hiv make breakthrough treatment loss productivity year prevention focus research novel treatment g preventable option allow people live hiv few condition people drug ve age source ilcuk develop longacte regiman prevent hiv trillion severe asthma health spending decade experience respiratory care project reach lead create treatment bring patient trillion source cms close remission severe asthma free exacerbation attack cause cumulative lung damage potentially prevention early avoid hospitalisation remove need oral intervention offer solution corticosteroid stabilise lung function controlling challenge help symptom improve people health outcome bring benefit hepatitis b health system late aiml technique scientist economy identify biomarker help work treatment combination fit patient potentially trillion increase likelihood achieve functional cure virus long present blood liver function normalise stop future add global gdp damage improve health half annual economic benefit come believe prevent want work patient policy large healthy get ahead disease good maker peer stop disease investment patient track create right condition workforce source mckinsey carer community health system champion prevention enable economy timely proactive access preventative intervention strategic report governance remuneration financial statement investor information gsk annual report culture people purpose unite science technology talent ahead disease put people heart success culture digital technology remain core purpose delivery ambition build people skill commit make gsk place people area global event datacon thrive culture ambitious employee experience immersive session patient accountable impact right thing hand apply digital datum tech tool include mean support people thing well generative ai digitally fluent year fast focus matter mean set clear employee take business objective create accountability result give unit country data academy employee support space need succeed access resource online training ve run mean responsibly integrity programme develop senior leader leadership care people patient world count skill digital age ve pilot career hub culture embed ai match employee mentor project recruitment onboarding training development potential job opportunity scale assessment performance promotion enhance onboarding experience new code set culture commitment joiner introduce monthly live virtual session gsk people deliver ceo senior leader access senior ambition right way people sign global leader begin career code annually personally commit m aim provide intimate connection gsk code gskcom patient serve create emotional connection purpose strategy culture complement ongoing help people thrive local onboarding activity make gsk place people thrive core support people manager ahead ambition thrive different individual common theme matter people manager play crucial role help firstly belief purpose desire team thrive connect contribution team live culture contribute deliver ambition make patient gsk broad impact expect secondly feeling include able people manager motivate focus care develop opportunity grow support feedback team deliver training anchor space need succeed finally feel good area vps invite attend positive mental physical financial social wellbeing day inperson event call lead leader programme mean gsk place people feel help leader bring good team foster welcome value environment include culture need succeed continue policy workplace way work enable invest grow generation senior leader support deliver good support talent succession need bespoke development intervention equip leadership welcome develop outstanding people skill future committed develop outstanding people give opportunity grow expect people agree development plan regardless grade role base conversation understand space support need succeed continue invest learn development initiative access grow campus training knowledge sharing platform httpswwwgskcomengbcompanygovernancecompliancethecode strategic report governance remuneration financial statement investor information gsk annual report culture people continue maintain momentum diversity equity performance choice inclusion performance choice approach hybrid work continue focus build diverse officebased role quarter organisation equitable inclusive culture people allow right balance onsite remote feel welcome value include take work clear expectation people step ensure equal opportunity nondiscrimination accountability spend time person deliver ambition leadership maintain flexibility help continue build team diverse inclusive support sense community connectedness enable development numerous offering development achieve ahead ambition employee include awardwinne leadership datum annual employee survey show broad development programme accelerate difference support approach expectation people complete mandatory dei module recognise reward people annual training year focus create inclusive workplace people thrive share success recognise reward people equitably progress detail dei aspiration responsible continue important business section culture addition bonus scheme reward performance company year award health wellbeing volunteer people extra ahead award health wellbeing benefit support people deliver exceptional performance line different life stage fair inclusive include accountable impact ambitious patient global minimum standard week parental leave right thing identify people primary secondary carer form family miss performance deliver global minimum standard care family member objective living culture end life health emergency insure benefit include samesex partner possible mental people experience gsk health training available ensure continue listen people regularly enhance financial wellbeing support employee measure experience gsk place work introduce nudge financial education platform include annual survey employee feature country help people manage finance question engagement confidence inclusivity achieve financial goal culture focus area trust priority proud reignite volunteer company engagement level remain high focused ambition charitable investment theme continue high score positive upward health people health planet innovator trend confidence delivery strategy future employee volunteer culture focus area ambitious patient accountability day year take teambase handson impact right thing measure day skillsbased volunteer inclusion expand analysis survey small number people volunteer day understand difference employee experience year select skillsbased volunteering project diverse characteristic continue good progress create culture workplace people feel sense belong thrive measure effectiveness global manager team provide feedback annual survey manager receive anonymised aggregate feedback manager rate highly effective team strategic report governance remuneration financial statement investor information gsk annual report research combine science immune system technology outstanding talent find development new way prevent treat challenging disease well fast strategic report governance remuneration financial statement investor information gsk annual report research development highlight vaccine medicine phase iiiregistration major approval pipeline arexvy world rsv vaccine old shingrix vaccine shingle approve adult approve eu japan people risk japan positive datum efficacy trial adult age apretude longacte preventative treatment china hiv approve hiv prevention option europe positive phase iii datum menabcwy vaccine candidate support filing ojjaaraomjjara approve eu uk treatment fda fasttrack designation gonorrhoea newly diagnose previously treat vaccine candidate myelofibrosis patient anaemia target business development include jemperli approve eu uk acquisition bellus health aiolos bio frontline immunooncology respiratory licence agreement janssen treatment combination chemotherapy infectious disease hansoh pharma patient dmmrmsih primary oncology advanced recurrent endometrial cancer rd approach focus execution technology culture rd purpose unite science technology talent priority rd ahead disease discover execution accelerate pipeline include develop vaccine medicine transform business development deliver innovative vaccine people live medicine rd expenditure billion aer technology deliver innovation well fast cer drive investment new platform datum technology speed portfolio ve strengthen pipeline discovery development improve chance technology capability business development success seek new differentiate opportunity disease high patient need vaccine culture create agile innovative environment s medicine development potential ambitious patient attract good people firstinclass bestinclass scientist partner revolutionary era science technology make rapid advance drive discovery development vaccine medicine prevention pipeline consider prevent disease underpin purpose ahead place intervene treat early change disease course prevent slow progression illness limit longerterm complication close early strategic report governance remuneration financial statement investor information gsk annual report research development continue execution pipeline acceleration business development reinforce status world leader transformational vaccine medicine infectious disease gain approval eu japan worldfirst respiratory syncytial virus broad portfolio pipeline base science rsv vaccine old adult arexvy japan immune system use new platform datum shingle vaccine shingrix people risk technology continue strengthen key milestone core therapeutic area positive hiv reshape treatment prevention momentum business development deliver longacte regimen apretude underpin confidence deliver upgrade growth approve europe hiv prevention oncology outlook medium long term optimise portfolio focus blood woman cancer breakthrough immunooncology phase pipeline vaccine approval ojjaara treatment medicine modulate immune system specifically indicate myelofibrosis patient similar proportion base genetic evidence anaemia jemperli frontline treatment begin phase programme move endometrial cancer positive phase iii result assets phase ii phase iii blenrep treatment multiple myeloma development cycle time shorten business development critical contributor growth year median year compare create extra value patient partner shareholder industry year major deal include acquisition bellus health invest heavily latestage pipeline aiolos bio new collaboration include janssen drive growth line therapeutic area strategy hansoh pharma believe bolster rigorously evaluate earlystage portfolio exist strength therapeutic area right programme maximise impact health focus therapeutic area unlock pipeline value infectious disease reflect progress plan major product launch hiv respiratoryimmunology oncology infectious disease infectious disease affect year ve pioneer novel research method put major strain society healthcare system technology help protect people infectious combine expertise vaccine medicine mean disease include chronic infection hepatitis b hiv focus prevention treatment shingle seasonal infection rsv influenza common infectious disease result significant public health childhood disease measle rare devastating benefit reduce death increase productivity condition meningitis range bacterial infection third vaccines medicine pipeline address challenging antimicrobial resistance amr infectious disease include hiv world disease predominantly affect low leader area income country malaria tb rotavirus billion people reach decade significant infectious disease responsible estimate majority infectious disease portfolio death globally broad industry billion people infect year key highlight include approval arexvy virus like rsv influenza virus sarscov worldfirst rsv vaccine adult age need hospital treatment positive phase iii data pentavalent meningitis millions struggle bacterial fungal infection vaccine candidate live chronic viral condition like hepatitis b hep b hiv vaccinepreventable disease impose significant medical economic cost relate treatment cover result productivity loss close early strategic report governance remuneration financial statement investor information gsk annual report research development continue tackle rsv world arexvy vaccine immunity protect old people infectious disease challenge old people year face hospital stay rsv shingrix approve japan prevention shingle people increase risk instance people underlie condition like chronic obstructive immune suppression immune deficiency pulmonary disease copd asthma diabete heart vaccine approve japan people age disease increase risk severe outcome old late approval follow rsv pneumonia clinical trial people age old increase risk people year die rsv shingle include undergone stem cell eu figure close transplant kidney transplant blood cancer solid tumour hiv regulatory application arexvy approve eu japan patient group accept review china country prevention low national medical product administration february respiratory tract disease cause rsv adult age older follow positive phase iii datum publish report datum firstever efficacy trial new england journal medicine show shingrix china demonstrate vaccine efficacy exceptional efficacy old people include result come phase iv trial zoster certain underlie medical condition severe evaluated efficacy safety vaccine rsv report datum season prevent shingles adult age old ongoing phase iii trial show vaccine efficacy progressing meningitis vaccine complete rsv season clinical development programme continue evaluate longerterm followup million people contract invasive optimal timing potential revaccination meningococcal disease imd year people diagnose die follow approval food drug administration fda centers disease control imd survivor longterm prevention advisory committee immunisation disability include brain damage deafness nervous practice recommend adult year age system problem old receive single dose vaccine share meningitis acwy vaccine menveo meningitis b clinical decisionmake vaccine bexsero protect form arexvy available canada multiple imd firstgeneration vaccine candidate european country regulatory review country combine vaccine aim protect ongoing approval launch expect serotype cause disease globally single vaccine present preliminary phase iii data european society paediatric infectious disease report positive preliminary datum show vaccine candidate perform statistically clinical trial people age increase risk rsv bexsero menveo people age show noninferior immune response compare adult currently investigational vaccine datum age old base datum february immunological effectiveness diverse fda accept regulatory application meningitis b invasive strain trial priority review extend vaccine indication adult aged increase risk regulatory submission multivalent vaccine kind potential adult age accept european support strategy eradicate meningitis medicines agency japanese ministry health second generation vaccine labour welfare expect generate phase ii development aim improve protection datum people age old increase risk rsv b strain broad age group trial explore coadministration trial investigational medicine chronic adult vaccine include shingles pneumococcal disease hepatitis b chb million people live chb expand use shingle vaccine people develop shingles lifetime people diagnosis consequence like longterm receive treatment million die year nerve pain loss vision currently patient nucleosidenucleotide analogue shingrix vaccine protect people shingle na life suppress virus launch country people people rarely clear increase risk shingle shingrix specifically year ve leader hepatitis b vaccination design combine adjuvant antigen bepirovirsen tripleaction antisense oligonucleotide select enhance protective immune response base potential cornerstone functional cure understanding virus cause shingles patient chb eliminate need continue formulation helps overcome natural agerelate decline therapy ultimately reduce longterm risk develop liver complication strategic report governance remuneration financial statement investor information gsk annual report research development continue hope hepatitis b not know hepatitis b husband adopt daughter maren months old say maureen hepatitis b caregiver advocate heart break watch baby cry receive injection endure result effect doubt chronic hepatitis b scary stigma make not lifelong burden reason hope m energise ongoing research new treatment option alleviate burden frequent invasive treatment management chronic hepatitis b people include scientist gsk work find functional cure maureen maren bepirovirsen single agent phase iii development map potentially enable high antibody response show clinically meaningful functional cure diseasecausing serotype broad response patient chb receive na therapy strong protection continue examine demonstrate bclear bsure clinical trial potential acceleration option plus valent develop bepirovirsen phase iii trial programme infant adult patient receive nas explore potential herpe simplex virus sequential therapy option aim help genital herpe chronic sexually transmit infection patient achieve functional cure cause herpe simplex type hsv herpe october announce exclusive licence simplex type hsv virus agreement phase ii small interfering rnabase worldwide estimate million people age therapeutic originally develop arrowhead live hsv genital hsv infection pharmaceutical provide opportunity develop potential novel sequential regimen patient suffer frequent outbreak benefit broad group patient potentially psychological morbidity stigma threefold increase drive high functional cure rate risk acquire hiv infectious disease gsk candidate hsv contain pneumococcal disease hsv antigen complement adjuvant design stimulate immune response people infect pneumococcal disease illness cause hsv follow successful completion phase streptococcus pneumoniae bacterium timeinhuman study phase ii firsttimeinpatient proof lead cause acute bacterial disease concept trial start late assess important area grow antimicrobial resistance formulation adult history genital herpe multiple license pneumococcal vaccine available outbreak successful hope help well burden pneumococcal disease remain control symptomatic outbreak viral shed significant mitigating associate emotional burden improve quality life people live genital herpe estimated pneumococcal pneumonia cause hospitalisation year influenza estimate million child die influenza remain world great public pneumococcal disease year health challenge novel valent vaccine candidate currently phase ii year estimate billion case development plusvalent pneumococcal vaccine world result severe illness candidate currently preclinical development add death pipeline acquisition affinivax incorporate innovative map platform technology strategic report governance remuneration financial statement investor information gsk annual report research development continue adjuvante pandemic influenza vaccine move potential treatment uncomplicate extensively study consist eggbase antigen urinary tract infection urogenital gonorrhoea pandemic adjuvant agreement half woman affect uncomplicate canada europe provide urinary tract infection uuti lifetime million dose pandemic influenza vaccine event quarter suffer recur disease global health emergency despite concern rise resistance exist eggbase influenza vaccine backbone treatment s new class antibiotic worldwide effort limit impact seasonal influenza uuti decade different platform technology continue investigational antibiotic gepotidacin novel need future committed playing mechanism triazaacenaphthylene antibiotic uuti meet important patient need gonorrhoea discover develop explore opportunity develop mrnabase partfunde partnership biomedical influenza vaccine collaboration curevac advanced research development authority barda building positive phase result modify monovalent positive phase iii datum show potential mrna vaccine candidate target covid new class oral antibiotic uuti monovalent flu develop nextgeneration year eagle eagle phase iii trial multivalent mrna flu vaccine protect multiple stop early efficacy november influenza virus strain phase iii trial underway follow plan interim analysis gepotidacin perform nitrofurantoin exist firstline treatment covid uuti eagle trial gepotidacin demonstrate acute phase covid pandemic statistically significant superiority nitrofurantoin focus nextgeneration platform combination vaccine potential protect treat complicated urinary tract infection multiple seasonal respiratory virus tebipenem covid mrna development programme curevac partnership spero therapeutics inc progress phase ii clinical trial recently exclusive licence agreement tebipenem hbr report positive interim datum monovalent latestage oral carbapenem antibiotic potential bivalent vaccine candidate treat complicated urinary tract infection cutis december patient dosed pivotpo human papillomavirus pivotal phase iii trial tebipenem approve human papillomavirus hpv common sexually tebipenem hbr address unmet medical need transmit infection affect million people novel oral antibiotic alternative intravenous year symptom hospital therapy drugresistant cutis cause genital wart type cancer hpv associate nearly case cervical cancer vulvovaginal candidiasis fourth common cancer woman sign exclusive licence agreement globally cause estimate death scynexis develop commercialise brexafemme year hpv account cancer fdaapprove firstinclass antifungal treatment worldwide include anal cancer vulvovaginal candidiasis vvc reduce oropharyngeal cancer work innovax incidence recurrent vvc brexafemme complement nextgeneration adjuvanted vaccine protect gepotidacin tebipenem reinforce type hpv commitment develop new antibiotic antifungal treatment area high unmet medical need antibiotic antimicrobial resistance fasttracking gonorrhoea vaccine antimicrobial resistance amr world health threat estimate action amr gonorrhoea secondmost prevalent bacterial include antifungal resistance contribute million sexually transmit infection worldwide death year cause economic loss estimate million new case year trillion medicine vaccine pipeline amr gonorrhoea increase past year project relevant amr render class antibiotic treat disease target pathogen deem critical urgent ineffective making vaccine important global effort tackle amr investigational neisseria gonorrhoeae ngg vaccine base generalise module membrane antigen gmma technology aim protect people age old currently ongoing phase iii efficacy trial ngg receive fasttrack designation fda accelerate path fda submission strategic report governance remuneration financial statement investor information gsk annual report research development continue hiv decade ve transform life people live transform patient live hiv make breakthroughs treatment longacting regimen prevention work develop longacte injectable cabenuva cabotegravir rilpivirine world medicine mean need therapy time complete longacte injectable regimen treat hiv year instead day mean patient treatment time year estimate approximately million instead take medicine orally day solar new hiv infection globally burden study datum announce show cabenuva greatest subsaharan africa effective daily biktarvy tablet treat hiv month finding show participant twothird people live hiv switch biktarvy cabenuva prefer long virally suppress new act regimen diagnose apretude longacting cabotegravir launch remain press need new approach world longacte injectable preexposure treatment prevention prophylaxis prep reduce risk sexually transmit hiv large phase iii study demonstrate apretude work hiv viiv healthcare superior daily oral prep tdfftc man majority pfizer shionogi shareholder woman open label phase give choice viiv healthcare company focus majority study participant choose apretude oral treatment prevention hiv goal tdfftc leave person live hiv european commission authorise apretude ve focus research transforming experience injectable tablet form follow positive opinion people live hiv novel treatment option european medicine agency ema committee allow few drug medicinal product human use chmp apretude ve develop longacte regiman approve australia south africa prevent hiv look future longacte treatment prevention new formulation reformulate cab focus progress injectable dose month double today interval cabotegravir treatment prep halve visit clinic time year year fight hiv official start aids epidemic consider june morbidity mortality weekly report notice rare pneumonia see previously healthy man sex man year hiv identify underlying cause marty st clair scientist burrough wellcome predecessor company gsk urgently begin search potential new medicine treat hiv aids group go develop zidovudine medicine approve nearly year marty continue work treat prevent hiv transmission role clinical director viiv healthcare optimistic outlook innovation hiv ve pretty give people live say marty hopeful time viiv positive action outreach strategic report governance remuneration financial statement investor information gsk annual report research development continue aim reality prevention move selfinjecte longacte registrational study start treatment aim treatment deliver evaluate possible combination main aim develop world long reformulate cab rilpivirine broadly neutralise act treatment people live hiv inject antibody nls complete study allow individual dose home combine nls halozyme recombinant reduce number clinic visit target dose hyaluronidase ph technology allow delivery month efficacy tolerability large volume drug subcutaneous dose similar cabenuva show possible deliver single subcutaneous dose s welltolerate month short goal develop new agent hiv treatment prevention reduce burden treatment sixmonthly dose goal end allow people improve quality life decade partner new integrase inhibitor vh vh newmechanismofaction agent capsid inhibitor respiratoryimmunology ve leader deliver medicine help nucala firstinclass antiilbiologic monoclonal manage asthma copd year research antibody target directly inhibit il look harness science immune system treatment europe indication il develop medicine reduce sign symptom mediate disease severe asthma eosinophilic disease address treatment resistance slow phenotype crswnp egpa s japanese progression immunemediate condition include ministry labour health welfare accept review lupus severe asthma eosinophilic phenotype supplementary new drug application nucala treat crswnp adult submission base datum inflammatory disease help million people pivotal phase iii merit trial study safety respiratory immune condition worldwide efficacy nucala people crswnp current portfolio january china national medical product advance science treatment il administration approve nucala addon maintenance mediate disease treatment severe asthma eosinophilic phenotype year leader research nucala target il treatment china adult role eosinophil type white blood cell adolescent patient condition interleukin il play health disease depemokimab novel monoclonal antibody develop eosinophildriven disease associate affinity il longacte inhibition il heighten level eosinophil eosinophil pathological process include suppression infiltrate certain tissue cause inflammation eosinophil activity potential ultralongacting organ damage time affect patient day antiil biologic treat range il mediate today life disease phase iii programme continue progress disease include severe asthma crswnp il major cytokine responsible proliferation s egpa activation survival eosinophil make prove treatment target patient high level currently approve il inhibitor dose eosinophil week depemokimab design administer month addressing challenge il mediate condition encompass range disease commonly associate frequent dosing include effective treatment adherence anxiety emotional burden include respiratory condition like severe asthma eosinophilic phenotype copd chronic reach broad range asthma patient rhinosinusitis nasal polyp crswnp rarer early acquire aiolos bio inc acquisition condition like eosinophilic granulomatosis add aio phase iiready longacte antibody polyangiitis egpa hypereosinophilic syndrome s target clinically validate tslp pathway research aim redefine treatment goal respiratory pipeline redefine standard care condition go optimal management daily asthma patient dose month aio symptom modify course disease slow potential expand reach broad portion halt disease progression reduce risk organ asthma patient include severe asthma damage mean people achieve patient low inflammation treatment option clinical remission need addition treatment adult patient asthma aio potential strategic report governance remuneration financial statement investor information gsk annual report research development continue additional indication include chronic rhinosinusitis systemic sclerosis ssc rare autoimmune disease nasal polyp cause atypical growth connective tissue affect musculoskeletal system heart lung kidney skin progress treatment refractory organ interstitial lung disease ild marked chronic cough camlipixant inflammation scar tissue buildup lung affect approximately million people suffer chronic half people live ssc current treatment cough million worldwide suffer option limit refractory chronic cough rcc year fda grant orphan drug designation rcc cough persist week odd benlysta potential treatment ssc not respond treatment underlie odd special status grant support development condition unexplained evaluation potential medicine treat diagnose prevent rare disease disorder affect few decade effective treatment people begin phase iiiii trial rcc patient suffer depression urinary sscassociate ild explore incontinence rib fracture loss sleep potential study wide range potential indication acquire bellus health include camlipixant potential bestindisease highly selective benlysta remain approve biologic oral px antagonist currently phase iii development systemic lupus erythematosus sle ln firstline treatment adult rcc current clinical datum year robust efficacy longterm safety selectively inhibit px receptor recognise update recommendation camlipixant reduce cough frequency patient european alliance association rheumatology suffer rcc relatively low incidence eular management sle ln endorse dysgeusia taste disturbance associate early use treatment pathway plan phase iv medicine broadly target px receptor study early inform proactive expect datum phase iii calm management lupus prevent organ damage development programme evaluate efficacy benlysta approve use country safety camlipixant treat adult sle extend include treat systemic sclerosis benlysta child age old sle japan eea country uk country continue work realise potential benlysta antib lymphocyte stimulator bly monoclonal benlysta currently approve treat adult ln antibody people affect range immune eea country uk country mediate condition lupus lupus nephritis ln indication include child age old benefit target mode action reassure ln review continue country safety profile remission possible severe asthma shelby gorman gsk employee know negative impact severe asthma child life doctor say time day feel good day shelby say daughter remember day feel life year frequently hospitalise exacerbation shelbys daughter joelle receive accurate diagnosis start appropriate target treatment time able live life respiratory infection daily antihistamines expertise respiratory disease deep understanding immune system scientist global specialist develop solution help people severe asthma achieve clinical remission shelby joelle strategic report governance remuneration financial statement investor information gsk annual report research development continue oncology cancer world major cause death field blenrep treatment multiple myeloma patient need widely unmet treatment multiple myeloma common blood option remain limited emerge portfolio cancer globally generally consider treatable oncology focus seek solution blood curable woman cancer make transformative break approximately new case multiple myeloma through immunooncology diagnose globally year ojjaara momelotinib blenrep belantamab mafodotin jemperli dostarlimab zejula niraparib strong research new therapy need multiple foundation work blood woman cancer myeloma commonly refractory available goal realise potential exist medicine treatment expand portfolio area high unmet need blenrep antibodydrug conjugate treatment receive approval ojjaara relapsedrefractory multiple myeloma dreamm treatment myelofibrosis omjjaara approve drive excellence approach multiple myeloma eu uk january receive approval clinical development programme continue evaluate eu uk immunooncology therapy potential blenrep address unmet need early line treatment combination novel therapy jemperli plus chemotherapy firstline treatment standard care treatment endometrial cancer patient certain biomarker november announce positive phase iii result continue evaluate dostarlimab study dreamm trial show potential blenrep reinforce ambition backbone combination therapy benefit patient early treatment ongoing immunooncology research development line interim analysis dreamm show patient programme receive blenrep combination bortezomib blood cancer dexamethasone bordex live long disease progress receive daratumumab plus ojjaara help myelofibrosis patient anaemia bordex exist standard care combination therapy myelofibrosis mf rare blood cancer affect share data health authority people scientific community await result nearly mf patient eventually develop anaemia dreamm phase iii combination trial explore require regular blood transfusion lead blenrep potential early therapy line stop treatment establish therapy health authority continue review addition anaemia patient experience exist monotherapy indication blenrep later therapy debilitate symptom like night sweat fatigue line base result previous study include bone pain enlarge spleen december ema recommend splenomegaly bring pain inflammation renewal conditional marketing authorisation frequent infection risk exist fourth line later monotherapy indication ojjaara take orally day medicine woman cancer specifically indicate newly diagnose previously jemperli backbone immunooncology therapy treat mf patient anaemia treat anaemia constitutional symptom enlarge spleen endometrial uterine cancer sixth common accompany disease mean potentially offer cancer woman worldwide estimate new standard care patient establish treatment new case death exacerbate anaemia endometrial cancer case september fda grant broad lineagnostic biomarker know dmmrmsih approval ojjaara treatment primary patient type endometrial cancer face secondary mf adult anaemia regardless significant unmet need typically experience poor previous mf therapy follow positive chmp longterm outcome standard care chemotherapy opinion november approval european commission mhra approval january jemperli immunooncology ve submit new drug application japan treatment approve eu uk frontline set combination chemotherapy patient mismatch repair deficient microsatellite instabilityhigh dmmrmsih primary advanced recurrent endometrial cancer ruby trial support approval jemperli plus chemotherapy show reduction risk disease progression death compare chemotherapy strategic report governance remuneration financial statement investor information gsk annual report research development continue announce additional positive datum azur global openlabel phase ii clinical trial readout ruby phase iii trial trial investigate efficacy safety dostarlimab jemperli plus chemotherapy show statistically significant monotherapy replace chemotherapy radiation andor clinically meaningful overall survival benefit compare surgery treatmentnave patient dmmrmsih chemotherapy overall population patient locally advanced rectal cancer successful s primary advanced recurrent endometrial cancer jemperli potential transform treatment patient immunooncology combination regimen locally advanced rectal cancer achieve ruby trial evaluate trial aim confirm result generate separate jemperli plus chemotherapy follow jemperli plus ongoing investigatorinitiated trial researcher zejula treatment primary advanced recurrent memorial sloan kettere cancer center trial endometrial cancer demonstrate significantly improve report participant treat dostarlimab progressionfree survival compare chemotherapy achieve clinical complete response enable overall mismatch repair proficient avoid surgery chemotherapy radiotherapy microsatellite stable mmrpmss patient population begin azur trial phase iii trial jemperli approve standalone treatment evaluate efficacy perioperative dostarlimab certain type endometrial cancer early monotherapy compare standard care adjuvant fda convert accelerate approval jemperli chemotherapy patient highrisk early stage dmmr secondline treatment approval msih colon cancer approve patient monotherapy adult patient dmmr recurrent new chemotherapyfree option reduce risk advanced endometrial cancer determine fdaapprove test progress follow disease progression dostarlimab treatment prior platinumcontaine regiman set neoadjuvant adjuvant setting not candidate surgery radiation lung cancer european commission conditional approval lung cancer second common cancer globally jemperli monotherapy adult patient common cancer man patient population convert approval million new case zejula parp inhibitor ovarian cancer lung cancer worldwide continue develop zejula multiple pivotal trial assess activity gynaecologic cancer solid majority lung cancer fall category call tumour evaluate potential combination nonsmall cell lung cancer nsclc form zejula therapeutic aim address unmet lung cancer progress slowly nsclc case medical need patient ongoing development spread lung diagnosis programme include phase iii trial assess publish datum phase ii perla clinical potential niraparib combination dostarlimab trial show favourable numerical trend overall survival firstline ovarian cancer maintenance zeal phase result dostarlimab plus chemotherapy compare iii trial evaluate niraparib combination standard pembrolizumab plus chemotherapy firstline metastatic care maintenance treatment firstline advanced nsclc data perla trial support ambition nonsmall cell lung cancer addition base promising dostarlimab backbone immunooncology early clinical datum niraparib glioblastoma november therapy combination standard explore step clinical care future novel cancer therapy include target development type cancer cd axis cancer access antibodie target know colorectal cancer cd checkpoint cd pvrig tigit goal cancer start colon rectum study immune checkpoint combination distinct section large intestine dostarlimab aim increase proportion classify colorectal cancer patient respond therapy improve durability response cd axis development colorectal cancer second leading cause cancer programme continue earlyphase trial relate death common cancer underway include galaxy lung phase ii worldwide account approximately platform study firstline metastatic nsclc combine cancer case dostarlimab belrestotug tigit antibody partner estimate worldwide iteo therapeutic galaxies lung million new case colorectal cancer explore triplet combination dostarlimab belrestotug death gsk cd antibody january fda grant dostarlimab fast addition phase iii trial nsclc continue track designation treatment dmmrmsih locally readout expect advanced rectal cancer costar lung phase iii randomised openlabel start azur clinical trial programme study threearm trial compare investigational compound dostarlimab certain colorectal cancer indication cobolimab plus dostarlimab plus docetaxel strategic report governance remuneration financial statement investor information gsk annual report research development continue dostarlimab plus docetaxel docetaxel bh surface antigen overexpresse ovarian patient advance nsclc progress endometrial cancer associate poor prior antipdl therapy chemotherapy prognosis target bh hs use clinically validate adc technology zeal phase iii randomise doubleblind trial topoisomerase inhibitor payload topoi validate assess niraparib combination standard care mechanism action approve anticancer medicine maintenance treatment firstline advanced nsclc prove standard care treat breast ovarian cancer pipeline growth business development december add oncology portfolio october announce exclusive licence clinicalstage adcs enter second exclusive licensing agreement chinese company hansoh pharma agreement hansoh pharma hs hs bhtargete adc support work develop treatment ovarian endometrial hs bh target adc utilise clinically cancer solid tumour validate topoi payload show promise initial clinical activity lung cancer potential address unmet medical need broad solid tumour indication include colorectal cancer technology new platform datum technology fundamentally expand ability identify novel vaccine transforming discover develop vaccine medicine option prevent medicine speed discovery development treat disease improve chance success invest platform technology include technology make effective stage multiple antigen presenting system map allow discovery development process progress develop multivalent vaccine complex bacterial vaccine medicine good infection introduce tcell mediate diseasespecific kind early investment capability antiprotein immunity potentially enable broad lead differentiate highimpact vaccine coverage certain disease type high medicine include new vaccine rsv longacte immunogenicity current vaccine high hiv prevention prospect functional cure antibody response develop map chronic hepatitis b acquisition affinivax ve mainly direct map combine power genetic datum genomic prevent pneumococcal disease insight speed scale ai well valent pneumococcal vaccine candidate phase ii prediction increase probability new vaccine development platform show medicine available patient ai promise pathogen include team large industry work cause hospitalacquire infection genomic team improve select disease target mrna enable protein synthesis human body determine good technology approach identify carry information require cell produce group patient treatment work good protein mrna technology vaccine partner world development specific protein antigen good mind academia tech biotech produce bodys cell elicit humoral industry large company small startup immune response enable human immune collaboration lead new way think system prevent fight disease develop mrna strive innovative solution patient inhouse parallel collaboration curevac biopharmaceutical company develop therapy base platform technology discover mrna currently develop rna vaccine base develop novel vaccine medicine curevacs secondgeneration mrna backbone major challenge address disease monovalent bivalent covid vaccine candidate vaccine medicine currently exist phase ii multivalent seasonal influenza vaccine difficult treat small molecule biologic candidate protect multiple strain phase iii overcome challenge invest innovation external collaboration develop small molecule design pair small molecule range platform technology platform technology generative ai tool system advantage pair disease target good treatment modality know chemical reaction building block create addressing disease think difficult large virtual library potential drug molecule target drug discovery specific biological target strategic report governance remuneration financial statement investor information gsk annual report research development continue molecule comprise virtual library combine power biology technology profound advantage easily synthesise free reshape way science example know problem associate small molecule generate datum quarter drug filter series machinelearne company year history end molecular property model base gsk historical datum aim bring predictive realtime insight inform clean public source progression development decision research oligonucleotide short strand dna rna combine ai genetic genomic unexpected reduce restore modulate rna possibility mechanism give unique capability address build inhouse team dedicate genomics wide range genomic target multiple therapeutic area ai include key rd site london tel aviv time oligonucleotide currently pipeline san francisco seattle philadelphia boston include bepirovirsen chronic hepatitis b gsk expertise help collect datum generate idea phase ii programme nonalcoholic arrive unexpected possibility bring steatohepatitis nash close find vaccine medicine disease feel outside reach make research process collaboration build lead fast effective predictable oligonucleotide platform invest build worldclass research datum enter collaboration wave life platform include world science pair genetic expertise wave prism oligonucleotide platform offer comprehensive large language model genetic disease rnatargete modality edit splicing silencing bring billion datum point single place include sirna antisense collaboration help map gene expression function activity enable accelerate drug discovery newly identify target scientist run experiment answer match good therapeutic modality question matter hour process take week month announce partnership elsie biotechnologies inc collaboration combine genetics genomics expertise dna encode library technology combination genetic functional elsie drug discovery platform genomics genetic engineering technique like crispr collaboration exercise option non cluster regularly interspace short palindromic exclusive licence elsie discovery platform repeat enable screen validate hundred pv chemistry technology use genetic target parallel instead time oligonucleotide drug discovery research screening process discover causal monoclonal antibodie produce single clone gene genomic link biomarker cell cell line consist identical antibody molecule predict disease target strong mean modulate patient immune system genetic evidence pipeline increase platform need bestinclass monoclonal antibodie like nucala bispecific antibodie apply data tech clinical research antibodydrug conjugate like blenrep clinical stage development aiml genomic develop generative design capability base help assess certain patient profile increase use generation sequence respond able sure right public proprietary protein structure tool structure people right trial offer potential design tool realise highly short expensive clinical trial great chance automate antibody synthesis isolation purification success process example research antisense adjuvant substance enhance bodys immune oligonucleotide bepirovirsen chronic hepatitis b response antigen use arexvy shingrix ml developed algorithm help categorise vaccine rsv shingle hsv vaccine patient distinct subtype base response candidate gsk work xiamen treatment double ability correctly innovax biotech nextgeneration adjuvanted vaccine predict future patient outcome compare protect type hpv traditional method significant help genetic datum well understand inform sequential combination therapy option disease choose right solution potentially lead well outcome ultimately right patient help people live hepatitis b experience functional cure datum technology combine aiml human genetic functional genomic understand patient human biology disease mechanism make well choose prioritise target design trial bring new vaccine medicine patient strategic report governance remuneration financial statement investor information gsk annual report research development continue collaborate change course work complement technology biology project disease patient underway laboratory genomic research cofounde researcher university work achieve well fast california san francisco project automate address disease area high unmet need advance crispr new discovery disease people possible mechanism immunology oncology neurology collaboration uk biobank andme finngen collaboration help advance multiple give access large genetic dataset deepen field human health understanding disease improve drug discovery found partner future health uk king college london tumour model initiative set recruit million people alongside digital pathology ai develop personalise capture genetic medical information work immunooncology treatment solid cancer gene health discover south africa pathai work accelerate rd oncology sure diverse genetic representation disease nash january announce join alliance genomic discovery expand establish oxfordgsk institute molecular access diverse genetic dataset computational medicine imcm oxford university combine human genetic functional collaboration functional genomic insight genomic ml focus disease include help select target likely amyotrophic lateral sclerosis al alzheimer medicine continue work genomic research parkinson centre like broad institute affiliate mit harvard university boston altius institute work precision medicine company tempus seattle uk partner include consortium focus datum enable clinical trial open target cofounde design target selection oncology culture create agile innovative environment s support ve take step focus ambitious patient attract good people intently core therapeutic area strengthen scientist partner decisionmake clear ownership simplify agile governance embed technology deeply ahead disease need good people work scientist researcher trial specialist technologists environment thrive ve create research unit dedicate vaccine expertise inside company infectious disease respiratory immunology partner rd people work inclusive oncology report directly chief scientific officer environment foster new idea connection use expertise pick right target right include scientist technologist data engineer patient lead clinical development phase ii working rd leadership team make recommendation phase iii programme start role past year bring year research team complement ongoing research combine experience add leadership hiv viiv healthcare deliver key priority close collaboration rd commercial culture unite ambitious patient manufacture medical leader make sure match accountable impact right thing scientific potential unmet patient need maximise culture encourage team focus matter impact disease deliver competitive commercial smart risk informed decision pace value ve create research technology help ownership objective seize organisation bring platform datum group opportunity solve problem create scale engine identify progress target partner strategic report governance remuneration financial statement investor information gsk annual report research development continue pipeline overview asset development latestage phase iiiregistration anticcl antibody osteoarthritis pain arexvy recombinant protein adjuvante rsv old adult yoa antiil antibody atopic dermatitis gepotidacin bti inhibitor uncomplicate uti antisortilin antibody alzheimer disease bepirovirsen antisense oligonucleotide chronic hbv infection belrestotug antitigit antibody nonsmall cell lung cancer bexsero recombinant protein omv meningitis b infant menabcwy vaccine recombinant protein omv conjugate vaccine hsdb sirna nonalcoholic steatohepatitis menabcwy stgen phase tebipenem pivoxil antibacterial carbapenem complicated uti bivalent conjugate salmonella typhoid paratyphoid ibrexafungerp antifungal glucan synthase inhibitor invasive candidiasis mtb cholesterol dependent inhibitor tuberculosis nucala antiil antibody copd crk inhibitor visceral leishmaniasis depemokimab longacte antiil antibody asthma proteasome inhibitor visceral leishmaniasis latozinemab antisortilin antibody frontotemporal dementia p falciparum cell inhibitor malaria camlipixant px receptor antagonist refractory chronic cough p falciparum cell inhibitor malaria low carbon version mdi ventolin beta adrenergic receptor fimh antagonist uncomplicate uti agonist asthma pik beta inhibitor viral copd exacerbation ojjaaraomjjara jak jak acvr inhibitor papdpapd inhibitor chronic hbv infection jemperli antipd antibody endometrial cancer tlr agonist chronic hbv infection zejula parp inhibitor ovarian cancer cabotegravir integrase inhibitor hiv blenrep antibcma adc multiple myeloma antiil antibody autoimmune disease cobolimab antitim antibody nonsmall cell lung cancer tg inhibitor pulmonary fibrosis linerixibat ibat inhibitor cholestatic pruritus primary biliary antiil antibody copd cholangitis rnaediting oligonucleotide alpha antitrypsin deficiency phase ii interferon pathway modulator systemic lupus recombinant protein adjuvante malaria fractional dose erythematosus live attenuate mmrv new strain antipvrig antibody cancer gmma shigella anticd antibody cancer viral vector recombinant protein adjuvante chronic xmt sting agonist adc cancer hbv infection belantamab antibcma antibody multiple myeloma recombinant protein omv conjugate vaccine dna polymerase theta inhibitor cancer menabcwy ndgen adctargeting bh gynecologic malignancy live attenuate varicella new strain dnmt inhibitor sickle cell disease map adult pneumococcal disease valent map paediatric pneumococcal disease valent asset order therapy area phase infectious recombinant protein adjuvante human papillomavirus disease hiv respiratoryimmunology oncology opportunity gmma gonorrhoea drive advanced indication show asset inlicence alliance relationship party mrna seasonal flu additional indication candidate investigation mrna covid registration adjuvante recombinant subunit cytomegalovirus phase iii trial patient progranulin gene mutation recombinant protein adjuvante therapeutic herpe meter dose inhaler simplex virus phase iii start expect hepatitis b virustargeted sirna chronic hbv infection approve eu bivalent gmma invasive nontyphoidal salmonella phase iii study phase ii study start imminent ganfeborole leucyl trna synthetase inhibitor tuberculosis transition activity underway enable progression partner sanfetrinem cilexetil serine beta lactamase inhibitor tuberculosis gsk exclusive global licence option codevelop alpibectir bvlgsk ethionamide booster tuberculosis commercialise candidate broadly neutralize antibody hiv rsv respiratory syncytial virus uti urinary tract infection hbv hepatitis b virus adc antibody drug conjugate copd chronic obstructive pulmonary maturation inhibitor hiv disease mmrv measle mump rubella varicella omv outer membrane capsid protein inhibitor hiv vasicle sirna small interfere rna gmma generalise module membrane antigen yoa year age capsid protein inhibitor hiv integrase inhibitor hiv benlysta antiblys antibody systemic sclerosis associate interstitial lung disease strategic report governance remuneration financial statement investor information gsk annual report commercial deliver strong sustained performance momentum successful operation commercial launch support integrate global supply chain strategic report governance remuneration financial statement investor information gsk annual report commercial operation highlight bn total sale aer cer cer exclude covid sale contribution product area bn sale contribution region bn l vaccines l speciality medicine l general medicines l l europe l international bar chart exclude covid solution absolute value aer change cer state strong operational performance detail performance driver growth ve continue focus operational vaccine performance performance strong growth product area specialty medicine performance region build good progress demonstrate strong sustained performance momentum general medicine performance mean confident deliver upgrade growth outlook period strong performance drive continue stepchange commercial execution underpin focus leadership develop outstanding people build meaningful connection healthcare professional hcp patient support datum technology strong insight good meet need strategic report governance remuneration financial statement investor information gsk annual report performance vaccine broad vaccine portfolio target infectious disease stage doubledigit growth vaccine life help protect people meningitis shingle rsv flu polio successful launch arexvy continued strong uptake shingrix turnover international europe bn aer cer l establish bn l shingles bn l meningitis bn l rsv bn l influenza l pandemic strategic report governance remuneration financial statement investor information gsk annual report performance vaccine continue key product product disease total revenue key information shingrix herpe zoster shingle bn aer cer marketleading recombinant adjuvante vaccine indicate prevention shingle adult launch market arexvy rsv bn world approve rsv vaccine adult approve country bexsero meningitis aer cer approved countries prevention invasive group b meningococcal disease imd cause neisseria meningitidis serogroup b boostrix diphtheria tetanus aer cer available country market leader acellular pertussis booster rotarix rotavirus aer cer marketleading pediatric vaccine country increase share launch liquid formulation fluarix flulaval seasonal influenza aer cer quadrivalent influenza vaccine available country infanrix pediarix diphtheria aer cer dtpa vaccine available country pediarix tetanus pertussis polio leading brand volume hepatitis b haemophilus influenza type b engerix twinrix havrix hepatitis aer cer grow hepatitis portfolio leadership increase coverage strengthen recommendation menveo meningitis aer cer menveo help protect imd cause neisseria group c w meningitidis serogroups c w available country synflorix invasive disease aer cer synflorix available country include pre pneumonia acute otitis qualification acquisition map technology expect medium enable great serotype disease coverage priorix priorix measle mump rubella aer cer priorix continue gain share priorix available tetra varilrix chickenpox country varilrix country priorix tetra country cervarix human papilloma virus aer cer important option hpv cervarix twodose schedule girl age launch china sale performance arexvy achieve billion sale drive strong uptake lead market share deliver vaccine sale grow aer cer billion total outstanding launch sale aer cer billion exclude covid arexvy available major retail pharmacy solution competitive contracting place shingrix grow aer cer billion increase influenza fluarixflulaval sale decline line demand favourable pricing q represent expectation aer cer million highest quarter sale growth drive drive competitive pressure low market public funding expansion strong private uptake demand primarily international europe establish vaccine grow aer cer billion meningitis vaccine sale grow aer cer drive rotarix favourable cdc stockpile movement billion largely deliver bexsero primarily drive mmrv vaccine increase supply international inclusion national immunisation programme europe hepatitis vaccine performance relate travel market menveo grow favourable impact cdc recovery center disease control stockpile replenishment strategic report governance remuneration financial statement investor information gsk annual report performance vaccine continue strategy growth shingrix continue grow available country penetration majority portfolio market vaccine market million adult industry broad deliver approximately million recommend receive shingrix dose vaccine day infant bear vaccinate million people protect year receive gsk vaccine vaccine shingrix ambition vaccinate portfolio target infectious disease stage life million people support enter help protect people rsv meningitis shingle exclusive agreement chongqe zhifei flu polio biological product ltd zhifei value billion initial threeyear period copromote shingrix vaccine critical deliver growth plan china zhifei import distribute shingrix china focus strong execution key market shingrix promote vaccine network exist portfolio deliver value vaccination point partnership significantly extend pipeline new launch particularly worldfirst rsv availability shingrix support rapid expansion vaccine arexvy bring vaccine patient access vaccine future potential patient possible indication vaccine complex highly technical develop continue lead meningitis market drive manufacture help protect portfolio bexsero menb menveo menacwy prepare potential disruption new technology s transition pentavalent menabcwy vaccine establish generic industry vaccine not generally combines establish vaccine continue face socalle patent cliff long lifecycle mean invest bexsero remain integral strengthen vaccine remain use decade initial leadership secure key national immunisation authorisation example boostrix infanrix priorix programme nip country like germany engerix remain important part portfolio term switzerland build realworld contribution performance evidence base helping improve immunisation rate globally focus adolescent population establish platform technology new improve competitiveness look drive future platform build map mrna growth multiple lifecycle innovation come technology key vaccine growth strategy year include launch menveo convenient liquid enable tackle complex disease formulation additional country birth adulthood establish vaccine remain key priority growth driver growth portfolio represent total vaccine business core launch arexvy support market leadership vaccine continue grow strongly seek maximise ambition multibillionpound sale potential uptake need achieve approximately million million adult age prioritise specific segment growth opportunity old risk vaccinate arexvy return travel strengthen recommendation launch underway europe canada hepatitis adult segment increase awareness vaccine approve japan importance vaccination work country strengthen relationship maintain strong performance key market make retailer give expertise old adult population sure resource team success shingrix draw expertise deliver supply commitment respiratory disease experience primary care sale force approval launch expect meeting need age population increase awareness impact rsv prioritise prevention adult increase risk look forward see focus prevention reduce burden impact vaccine help prevent disease create healthy thriving world vaccination severe consequence rsv globally critical element prevention infectious disease especially child old adult age immune system start decline effective lead increase risk infectious disease focus effort helping old adult healthy move sick care true healthcare prioritise prevention make adult immunisation standard care help vaccination adult remain active healthy participant society economy prolong productivity contribute local economy reduce healthcare cost improve uptake adult immunisation work build investment case vaccination ease access increase belief importance vaccine strategic report governance remuneration financial statement investor information gsk annual report performance vaccine continue support healthcare professional routinely initiate year commission research spotlight vaccination conversation patient build hyperlocal factor contribute inhibit adult broad belief importance vaccination hold immunisation uptake diverse geographically vaccine virtual day bring healthcare representative city world research build professional expert international vaccine exist global framework progress vital community discuss present important update initiative un decade age datum trend adult immunisation ve agefriendly city network continue series vaccinology master class help coimmunity support public well equip healthcare professional conversation health effort make data vaccination trend patient vaccine available vaccine track platform adult immunisation rate not recover sharing tool resource healthcare organisation fully covid pandemic help address gap adult immunisation commission report publish iqvia institute coimmunity initiative build recent regulatory human data science global coalition age industry change vaccine estimate million few dose available easy access medicare medicaid adult vaccine exclude covid solution beneficiary support community vaccine infrastructure administer anticipate help address launch coimmunity initiative commit million grant fund national state local nonprofit organisation address longterm barrier immunisation particularly old adult susceptible decline immune system strategic report governance remuneration financial statement investor information gsk annual report performance specialty medicine continue global leader specialty medicine growth exclude infectious disease respiratory covid solution aer cer hiv medicine emerge portfolio cancer continue growth momentum hiv medicine growth acceleration oncology turnover respiratoryimmunology bn aer cer l hiv bn l respiratoryimmunology bn l oncology l pandemic strategic report governance remuneration financial statement investor information gsk annual report performance specialty medicine continue key marketed product product disease total revenue key information dovato hiv treatment bn aer cer dolutegravirbased twodrug regimen launch market nucala respiratory eosinophil bn aer cer treatment indicate europe drive disease use il mediate disease triumeq hiv treatment bn aer cer dolutegravirbase fixeddose combination tablet market country tivicay hiv treatment bn flat aer cer dolutegravir tablet use combination antiretroviral agent market country benlysta lupus lupus nephritis bn aer cer biologic approve treat sle ln europe cabenuva hiv treatment aer cer complete longacte injectable regimen vocabria rekamby cabotegravir rilpivirine market country europe japan juluca hiv treatment aer cer dolutegravirbased twodrug regimen market country zejula ovarian cancer aer cer parp inhibitor commercially available l maintenance market l maintenance market apretude hiv prevention aer cer longacte injectable cabotegravir hiv prevention launch jemperli endometrial cancer aer cer pdblocking antibody available country continue investigate future monotherapy combination regimen multiple tumour type rukobia hiv treatment aer cer extendedrelease tablet people live multidrug resistant hiv use combination antiretroviral launch market xevudy covid treatment aer cer monoclonal antibody early treatment covid blenrep blood cancer multiple aer cer antibodydrug conjugate patient relapse myeloma refractory multiple myeloma ojjaaraomjjara myelofibrosis approve eu uk treatment specifically indicate myelofibrosis patient anaemia jesduvroqduvroq anaemia chronic aer cer approve treatment anaemia kidney disease ckd chronic kidney disease ckd adult patient dialysis sale performance respiratoryimmunology sale aer cer billion consistent sustain double report speciality medicine sale digit growth benlysta nucala nucala grow aer cer million total exclude covid billion continue strong growth region solution grow aer cer million reflect high patient demand severe eosinophilic hiv sale grow aer cer billion primarily asthma new indication benlysta grew drive percentage point increase market share billion represent strong demand europe broadly flat global treatment market attributable continued market expansion patient demand oral twodrug regimen dovato oncology sale grow million drive strong juluca longacting medicine cabenuva apretude growth jemperli zejula uptake ojjaara post oral twodrug regimen longacte medicine sale launch q partially offset impact grow billion represent total blenrep withdrawal market november hiv portfolio growth jemperli continue accelerate particularly follow approval q zejula sale grow million strong growth region growth line indication offset reduction use second line follow update prescribing information agree fda q strategic report governance remuneration financial statement investor information gsk annual report performance specialty medicine continue strategy growth benlysta remain biologic approve systemic lupus erythematosus lupus nephritis portfolio specialty medicine focus benlysta see consistent growth major market therapeutic area infectious disease hiv respiratory patient start therapy immunology oncology reinforce strength focus helping identify treat patient leadership infectious disease respiratory hiv early lupus progress organ damage occur build emerge capability oncology drive growth oncology jemperli continue demonstrate potential sale come specialty medicine backbone ongoing immunooncologybased expect provide durable profitable growth research development programme year drive growth accelerate pipeline combination standard care future novel cancer prioritise business development target therapy potential transform patient live acquisition partnership strengthen multiple tumour type include endometrial cancer complement core therapy area help jemperli plus chemotherapy approve deliver current longterm outlook eu uk immunooncology acquisition bellus health announce april regimen treatment frontline primary advanced example build respiratory expertise recurrent dmmrmsih endometrial cancer complement broad respiratory pipeline approval significant driver performance increasingly confident major source sale growth oncology new longterm growth ojjaaraomjjara jak acvrinhibitor acquire driver growth portfolio purchase sierra oncology april hiv strategy growth build innovative approve eu uk treat myelofibrosis portfolio medicine transform hiv treatment anaemia make ojjaara medicine prevention strong competitive execution specifically indicate newly diagnose previously treat myelofibrosis patient anaemia launch dolutegravirbased oral twodrug address anaemia constitutional symptom regimen dovato continue perform strongly enable splenomegaly enlarge spleen hallmark people live hiv remain virally suppress complex blood cancer lineagnostic label few medicine broader anticipate expand opportunity reach patient novel treatment option longacte portfolio medicine central additional regulatory filing initiate growth deliver strong result launch aim expand access patient market market ovarian cancer zejula continue provide significant cabenuva world complete longacting opportunity firstline maintenance therapy reach regimen hiv treatment available europe patient month work japan china australia twomonthly cabenuva develop combination therapy zejula woman address challenge associate daily oral therapy cancer solid tumour include fear disclosure adherence anxiety pill fatigue ensure focus area big impact patient ve withdraw filing apretude world longacte medicine hiv jesduvroq eu stop file market prevention offer superior efficacy daily oral prevention medicine available patient ftctdf tablet twomonthly dose living anaemia ckd apretude expand approval europe subsaharan africa countries important lever end global epidemic respiratoryimmunology marketleade medicine nucala benlysta continue deliver doubledigit growth nucala target biologic therapy approve use il mediate disease eosinophil disease continue drive growth consistent evidence multiple indication combine marketleading safety datum reinforce nucala biologic choice hcp severe asthma market continue grow market offer opportunity nucala help patient strategic report governance remuneration financial statement investor information gsk annual report performance general medicine antibiotic inhale medicine asthma copd growth drive respiratory general medicine general medicine product leader ongoing strong demand trelegy class make life well region anoro europe million people worldwide international continue post pandemic recovery turnover antibiotic market europe international region bn aer cer l respiratory bn l general medicine bn strategic report governance remuneration financial statement investor information gsk annual report performance general medicine continue key marketed product product disease total revenue key information trelegy ellipta copd asthma bn aer cer prescribe single inhal triple therapy sitt worldwide reach estimate million patient launch seretideadvair asthma copd bn aer cer marketleade icslaba treatment worldwide sale value relvarbreo ellipta asthma copd bn aer cer lead icslaba treatment worldwide sale value ventolin asthma copd aer cer global marketleading saba reliever sale value augmentin common bacterial aer cer global leader oral antibiotic sale value available infection country anoro ellipta copd aer cer global market leader lamalaba class volume unit sale approve country avodart duodart benign prostatic aer cer market leader sale value global dutasteride hyperplasia bph dutasteridetamsulosin fdc market respectively approve country respectively avamysveramyst allergic rhinitis aer cer global leader inhale corticosteroid prescription class sale value dermovate betnovate inflammatory skin aer cer global leader topical corticosteroid market cutivate eumovate condition globally value sale exclude icslaba inhale corticosteroidlongacte beta agonist saba shortacte beta agonist labalama longacte beta agonistslongacte muscarinic antagonist fdc fixeddose combination key information source iqvia sale performance strategy impact general medicine sale grow aer cer billion reflect growth trelegy single general medicine portfolio include medicine inhal triple therapy class region anoro typically prescribe primary care general europe international medicine contribute gsk sale help fund growth investment rd return trelegy grow aer cer billion growth shareholder deliver region reflect increase patient demand growth sitt market penetration expect combination product class market leader positive impact live hundred million patient seretideadvair sale decrease aer increase year supply product cer billion primarily reflect favourable country comprise total pricing offset generic erosion impact medicine vaccine supply volume day europe certain international market medicine improve health life well million general medicine decrease aer grow people world cer billion reflect ongoing post pandemic demand antiinfective europe international respiratory infectious disease therapeutic certain party manufacturing arrangement generate general medicine revenue overall growth product group continue expect growth trelegy anoro establish impact ongoing generic competition product portfolio emerge market commit positively impact life day focus investment brand grow strongly maximise return manage expect decline product mature market lose exclusivity strategic report governance remuneration financial statement investor information gsk annual report performance general medicine continue driver growth portfolio augmentin global leader oral antibiotic sale value available country reach main source growth general medicine billion patient launch year ago trelegy anoro augmentin continue grow strongly region augmentin trelegy sitt asthma copd deliver sale grow aer cer million strong ongoing billion time trelegy demand region continue accelerate strongly growth region launch ventolin remain important include big growth driver medicine patient country portfolio trelegy license country copd significant proportion carbon emission come dual indication asthma copd country include japan receive new ventolin meter dose inhaler mdi start rd programme redevelop ventolin mdis approval expand trelegys availability asthma patient turkey hong kong bahrain kuwait low global warming potential gwp propellant clinical assessment successful reduce trelegy number sitt globally sell greenhouse gas emission rescue mdi million pack twice volume nearest approximately competitor trelegy market leader large market japan market share significantly exceed nextlargest competitor respectively november global initiative chronic obstructive lung disease gold guideline recommend triple therapy icslaba exacerbate patient helped continue growth sitt market year launch grow year year expect trelegy key driver growth general medicine come year anoro approve approximately country treat symptomatic copd anoro remain global market leader lamalaba class volume unit sale continue growth global sale exclude anoro robust clinical datum profile include headto head datum lamalaba class versus common initial maintenance therapy option lama regulatory data file late update august asthma july copd regulatory datum file late update august iqvia patient volume datum october source iqvia strategic report governance remuneration financial statement investor information gsk annual report operation manufacturing supply global supply chain critical significant progress bring vaccine medicine supply chain create successful manufacture global supply chain integration helps drive efficiency supply vaccine medicine ensure capacity capability include good digital technology capability enable deliver reliable deliver new product highquality product meet global network vaccine medicine patient need maintain manufacturing site deliver million vaccine performance dose billion pack medicine help positive impact health million people invest future productivity investing manufacturing supply chain increase productivity efficiency open million adjuvant manufacturing facility hamilton mean produce qs adjuvant inhouse contribute rsv shingles malaria cervical cancer vaccine late open manufacturing testing facility jurong singapore produce cytotoxic agent antibody drug conjugate need nextgeneration cancer treatment tuas site singapore ve begin build new vaccine manufacturing facility hepatitis b vaccine feature late advanced technology sustainable design strategic report governance remuneration financial statement investor information gsk annual report operation manufacturing supply continue ware uk open new oral solid dose facility support innovation bring rd supply chain specialist use global supply chain play central role bring new technology rapid knowledge transfer deliver innovation patient quickly efficiently effectively new medicine fast efficiently possible team involve early product wavre site belgium ve start build development work rd sure million freezedrying centre automation work clinical trial produce commercially robotic create capacity adult vaccine scale barnard castle uk multimillionpound q supply rsv vaccine arexvy record time block smart manufacturing facility start commercial country include eu production immunology product canada follow regulatory approval ship patient world facility bring additional capacity deliver use digital technology robotic production jemperli patient world follow efficient regulatory approval europe exceed target ongoing programme work external manufacturing partner productivity efficiency improvement year deliver supply chain excellence launch ojjaara programme deliver million saving medicine vaccine embrace technology datum site productivity increase year harnessing power technology datum transform manufacture supply chain promote quality safety reliability identify implement good digital quality safety reliable supply critical meeting technology capability unlock growth patient patient need create competitive advantage shareholder people reliability remain strong ontime infull otif work industrialise new platform measure specialty medicine technology oligonucleotide medicine general medicine vaccine deviation mrna map vaccine map clinical trial rate improve medicine increase marginally continue new binney street site cambridge vaccine clear action plans improvement plan scale production bring map market information product governance responsible digital twin simulate process anticipate business section issue use learn accelerate manufacturing ve receive external recognition technology help increase production yield feature gartner supply chain company vaccine medicine base financial metric esg criterion opinion invest automation robotic site industry analyst expert improve ergonomic increase efficiency help deliver medicine vaccine patient world increase environmental sustainability manufacturing site key role contribution net zero nature positive healthy planet environmental sustainability fundamental global supply chain strategy responsible business section information carbon emission water use waste invest plan improve natural habitat protect biodiversity improve soil water quality near site approach sustainability progress site esg performance report strategic report governance remuneration financial statement investor information gsk annual report responsible esg embed strategy help deliver purpose support business sustainable performance longterm growth strategic report governance remuneration financial statement investor information gsk annual report responsible business approach continue evolve esg performance rating ensure meet expectation stakeholder executive global biopharma company purpose leadership team board corporate unite science technology talent ahead responsibility committee review metric disease deliver purpose need rating year ensure sufficiently consider esg impact lab challenge ambitious year remove patient s esg embed strategy metric relate access ethical standard add support sustainable performance longterm relate antimicrobial resistance amr meet growth help build trust generate value metric relate access develop stakeholder reduce risk operation create publish pricing access principle positive social impact remove ethical standard metric track identify esg focus area address number employee leave gsk misconduct increase material business issue matter decrease number indicate high stakeholder focus area core low number breach strongerweaker enforcement strategy great positive process set threshold effective impact society urgent challenge measure success uphold standard continue include set un sustainable development monitor datum internally publish externally goal un sdgs additional metric provide strong measure commitment ethical standard access healthcare add metric global health health security global health health security focus amr amr urgent public health threat see increase stakeholder interest approach environment update biodiversity target achieve diversity equity inclusion dei new target focus deforestation free source paper palm oil ethical standard product governance assess performance gsk leadership team glt accountable focus area inform recent deliver progress metric regularly review materiality assessment reaffirm performance board corporate material issue business align responsibility committee crc individual metric esg focus area recognise assess track metric meet exceed responsible business static requirement track work metric mean continue evolve approach achieve track metric miss response rapidly change operate environment strive continuous improvement ensure addition order calculate overall esg maintain strong esg performance performance rating performance metric aggregate single score illustrate esg performance rating track track work track rating define esg performance rating help integrate esg delivery strategy allow measure track metric track verify progress make rate track work metric corporate kpis measure progress key metric track track work align focus area include metric summarise esg performance track metric track report esg performance rating esg performance rating track base assessment performance annual target performance metric meet exceed review overall esg performance rating score subject independent limited assurance detail progress focus area esg performance rating metric independent limited assurance report esg performance report strategic report governance remuneration financial statement investor information gsk annual report responsible business continue external benchmarking detailed perform key esg rating ftsegood member ftsegood index frequently ask investor cdp climate change water security access medicine rank st access b forest palm oil b forest timber medicine index industry leader sustainalytic low risk rating antimicrobial resistance benchmark msci aa rating sp corporate sustainability assessment rank st pharmaceutical industry score moody analytic esg overall score november include djsi world sector average europe index iss corporate rating b rating access aim positively impact health billion people provide access patient low income country end make vaccine collaborate global health partner include medicine available widely possible ngo generic manufacturer increase reach responsible pricing strategic access programme patient low income country reach partnership million people vaccine antiretroviral low income country commitment product available valuebase price vaccine sustainable business implement access reserve low vaccine price gavi vaccine strategy increase use medicine alliance similar organisation partner vaccine treat protect underserved people gavi foundation supply billion vaccine dose date low price esg performance rate metric low income country progress goal reach billion people low income country product partnership significantly increase supply deliver million dose cervarix progress critical vaccine low income country address put right value innovation cervical cancer set responsible price line benefit supply million dose bring patient health system measure clinical pneumococcal vaccine synflorix gavieligible economic social outcome compare offer country low price vaccine rotavirus available patient generate rotarix reach child gavieligible country evidence clinical trial establish add value gavi country offer vaccine provide medicine vaccine adjust civil society organisation serve refugee work pricing line socioeconomic status country emergency situation humanitarian ensure affordability availability mechanism longstanding supplier operate robust pricing approval develop oral polio vaccine unicef access plan inform payer work create supply million dose help eradicate polio stability predictability payer business neglect tropical disease engage proactively upcoming product launch donate million albendazole tablet help budget planning adjust price account tackle lymphatic filariasis lf soil transmit helminth inflation combine average net price echinococcosis take total donate discount rebate allowance billion pharmaceutical vaccine portfolio increase average list price increase compare remain committed supply albendazole endemic list industry past year country lf eliminate far lf average net price product increase eliminate country include bangladesh annually average list price rise lao pdr announce elimination disease compare list industry significant milestone collaborative effort ahead disease number tablet donate decline year give gradual eradication neglect tropical disease ntd medicine target strategic report governance remuneration financial statement investor information gsk annual report responsible business continue programme benefit million people gsk partner mosquirix significant scientific begin accord data breakthrough world malaria vaccine vaccine human parasite hiv aurobindo cipla viatris generic july gavi announce african manufacturer sign sublicence viiv healthcare country allocate dose mosquirix early licence medicine patent pool mpp develop committed supply total million manufacture supply generic version cabotegravir dose gavieligible country longacte hiv preexposure prophylaxis cabotegravir plan produce million dose annually la prep country subject obtain regulatory approval viiv healthcare work global health landmark study london school hygiene agency ngos government community partner tropical medicine show combine mosquirix plan support introduction viivmanufacture antimalarial drug areas africa seasonal malaria cabotegravir la prep introduction national reduce malaria case death young child programme late order cabotegravir period year la prep deliver global partner programmatic use low middleincome country finding confirm potential seasonal vaccination provide high level protection year viiv healthcare voluntary licensing agreement life protection need generic manufacturer produce sell lowcost single fixeddose combination product contain help strengthen healthcare system hiv medicine dolutegravir adult agreement gsk viiv healthcare join force cover low middleincome country direct global fund pledge million year create licence mpp similar gender equality fund support community agreement generic manufacturer child base lead organisation work deliver cover country separate agreement last change health policy programme focus enable great access dolutegravir certain upper tb hiv malaria woman girl middleincome country total million people diversity bill melinda gates foundation live hiv country access generic commit match donation renew product contain dolutegravir end partnership save child year people live hiv antiretroviral build learning decade focus genericaccessible low middleincome country partnership reduce number zero dose child receive vaccine malaria ethiopia nigeria represent date million child ghana kenya zerodose children africa malawi reach dose mosquirix rtssase whocoordinate detail progress focus area esg performance report malaria vaccine implementation programme develop global health health security want help address big health challenge progress face people world global health rd commitment viiv healthcare announce investment billion year accelerate global health rd develop novel product technology treat end invest prevent priority disease include pandemic threat progress global health pipeline asset address esg performance rating metric priority disease include climateaggravate progress global health pipeline asset address disease disproportionate impact low priority disease income country progress active rd project address promise avenue tuberculosis prevention pathogen prioritise cdc pose treatment high level concern drug resistance gsk commit tackle tuberculosis tb critical andor urgent threat world deadly disease develop promising candidate vaccine mase proof concept phase iib building longstanding successful history work external partner partner bill melinda gates medical research institute mri development budget phase linear year period strategic report governance remuneration financial statement investor information gsk annual report responsible business continue gate mri position lead large complex rd project medicine phase iii study require june wellcome vaccines relevant amr range early bill melinda gates foundation announce funding latestage development rd project target million phase iii trial trial pathogen deem critical urgent successful mase new vaccine centers disease control prevention help prevent pulmonary tb century include gepotidacin novel breakthroughs malaria research treatment oral antibiotic treatment uncomplicated urinary tract august announce gsk scientist infection utis year positive phase iii datum discover strain naturally occur bacterium eagle eagle trial present potentially help eradicate disease tre european congress clinical microbiology infectious canto tc strain delftia tsuruhatensis bacterium disease copenhagen april significantly reduce load p falciparum malaria march announce exclusive licence parasite mosquito potentially inhibit agreement scynexis brexafemme ibrexafungerp transmission parasite human continue tablet firstinclass antifungal treatment pursue groundbreake research engage vulvovaginal candidiasis vvc reduction global health institution partner identify incidence recurrent vvc effective sustainable approach development mobilisation successful progress vaccine enteric disease reduce burden antimicrobial resistance support innovation capacity capability antimicrobial resistance amr major threat health building globally particularly prevalent lowresource africa open lab initiative launch setting continue progress candidate vaccine support earlycareer scientist base subsaharan africa enteric disease contribute focus infectious disease disproportionately burden amr include invasive nontyphoidal affect subsaharan population malaria tb salmonella klebsiella shigella typhoid paratyphoid amr agree grant researcher fever announce partnering country subsaharan africa announce limmatech biologics development proposal november work candidate vaccine shigellosis continue african academic institution provide grantee develop candidate vaccine disease supplemental training area include epidemiology use vaccine platform technology gmma statistic clinical research currently vaccine help prevent shigellosis strengthen health security disease cause death year factor jeopardise health rd pipeline security new emerge infectious disease detail progress focus area esg rise amr primary contribution strengthen performance report health security innovation prevent mitigate infectious disease environment climate change nature loss urgent threat average percentage gsk site supplier human health risk business resilience compliant wastewater active pharmaceutical ahead disease help ensure longterm business ingredient limit percentage supplier success need action climate nature compliant amr industry alliance common antibiotic manufacturing framework discharge limit commitment percentage paper palm oil deforestation free commit net zero nature positive healthy planet ambitious goal set operational waste material reduction site esg performance rating metric operational emission reduction scope market base emission industrialisation lowcarbon ventolin initiate clinical nonclinical datum available support regulatory submission percentage carbon offset volume project pipeline metric relate esg performance rating outline esg performance report measure report performance public environmental sustainability target publish gskcom strategic report governance remuneration financial statement investor information gsk annual report responsible business continue progress overall scope emission low baseline year increase climate late available datum compare clear pathway net zero impact climate primarily drive high sale meter dose ambitious goal inhaler mdi product overall scope emission science base target initiative sbti increase period approve gsk net zero target line reduce upstream scope emission supplier corporate netzero standard world framework good service buy medicine corporate net zero target set line climate vaccine additional upstream emission account science approximately total emission footprint value chain carbon footprint supply chain emission fall scope emission operation use medicine vaccine make total footprint propellant scope emission supply chain mdi asthma chronic obstructive pulmonary disease scope emission patient product copd metereddose inhaler mdis gsks rescue mdi medication ventolin salbutamol scope emission logistic essential medicine prescribe approximately million people respiratory condition worldwide patient use scope emission disposal product inhal current propellant account target half carbon footprint invest lowcarbon programme potential reduce absolute reduction greenhouse gas emission greenhouse gas emission inhaler baseline scope investment transition generation low carbon propellant naturebase solution remain phase iii trial begin successful footprint regulatory submission start import renewable electricity supplement exist low carbon dry powder inhaler renewable electricity import generate page disclosure climate risk scope resilience line task force climaterelate net zero greenhouse gas emission value financial disclosure tcfd framework chain absolute reduction emission baseline scope residual nature emission neutralise share detail plan contribute naturepositive world line goal global performance biodiversity framework halt reverse biodiversity loss reduce scope carbon emission compare compare set approach nature focus baseline primarily energy efficiency area freshwater land ocean atmosphere measure increase renewable include biodiversity live specie electricity use member initiative area aim deliver contribution way commit reach import electricity avoid reduce impact nature protect renewable source electricity restore nature helping accelerate collaborative generate import renewable source action approach align work reach import renewable electricity taskforce naturerelate financial disclosure tnfd increase science base target network sbtn sign power purchase agreement source select group renewable electricity cover electricity demand company participate initial target validation site europe mid additional wind process sbtn set validate sciencebase target turbine new solar farm manufacturing nature start target freshwater land facility irvine scotland began generate renewable follow target ocean biodiversity energy started implement final tnfd recommendation disclosure read base datum target boundary include biogenic landrelate emission removal bioenergy feedstock previously report nature target group water waste material biodiversity update target category align area nature define tnfd sbtn underlie target waste material target remain strategic report governance remuneration financial statement investor information gsk annual report responsible business continue freshwater roadmap place achieve sustainably continue work exist water target source paper packaging palm oil paper packaging derive certify target source recycle raw material core achieve good water stewardship site palm oil material certify thirdpartie sustainable source reduce overall water use operation work supplier key goal reduce impact nature appropriate look opportunity reduce avoid use water neutral operation key natural material include process efficiency supplier waterstresse region synthetic alternative example work zero impact api level site key supplier process improvement deliver significant yield increase reduce nature impact improve supply resilience performance ocean achieve overall water reduction target continue deliver exist ocean target reduce overall water use operation set apply relevant sciencebase additional compare site methodology ocean available high water stress region decrease target overall water use site high water stress region baseline marinederive material sustainably source site key supplier locate waterstresse area develop catchmentlevel water performance replenishment restoration regeneration project impact dependencie ocean come primarily include partner ngo deliver water marinederive material critical neutrality target manufacture vaccine medicine example site key supplier compliant use horseshoe crab blood important substance amr alliance api wastewater discharge limit require regulator primarily scope pharmaceutical biomedical quality control process expansion drive expand scope ensure quality safety medicine vaccine include api supplier lead decrease device continue progress volume percentage key supplier confirm reduction advance pilot wastewater api discharge limit site test use nonanimal alternative time engage regulator support wide work strengthen responsible manufacturing uptake alternative antibiotic highlight example good practice report issue access medicine progress reduce volume move foundation amr benchmark synthetic alternative work supplier improve sustainability new sustainable source land standard include specific marine sustainable source continue deliver exist land target standard outline requirement supplier target marinederive material adhere positive impact biodiversity site conduct physical site audits key supplier atmosphere agricultural forestryderive material sustainably source deforestation free air pollution significant risk human health particularly patient respiratory condition like asthma copd performance performance complete baseline assessment site mean assess site approach air pollution include reduce pollutant natural england biodiversity net positive methodology link burn fossil fuel address parallel plan place improve biodiversity sbtialigne climate target set manufacturing site look broadly air pollution footprint member alliance clean air clean air set ambitious new sustainable source standard fund world economic forum supplier provide material highly initial assessment establish air pollution footprint dependent nature like lactose gelatine soy operation supply chain create reduction plan align pathway net zero aim positive impact air quality predict noeffect level gskowne site strategic report governance remuneration financial statement investor information gsk annual report responsible business continue waste material product stewardship overuse natural resource generation approach product stewardship new waste pollution key driver climate change exist product build scientific method nature loss environmental footprinting call life cycle assessment lca target complete lca analysis approach product stewardship mean product lca methodology enable consider aim address impact nature climate identify need improve manufacture stage product lifecycle discovery design assess potential saving design change design source manufacturing product use provide productlevel information key customer disposal set target help accelerate specific product gsk site manufacture adoption approach pvcfree secondary tertiary packaging environmental impact reduction product waste packaging reduce operational waste set target reduce operational supply year total increase chain waste material recover circular route zero operational waste include eliminate single use maintain zero operational waste landfill plastic continue build longstanding operational waste reduction supply chain waste management programme identify opportunity find beneficial use waste detail progress focus area esg performance report diversity equity inclusion want inclusive business people progress thrive ensure diversity clinical trial clinical trial diversity support diverse community continue progress advance clinical trial commitment diversity meet objective phase iii interventional trial initiate proactive create diverse equitable inclusive workplace diversity plan challenge actively enhance recruitment diverse patient population monitor patient recruitment real time ensure clinical trial support diverse community reach diversity goal esg performance rating metric february publish study year gsk phase iii trial initiate proactive viiv healthcare clinical trial diversity datum show plan place design enrol appropriately diverse trial enrol participant clinical trial base real participant consistent disease epidemiology world disease epidemiology datum census datum improve yearonyear spend usbased certify ensure trial reflect population diverseowne supplier affect different disease publicly share research hope advance discussion clinical update people aspiration fair trial diversity improve pharmaceutical sector equitable opportunity approach issue clinical trial diversity aspire woman hold vpand role globally end support diversity supply chain engage mentor small diverseowne aspire ethnically diverse leader business supply chain help identify role vpandabove end potential area growth increase spend increase percentage black african annually usbase certify diverseowned supplier american hispanic latinx vpandabove leader year year year expand successful supplier diversity aspire ethnically diverse leader programme uk group benefit role vpandabove uk end programme include woman ethnic minority member increase percentage black vpand lgbtq community people disability leader year year military veteran small business high unemployment low income community include reduction routine hazardous nonhazardous waste regulatory obligation allow exclude plastic critical product discovery development health safety strategic report governance remuneration financial statement investor information gsk annual report responsible business continue ensure diversity workplace addition uk ethnicity pay gap report fundamentally commit equal employment share pay gap compare average pay opportunity nondiscrimination employee white employee ethnic grouping want leadership reflect gsk people black mixed asian reference people reflect community work hire uk government recently publish guidance provide granular view end woman hold vpandabove role globally compare woman year add disability confidence training employee management line leader training aim people manager role uk end ethnically training design develop inclusive leader diverse leader vpandabove compare able promote disability confidence team black leader vpandabove continue work sure lgbtq compare end colleague feel welcome value include ethnically diverse leader vpandabove recognise gold employer stonewall compare black african global employer index american leader vpandabove compare hispanic latinx leader vpand relaunche mental health matter train compare available globally design help people spot sign poor mental health know start remain committed application fair conversation signpost resource support equitable pay practice ensure equal opportunity everyone wellbee equal pay equal work gender pay gap permanent ukbased gsk employee mean support diverse innovator future compare national average uk launch million tenyear stem equity publishing second uk ethnicity pay gap compare programme target yearold girl young average pay white ethnically diverse employee woman black people people low socioeconomic uk ethnicity pay gap permanent ukbased background programme include nationwide stem gsk employee mean compare mentor deliver partnership establish mentoring organisation year aim reach approximately young people programme detail progress focus area esg performance report ethical standard culture guide people behave ethical way progress right thing speak concern support gsk people right thing expect work live code conduct code reflect purpose expect supplier unite science technology talent ahead commitment disease set commitment company deliver purpose promote ethical behaviour business ambition support employee right thing work supplier share standard code support additional global policy operate responsible way standard accompany global mandatory learning curriculum live code esg performance rating metric people require complete employee complementary worker employee complementary worker complete complete gsk mandatory training training yearend percentage employee believe antibribery corruption abac training speak thing not feel right general industry benchmark people certain highrisk role geographic region helps identify mitigate potential direct highrisk supplier achieve gsk abac risk especially thirdparty relationship minimum ecovadi score improvement recognise report manage conflict interest plan place employee complementary worker complete train general industry benchmark accord research kornferry strategic report governance remuneration financial statement investor information gsk annual report responsible business continue reporting investigate concern visit site person virtually help supplier well see overall decrease number understand control ehs risk year employee concern raise conduct physical visit priority supplier employee discipline policy violation open case conduct supplier audits follow industry year end reflective factor include standard pharmaceutical supply chain initiative guideline external geopolitical economic issue affect train supplier employee ehs country change nature concern raise strengthen ehs contractual obligation work internally continue emphasis appropriate supplier help improve ecovadis score management closure case datum responsibly commitment human right datum essential foundation realise ambition signatorie un global compact patient advance artificial intelligence ai human right position statement lay commitment machine learning ml technology present tremendous un guiding principle business human right opportunity technology approach crossbusiness human right steering group correctly responsibly ethically increase volume report glt board corporate datum process aiml use result responsibility committee drive progress human great focus datum governance ethical use right impact risk business personal information compliance datum privacy law responsibility datum privacy carry human right training priority seriously exercise high standard integrity supplier aim ensure good understanding deal personal information human right labour principle align international standard continue human digital privacy governance board oversee right training procurement thirdparty engagement overall data ethic privacy operating model support lead well equip spot human right issue digital privacy legal expert compliance visit supplier conduct audits site visit professional monitor mitigate new emerge cover environment health safety ehs labour cyber threat protect cyber security risk right priority supplier issue additional governance board oversee identify supplier visit relate policy use datum research development manufacture wage compliance observation action plan supply product ensure follow regulation place drive improvement meet ethical obligation commit fair equitable pay ensure create crossfunctional ai governance employee globally receive pay competitive council oversee ai strategy ensure responsible local market sufficient support sustainable adoption aiml complement internal standard live fair wage network certify policy ensure aiml adoption safe align gsk living wage employer review global gsk culture establish ai principle underpin gap analysis conduct confirm ethical standard set gsk code gsk worker pay living wage political engagement relevant market develop consistent gsk seek contribute public policy debate approach gsk manage global fair wage analysis especially relation life science healthcare annually methodology fair wage commit high ethical standard legislative network use continue assess requirement political engagement work party corporate political contribution sponsor expect party comply applicable law party political meeting world regulation adopt minimum abac detail progress focus area esg labour right principle relevant comply performance report standard quality patient safety health safety environment perform assessment highrisk party risk area organisation additional support ehs risk large supplier include supply globally medicallycritical product critical rd large spend large supplier include supply globally medically critical product critical rd large spend gsk maintain list globally medically critical product drug product approve treat lifethreatening disease medical condition adequately available alternative gsk provider ehs priority supplier api supplier medically rd revenuecritical gsk high spend supplier strategic report governance remuneration financial statement investor information gsk annual report responsible business continue product governance commitment inspection recall audit commit maintain robust quality safety regulatory inspection process datum new technology manufacturing site local operating company responsibly compare receive zero warning letter united states food drug esg performance rating metric administration fda critical finding medicine average number critical major finding healthcare product regulatory agency mhra inspection fdamhraema regulator european medicine agency ema regulator respond learn inspection finding percentage inspection regulator take necessary action address critical finding official action indicate number fda warning letter class product recall few class ii recall compare total number class iii external product recall necessary protect patient hesitate market recall product voluntarily register disclose human subject research gsk quality management supply chain product specifically register protocol summary conduct quality audits contract study initiate disclose result summary manufacturer supplier verify comply study result gsk standard comprehensive quality oversight progress model align quality management system maintain quality gsk use riskbase approach assess qualify manage monitor thirdparty supplier ongoing basis detailed specific quality framework drive continuous performance describe comply regulatory requirement standard market address global pharmacovigilance times local regulation manufacture distribution wellestablishe rigorous worldwide system process base principle define monitor review safety product international council harmonisation technical clinical development regulatory approval requirement pharmaceutical human use expect partner meet high standard gsk quality function responsible manage quality safety governance conduct review thirdparty ensure quality mindset embed safety system monitor contractual obligation organisation level bring extensive foster collaboration lifecycle global network quality compliance professional relationship business unit site level senior tackling counterfeit medicine vaccine management falsify product health patient risk quality management depend comprehensive threaten brand reputation report case ongoing patient safety quality process training confirm counterfeit product relevant quality management system detail train regulatory authority actively participate legal require gsk people include induction hygiene safety proceeding illegal actor support customs technical skill train good distribution local authority regular training monitor manufacturing practice training employee carry online marketplace social medium request takedown specific qualitycritical sensitive activity subject site illicitly sell prescriptiononly medicine additional training necessary clinical datum transparency commitment transparency protocol summary summary result available gsk trial register set list clinical trial datum share wwwvivliorg detail progress focus area esg performance report consider observation fda major class recall trigger reasonable probability use exposure violative product cause adverse health consequence death class ii recall address use exposure violative product cause temporary medically reversible adverse health consequence probability adverse health consequence remote class iii recall relate use exposure violative product likely cause adverse health consequence gsk annual report risk management disclosure statement section risk management principal risk summary climaterelate financial disclosure naturerelate financial disclosure nonfinancial sustainability information statement employee gender viability statement strategic report governance remuneration financial statement investor information gsk annual report risk management deliver bold ambition patient maintain wellembedded risk management internal control framework oversee evaluate board control guidance manage risk effectively consider likelihood impact wellembedde risk management internal control timescale risk framework give board ability evaluate enterprise risk assessment methodology oversee company manage principal emerge mechanism assess risk include risk line strategy longterm prioritie principal risk enterprise risk assessment methodology companywide policy set requirement role consider likelihood impact risk responsibilitie management governance timescale risk occur base risk control support guidance probable scenario consider exist internal essential element internal control framework control impact assessment include consideration routinely evaluate risk management internal control patient safety quality supply environment framework improvement health safety legal people regulatory reputation strategic objective finance incorporate materiality board oversight set tone threshold consider current evolving risk board oversee system risk management evaluate emerge risk affect ability internal control establishe risk appetite support achieve longterm priority threeyear horizon audit risk committee arc corporate line viability statement define risk responsibility committee crc science committee emerge need know likely assess effectiveness risk management materialise impact strategy fall define remits arc evaluate emerge risk impact board oversee cyber security risk company assess elevated detail board committee responsibilitie principal risk risk management compliance remit risk oversight compliance board level identify emerge risk ongoing council rocc cochaired group general counsel basis rocc discuss evolve emerge risk chief compliance officer help arc crc meeting time scan risk horizon science committee oversee risk strategy year identify external trend address risk management opportunity andor emerge risk monitor compliance board rmcbs group promote business activity internal environment rocc tone establish risk culture oversee conduct annual risk review assess principal effectiveness risk management activity emerge risk company review support communicate information internal control extensive analysis external trend insight management hold accountable deliver seniorlevel interview recommendation risk objective line establish risk appetite management compliance board risk owner pertain principal risk disclosure committee rocc share annual review arc board responsibility consider materiality assessment agreement form basis information determine disclosure follow year risk management focus information timely way enterprise risk owner responsible principal risk oversee glt business strategy result operation financial member risk owner report risk mitigation rocc condition materially affect risk appropriate board committee quarter cyber security threat include result previous cyber significant risk issue escalate glt security incident provide assurance rmcb appropriate risk governance forum eg global materially affected future safety board year need legal risk future material incident compliance support effort advise business strategy activity risk control audit assurance provide assessment adequacy effectiveness framework strategic report governance remuneration financial statement investor information gsk annual report risk management continue risk management internal control report current risk framework table start show current principal risk management internal control framework risk respective trend assessment mitigation align industry standard legal regulatory activity year order significance requirement define essential element expect risk definition potential impact context help identify assess manage report oversee mitigating activity principal risk uncertainty risk relevant business activity framework help risk level principal risk ensure risk proportionately manage line relate esg include environmental sustainability risk appetite year timely climate change manage focus area transparent manner support strategic objective describe esg performance report additional information climaterelate risk management principal risk include information cyber climaterelate financial disclosure security define enterprise risk plan include description risk context assessment risk change risk appetite treat risk action december annual risk review arc agree business line internal control roccs recommendation principal risk framework mitigate risk plan enable remain largely unchanged emerge risk datum board committee assess effectiveness risk management continue evaluate year management strategy report principal risk emerge risk rocc respective board viability statement arc report committee quarter drive dynamic datum internal control framework drive discussion agile risk management strategy legal proceeding environment oversight report exist control measure climaterelate financial disclosure implementation emerge risk external insight key risk indicator risk reporting threshold align risk appetite include risk mitigation associate relevant event geopolitical tension code set overarch expectation employee complementary worker aim right thing integrity care culture risk management framework complement culture speak process make sure identify mitigate risk effectively monitor important risk action address issue annual confirmation exercise general manager site director senior leader glt check key risk manage action place address gap principal risk include control respond problem risk plan business continuity planning embed framework critical process continue business operation event crisis strategic report governance remuneration financial statement investor information gsk annual report principal risk summary trend versus risk prior year assessment mitigation activity patient external risk environment remain stable pharmacovigilance function like safety industry contend challenge legal regulatory environment external optimise stateoftheart pharmacovigilance system predict issue impact safety efficacy potentially result regulatory action andor litigation particularly true issue base robust scientific evidence ongoing benefitrisk assessment product internal risk environment remain stable continue focus ensure optimise benefitrisk profile vaccine medicines appropriate safety expertise gsk oversight successfully complete significant transition simplify thirdparty support model global pharmacovigilance operational activity product external risk environment stable remain high regulatory agency end quality emergency covid measure resume onsite inspection site plan external unannounced sure meet product quality expectation increase nationalism follow pandemic drive broader spectrum regulatory requirement continues rapidly evolve new pharmaceutical chemical environmental expectation product focus datum governance datum integrity remain application aiml improve manufacture quality infancy uncertainty regulate gxp arena fda work industry understand application develop guidance risk exposure remain stable ongoing inspection readiness programme ensure preparedness regulatory authority inspection continue invest technology gsk strengthen datum management control modernise quality process proactive anticipate regulatory expectation continue work industry level refine quality standard build new competency assure product quality legal external risk environment increase wideranging regulatory environment remain matter challenge uncertainty volatility conflict requirement influence external ability determine exact requirement market government agency notably increasingly look use competition law tackle perceive issue access medicine pricing acquisition government continue enforce anticorruption law regulation include nationwide oneyear campaign fight corruption healthcare china sanction continue complex current geopolitical environment particularly concern russia risk exposure stable robust internal system process monitor ensure proactive timely response change adapt internal control design gsk accommodate external regulatory fluctuation change risk financial external risk environment remain challenge political uncertainty propose control increase obligation director auditor increase threat cyber attack external reporting fraud increase disclosure requirement include esg nonfinancial information risk exposure remain stable ongoing focus resilience personnel test internal control framework implement optimal risk mitigation gsk transformational programme technology centralise process risk control assessment maintain effective tax treasury strategy continually strengthen control framework collaborate external body set standard commercial external risk environment stable government remain focused initiative drive practice medicine vaccine cost consumer pass inflation reduction act ira external introduce new medicare inflationbase drug rebate drug pricing negotiation programme overall negative effect macroeconomic factor inflationary pressure contribute challenge environment stakeholder competitive pressure remain intense therapy area market segment risk exposure remain stable mature robust control environment evolve match competitive enhancement commercial digital practice gsk include significantly high volume engagement healthcare professional support embedding endtoend speaker engagement system eliminate zerovalue contract enhance case study training medical commercial interface implement new tender procedure implement enhance interactive digital medium channel oversight strategic report governance remuneration financial statement investor information gsk annual report principal risk summary continue trend versus risk prior year assessment mitigation activity scientific external risk environment change diversity engagement platform continue patient increase digital health technology generative ai advance rapidly external engagement environment continue characterise complex dynamic disease area treatment increase volume patientcentric activity phase product lifecycle risk exposure remain stable continue build innovative digital capability improve engagement practice internal control mitigate risk rapidly evolve gsk environment use datum system monitor emerge risk associate scientific patient engagement activity datum ethic external risk environment continue increase global landscape datum protection privacy privacy cyber law develop give current pace technologyfocuse innovation external expect continue company need mindful relevant potential legislation regulation increase trend datum sovereignty affect healthcare company ability drive medical innovation operate internationally global regulator eu uk china introduce legislation use ai ml closely align privacy regulation regulation play key role safeguard privacy ensure responsible data usage transparency ethical use datum prevent bias manage international datum flow internal risk exposure increase give focus datum uncertain external environment datum ethic privacy operating model transform sure gsk flexible adapt emerge privacy law eu uk china india include address restriction impose regulator relation international data transfer mechanism focus simplify principle process allow flexibility deployment model different territory business function research external risk environment increase technologyfocused innovation accelerate practice discovery development medicine vaccine advance technology expand use external datum digital footprint sophisticate cyber security threat rise trend datum sovereignty develop global landscape quality standard datum protection privacy cyber law new entrant sector continue influence environment company consider relevant emerge legislation regulation impact ability drive innovation operate internationally risk exposure increase adopt new technology scale adoption ai discovery development medicine vaccine continue adapt internal gsk business process enable innovation meet ethical societal regulatory expectation environment external risk environment remain stable currently external ehs risk factor health reduce ability discover manufacture vaccine medicine safely external safety eh risk exposure remain stable ve continue safety leadership training embed life save rule adhere ehs standard initiate contractor safety gsk programme deliver improvement reduce risk profile associate contractor business unit strengthen driver safety programme information external risk continue rise digital footprint increase threat cyber security cyber sophisticated include threat actor access sophisticated ai external security capability continue geopolitical conflict increase cyber security risk large corporation risk exposure continue increase adopt new technology scale adoption ai gsk remain track deliver multiyear cyber maturity programme cmp gsk risk mitigation programme include china high risk jurisdiction process accountabilitie datum management improve control governance identify protect detect respond recover cyber security incident strategic report governance remuneration financial statement investor information gsk annual report principal risk summary continue supply external risk environment remain stable cyber attack continuity thirdparty logistic provider test business continuity plan external constraint see source bioscience material abate new constraint emerge thirdparty sterile manufacturing capacity increase competition contract manufacturing operation extreme weather event continue present challenge industry facility worldwide risk exposure remain stable maintain combination welldefine supply chain management process clear escalation pathway ensure supply continuity clear gsk succession plan place critical supply chain role supply chain initiative integration medicine vaccine supply chain organisation demonstrate commitment evolve technology platform product portfolio affect supply continuity remain consistently high strategic report governance remuneration financial statement investor information gsk annual report climaterelate financial disclosure climaterelate financial disclosure consistent management role assess manage climate recommendation recommend disclosure relate risk opportunity task force climaterelate financial disclosure tcfd gsk leadership team glt include tcfd allsector guidance compliance glt meet regularly give member opportunity requirement lr r uk list rule discuss strategic financial reputational matter disclosure compliance company strategic report climaterelate financial disclosure president global supply chain glt member regulation company act management responsibility environmental sustainability update risk assessment reflect change include climate change responsible supply chain progression sustainability governance oversight risk opportunitie transformation programme make sure effective framework manage risk opportunity business unit governance deliver commitment net zero board oversight climaterelate risk nature positive healthy planet ambitious goal set opportunity entire value chain board glt review discuss midyear board consider climaterelate matter performance key environmental metric include year include assess risk management process climaterelate one review challenge endorse business plan budget gsk esg performance rating include oversee major capital expenditure gsk sustainability council acquisition divestment board approve progression phase development low sustainability council hold quarterly attend carbon ventolin programme senior leader business member include leader procurement finance hr compliance rd corporate responsibility committee crc exercise manufacture corporate affairs council co oversight provide guidance review esg chair president global supply chain vp performance include climaterelated risk sustainability support global sustainability opportunity environmental performance team external party provide specialist target expertise advice business crc receive quarterly update environmental council sustainability include climate regular attendee include ceo president global supply chain approve annual target climate key detail board architecture performance indicator kpi sustainability programme crc review approve gsk twin goal review monthly performance escalation climate nature follow demerger potential concern issue consumer healthcare business july crc approve gsk submit update refreshed approve annual climate risk review approach target science base target initiative sbti risk disclosure align c pathway align sbti net agree newly form esg report hub zero standard reduce carbon emission accountable assurance environmental datum crc meet time discuss climate review progress core programme improve related issue separate occasion sustainability supply chain management focus review progress secure portfolio carbon credit support commitment progress deliver climate ambition include low carbon ventolin nature plan update implication geopolitical landscape key milestone decision require achieve net zero target midyear performance key environmental metric include climaterelated metric review interim esg performance rating approve climate disclosure statement final esg performance rating public environmental reporting disclosure strategic report governance remuneration financial statement investor information gsk annual report climaterelate financial disclosure continue business support long term year enable explore sustainability council support assess uncertainty change weather disease pattern manage climaterelate risk opportunity societal response climate change globe sustainability programme steering team chair vp sustainability meet monthly identify prioritise climaterelate coordinate sustainability programme risk opportunity associate workstream team monitor programme risk performance progress enabler require deliver sustainability programme change regulation govern supply high global warming potential gwp substance eu sustainability council business meet uk government restrict ability quarterly review business unit performance manufacture meter dose inhaler delivery company sustainability ambition chair senior leader business future regulatory policy response address climate attend gsk sustainability council change lead imposition carbon taxis country manufacture source good meter dose inhaler steering team party attend senior leader commercial supply chain regulatory rd business align increase level water stress lead interruption respiratory business team chair supply water thirdparty supply site president global supply chain chair increase frequency impact extreme weather sustainability council decisionmake body event disrupt gsk thirdparty programme reduce climate impact meter supplier site dose inhaler contribute approximately gsk total ghg emission naturebase project deliver sufficient volume carbon credit offset million tonne coe capital allocations board cab chair year require buy additional credit cfo include group financial controller high cost review climaterelate capital expenditure annual planning capital allocation process opportunitie esg report hub establish cop country commit provide oversight assurance esg performance provide lowcarbon healthcare system lead datum include carbon emission datum increase demand lowcarbon medicine carbon offset programme steering committee vaccine include group financial controller vp report explore impact climate change sustainability attend sustainability council health show climate change affect review diligence outcome potential carbon water vectorborne disease lead offset project performance establish increase demand new medicine vaccine investment make new investment decision process identify assess climaterelated crossfunctional team sustainability finance risk opportunity set risk management supply chain procurement function perform section continue monitor emerge risk annual review climate risk monitor previously new datum include future assessment identify climate risk escalate new emerge climate risk sustainability council impact climaterelate risk opportunitie business strategy financial planning result climate scenario modelling share business unit risk management control board rmcb commitment work net zero nature positive healthy planet ambitious goal set strategy embed strategic longterm priority climaterelate risk opportunity consider social environmental governance identify short medium long term impact laboratory patient climaterelate risk opportunity consider nearterm carbon reduction target reduction different time horizon scope scope carbon emission longterm carbon reduction target reduction short term year align financial scope scope carbon emission planning timeframe target measure baseline medium term year align longterm target align c pathway business forecasting timeframe approve science base target initiative sbti strategic report governance remuneration financial statement investor information gsk annual report climaterelate financial disclosure continue transition plan energize programme encourage use take action reduce emission renewable energy pharmaceutical sector supply chain value chain prioritise highestimpact area invest billion deliver emission manufacture initiative encourage supplier reduction removal achieve target measure manage reduce emission activity outline pharma lca consortium group global expect leave hard pharmaceutical come totackle emission supply chain pharmaceutical environment group support operation logistic disposal case sustainable market initiative codevelop share address residual emission likely depend way measure report environmental technology infrastructure regulatory framework product footprint require broad publicprivate collaboration risk uncertaintie decarbonisation plan interdependent broad economic transition follow similar timeframe pharmaceutical manufacturing process highly regulated different agency world progress reduce carbon emission find slow implementation decarbonisation initiative direct operation supply chain complex involve order continue reduce scope emission intermediate stage production highly product operation focus specific volume demand specific material low reduce ability influence maximise energy efficiency site purchase small share supplier production longstanding energy efficiency programme transition import renewable electricity supplier base region renewable investing power purchase agreement electricity heat available supplement purchase energy attribute measure scope emission complex challenging certificate lack primary data supplier increase use electric vehicle sale fleet methodology involve spendbase estimate mixed activitybased data industry average data risk uncertainty extrapolation base subjective choice judgment market operate singapore data system process control mature access renewable electricity challenge primary datum available need limited generation capacity market boundary restate report emission datum future rule govern import electricity product impact uncertainty transition renewable heat use product make carbon hightemperature heat produce electricity footprint patient use gsk rescue meter dose inhaler generally commercially available today biogas replace mdi medication ventolin salbutamol account natural gas introduce major change facility half carbon footprint invest widely available location rd programme large factory upgrade project operate use biomass fuel introduce issue redevelop inhaler transition lowercarbon land use change impact local air quality propellant recent datum early clinical trial support decision progress phase iii dose transition electric vehicle patient plan half restrict vehicle availability lack charge successful regulatory submission begin infrastructure source key material battery production risk uncertainty supply chain meter dose inhaler complex device new sustainable procurement programme require medical propellant meet specific range technical supplier disclose emission set carbon reduction performance characteristic safe efficacious target align c reduction pathway patients work supplier particularly large engaging medical regulator footprint encourage adopt new sustainability food drug administration fda european medicine measure agency ema uk medicine healthcare supply chain emission share challenge product regulatory agency mhra advance sector work peer collaborative pharmaceutical product design reduce initiative environmental impact medicine activate programme help active pharmaceutical ingredient api supplier accelerate decarbonisation initiative strategic report governance remuneration financial statement investor information gsk annual report climaterelate financial disclosure continue carbon credit net zero scenario ssp rcp focused emission reduction meet scenario set narrow achievable pathway carbon target invest high quality nature global energy sector achieve net zero co emission protection restoration project support net rely emission reduction zero nature positive goal deliver cobenefit outside energy sector achieve goal scenario human health generate carbon credit offset annually consistent limit global temperature rise c baseline value chain carbon footprint temperature overshoot net zero mean huge volume credit require taper decline use coal oil gas shift continue reduce emission aim achieve renewable energy source net zero emission value chain lowcarbon scenario ssp rcp criterion high quality project include avoidance scenario current net zero pledge achieve harm transparency additionality permanence mitigation extensive effort realise nearterm leakage project monitor report verification emission reduction advanced economy reach net zero claim avoidance double counting emission china target prioritise carbon removal country late scenario consistent credit secure proportion carbon limit global temperature rise c avoidance reduction credit recognition level net negative emission critical role conserve exist carbon stock temperature rise reduce c protect nature net zero target current trajectory scenario ssp rcp aim secure carbon removal credit scenario set extent announce risk uncertainty ambition target path deliver recognise fastmove field emission reduction require achieve net zero emission methodology guideline likely evolve temperature rise exceed c implement plan commit remain flexible noticeable shift happen half transparent progress learn century net zero pledge emission scenario necessarily mean co emission risk naturebase project deliver energy sector need reach net zero sufficient volume carbon credit meet need allocation carbon offset pledge give year need purchase credit high cost breach planetary boundary scenarios ssp rcp scenario align pledge lay climate scenario paris agreement country unable use climate scenario inform management meet united nations sustainable development goal climate risk report result risk management scenario severe physical control board rmcb business consequence planet temperature rise sustainability council exceed c lead high loss biodiversity develop modelling tool support specie extinction party enable model impact physical risk management transition risk site supply chain locate example model probability process identify assess climaterelate interruption extreme weather event key risk site supplier site subsequent financial impact nature risk opportunitie climate interruption assume inventory level carry change depend physical aspect climate exist business continuity plan model change regulatory commercial change impact future carbon taxis direct taxis market operate include pressure reduce energyrelated emission emission trading scheme climate impact meter dose inhaler medicine taxis carbon border adjustment mechanism assume deliver carbon reduction glidepath risk management policy design address type risk include group principal risk uncertaintie climate risk management follow review update climate scenario policy framework risk climate change group develop intend review scenario level fall governance crc support sure remain date sustainability council individual risk climate change raise appropriate business unit iea net zero emission scenario httpswwwieaorgreportsglobal functional risk management control board sure energyandclimatemodelnetzeroemissionsbyscenarionze integrate risk business risk management access november process iea world energy outlook chapter p download report httpswwwieaorgreportsworldenergyoutlookoverview access november iea announce pledge httpswwwieaorgreportsglobalenergy andclimatemodelannouncedpledgesscenarioap access november strategic report governance remuneration financial statement investor information gsk annual report climaterelate financial disclosure continue specific dedicated environmental sustainability risk communication government affair team management plan place risk manage corporate reputation identify management plan cover expectation monitor climaterelate issue undertake address impact environment proactive reactive engagement relevant environment increase impact operational stakeholder group communicate position resilience access energy water natural detail manage prioritise risk resource product anticipate cost risk table increase regulatory change environmental taxis review development policy regulation global process identify assess manage national level receive quarterly monitoring report climate relate risk integrate overall risk management procedure identify risk climate change factor evolve example assess climate annual basis crossfunctional team impact merger acquisition activity sustainability finance supply chain procurement construction new building use shadow carbon function review climate risk climaterelate risk price tonne coe inform decisionmake consider strategic operational perspective investment major capital expenditure understand sure maintain comprehensive view implication potential carbon offset cost carbon different type climate risk face different emission value chain value base time horizon affect team review recommendation carbon pricing leadership previously identify climate risk plus new emerge risk coalition conclude explicit carbon opportunity recommendation paper price level require drive change restrict temperature sustainability council risk assessment paper increase c ustco prepare prioritise risk consider likelihood monitor value internal carbon pricing financial impact risk different estimate future cost carbon credit climate scenario process manage climaterelated risk risk opportunity analyse understand manage metric target purpose disclosure differentiate potential impact total profit low physical transition climaterelate risk million medium million million high physical risk typically identify asset project million threshold level manage depend level risk impact assessment approve vp assess use climate scenario analysis model sustainability finance vp global supply potential impact prioritise physical risk help chain business unit result share business understand resilience supply chain unit risk management compliance board rmcb climate change finance rmcb sure risk transition risk typically risk associate change contextualise business risk manage regulation societal expectation transition appropriately allow management holistic lowercarbon economy identify enterprise view optimise risk mitigation response ensure level market level manage transition risk response climaterelate risk properly integrate investment decision sustainability relevant business unit function activity transformation programme procedure resilience strategy consider different climate example manage risk arise product relate scenario include c low scenario claim base environmental performance external accreditation process organisation climate scenario describe stress review evidence support claim test resilience organisation consider impact potential physical transition risk opportunity location operate describe table modelling identify material impact business resilience report highlevel commission carbon price carbon pricing leadership coalition p https wwwcarbonpricingleadershiporgreportofthehighlevelcommission oncarbonprice strategic report governance remuneration financial statement investor information gsk annual report climaterelate financial disclosure continue potential physical risk financial impact description gsk response scenario timeframe metric target risk identify water basin water current medium site achieve increase level stress area algeria india pakistan trajectory achieve good water water stress lead manufacturing site water stewardship interruption supply aim water neutral long term stewardship water site manufacturing facility nashik india year total supply site thirdparty supply build plant rainwater harvesting water site climate scenario analysis identify reduce thirdparty number site supplier site locate overall water supplier use water basin water stress use freshwater main add watch breach medium operation source water list monitor change risk level planetary manufacture medicine update site water risk assessment boundarie water vaccine water appropriately long term neutral availability financial impact assume manage year restrict factory inventory supply chain level operation operation water stress lead key interrupted threemonth supply interruption bad supplier water case stress region increase frequency climate scenario modelling indicate current medium business extreme weather seven physical peril flood rainfall trajectory continuity climate event cause present high likelihood acute scenario plan related risk disruption interruption risk flooding long term review business thirdparty supplier rainfall extreme weather year annually continuity site event expect remain low identify extreme weather perform risk assessment take event manufacturing operation action precipitation rainfall business continuity plan review mitigate flood annually respond impact extreme risk precipitation riverine weather event include adopt flood extreme wind appropriate mitigation plan breach medium wildfire extreme wellestablishe loss prevention planetary heat result short risk engineering programme identify boundary term interruption range risk impact site scenario long term manufacture flood risk exist take action year supplier site mitigate financial impact assume manage inventory supply chain level extreme weather event lead threemonth supply interruption bad case potential transitional risk financial impact description gsk response scenario timeframe metric target regulation govern invest rd programme current high onoff track use high gwp large manufacturing site upgrade project trajectory substance redevelop ventolin salbutamol inhaler scenario medium term delivery key absolute update eu transition lowercarbon propellant year milestone reduction uk update potentially reduce carbon emission rd recently clinical trial programme greenhouse lead successful plan gas emission increase cost restrict ability portfolio dry powder baseline manufacture inhaler product use propellant meter dose inhaler affect risk scope mdi product financial impact assume use high gwp reformulate product approve propellant hfaa respectively regulator launch accord plan strategic report governance remuneration financial statement investor information gsk annual report climaterelate financial disclosure continue potential transitional risk select financial impact description gsk response scenario timeframe metric target future regulatory manage risk reduce value net zero medium scope policy response chain carbon emission line transition mm carbon address climate plan describe medium emission absolute change lead financial impact assume deliver year long scope reduction imposition reduction carbon emission term year carbon carbon taxis assume carbon tax value iea emission greenhouse country scenario supplement datum policy gas manufacture pledge small number country lowcarbon medium emission source good mm party medium term year baseline fall low mlong scope term year respectively current low trajectory medium term year long term year naturebase project establish governance framework lowerthan low fail deliver manage project external partner anticipate medium term development anticipate volume issue escalate carbon offset growth year absolute carbon credit programme steering committee scenario reduction lowerthanexpecte growth result assume future cost tonne co e natural medium greenhouse natural catastrophe catastrophe gas lead lowerthananticipated growth scenario scenario medium term emission buying carbon assume underdelivery single year year credit high cost issue identify early baseline preventative action shortfall natural catastrophe scenario assume scope project affect impact year respectively potential profit impact opportunity gsk response scenario timeframe metric target cop november reduce scope carbon net zero scope emission turn reduce scope country commit footprint customer supplier carbon absolute provide lowcarbon ecodesign programme reduce emission reduction healthcare system impact product package total waste lead invest rd programme reduce greenhouse increase demand greenhouse gas emission meter dose low material gas l ao nw c va ar cb co inn e sedicine hn ah va ele mrs u ds ee g oto dtr e pa rot ga rs et sh sm toa w rd sc ro efp od rm un ld ting low carbon l yeo rg term fe rm omiss aio ns alternative gas potentially reduce baseline climate impact clinical trial successful scope portfolio dry powder inhaler product low carbon footprint consortium global respectively pharmaceutical company codevelop current zero share way measure report trajectory operational environmental product footprint waste financial impact base research perform detail publish commitment transition lowcarbon healthcare major market strategic report governance remuneration financial statement investor information gsk annual report climaterelate financial disclosure continue metric target metric use assess climaterelate risk opportunitie line strategy risk management process disclose consider key metric follow tcfd guidance table metric metric consistent crossindustry climaterelate metric base strategic metric organisation scope emission marketbase locationbased approach describe table assess climate risk scope emission describe table opportunity line strategy renewably source electricity describe table risk management total supply water describe table process total waste material describe table esg composite metric senior leader remuneration policy site achieve water stewardship describe table esg performance report include metric support strategic metric list b disclose scope energy carbon emission table applicable scope scope emission energy ghg emission scope emission source relate risk scope emission marketbase scope emission locationbase scope emission metric scope emission intensity metric prioritise physical transition risk include risk table c describe target target measure baseline applicable organisation absolute reduction greenhouse gas emission baseline scope manage climate investment naturebase solution remain footprint relate risk net zero greenhouse gas emission value chain absolute reduction emission opportunity baseline scope residual emission neutralise performance target renewable electricity scope achieve good water stewardship site reduce overall water use operation zero operational waste include eliminate single use plastic water neutral operation key supplier waterstresse region performance target include reduction routine hazardous nonhazardous waste regulatory obligation allow exclude plastic critical product discovery development health safety basis report esg resource section gskcom httpswwwgskcomengbresponsibilityesgresource detailed methodology measure reporting gsk environmental kpis commit net zero nature positive healthy planet ambitious goal set entire value chain report progress reduce scope carbon emission scope carbon emission energy use water waste annually target esg performance report public response cdp climate water forest questionnaire strategic report governance remuneration financial statement investor information gsk annual report climaterelate financial disclosure continue metric datum carbon emission carbon emission tonne coe scope emission energy scope emission scope emission marketbase scope emission locationbase scope emission uk scope emission metric scope emission energysale revenue tonne coem scope emission energyfte tonne coefte total energy gwh uk energy gwh renewably source electricity total supply water million total supply water area high water stress million total waste material metric tonne site achieve water stewardship datum report exclude previous consumer healthcare business specify carbon emission calculate accord greenhouse gas protocol corporate accounting reporting standard revise edition use marketbase scope emission reporting purpose report scope emission category esg performance report ask external assurance provider deloitte provide limited assurance isae energy scope select scope carbon emission datum water wastewater data methodology report measurement provide basis report esg resource section gskcom httpswwwgskcomengbresponsibilityesgresource refer emission sale force vehicle propellant emission release manufacture inhaler majority propellant emission release patient use include scope carbon emission onsite waste wastewater treatment refrigerant gas loss collect publish scope datum category recent scope datum available process compile datum complete scope emission patient use inhaler disclose esg performance report publish datum available include esg performance report datum restate esg performance report naturerelate financial disclosure gsk commit play minimise governance impact dependencie nature help board oversight naturerelate dependency protect restore nature impact risk opportunity human health relie fundamental nature clean describe air fresh water nature loss range negative impact health example reduce air quality management role assess manage nature increase incidence severity respiratory disease relate dependency impact risk opportunitie habitat degradation deforestation increase addition disclosure sustainability risk new human pathogen pandemic council review gsk nature strategy ensure alignment protect human health ahead disease way work require science base target need protect nature nature sbtn long term budgetary gsk active member working group requirement consider taskforce naturerelate financial disclosure tnfd human right policy engagement activity commit disclosure oversight respect indigenous people local tnfd framework early base datum community affect stakeholder make initial disclosure fully compliant framework progress position human right publish gskcom nature programme responsibility respect human right engagement patient employee supplier community live operate strategic report governance remuneration financial statement investor information gsk annual report naturerelate financial disclosure continue begin nature journey concern longterm exposure working formalise policy procedure relate pharmaceutical environment pose risk stakeholder engagement human right specifically environmental specie include aquatic life presence relation assessment impact action antibiotic environment potential impact nature drive antibiotic resistance reduce microbial biodiversity grow concern stakeholder protect restore nature key active area research climate nature strategy nature investment context dependant key work clinical agricultural practice generally expert partner ngo ensure project recognise dominant source antibiotic enter implementation include local expert local environment unregulated manufacturing practice community contribute antimicrobial resistance decision protection restoration land project run human right assessment primary dependency land natural broad diligence assessment allow material source derive agricultural understand local context history process commodity key driver deforestation land use partner use plan use engage involve local change globally supply chain community include free prior inform consent commodity long complex fpic grievance mechanism benefit tier remove direct engagement operational share land holding relatively small rd connection nature project health site belgium spain locate key benefit consistently include nature biodiversity area project work thirdparty expert develop publish toolkit enable project ocean developer investor impact dependencie ocean come primarily marinederive material critical strategy manufacture vaccine medicine include naturerelate dependency impact risk example horseshoe crab blood important opportunity identify short medium substance require regulator long term pharmaceutical biomedical quality control process impact dependency ensure quality safety medicine vaccine device water water essential production vaccine atmosphere medicine map water footprint leader medicine vaccine respiratory health calculate volume water use value chain want play improve air quality operation improve initial assessment establish air pollution understand world footprint operation supply chain big impact water show directly relatively low impact air quality large proportion primary operational impact water availability emission sit supply chain manufacturing site locate area water stress water risk datum world waste material resources institute world wildlife fund approach product stewardship mean identify site locate waterstresse area consider aim address impact nature climate algeria india pakistan face increase water stage product lifecycle discovery availability quality risk design source manufacturing product release active pharmaceutical ingredient priority use disposal set target help accelerate focus water quality pharmaceutical adoption approach residue pass environment effect naturerelate dependency impact risk normal biological process follow patient use opportunity business model value chain less extent pharmaceutical enter strategy financial planning transition environment unused medical product factory plan analysis place discharge commit net positive impact nature reduce environmental impact water waste material biodiversity invest nature protection restoration set target focus realm nature supportive information public policy httpswwwgskcom target waste material report progress mediagskpositiononpharmaceuticalsintheenvironment nature plan target annually marchpdf read position antimicrobial resistance public policy strategic report governance remuneration financial statement investor information gsk annual report naturerelate financial disclosure continue select group deepen understand company work science base target value chain nature impact dependencie network sbtn pilot develop set validate continued align evolving practice guidance sciencebase target nature start target follow tnfd leap locate evaluate assess freshwater land follow target ocean prepare methodology well understand biodiversity target focus location naturerelate risk opportunity involve value chain nature particularly pilot work science base target network pressure aim pilot sciencebase target sbtn set validate sciencebase target nature nature start target freshwater land follow target ocean biodiversity resilience strategy naturerelate risk opportunity take consideration different scenario process manage naturerelate dependency impact risk opportunity manage organisational resilience nature relate risk implementation sustainability set target focus realm programme delivery plan evolve external nature supportive target waste material guidance continue evolve report progress nature plan target annually location direct operation meet criterion priority location water site maintain high quality water freshwater infrastructure ensure leakage reduce identify initial water basin water overall water use waterefficiency project stress area manufacture site include behaviour change programme introduce include india pakistan algeria waterefficient cleaning procedure prioritise investment water neutrality achieve measurable positive impact waterstresse today gsk site complete gsk water stewardship basin availability quality accessibility assessment align alliance water stewardship aws standard implement action plan comply land standard site locate waterstresse operational land holding relatively small area aim secure certification aw rd site belgium spain standard locate key biodiversity area land pilot approach biodiversity work avoid reduce impact assess baseline assessment action plan site opportunity improve efficiency material change improve habitat protect specie improve soil switch alternative set ambitious standard water quality commence biodiversity supplier provide material highly uplift project large rd facility dependent nature sugar paper palm oil stevenage uk upper providence upper lactose gelatine soy merion pennsylvania standard develop collaboration address critical agricultural forestry party expert aim support supplier assess marinederive material engage improve verify approach addressing range associate supplier external independent expert nature impact associate climate social map supply chain involve understand exist impact include land use water stewardship sustainability standard identify gap establish biodiversity improvement plan stage address critical ocean material include paper palm oil roadmap commit restore mangrove indonesia place aim achieve sustainable sourced communityle project mangrove play crucial role paper palm oil engage climate regulation climate change mitigation associate supplier map supply chain involve carbon sequestration potential mangrove understand exist sustainability standard identify gap local population resilient flooding improve establish action plan local fish ecosystem water quality contribute health livelihood local community commit positive impact biodiversity operational site integrate risk impact management biodiversity assessment tool ibat work process identify assess prioritise ecological expert complete mapping baseline naturerelate dependency impact risk biodiversity assessment site opportunitie direct operation value chain implement biodiversity action plan estate aim improve habitat protect specie improve soil water quality strategic report governance remuneration financial statement investor information gsk annual report naturerelate financial disclosure continue oceans collective measurement direct value chain reduce impact ocean implement emission clean air fund membership aim marine sustainable source standard outline build picture activity rise poor air specific requirement supplier marinederive quality globally intend enable policy maker material adhere industry informed decision consider broad global impact health poor air quality approach product stewardship work reduce volume marinederive material waste material example process efficiency long term embed approach product stewardship reduce seek transition alternative marine impact nature mean work minimise waste derive material possible technical material waste pollution generate regulatory perspective deliver medicine vaccine product lifecycle achieve zero atmosphere operational waste landfill continue build outcome initial air quality assessment highlight longstanding operational waste management programme opportunity reduction emission link onsite identify opportunity achieve beneficial use electricity generation use solid fuel car use waste risk circular route electric fleet indicate opportunity recovery waste stream exist value chain source plastic glass product supply chain work waste footprint assessment help supplier engagement waste create reduction plan key area reduction product design build align pathway net zero aim circularity reduce waste design positive impact air quality process identify assess prioritise conduct additional air quality assessment monitoring naturerelate risk integrate working stockholm environment institute sei inform overall risk management process university york broaden suite air pollutant take consideration understand impact group company work value chain connection human science base target network sbtn set health validate sciencebase target nature start target freshwater land follow target help accelerate collective action air pollution ocean biodiversity target focus member alliance clean air clean air location value chain nature particularly fund caf world economic forum aim pressure aim sciencebase target drive corporate action clean air accelerate climate nature action create healthy community world continue work exist target work sbtn pilot delivery plan continue evolve sbtn target validation external guidance continue evolve datum develop primarily great supply chain traceability metric target report performance exist target metric water use waste material table realm key performance indicator freshwater average percentage gsk site supplier compliant wastewater active pharmaceutical ingredient limit percentage supplier compliant amr industry alliance common antibiotic manufacturing framework discharge limit land percentage paper palm oil deforestation free waste material reduction routine operational hazardous nonhazardous waste strategic report governance remuneration financial statement investor information gsk annual report naturerelate financial disclosure continue gsk set follow target manage nature commitment focus area target freshwater site achieve good water stewardship reduce overall water use water neutral operation key supplier waterstresse region zero impact active pharmaceutical ingredient level site key supplier land positive impact biodiversity site agricultural forestry derive material sustainably source deforestation free ocean marinederive material sustainably source atmosphere renewable electricity scope reduction carbon emission value chain net zero carbon emission value chain waste material zero operational waste include eliminate single use plastic waste reduction supply chain environmental impact reduction product packaging predict noeffect level link remuneration senior leader gsk site target update december reflect priority material include reduction routine hazardous nonhazardous waste regulatory obligation allow exclude plastic critical product discovery development health safety strategic report governance remuneration financial statement investor information gsk annual report nonfinancial sustainability information statement follow align nonfinancial reporting requirement contain section cb company act description business model human right policy diligence outcome business model human right risk management social matter work party viability statement access datum engagement audit risk committee report global health health security antibribery corruption principal risk uncertaintie employee ethical standard nonfinancial key performance indicator culture people report investigate concern performance key employee engagement performance indicator environmental matter wellbee development policy environment diversity equity inclusion public policy code climaterelate financial gender pay gap standard available gskcom disclosure ethical standard naturerelate financial disclosure board diversity employee gender male female total board management employee headcount december senior manager define company act strategic report director report regulation total calculate fulltime equivalent employee fte december male female calculate apply employee gender diversity percentage total fte number strategic report governance remuneration financial statement investor information gsk annual report viability statement accordance provision revision downside scenario consider gsk cash flow code gsk assess prospect group sustainability dividend fund strategy insurance long period month require go provision recovery key financial ratio concern provision director confirm period metric subject reasonable expectation gsk continue operate sensitivity analysis involve flex number meet liability fall main assumption underlie forecast individually year director assessment combination mitigate action reference gsk current position prospect realistically take avoid reduce impact strategy board risk appetite gsk principal risk occurrence underlie risk manage detailed page follow hypothetical downside scenario strategic report evaluate board review internal control risk scenario business performance risk include key management policy approve governance performance risk include low sale new product structure code conduct appraise great adverse impact generic competition approve major financing investment license competitive launch gsk product decision evaluate monitor performance possible supply manufacturing challenge prospect gsk focus largely improve longterm financial performance scenario external macroeconomic risk scenario delivery company business strategy align reflect incremental risk business drive outside priority factor intense competition increase pricing pressure europe potential board review gsk strategy make significant impact material negative change macro capital investment decision longterm time horizon economic healthcare environment base multiyear assessment return capital performance company market opportunity scenario principal risk scenario include severe medicine vaccine approach align assessment potential loss impact principal gsk model achieve balanced growth invest risk relate patient safety product quality supply chain high quality innovative product patient healthcare continuity information cyber security provider internal external environmental harm antibribery corruption parameter increasingly unpredictable long consequent regulatory action fine significant time horizon gsk focus detailed bottomup plan litigation fundamentally threaten threeyear cycle plan review annually operation risk manage mitigate director approve business forecast show activity describe page expect financial impact director believe scenario option exercise scenario evaluate threeyear assessment period viability statement additional funding requirement assume early appropriate align group potential exercise outstanding option hold establish business planning process balance pfizer inc longterm nature investment medicine vaccine assessment period analysis threeyear review make certain assumption nearterm business performance realistically visible normal level capital recycling likely occur consider additional financing facility plan stress test series robust require respective level funding flexibility operational principal risk downside scenario headroom board review risk plan assume year challenge healthcare industry result stress testing certain continue pressure pricing pharmaceutical combination hypothetical scenario increase uncertain economic condition prevail funding demand gsk require mitigate change market gsk operate gsk assume premature group funding strategy light loss exclusivity key product period liquidity available group base analysis anticipate launch proceed plan director reasonable expectation severe stress test group able continue operation meet liability fall threeyear period assessment gsk annual report group financial review section summary year result financial performance summary reporting framework financial performance adjust item cash generation conversion financial position resource approach tax treasury policy critical accounting policy strategic report governance remuneration financial statement investor information gsk annual report group financial review summary year result year growth growth year year aer cer result summary turnover turnover exclude covid solution total continue operate profit total operating margin ppt ppt total continue eps p p p adjust operating profit adjust operate margin ppt ppt adjust eps p p p cash flow cash generate operation free cash flow financial result state growth commentary cer ex covid exclude covid solution define gsk deliver excellent performance sale billion double digit adjust operating profit adjust ep share growth cer consequence performance please increase dividend year expect year meaningful growth gsk drive continue focus execution strengthen pipeline capital allocation deliver stepchange financial total continue ep grow reflect strong profit growth low charge relate remeasurement performance contingent consideration liability partly offset fair value sale million increase loss retain stake haleon plc compare fair overall reflect continue strong business performance value gain period prior year addition strong growth vaccine arexvy shingrix hiv unfavourable comparison upfront income exclude covid solution sale grow total operating receive settlement gilead sciences inc profit increase million drive overall adjust ep grow overall positive impact performance favourable contingent consideration exclude covid solution benefit low liability ccl movement adjust operating profit grow net finance expense decrease follow debt million positive impact restructure effective adjust tax rate line exclude covid solution adjust operate margin guidance increase drive largely favourable product mix operational efficiency increase royalty improve operating margin reconciliation total adjust result include total operating profit margin high profitable growth portfolio favourable movement total adjust cost sale percentage sale contingent consideration liability partly offset decrease year reflect reduce sale lower unfavourable comparison upfront income receive margin xevudy compare total adjust sga settlement gilead sciences inc growth focus investment vaccine include adjusted operate profit margin improve primarily disease awareness launch arexvy reduce sale lowermargin xevudy exclude covid shingrix longacte hiv jemperli ojjaara rd cost solution adjust operate profit margin improve increase investment latestage programme product mix productivity improvement increase royalty vaccine respiratoryimmunology infectious disease income growth sga reflect investment vaccine include disease awareness launch arexvy shingrix longacte hiv jemperli ojjaara royalty income contribute margin improvement strategic report governance remuneration financial statement investor information gsk annual report group financial review continue cash flow performance net debt improvement total year cash generate operation net debt position decrease billion end increase million despite annualise gilead look deploy fund enhance growth deliver sciences inc settlement quarter billion attractive shareholder return start year net higher adjust operating profit favourable timing xevudy debt billion strong free cash generation cash flow low uk pension contribution partly offset addition monetisation stake haleon plc high receivables arexvy sale net capital investment support billion investment target business increase primarily lower proceed asset development capital expenditure billion disposal result free cash flow return shareholder dividend continue operation increase million capital deployment support business growth shareholder return free cash flow fcf bn include capital expenditure net disposal proceed plant property equipment intangible bn bn include dividend distribution income exchange net debt financing item capital allocation framework support capital allocation framework support investment return investment return priority invest growth couple attractive capital allocation framework mean priority shareholder return remain invest business capital allocate development pipeline organic target business development remain committed deliver attractive return shareholder pursue progressive dividend policy guide percent payout ratio investment cycle set dividend policy gsk consider priority group investment strategy growth alongside sustainability dividend consistent reflect strong business performance year gsk expect declare increase dividend p share year expect dividend p event surplus cash excess return shareholder remain committed maintain balance sheet strong investment grade credit rating gsk group dividend gsk relate exclude dividend relate consumer healthcare h fy dividend pshare strategic report governance remuneration financial statement investor information gsk annual report group financial review continue guidance cer exclude covid outlook cer solution january gsk announce upgrade outlook expect year meaningful growth previously give period gsk guidance provide cer exclude impact period gsk expect sale grow covid solution sale expect increase cagr basis adjust operating profit cent adjust operating profit expect increase basis compare increase cent adjust earning previous outlook share expect increase cent respectively adjust operate profit margin expect guidance support follow turnover expectation year gsk expect achieve sale billion riskadjuste basis cer gsk expect vaccine expect high single digit low double maintain continue strong focus margin improvement digit percent growth retain flexibility invest future growth specialty medicine expect low doubledigit recognise gsk likely face loss exclusivity cent growth dolutegravir eu majority impact gsk state expect general medicine expect sale decrease operate margin broadly stable period midsingledigit cent gsk expect effective transition hiv portfolio adjust operating profit expect grow new longacte treatment prevention therapy cent cer despite percentage point impact margin mix benefit growth high operating margin operate profit growth follow loss gardasil royalties vaccine specialty medicine product continue effective beginning gsk expect deliver focus achievable productivity gain notably supply leverage gross margin level improved product mix chain sga vaccines specialty medicine growth expectation guidance outlook future continued operational efficiency addition gsk performance dividend payment read anticipate leverage operating profit step guidance outlook assumption cautionary sga growth low singledigit increase rd statement inside cover expect increase broadly line sale support growth pipeline adjust earning share expect increase cent cer reflect high operating profit favourable net finance cost expectation noncontrolle interest remain unchanged relative gsk anticipate previously communicate increase adjust effective tax rate follow implementation global minimum corporate income tax rate align organisation economic cooperation development pillar initiative covid solution anticipate future revenue covid solution reduce sale growth adjust operate profit growth currency impact exchange rate hold closing rate january yen rest estimate impact sterling turnover growth gsk exchange gain loss recognise level estimate impact sterling adjust operate profit growth gsk strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance summary total result group set growth turnover turnover cer turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operating profit net finance cost share tax profitslosse associate joint venture profitloss disposal interest associate joint ventures profit taxation taxation profit taxation continue operation profit taxation discontinue operation gainslosse demerger remeasurement discontinue operation distribute shareholder demerger profit taxation discontinue operation total profit taxation year profit attributable noncontrolle interest continue operation profit attributable shareholder continue operation profit attributable noncontrolle interest discontinue operation profit attributable shareholder discontinue operation total profit attributable noncontrolle interest total profit attributable shareholder earning share continue operation pence p p earning share discontinue operation penny p total earning share penny p p earning ad continue operation earning ad discontinue operation total earning ad adjust result group set reconciliation total result adjust result set page growth turnover turnover cer turnover cost sale sell general administration research development royalty income adjust operate profit adjust profit attributable noncontrolle interest adjust profit attributable shareholder adjust profit taxation adjust earning share p p p strategic report governance remuneration financial statement investor information gsk annual report group financial review continue report framework total adjust result cost ordinary course small scale restructure legal charge expense retain total group financial review discuss operate adjust result financial performance group cash flow financial position resource result year adjust result include benefit major restructuring compare primarily result precede year programme exclude significant cost amortisation intangible asset computer software total result capitalise development cost significant legal major total report result represent group overall restructure transaction item performance regard complete picture group financial performance present total result gsk use number adjust nonifrs measure exclusion adjust item result adjusted report performance business adjust result earning materially high low total earning nonifrs measure consider addition particular significant impairment restructure charge substitute superior information present legal cost exclude adjusted earning high accordance ifrs adjust result define total earning nonifrs measure define gsk undertake number major restructuring gsk believe adjust result consider programme response significant change group total result provide investor analyst trade environment overall strategy follow material stakeholder helpful complementary information acquisition pharmaceutical sector highly understand well financial performance position regulate manufacturing operation supply chain group period period allow group long lifecycle business mean restructure performance easily compare majority programme particularly involve rationalisation peer company measure closure manufacture rd site likely management planning reporting purpose year complete cost cash noncash determine compensation directly programme provide individual element comparable similarly describe measure approve meet accounting recognition criterion company result charge incur number year gsk encourage investor analyst rely follow initiation major restructure programme single financial measure review gsk annual report significant legal charge expense arise include financial statement note entirety settlement litigation government investigation adjust result normal course materially large regularly occur individual matter include adjust result exclude profit discontinue certain major legacy matter operation consumer healthcare business detail follow item relation reconciliation total adjust result provide continue operation total result tax information key adjust item effect item set page amortisation intangible asset exclude computer gsk provide earning guidance investor community software capitalise development cost basis adjust result practice line peer impairment intangible asset exclude computer company expectation investor community software goodwill support easy comparison group performance major restructuring cost include impairment peer gsk able guidance total result tangible asset computer software specific reliably forecast certain material element total board approve programme structural result particularly future fair value movement significant scale cost individual relate contingent consideration option project exceed million include integration cost give rise significant adjustment drive external factor follow material acquisition currency movement capital market transactionrelate accounting adjustment relate significant acquisition proceed cost disposal associate product business significant settlement income significant legal charge net insurance recovery expense settlement litigation government investigation operate income royalty income item strategic report governance remuneration financial statement investor information gsk annual report group financial review continue report framework continue historical record adjust item reconciliation total adjust operating profit continue operation year summarise follow total operating profit continue operation intangible amortisation intangible impairment major restructuring transactionrelate item divestment significant legal item adjust result analysis impact transactionrelated item operating profit year follow contingent consideration shionogiviiv healthcare jv include shionogi preferential dividend viiv healthcare option pfizer preferential dividend contingent consideration novartis vaccine business contingent consideration acquisition affinivax adjustment transactionrelate item reconciliation total adjust result include continue discontinue operation set page explanation adjust item report nonifrs measure return capital employ return capital employ calculated total profit free cash flow taxation percentage average net asset year free cash flow define net cash inflowoutflow total net debt continue operating activity capital expenditure net debt define total borrowing cash cash property plant equipment intangible asset equivalent liquid investment shortterm loan contingent consideration payment net finance cost party subject insignificant risk change dividend pay noncontrolle interest contribution value note net debt calculation net noncontrolle interest plus proceed sale debt property plant equipment intangible asset dividend receive joint venture associate total operating margin attributable continue operation total operating margin operating profit divide turnover management planning report purpose discussion presentation investment analyst adjust operate margin rating agency free cash flow growth calculate adjust operate margin adjust operating profit divide report basis reconciliation net cash inflow turnover continue operation free cash flow continue operation set compound annual growth rate cagr working capital cagr define compound annual growth rate show annualise average rate revenue growth work capital represent inventory trade receivables number give year assume growth take place trade payable exponentially compound rate cer aer growth order illustrate underlying performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged comparative period cer represent growth constant exchange rate aer represent growth actual exchange rate strategic report governance remuneration financial statement investor information gsk annual report group financial review continue report framework continue noncontrolle interest viiv healthcare cash payment reflect cash flow statement partly operate cash flow partly invest trading profit allocation activitie tax relief payment reflect viiv healthcare subsidiary group group adjust item tax charge operate result turnover operate profit profit payment relate original estimate fair value tax include group income statement contingent consideration acquisition portion earning allocate noncontrolle shionogiviiv healthcare joint venture million interest own shareholder line report investing activity cash flow statement respective equity shareholding pfizer inc pfizer payment relate increase shionogi co ltd shionogi shareholder liability acquisition report operate cash include gsk entitle preferential dividend flow determined performance certain product movement contingent consideration payable shionogi shareholder contribute relative performance follow product change time proportion overall earning allocate shareholder change particular increase proportion sale dolutegravir cabotegravircontaine product favourable contingent consideration begin impact proportion preferential dividend year allocate gsk adjust item allocate remeasurement income statement shareholder base equity interest gsk entitle movement approximately total earning cash payment operate cash flow adjust earning viiv healthcare cash payment invest activity contingent consideration end year remeasurement liabilitie preferential dividend allocate pfizer shionogi include operating incomeexpense contingent consideration payable posttax basis shionogi december million december acquisitionrelate arrangement million expect pay year consideration acquisition shionogis interest exit right shionogiviiv healthcare joint venture shionogi receive equity stake viiv healthcare viiv pfizer request ipo viiv healthcare time healthcare agree pay additional future cash gsk consent ipo offer consideration shionogi contingent future sale complete month pfizer require gsk performance product develop joint acquire shareholde original agreement gsk venture dolutegravir cabotegravir ifrs business unconditional right long subsequent combination gsk require provide estimate distribution shareholder withhold consent fair value contingent consideration time exercise pfizer option result accordance acquisition require update liability late ifrs gsk recognise liability option estimate fair value subsequent period end balance sheet q gsk notify pfizer liability contingent consideration recognise irrevocably give right accordingly balance sheet date acquisition million recognise liability option group subsequent remeasurement reflect balance sheet q initial value operating incomeexpense adjust item million consistent revise treatment end q income statement period gsk recognise liability future preferential dividend anticipate payable pfizer cash payment settle contingent consideration shionogi group balance sheet shionogi viiv healthcare quarter base actual sale performance income relevant pfizer right require gsk acquire shareholding product previous quarter payment reduce viiv healthcare certain circumstance time balance sheet liability record option liability record group balance income statement include cash flow cash sheet current liability measure gross payment shionogi viiv healthcare redemption basis derive internal valuation viiv million healthcare business liability require record fair value closing balance liability relate pfizer estimate future payment significant timing shareholding follow difference charge record total income statement reflect movement fair value liability actual cash payment settle pfizer option liability strategic report governance remuneration financial statement investor information gsk annual report group financial review continue report framework continue original agreement shionogi specialty medicine request gsk acquire shareholding viiv healthcare specialty medicine typically prescription medicine sixmonth window commence gsk treat complex rare chronic condition gsk unconditional right long subsequent comprise medicine infectious disease hiv oncology distribution shareholder withhold consent respiratoryimmunology exercise shionogi option result gsk recognise liability option balance sheet share consolidation q gsk notify shionogi follow completion consumer healthcare business irrevocably give right accordingly recognise demerger july gsk plc ordinary share liability option group balance sheet consolidate maintain share price comparability q initial value million q shionogi demerger shareholder receive new ordinary share irrevocably agree waive option result gsk nominal value pence exist derecognised liability option group ordinary share nominal value pence balance sheet directly equity value liability earning share dilute earning share adjust million derecognised earning share dividend share retrospectively gsk option shionogis shareholding viiv adjust reflect share consolidation period healthcare original agreement present exercisable sixmonth window commence earning share gsk irrevocably agree waive exercise window sixmonth window earning share retrospectively adjust remain option fair value value share consolidation july apply ratio new accounting purpose ordinary share exist ordinary share report definition total earning share state total earning share refer total covid solution basic earning share covid solution include sale pandemic adjuvant rar return rebate covid solution include vaccine manufacturing xevudy associated costs gsk sell customer commercial government include reinvestment rd categorisation mandate contract reimbursement arrangement management believe helpful investor include rebate chargeback right return certain providing clarity result group show pharmaceutical product principally revenue contribution growth covid solution recognition reflect grosstonet sale adjustment result adjustment know rar accrual turnover exclude covid solution source significant estimation uncertainty fluctuation turnover exclude covid solution exclude impact material impact report revenue sale pandemic adjuvant vaccine xevudy accounting period specialty medicine relate covid pandemic total operating margin management believe exclusion impact covid solution sale aid comparability report total operating margin total operating profit divide period understand gsk growth include region turnover versus prior period guidance exclude adjust operate margin contribution covid solution adjust operate margin adjust operating profit divide adjust operating profit exclude covid turnover solution discontinue operation adjust operating profit exclude impact commercial consumer healthcare present discontinued operation covid solution xevudy pandemic operation q demerger consumer adjuvant healthcare complete july group income adjust earning share exclude covid statement group cash flow statement distinguish solution discontinue operation continue operation adjust earning share exclude impact percentage point commercial operation covid solution xevudy percentage point growth abbreviate ppt pandemic adjuvant noncontrolle interest general medicine noncontrolle interest equity subsidiary general medicine usually prescribe primary attributable directly indirectly parent care community setting general healthcare practitioner gsk include medicine inhale respiratory brand name partner acknowledgement dermatology antibiotic disease brand name appear italic document trademark gsk associate company licence group strategic report governance remuneration financial statement investor information gsk annual report financial performance group turnover vaccine group turnover million year turnover bn aer cer sale grow aer cer aer growth cer growth exclude covid solution bn group turnover business l vaccine group turnover bn aer growth cer growth l speciality medicine bn aer decline cer decline vaccine turnover l general medicine vaccine turnover exclude covid solution bn bn aer growth cer growth aer growth cer growth pandemic turnover bn group turnover geographic region aer growth cer growth l bn doubledigit growth vaccine year drive successful launch arexvy continue strong aer growth cer growth uptake shingrix international europe pandemic l europe vaccine sale include gsk share contract bn european volume relate covid booster vaccine co develop sanofi aer growth cer growth shingle l international bn growth growth cer aer decline cer growth shingle shingrix vaccine herpe zoster shingle grow gsk report result segment commercial aer cer increase demand favourable pricing operation total rd note turnover segment growth drive public funding expansion strong information consolidated financial statement private uptake international europe region detail represent global turnover compare commercial operation segment product group shingrix launch market outside vaccines specialty medicine general medicine cumulative immunisation rate international sale drive launch uptake vaccine product include sale shingrix market strong momentum channel inventory build arexvy china transition distributor new public programme australia sales europe include delivery specialty medicine product include gsk market uk national immunisation programme begin product hiv oncology respiratoryimmunology offer shingrix vaccination september specialty medicine include nucala retail demand grow overall sale decline versus general medicine product include product challenge comparator period higher previously report establish pharmaceutical sale nonretail purchase cumulative immunisation trelegy ellipta anoro ellipta previously report penetration end q reach respiratory category specialty product million adult currently recommend product typically access patient primary receive shingrix percentage point time care setting year united states census bureau international database year strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue meningitis specialty medicine growth growth cer turnover bn meningitis bn aer decline cer decline doubledigit meningitis vaccine sale growth largely deliver bexsero vaccine meningitis b primarily drive inclusion national immunisation programme group turnover europe menveo vaccine meningitis acwy grow favourable impact cdc center disease control stockpile borrow q replenishment q meningitis growth benefit favourable impact cdc stockpile movement percentage point rsv growth growth specialty medicine turnover cer rsv arexvy specialty turnover exclude covid solution bn arexvy world approve respiratory syncytial virus aer growth cer growth rsv vaccine old adult achieve billion sale drive strong uptake lead market share pandemic turnover deliver outstanding launch sale bn arexvy available major retail pharmacy aer decline cer decline competitive contracting place retailer administer dose arexvy achieve twothird specialty medicine growth exclude covid solution share retail vaccination approximately million aer cer reflect continued growth momentum million adult age old risk hiv portfolio growth acceleration oncology vaccinate arexvy respiratoryimmunology covid solution negatively impact growth percentage point influenza hiv growth growth cer growth growth influenza cer hiv fluarixflulaval sale decline line expectation growth hiv primarily drive percentage point drive competitive pressure low market demand increase market share broadly flat global treatment primarily market attributable patient demand oral dr establish vaccines dovato juluca longacting medicine cabenuva apretude growth drive patient demand growth growth percentage point remainder favourable pricing cer dynamic tender growth dovato continue establish vaccine high selling product hiv portfolio establish vaccine growth drive rotarix favourable oral dr long act cdc stockpile movement mmrv vaccine increase growth growth supply international hepatitis vaccine performance cer relate travel market recovery establish vaccine oral dr long act growth exclude impact cdc stockpile movement oral dr dovato juluca longacting medicine cabenuva apretude sale growth continue end year represent total hiv portfolio compare q drive market share growth united states census bureau international database year percentage point versus q strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue respiratoryimmunology general medicine growth growth cer turnover bn respiratoryimmunology aer growth cer growth bn therapy area include sale nucala benlysta jesduvroq duvroq japan patient anaemia chronic kidney disease consistent group turnover sustain doubledigit growth benlysta nucala nucala growth growth cer nucala nucala il antagonist monoclonal antibody treatment severe asthma additional indication include chronic growth drive respiratory general rhinosinusitis nasal polyp eosinophilic granulomatosis medicine ongoing strong demand trelegy polyangiitis egpa hypereosinophilic syndrome s region anoro europe international continue continue strong growth region reflect high patient post pandemic recovery antibiotic market europe demand severe eosinophilic asthma additionally international region increase sale growth contribution new respiratory indication growth growth benlysta cer growth growth respiratory cer performance reflect growth trelegy single inhale benlysta triple therapy class region anoro europe benlysta monoclonal antibody treatment lupus continue international consistent growth represent strong demand trelegy europe bio penetration volume uptake certain international market particularly japan china growth growth cer oncology trelegy growth growth trelegy prescribe single inhaler triple therapy sitt cer treatment worldwide copd asthma strong growth oncology deliver region reflect increase patient oncology demonstrate strong growth drive jemperli demand growth sitt market penetration zejula performance uptake ojjaara post launch class growth momentum continue support output q partially offset impact blenrep withdrawal recently update primary care guideline global market november initiative chronic obstructive lung disease zejula seretideadvair growth growth growth growth cer cer zejula seretideadvair zejula parp inhibitor treatment ovarian cancer grow seretideadvair icslaba treatment asthma strong growth region growth copd seretideadvair sale growth increase primarily line indication offset reduction use reflect favourable pricing offset second line following update prescribing information generic erosion impact europe certain international agree fda q market growth impact unfavourable rar adjustment impact channel inventory reduction ahead price change general medicine growth growth cer general medicine decline aer reflect adverse currency impact low single digit growth reflect ongoing post pandemic demand antiinfective europe international certain party manufacturing arrangement overall growth product group continues impact ongoing generic competition strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue turnover region international growth growth cer growth growth total cer exclude covid total exclude covid covid solution impact growth percentage point exclude impact covid solution international continue grow aer cer strong growth sale growth adversely impact percentage point product group decrease sale xevudy vaccine double digit growth drive shingrix launch vaccine grow strongly drive arexvy launch uptake uptake market strong momentum channel lead market share partly offset competition low inventory build china new public programme market demand influenza vaccine growth benefit australia establish meningitis vaccine contribute favourable cdc stockpile movement percentage growth point specialty medicine grow hiv nucala benlysta zejula specialty medicine grew drive strong hiv performance benlysta nucala continue growth strong oncology general medicine growth drive trelegy growth growth despite partial offset impact withdrawal establish respiratory general medicine blenrep november growth drive augmentin strong post pandemic antibiotic demand general medicine growth largely drive trelegy increase patient demand growth sitt market partially offset establish respiratory general medicine europe growth growth cer total exclude covid covid solution impact growth percentage point exclude impact covid solution europe deliver strong growth aer cer vaccine growth reflect shingrix national immunisation programme initiation uk launch uptake market bexsero national immunisation campaign france spain ongoing travel vaccine recovery specialty medicine double digit growth drive growth hiv oncology benlysta nucala include impact new indication launch general medicine low single digit growth maintain strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue cost sale late stage increase investment vaccine drive continued acceleration progression pipeline growth growth include rsv pneumococcal mrna therapeutic hsv cer vaccine total cost sale sale respiratoryimmunology investment continue adjust cost sale depemokimab phase iii programme asthma nasal polyp camlipixant new asset sale refractory chronic cough nucala copd paediatric benlysta ccl osteo arthritic pain offset decrease total adjust cost sale percentage sale expense completion clinical programme decrease primarily reflect low sale low margin otilimab xevudy compare exclude xevudy year benefit increase margin contribution infectious disease investment bepirovirsen treatment vaccine sale particularly launch arexvy q chronic hepatitis b increase support monotherapy shingrix outside addition specialty combination programme investment key asset oncology medicine particularly hiv contribute improve margin continue jemperli ojjaara offset continue operational efficiency partly reduction terminate cell gene therapy programme offset adverse inventory provision adjustment year inflationary impact input cost earlystage investment increase il atopic dermatitis hiv portfolio focus generation sell general administration longacte treatment preventative medicine growth growth total rd include high impairment charge compare cer total selling general administration royalty income sale growth growth adjust sell general cer administration total royalty income sale adjust royalty income growth total adjust sga primarily reflect growth total adjust royalty income primarily relate increase investment growth vaccine include disease gardasil royaltie million awareness launch global market expansion arexvy kesimpta biktarvy royalty overwhelm majority investment global market expansion disease income gardasil royalty cease end awareness shingrix specialty medicine increase operating incomeexpense investment target longacte injectable hiv launch ojjaara myelofibrosis oncology growth growth partly offset continue benefit restructuring cer tight control ongoing cost reflect zejula operating income royalty dispute q total sga include expense increase significant legal cost detail operating expense reflect charge million research development million arise remeasurement growth growth contingent consideration liability liabilities cer pfizer option fair value loss million total research million gain retain stake haleon plc partly offset development million million net income primarily sale relate equity investment milestone income include adjusted research million dividend receive retain investment development haleon plc q upfront income billion sale receive settlement gilead sciences inc rd operating expense growth drive investment portfolio strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue operate profit share tax profit associate joint growth growth venture cer share tax loss associate joint venture total operating profit million million share loss sale adjust operate profit profit disposal interest associate sale group report profit disposal interest associate joint venture million total operating profit margin high profitable growth portfolio favourable profit tax movement contingent consideration liability partly offset take account net finance cost share profit unfavourable comparison billion upfront loss associate profit loss disposal interest income receive settlement gilead sciences inc associates profit taxation million compare q million adjust operating profit benefit strong sale taxation favourable product mix increase royalty income partly offset increase investment product launch rd include increase legal charge primarily relate zejula royalty dispute uk current year charge rest world current year charge adverse impact low sale covid solution chargecredit respect prior period percentage point total operating profit growth aer percentage point cer impact total total current taxation operate profit margin percentage point total defer taxation taxation total profit adverse impact low sale covid solution percentage point adjust operate profit growth charge million represent effective tax rate impact adjust operate profit margin total result reflect different percentage point tax effect adjust item tax adjust profit adjust operate profit business amount million represent effective adjust tax rate issue relate growth growth taxation describe note taxation financial cer statement group continue believe commercial operation adequate provision liability likely arise period sale open agree tax authority rd ultimate liability matter vary amount provide dependent outcome agreement commercial operation adjust operating profit benefit relevant tax authority strong sale favourable product mix minimal xevudy sale increase royalty income partly offset noncontrolle interest nci increase investment growth launch asset growth growth increase legal provision cer rd segment operating expense growth drive total continue progression late stage vaccine respiratory adjust immunology infectious disease include pneumococcal mrna programme decrease total profit continue operation newly acquire camlipixant ongoing investment key allocate ncis primarily drive low viiv healthcare programme depemokimab bepirovirsen profit allocation million million low net profit group entity net finance cost decrease adjust profit continue operation growth growth allocate ncis reflect low net profit cer group entity ncis partly offset high profit total net finance cost viiv healthcare allocation million adjust finance cost million total net finance cost million compare million adjust net finance cost million compare million decrease mainly drive net saving mature bond include sterling note repurchase q high interest income cash partly offset high interest shortterm finance strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue earning share continue operation dividend growth growth board declare interim dividend result p cer total dividend year p share total continue earning dividend share p retrospectively adjust share p p share consolidation gsk group dividend adjust earning share p p p share gsk relate exclude dividend relate consumer healthcare h increase total continue ep primarily reflect refer note dividend financial statement low charge relate remeasurement contingent consideration liability partly offset fair value loss dividend policy retain stake haleon plc compare fair value gain period year addition unfavourable dividend remain essential component total shareholder comparison upfront income receive settlement return gsk recognise importance dividend gilead sciences inc q shareholders june gsk investor update gsk set progressive dividend policy adjust ep reflect growth adjust operating profit implement guide percent payout ratio low finance cost growth reflect investment cycle consistent favourable benefit lower noncontrolling interest reflect strong business performance year gsk low sale low margin covid solution reduce declare increase dividend p q adjust eps percentage point p share year expect dividend p set dividend policy gsk consider currency impact result capital allocation priority group investment growth growth strategy growth alongside sustainability dividend mp mp cer turnover total continue earning share p p adjust earning share p p adverse currency impact primarily reflect weaken emerge market currency yen sterling strengthen sterle dollar partly offset weaken sterling euro exchange gain loss settlement intercompany transaction minimal impact adjust eps strategic report governance remuneration financial statement investor information gsk annual report group financial review continue adjust item adjust result reconciliation divestment intangible intangible significant december total asset asset major transaction legal adjust result amortisation impairment restructure relate item result turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax loss associate joint venture profitloss disposal interest associates profit taxation taxation tax rate profit taxation continue operation profit attributable noncontrolle interest continue operation profit attributable shareholder continue operation earning share continue operation p p p p p p p weight average number share million strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue adjust result reconciliation divestment profit intangible intangible significant december total discontinue asset asset major transaction legal adjust result operation amortisation impairment restructure relate item result turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation continue operation profit taxation discontinue operation gainslosse demerger remeasurement discontinue operation distribute shareholder demerger profit taxation discontinue operation total profit taxation year profit attributable noncontrolle interest continue operation profit attributable shareholder continue operation profit attributable noncontrolle interest discontinue operation profit attributable shareholder discontinue operation total profit attributable noncontrolle interest total profit attributable shareholder earning share continue operation p p p p p p p earning share discontinue operation p p total earning share p p p p p p p p weight average number share million strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue adjust result reconciliation divestment profit intangible intangible significant december total discontinue asset asset major transaction legal adjust result operation amortisation impairment restructure relate item result turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost loss disposal interest associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation continue operation profit taxation discontinue operation gainslosse demerger profit taxation discontinue operation total profit taxation year profit attributable noncontrolle interest continue operation profit attributable shareholder continue operation profit attributable noncontrolle interest discontinue operation profit attributable shareholder discontinue operation total profit attributable noncontrolle interest total profit attributable shareholder earning share continue operation p p p p p p p earning share discontinue operation p p total earning share p p p p p p p p weight average number share million strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue intangible asset amortisation transactionrelate adjustment description information intangible transactionrelated adjustment continue operation asset amortisation result net charge million million majority relate chargescredit intangible asset impairment remeasurement contingent consideration liability description information intangible liability pfizer option pfizer shionogi asset impairment individual intangible asset account preferential dividend viiv healthcare material impairment major restructure integration chargecredit pharmaceutical sector highly regulate contingent consideration shionogiviiv healthcare joint venture manufacturing operation supply chain long life cycle include shionogi preferential dividend business mean restructure programme particularly involve rationalisation closure viiv healthcare option pfizer manufacture rd site likely year preferential dividend complete contingent consideration novartis vaccine business major restructuring cost relate specific board approve major restructuring programme exclude contingent consideration acquisition adjust result major restructuring programme affinivax include integration cost follow material acquisition adjustment structural significant scale total transactionrelated charge cost individual relate project exceed million ordinary course smallerscale restructuring cost retain million charge relate contingent total adjust result consideration shionogiviiv healthcare joint venture represent increase valuation total major restructuring charge incur contingent consideration shionogi drive million million analyse follow million update future sale forecast exchange rate unwind discount million non non million credit relate viiv healthcare cash cash total cash cash total option pfizer preferential dividend represent reduction valuation option result update separation exchange rate sale forecast cash balance viiv preparation restructure healthcare contingent consideration liability fair value programme ifrs explanation accounting non control interest viiv healthcare set significant acquisition million credit relate contingent consideration legacy program novartis vaccine business primarily relate change future sale forecast million charge relate contingent consideration separation preparation programme incur cash charge acquisition affinivax primarily relate unwind million primarily restructure discount commercial administrative function global supply chain noncash charge million primarily divestment significant legal charge reflect writedown asset administrative item manufacturing location divestment significant legal charge item primarily benefit year restructuring programme include million net income dividend billion primarily relate separation preparation milestone relate investment include million restructure programme programme largely dividend receive retain investment haleon plc complete deliver target billion annual partly offset million fair value loss investment saving total cost expect billion slightly haleon plc legal charge provide significant legal high cash charge billion low noncash charge matter include zantac break separately billion litigation investigation significant legal charge year primarily reflect increase legal charge zantac cost significant acquisition relate integration cost vast majority relate prospective legal cost sierra oncology inc sierra affinivax inc affinivax defence litigation acquire q bellus health inc acquire q strategic report governance remuneration financial statement investor information gsk annual report group financial review continue cash generation conversion summary consolidate cash flow statement set capital expenditure financial investment cash payment tangible intangible fix asset amount million million disposal realise million million cash payment total net cash inflow operating activity acquire equity investment amount million total net cash outflow invest million sale equity investment realise activity million million total net cash inflowoutflow finance free cash flow activity free cash flow cash generate group decrease cash bank overdraft meet obligation contingent consideration cash bank overdraft begin year interest tax dividend pay noncontrolle interest exchange adjustment capital expenditure property plant equipment decrease cash bank overdraft intangible asset cash bank overdraft end year cash bank overdraft end year comprise free cash inflow cash cash equivalent total cash payment shionogi relation viiv overdraft healthcare contingent consideration liability year million million recognise cash flow operating activity payment reconciliation net cash inflow continue deductible tax purpose operating activity free cash inflow future cash flow reconciliation net cash inflow operating activity close equivalent ifrs measure free cash flow long term expect future cash generate show operation sufficient fund operate debt servicing cost normal level capital expenditure obligation exist licensing agreement expenditure arise restructure programme routine outflow include net cash inflow continue operate tax pension contribution dividend subject activity principal risk uncertainty discuss page purchase property plant equipment time time additional demand finance acquisition access multiple purchase intangible asset source liquidity short longterm capital market proceed sale property plant financial institution need addition cash equipment flow operation proceed sale intangible asset net finance cost dividend disposal proceed joint venture associate contingent consideration pay report investing activity contribution noncontrolle interest distribution noncontrolle interest free cash inflow strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial position resource property plant equipment asset business sciencebase technologyintensive highly regulate governmental authority allocate significant noncurrent asset financial resource renewal maintenance property plant equipment property plant equipment vehicle minimise risk right use asset interruption production ensure compliance goodwill regulatory standard number process use hazardous intangible asset material investment associate joint venture total cost property plant equipment investment december million net book value defer tax asset million land building represent noncurrent asset million plant equipment vehicle million asset total noncurrent asset construction million invest million new property plant equipment mainly current asset relate large number project renewal inventory improvement expansion facility worldwide current tax recoverable site support new product development launch trade receivables improve efficiency exist supply chain property derivative financial instrument mainly hold freehold new investment finance liquid current equity investment resource december contractual liquid investment commitment future capital expenditure million cash cash equivalent believe property plant facility adequate asset hold sale current requirement total current asset right use asset total asset right use asset amount million december liability compare million december current liability increase year reflect impact addition shortterm borrowing business combination million addition million partly offset depreciation million disposal contingent consideration liability impairment amount million trade payable derivative financial instrument goodwill current tax payable goodwill decrease million december shortterm provision million primarily result exchange rate loss total current liability million partially offset increase million acquisitionsrelate transaction noncurrent liability longterm borrowing intangible asset corporation tax payable intangible asset include cost intangible acquire defer tax liability party computer software net book value pension postemployment benefit intangible asset december provision million million increase primarily reflect contingent consideration liability addition net disposal writeoff million partly noncurrent liability offset impairment loss net reversal amortisation total noncurrent liability million exchange rate loss million total liability net asset total equity strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial position resource continue investment associate joint venture trade payable hold investment associate joint venture december trade payable carry value december million million compare million december million note investment associate joint decrease primarily drive low accrual relate venture financial statement detail profit share collaboration partly offset high customer return rebate accrual note trade current equity investment payable financial statement current equity investment amount million provision december million current equity investment comprise equity investment group hold carry defer tax provision shortterm intention sell sell short term noncurrent provision million december acquire intention measure fair million provision yearend include value profit loss fvtpl initially million million relate legal record fair value plus transaction cost dispute million million related major remeasure subsequent reporting date fair value restructure programme provision legal unrealised gain loss recognise income dispute indemnify disposal liability employee statement investment million relate liability cost restructure programme million represent share hold haleon plc extent balance sheet date legal demerger disposal haleon plc share result constructive obligation exist reliably estimate gross proceed million nil pension postemployment benefit investment account pension postemployment december hold investment carry arrangement accordance ias net deficit value million million significant million million pension arrangement investment hold december crispr million million unfunded post therapeutic ag vir biotechnology inc sr capital employment liability note pension post fund ib lp investments fair value employment benefit financial statement december million million noncurrent liability million million million million respectively investment include equity stake noncurrent liability amount million company research collaboration december million provide access biotechnology development potential interest interest company arise contingent consideration liability business divestment contingent consideration amount million december million million derivative financial instrument asset million represent estimate present value hold current derivative financial asset fair value amount payable shionogi relate viiv healthcare million million majority financial million million represent estimate instrument relate foreign exchange contract present value contingent consideration payable designate designate accounting hedge shareholder affinivax million million represent estimate present value contingent inventory consideration payable novartis relate vaccine inventory amount million million acquisition december liability shionogi million respect trade receivables preferential dividend explanation accounting noncontrolle interest viiv healthcare set trade receivables amount million million december increase mainly drive arexvy sale total contingent consideration payable posttax basis december million million defer tax asset expect pay year shionogi defer tax asset amount million consideration payable expect pay number million december year result total estimate liability discount present value posttax basis posttax discount derivative financial instrument liabilitie rate hold current derivative financial liability fair value shionogiviiv healthcare contingent consideration liability million million primarily relate discount affinivax contingent consideration foreign exchange contract designate liability discount novartis vaccine designate accounting hedge contingent consideration liability discount partly partly strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial position resource continue maturity profile bond debt equivalent usd bond eur bond gbp bond jpy bond net debt cash liquid investment billion billion hold centrally december analysis cash gross debt effect hedge liquid investment follow cash cash equivalent short term borrowing long term borrowing liquid investment net debt end year cash cash equivalent gross debt fix december net debt billion compare float billion december comprise gross debt net debt billion cash liquid investment billion net debt decrease billion primarily billion movement net debt free cash inflow billion proceed disposal investment include partial sale retain stake haleon plc net favourable exchange impact billion translation nonsterle denominate debt total net debt begin year partly offset dividend pay shareholder decrease cash bank overdraft billion net acquisition cost bellus health inc decrease liquid investment billion net decreaseincrease longterm loan december gsk shortterm borrowing net decrease shortterm loan include overdrafts lease liability repayable repayment lease liability month billion billion repayable debt subsidiary undertaking acquire subsequent year exchange adjustment december gsk cash liquid investment noncash movement hold follow decreaseincrease net debt continue operation decreaseincrease net debt bank balance deposit discontinue operation treasury treasury repo money total net debt end year market fund liquidity fund cash cash equivalent liquid investment government security strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial position resource continue total equity contractual obligation commitment december total equity increase financial commitment summarise note million december million commitment financial statement summary movement equity set follow table set contractual obligation commitment december fall payment total equity beginning year total yr yrs yrs yrs total comprehensive income year noncash distribution noncontrolle loan interest interest loan deconsolidation subsidiary finance lease dividend shareholder obligation ordinary share issue future finance change noncontrolle interest charge lease noncash dividend shareholder lease contract hedge gainloss transfer nonfinancial asset commence intangible asset sharebase incentive plan tax sharebase incentive plan property plant equipment contribution noncontrolle interest investment distribution noncontrolle interest purchase total equity end year commitment total share purchase december gsk hold million share treasury commitment respect loan future interest payable share million share cost million loan disclose take account effect million deduct retain derivative earning enter number research collaboration ordinary share repurchase period january develop new compound pharmaceutical february company expect company term arrangement include ordinary share repurchase remainder upfront fee equity investment loan commitment million treasury share transfer fund specify level research addition agree employee share ownership plan esop trust share hold payment future milestone achieve trust satisfy future exercise option award agreement relate compound early group share option award scheme stage development potential obligation proportion share hold trust respect milestone payment continue number year award rule scheme require gsk satisfy compound successfully development exercise market purchase issue process generally close product market new share share hold trust match approval great probability success amount option award grant show intangible asset represent maximum pay milestone achieve december esop trust hold million increase commitment mainly million gsk share future exercise attributable new rd collaboration result high share option share award executive intangible asset commitment supplemental saving plan carry value million million deduct reserve market value share million million strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial position resource continue connection demerger consumer healthcare normal course business provide december pension scheme valuation identify cash indemnification guarantee respect business disposal fund technical provision deficit gsk uk pension legal dispute subsequently arise scheme scottish limited partnership slp establish provision outflow resource consider provide funding mechanism gsk uk define probable reliable estimate likely benefit pension scheme slp hold share outcome dispute include note represent total issue share capital haleon provision financial statement plc provide outcome tax legal dispute pension scheme slp interest entitle outflow resource consider probable receive distribution slp equal reliable estimate outflow december net proceed sales haleon plc share receive dispute provision dividend income haleon plc share receive possible reliable estimate aggregate equal agree threshold proceed potential outflow fund require settle threshold proceed threshold total million dispute possibility outflow increase notional interest remain balance remote time time payment fully fund ultimate liability matter vary significantly cash funding technical provision deficit amount provide dependent scheme show december valuation negotiation relevant tax authority outcome proceed threshold reach gskcontrolled litigation proceeding relevant discuss general partner slp entitle sell remain principal risk uncertaintie page haleon plc share hold slp distribute proceed note legal proceeding financial statement gsk december total cash contribution total million million proceed threshold leave outstanding uk pension scheme cash contribution include million distribution dividend haleon plc share slp scheme contingent liability contingent liability set note contingent liability financial statement follow table set contingent liability comprise performance guarantee letter credit item arise normal course business expect expire total yr yrs yrs yrs guarantee contingent liability total strategic report governance remuneration financial statement investor information gsk annual report group financial review continue approach tax business make major contribution public purse tax risk country operate manage tax contribution include direct taxis robust internal policy process train compliance corporate income tax indirect taxis vat programme board director audit risk custom duty tax employment committee responsible approve tax policy tax property taxis important risk management arrangement wide internal company explain approach tax help inform control framework dialogue tax tax policy seek maintain open constructive relationship supportive effort ensure company tax authority worldwide meeting regularly discuss tax appropriately transparent tax affair affair real time business update possible manage tax strategy set detail monitor government debate tax policy key public policy section website jurisdiction understand share inform support exchange countrybycountry reporting point view potential future change tax law cbcr datum tax authority validate support transparent sustainable tax system exist information hold taxpayer support ability relevant provide pragmatic constructive business input ensure multinational group pay right tax tax policy maker directly industry trade right place body advocate reform support economic growth job creation need patient key global biopharmaceutical company substantial stakeholder business employment presence country world pay significant tax include group corporate tax charge million corporate income tax business taxis tax million profit tax million associate employee collect significant million represent effective tax rate tax behalf government supply cash tax payment million chain include employee year million addition taxis pay profit pay duty levy transactional subject taxation supply chain employment taxis worldwide nature operation mean cross border supply route necessary ensure supply medicine group total tax rate numerous country result conflict claim tax lower adjust tax rate reflect different tax authority profit tax individual country effect adjust item lead double taxation profit tax adjust tax rate country rate benefit innovation incentive available key profit recognise territory reference activity territory operate uk belgium perform value generate ensure patent box regime uk government enact profit recognise jurisdiction align activity legislation introduce global minimum corporate income tax undertake line current oecd guidelines rate effect line organisation base transfer pricing policy arm length principle economic cooperation development oecd pillar support transfer price economic analysis model framework anticipate rule restrict report ability benefit innovation incentive consequentially effective adjusted tax rate forecast increase engage artificial tax arrangement business commercial substance seek avoid tax use tax haven transaction detail corporate tax charge year fully disclose tax authority zerotolerance set note taxation financial statement approach tax evasion facilitation tax evasion strategic report governance remuneration financial statement investor information gsk annual report group financial review continue treasury policy report sterling pay dividend sterling cash interest rate risk management flow role treasury monitor manage gsk objective minimise effective net interest cost group external internal funding requirement balance mix debt fix float interest rate financial risk support strategic objective gsk time policy interest rate risk management limit operate global basis primarily subsidiary net float rate debt specific cap review company manage capital ensure agree annually board subsidiary able operate go concern optimise return shareholder appropriate foreign exchange risk management balance debt equity treasury activity govern objective minimise exposure overseas operating policy approve annually board director subsidiarie transaction risk match local currency recently october treasury management group income local currency cost possible foreign tmg meeting chair chief financial officer take currency transaction exposure arise external internal place regular basis review treasury activity trade flow selectively hedge gsk internal trading member receive management information relate transaction match centrally manage inter activity company payment term reduce foreign currency risk treasury operation possible manage cash surplus borrowing requirement subsidiary company centrally forward objective gsk treasury activity minimise contract hedge future repayment originate posttax net cost financial operation reduce volatility currency order benefit earning cash flow gsk use variety financial instrument finance operation derivative order reduce foreign currency translation exposure financial instrument manage market risk seek denominate borrowing currency principal operation derivative principally comprise foreign exchange asset cash flow primarily denominate forward contract swap swap dollar euro sterling borrowing liquid asset currency require group borrowing swap currency require purpose interest rate swap borrowing denominate swap foreign currency manage exposure financial risk change interest match investment overseas group asset rate treat hedge relevant asset forward derivative exclusively hedge purpose relation contract major currency reduce exposure underlie business activity trading group investment overseas group asset tmg speculative instrument review ratio borrowing asset major currency regularly capital management commodity risk management gsk financial strategy implement group financial architecture support gsk strategic priority objective minimise income statement volatility arise regularly review board manage capital fluctuation commodity price practical cost structure group appropriate mix debt effective tmg authorise approve equity continue manage financial policy credit execution certain financial derivative hedge commodity profile particularly target rating aa price exposure cycle counterparty risk management gsk longterm credit rating standard poor set global counterparty limit bank stable outlook moodys investor service moodys investment counterpartie base longterm credit rating stable outlook shortterm credit rating moodys standard poor usage limit p standard poor moodys respectively actively monitor breach limit liquidity risk management report chief financial officer immediately gsk policy borrow centrally order meet anticipate addition relationship bank credit rating funding requirement cash flow forecast funding review regularly change rating occur requirement monitor tmg regular basis change investment level authority limit strategy diversify liquidity source range facility appropriate banking counterparty limit review maintain broad access financial market annually day sweep cash number global subsidiary central treasury account liquidity management purpose strategic report governance remuneration financial statement investor information gsk annual report group financial review continue critical accounting policy group consolidated financial statement medicaid programme stateadministere prepared accordance ukadopte international programme provide assistance certain poor accounting standard conformity requirement vulnerable patient medicaid drug rebate company act international financial program establish reduce state federal reporting standard ifrs issue international expenditure prescription drug patient accounting standard board iasb protection affordable care act law participate provide rebate state accrual require estimate assumption medicaid rebate calculate base specific term affect amount asset liability revenue expense relevant regulation patient protection report financial statement actual amount result affordable care act differ estimate cash discount offer customer encourage critical accounting policy relate follow area prompt payment accrue time invoicing adjust subsequently reflect actual turnover experience taxation note record accrual estimate sale return apply legal dispute note historical experience customer return amounts invoice marketrelate information contingent liability note stock level wholesaler anticipate price increase pension postemployment benefit note competitor activity information judgement estimate area give note critical accounting judgement reconciliation gross turnover net turnover key source estimation uncertainty financial commercial operation follow statement turnover margin margin margin respect turnover accounting policy large gross turnover business commercial operation market complex arrangement rebate discount marketdriven allowance follow briefly describe nature segment arrangement existence commercial operation government arrangement certain indirect customer mandate customer able buy product state programme wholesaler reduced price chargeback represent cash discount difference invoice price wholesaler customer return indirect customer contractual discount price accrual prior year estimate chargeback calculate base adjustment term agreement historical experience product growth rate item customer rebate offer key manage care total deduction group purchasing organisation direct net turnover indirect customer arrangement require customer achieve certain formulary status performance target marketdriven segment consist primarily manage care relate value product purchase predetermine medicare plan negotiate contract pricing market share relative competitor accrual honour rebate chargeback mandate segment customer rebate estimate base specific term consist primarily medicaid federal government agreement historical experience product growth programme receive governmentmandate pricing rate rebate chargeback strategic report governance remuneration financial statement investor information gsk annual report group financial review continue critical accounting policy continue overall sale deduction percentage sale consistent involved significant legal proceeding year year sale growth come primarily trelegy respect possible meaningfully assess arexvy specialty product include hiv deduction outcome result probable outflow year split approximately follow general medicine quantify reliably estimate liability result specialty medicine vaccine ultimate resolution proceeding case appropriate disclosure case include december total accrual discount rebate annual report provision allowance return commercial operation amount million million position change time monthly process operate monitor inventory level assurance loss result outcome wholesaler abnormal movement process use legal proceeding exceed material gross sale volume prescription volume base party provision report group financial datum source information receive key wholesaler statement aim maintain inventory consistent level like pharmaceutical company face year year base pattern consumption complex product liability antitrust patent litigation basis commercial operation inventory level investigation operation conduct wholesaler distribution channel december governmental regulatory agency year estimate approximately week general counsel group head group legal turnover calculation use party information function support senior vice president head accuracy totally verify believe global litigation group responsible sufficiently reliable purpose litigation government investigation routinely brief chief executive officer chief financial officer legal dispute board director significant litigation pende respect accounting policy legal dispute group governmental investigation group follow briefly describe process meeting appropriate detail status significant determine level provision necessary litigation government investigation review matter accordance requirement ias provision number claim notify information contingent liability contingent asset provide potential claim notify assessment validity anticipate settlement cost outflow resource claim progress settle claim recent settlement consider probable reliable estimate level potential reimbursement insurer likely outcome dispute legal expense meeting include assessment arise claim group sufficient information available able reliable estimate potential outcome dispute external counsel assist litigation matter investigation assist briefing board senior management follow discussion matter possible reliable estimate provision require level provision legal dispute review adjust appropriate matter discuss note legal proceeding financial statement strategic report strategic report approve board director february julie brown chief financial officer february gsk annual report corporate governance section board gsk leadership team chair governance statement corporate governance architecture ahead board oversight continuous engagement key decision board committee report remuneration committee chair annual statement annual report remuneration director report strategic report governance remuneration financial statement investor information gsk annual report board sir jonathan symonds cbe skill experience nonexecutive chair jon extensive international financial life science governance experience jon serve independent nonexecutive director hsbc holdings plc april age chairman group audit committee september deputy group chairman nationality british august retirement board february previously appoint september chairman hsbc bank plc chief financial officer novartis ag partner managing n director goldman sachs chief financial officer astrazeneca plc partner kpmg jon fellow institute chartered accountant england wale external appointment nonexecutive director genomics england limited previously serve chairman nonexecutive chair energy aspect member european round table industry senior advisor chatham house dame emma walmsley skill experience chief executive officer appoint gsk ceo emma ceo gsk consumer healthcare joint venture gsk novartis creation march emma join gsk age loreal work year variety role paris london new york nationality british shanghai emma previously nonexecutive director diageo plc emmas position appoint january independent director microsoft inc supplement technology cyber security chief executive officer experience bring board april emma hold classic modern language oxford university external appointment independent director microsoft inc julie brown skill experience chief financial officer julie extensive financial life science background group cfo smith nephew serve nonexecutive director audit chair age roche holding ag julie interim group cfo astrazeneca nationality british plc work wide range commercial strategic financial position appoint april continent year period julie chief operating officer cfo executive chief financial officer director burberry group plc responsibility include finance transformation information technology oversight cyber security julie fellow institute chartered accountants institute tax external appointment cochair cfo leadership network accounting sustainability king charles iii charitable fund group company patron oxford university women business non executive director chair audit committee diageo plc effective august elizabeth liz mckee anderson skill experience independent nonexecutive director liz bring significant experience commercial biopharmaceutical season biotech board member significant experience commercial biopharmaceutical operationally age board level deep understanding biotechnology sector nationality american application technology invaluable gsk pure biopharma company appoint september current role liz serve worldwide vice president commercial leader infectious disease vaccine immunology oncology janssen r pharmaceuticals vice president general manager wyeth vaccine liz previously board member huntsworth plc board member chair science technology investment committee bavarian nordic liz degree engineering technical management mba finance external appointment board member biomarin pharmaceutical inc board member revolution medicines inc board member insmed inc trustee wistar institute director aro biotherapeutic company private company key committee chair c corporate responsibility science n nomination corporate governance audit risk r remuneration strategic report governance remuneration financial statement investor information gsk annual report board continue charles bancroft skill experience senior independent nonexecutive director charlie wealth financial management experience global biopharma charlie retire successful career bristol myers squibb bms march age hold number leadership role commercial strategy finance begin career nationality american bms hold position increase responsibility finance organisation appoint commercial operational responsibility latin america middle east africa canada japan senior independent nonexecutive director pacific rim country appoint chief financial officer chief july financial officer executive vice president global business operation executive vice president head integration strategy business development chief n r financial officer charlie line management responsibility information technology include cyber security charlie successfully steer bms period strategic transformation include billion acquisition celgene charlie serve member board colgatepalmolive company march external appointment board member kodiak sciences inc board member biovector inc advisory board member drexel university lebow college business board determine charlie recent relevant financial experience agree appropriate qualification background audit committee financial expert dr hal barron skill experience nonexecutive director hal distinguished career bioscience strong track record research development rd join board gsk chief scientific officer president age rd bring new approach rd focus science relate immune nationality american system use human genetic advanced technology help identify appoint january generation transformational medicine august transition nonindependent chief scientific officer nonexecutive director additional responsibility support rd president rd april join gsk hal president rd calico llc california life company transition role nonexecutive alphabetfunde company use advanced technology increase understand director august lifespan biology hal previously executive vice president head global product development chief medical officer roche responsible product combine portfolio roche genentech genentech senior vice president development chief medical officer hal nonexecutive director chair science technology committee juno therapeutics inc march acquire celgene corporation previously serve nonexecutive board director grail inc advisory board member verily life sciences llc external appointment ceo board cochair altos labs inc associate adjunct professor epidemiology biostatistics university california san francisco dr anne beal skills experience independent nonexecutive director anne bring extensive healthcare experience board physician entrepreneur combine passion patient advocacy recognise health policy expert age development global national programme improve healthcare access patient nationality american group ensure voice patient reflect research programme appoint current role anne spend year harvard medical school massachusetts general hospital instructor paediatric hold leadership role c n r commonwealth fund aetna foundation anne previously deputy executive director chief engagement officer patientcentere outcomes research institute chief patient officer global head patient solution sanofi external appointment founder ceo absolutejoi skincare board member academyhealth board member prolacta bioscience key committee chair c corporate responsibility science n nomination corporate governance audit risk r remuneration strategic report governance remuneration financial statement investor information gsk annual report board continue wendy becker skill experience independent nonexecutive director wendy highly experienced nonexecutive director hold significant leadership position wide range global business public private nonprofit sector age possess wealth strategic consumer marketing expertise particular nationality american technology life science sector appoint october wendy strong executive management experience chief executive officer jack will limited group chief marketing officer vodafone group plc partner r mckinsey company wendys interest science healthcare medical research date time mckinsey work range healthcare client europe further year serve board cancer research uk recently wendy spend time nonexecutive director nhs england chair british heart foundation wendy hold nonexecutive director role chair remuneration committee great portland estates plc ocado group plc member remuneration audit committees whitbread plc current prior role technology company wendy add board experience cyber security external appointment chair logitech international sa board member chair compensation committee sony group corporation senior independent director chair remuneration committee oxford nanopore technologies plc member governing body university oxford dr harry hal c dietz skill experience independent nonexecutive director hal bring extensive experience field human genetic central gsk approach scientific medical expert rd president american society human genetic recognise world lead authority genetic disorder know marfan syndrome age bring experience develop novel therapy particularly relation diseasemodifye nationality american treatment fibrotic neurodegenerative disease total hal author original appoint january publication peerreviewe journal career physician scientist dedicate entire career care study individual heritable connective tissue disorder primary perturbation extracellular matrix homeostasis function lab identify gene condition use model system explain disease mechanism hal receive prestigious award include curt stern award american society human genetics colonel harland sanders lifetime achievement award medical genetics taubman prize excellence translational medical science harrington prize american society clinical investigation harrington discovery institute pasarow award cardiovascular research inbevbaillet latour health prize belgium research achievement award american heart association inductee american society clinical investigation american association advancement science association american physicians national academy medicine national academy sciences external appointment victor mckusick professor paediatric medicine molecular biology genetics department genetic medicine johns hopkins university school medicine investigator howard hughes medical institute nonexecutive board director altius institute biomedical sciences independent chair gsk human genetic scientific advisory board key committee chair c corporate responsibility science n nomination corporate governance audit risk r remuneration strategic report governance remuneration financial statement investor information gsk annual report board continue dr jesse goodman skill experience independent nonexecutive director jesse bring scientific public health expertise board deliberation wealth scientific medical expert experience span science medicine vaccine regulation public health prove record addressing press public health need academic federal sector age jesse previously serve senior leadership position food drug administration nationality american fda include recently fdas chief scientist previously deputy appoint january commissioner science public health director center biologic evaluation research cber c jesse play leadership role develop fda regulatory science medical countermeasure initiative work collaboratively industry academia government global public health regulatory partner prepare respond major public health threat include emerge infectious disease disaster terrorism lead fdas response west nile virus hn influenza pandemic serve senior leadership team white house medical countermeasure review jesse previously member scientific advisory committee regulatory legal working group coalition epidemic preparedness innovation cepi external appointment professor medicine attend physician infectious disease georgetown university direct georgetown university center medical product access safety stewardship compass board member president united states pharmacopeia usp board member scientific counselor infectious disease center disease control prevention cdc board member intellia therapeutics inc member national academy medicine board member adaptive phage therapeutics inc urs rohner skill experience independent nonexecutive director urs broad business bank legal background extensive senior level experience multinational company age urs serve chairman number board recently credit suisse group nationality swiss april join credit suisse urs serve chairman executive appoint january board ceo prosieben prosiebensat media ag follow number year private practice major law firm switzerland admit bar r n canton zurich switzerland state new york found partner chair vega cyber associates ag bring current technology cybersecurity experience board supplement digital transformation time chair credit suisse external appointment member international advisory board investcorp chair vega cyber associates ag dr vishal sikka skill experience independent nonexecutive director vishal distinguished background technology particularly artificial intelligence ai machine learn ml central gsk approach rd bring deep age understand cyber security board founder ceo vianai systems inc nationality american silicon valleybase company provide advanced technological software service ai appoint july ml large enterprise world found vianai system vishal serve ceo infosys limited lead c innovative strategy help client renew exist landscape automation design thinking nextgeneration technology transform customer experience serve member executive board sap se prior chief technology officer vishal phd ai stanford university coauthore research abstract relate ai technology database management external appointment founder ceo vianai systems inc board member oracle corporation member supervisory board bmw ag member advisory board stanford university ai center center humancentere artificial intelligence key committee chair c corporate responsibility science n nomination corporate governance audit risk r remuneration director depart iain mackay january step board retire company december strategic report governance remuneration financial statement investor information gsk annual report gsk leadership team glt skill experience emma walmsley emma join gsk glt board biography page chief executive officer julie brown julie join gsk glt board biography page chief financial officer diana conrad diana appoint chief people officer member glt april chief people officer previously senior vice president hr pharmaceuticals rd play key strategic role leader rd people culture agenda support transformation diana join gsk canadas hr team hold role increase responsibility senior vice president hr consumer healthcare prior join gsk hold hr role company include ge capital gennum corporation zenon environmental laboratories diana honour bachelor art mcmaster university canada james ford james join glt appoint senior vice president group general svp group general counsel counsel later take responsibility compliance corporate security investigation legal compliance join gsk serve general counsel consumer healthcare general counsel global pharmaceutical vice president corporate legal act head global ethic compliance prior gsk james solicitor clifford chance dla hold law degree university east anglia diploma competition law king college qualified solicitor england wales attorney new york state bar james base london practise law live singapore hong kong james cochair usbase civil justice reform group director european general counsel association association corporate counsel sally jackson sally join glt march senior vice president global communications ceo svp global communication office lead communication government affair function globally ceo office ceo chief staff prior sally senior vice president office ceo cfo previously serve head investor relation join gsk sally hold degree natural science university cambridge luke miel luke join gsk glt chief commercial officer responsible chief commercial officer commercial portfolio medicine vaccine luke cochair portfolio investment board tony wood member viiv healthcare board outside gsk luke member singapore economic development board previously work astrazeneca executive vice president european business prior executive vice president global product portfolio strategy global medical affair corporate affair head asia roche base shanghai singapore prior hold role increase seniority roche sanofiaventis europe asia luke hold bachelor science degree biology flinder university adelaide mba macquarie university sydney shobie ramakrishnan shobie join glt appoint chief digital technology officer chief digital technology officer join gsk deep broad experience biotech hitech company recently lead digital technology gsk global commercial organisation transform company capability digital data analytic play pivotal role establish agile commercial operating model join gsk shobie hold senior technology leadership role organisation include astrazeneca salesforce genentech roche nonexecutive director deliveroo board member emeritus sustainableitorg member board director remediant shobie hold bachelor degree electronic engineering vellore institute technology university madra india strategic report governance remuneration financial statement investor information gsk annual report gsk leadership team glt continue skill experience david redfern david join glt chief strategy officer responsible corporate president corporate development development strategic planning previously senior vice president northern europe responsibility gsk pharmaceutical business region senior vice president central eastern europe join gsk david appoint chairman board viiv healthcare limited nonexecutive director aspen pharmacare holdings limited board bachelor science degree bristol university chartered accountant regis simard regis join glt president pharmaceutical supply chain president global supply chain responsible manufacturing supply gsk medicine vaccine addition lead quality environment health safety sustainability corporate level regis join gsk site director france rise senior vice president global pharmaceutical manufacture current role previously hold senior position sony konica minolta tyco healthcare member board viiv healthcare mechanical engineer hold mba phil thomson phil join glt appoint president global affairs president global affair responsibility group strategic approach stakeholder engagement reputation policy development previously phil senior vice president communication government affair join glaxo wellcome commercial trainee phil hold degree english history russian study durham university deborah waterhouse deborah appoint glt january chief executive officer viiv ceo viiv healthcare president healthcare april addition viiv deborah lead gsk global health gsk global health organisation deborah join gsk prior viiv senior vice president primary care gsk business strong track record performance specialty primary care deborah lead hiv business uk head hiv centre excellence pharma europe hold role general manager australia new zealand senior vice president central eastern europe deborah nonexecutive director schroders plc hold degree economic history english literature liverpool university tony wood tony appoint chief scientific officer cso head rd member glt chief scientific officer august follow appointment cso designate january join gsk pfizer senior vice president medicinal science technology responsible science technology platform drive delivery new innovation tony lead largescale global organisation drug discovery development multiple therapeutic area include immunology oncology infectious disease time pfizer tony responsible invention new antiretroviral medication treat hiv infection fellow academy medical sciences honorary fellow royal society chemistry rsc high honour give rsc fellow royal society biology tony bsc chemistry phd organic synthesis university newcastle postdoctoral fellow imperial college london currently visit professor imcm oxford glt member depart iain mackay member glt cfo step board retire company december strategic report governance remuneration financial statement investor information gsk annual report chair governance statement gsk continue significant progress pure biopharma company board skill capabilitie challenge support gsk performance longterm success board evolution board succession board composition continue evolve succession process begin urs rohner tailor pure biopharma company chair remuneration committee reach relevant skill experience deep industry year service agm scientific expertise broad pharma business succeed follow agm wendy becker join commercial experience board october wendy strong background science life science technology heart business science choice experienced remuneration committee chair equip drs hal dietz hal barron jesse understand global corporate oversee goodman provide breadth depth scientific iteration remuneration policy present knowledge combine vishal sikkas deep agm expertise technology artificial intelligence machine learn aiml liz anderson provide strong commercial second succession planning focus continue expertise dr anne beal bring strong focus patient refreshment board scientific expertise dr laurie patient experience charlie bancroft extensive glimcher step board october expertise pharma company executive cfo mean replace unsure precisely board meet need gsk today additional skill need focus deepen rna oligonucleotide undertake detailed search management level transition cfo iain scientist deep experience rna mackay guide separation haleon julie brown deep industry expertise successor dr jesse goodman retire year service agm seek board industry experience expertise public health infectious disease regulation invaluable necessary board priority focus gsk deliver meaningful consistent improvement performance need sustain effective capital allocation strategic choice reflect recent upgrade longerterm outlook announce beginning year pharmalife tech finance consumerother sciences board management agenda completely align clear focus time periods management l prebiopharma board communicate financial performance pipeline l biopharma board progress business development support growth ambition science technology nonexecutive director tenure support longterm growth business primary focus board work build confidence growth outlook significant opportunity come aiml theme run board meeting l year l year l year l year board priority focus value creation governance oversight ahead strategy delivery performance target execution rd pipeline business development longterm rd strategy approach endtoend business impact aitechnology peopletalentculture esg leadership zantac litigation defence mitigation focus shareholder value creation strategic report governance remuneration financial statement investor information gsk annual report chair governance statement continue board support modular communication plan similarly gsk year travel include include deep insight vaccine infectious china middle east europe disease hiv respiratory immunology oncology board opportunity meet local employee level small review strategy priority prior group impressive hear meet talk pride communication market revise outlook present purpose mission prevention improve annual result review extensively human health second half year longerterm strategic esg continue right heart gsk plan term business development board science ambition particularly proud progress committee work alongside emma management team make dei term people diversity understand scientific rationale competitiveness clinical trial asset consideration potential return value creation significant activity board shareholder perspective engagement board visit important element board programme board believe importance maintain march board spend day visit vaccine site continuous level engagement shareholder wavre belgium board member deep immersion year continue meet range investor combine vaccine business work site inspire represent approximately share register passion commitment group year nonexecutive board member attend employee spend time visit similarly annual governance meeting hear shareholder view board hold march meeting north hand feedback shareholder provide invaluable carolina immersive briefing hiv business shaping board work appreciate clarity efficiency direct engagement bring continue rd progress technology welcome opportunity engage investor directly longerterm future company come deep aspect gsk board work sustainable productivity internal externally source rd welcome approach take financial reporting investment technology path set council update uk corporate governance code year ago route commitment transform encourage board bolder choose right approach productivity use technology business explain important year board rd update centre antibody drug necessary conjugate oligonucleotide amr vaccine rna shareholder value liver disease discussion support validate prior deepdive science committee progress key improved return consistency embrace potential aiml business performance consistency communication crucial medium longterm success deliberately believe management deliver wealth tech experience board range dr translate sustained shareholder value creation hal barron rd experience verily google vishal acutely aware happen sikkas unique tech vantage point expertise ai ml ceo bring unique insight role microsoft term zantac litigation board deeply involve experience use technology overall strategy ceo general counsel biotechs uks national genomics programme addition quarter audit risk committee review collectively deep appreciation tremendous potential disclosure auditor ensure complete technology unlock reassurance execute fair accounting judgment appropriate confidence big investment course believe year significant progress rd gsk technology build time period optimise priority clear align work programme board culture responsibility different year ago delight progress emma board receive regular briefing people talent management team performance culture board interaction board board meet member local employee talent enable hand impression culture encourage read board colleague committee mood employee hear view company update follow page provide great detail work thank continued support look forward connect year annual general meeting sir jonathan symonds chair february strategic report governance remuneration financial statement investor information gsk annual report corporate governance architecture corporate governance architecture framework design improve board effectiveness support oversight gsk leadership team glt deliver company strategy framework continue evolve support infrastructure priority pure biopharma business gsk internal control risk management arrangement integral overall corporate governance framework describe page page ensure framework optimal effectiveness clear division responsibility individual collective board role describe appropriate distribution workload board committee requisite focus skill highly commit board director motivate carry role responsibility success company committee role committee report committee role focus membership chair act behalf board schedule meeting decision urgent sir jonathan symonds matter accordance matter authority delegate board time company chair time senior independent director chair board committee corporate consider gsk trust priority oversight responsible business approach dr anne beal chair responsibility esg strategy performance reporting reflect important issue dr jesse goodman responsible sustainable business growth oversight view interest dr vishal sikka internal external stakeholder review issue impact gsk business reputation science support board understand business development transaction key dr hal dietz chair strategic theme company rd strategy base review underlie dr jesse goodman scientific assumption detail give board technical assurance indepth dr hal barron oversight rdrelate risk nomination review structure size composition board appointment member sir jonathan symonds corporate board committee appointment corporate officer make recommendation chair governance board appropriate plan assess orderly succession executive non charles bancroft executive director review management succession plan ensure adequacy dr anne beal urs rohner responsible overseeing monitoring make recommendation board corporate governance arrangement review board glt conflict interest audit risk review financial reporting process integrity company financial statement charles bancroft external internal audit process system internal control identification chair management risk information cyber security company elizabeth mckee process monitor compliance law regulation ethical code practice anderson wendy becker oversee esg datum report assurance initiate audit tender selection urs rohner appointment external auditor set auditor remuneration oversee work remuneration set company remuneration policy regard gsk workforce remuneration urs rohner chair gsk able recruit retain motivate executive wendy becker chair designate regularly review remuneration policy sure consistent charle bancroft company scale scope operation support business strategy growth plan dr anne beal align wide workforce helps drive creation shareholder value elizabeth mckee chair ceo responsible evaluating make recommendation anderson board remuneration arrangement policy nonexecutive director board committee write term reference approve board review annually sure comply late legal regulatory requirement reflect good practice development term reference board committee available gskcom strategic report governance remuneration financial statement investor information gsk annual report corporate governance architecture continue leadership independent oversight rigorous challenge chair senior independent director jonathan symonds charles bancroft lead manage business board act sound board chair trust provide direction focus intermediary director ensure clear structure board nonexecutive director lead committee operate effectively annual review chair performance take maintain dialogue shareholder account view executive director governance company discuss result chair effectiveness review set board agenda ensure sufficient time chair allocate promote effective debate support sound lead search appointment process make decisionmake recommendation board new chair ensure board receive accurate timely clear act additional point contact shareholder information maintain understand issue concern meet regularly nonexecutive director meeting shareholder briefing discuss individual contribution performance company secretary investor relation training development need gsk senior independent nonexecutive director role description share peer feedback provide available gskcom board evaluation process meet regularly nonexecutive director nonexecutive director independently executive director provide strong independent element board chair role description available gskcom constructively support challenge management scrutinise performance achieve agree deliverable chief executive officer emma walmsley shape proposal strategy offer specialist advice management manage group business letter appointment set term develop group strategic direction board condition directorship consideration approval devote time necessary proper implement agree strategy performance duty support glt expect attend meeting require maintain continuous dialogue shareholder respect company performance independence statement chief executive officer role description available gskcom board consider nonexecutive director identify page dr hal barron independent assess provision financial reporting council frc uk corporate governance code code gsk nonexecutive director role description available gskcom company secretary secretary board board committees victoria whyte supports board committee chair plan future agenda annual programme ensure information available board member timely fashion support chair design deliver board induction coordinate continue business awareness train nonexecutive director undertake internal board committee evaluation chair request advise director board practice procedure corporate governance matter chair group disclosure committee operate boardapprove appointment policy reflect board external appointment requirement code point contact shareholder corporate governance matter strategic report governance remuneration financial statement investor information gsk annual report corporate governance architecture continued board committee attendance nomination corporate corporate board chair responsibility science governance audit risk remuneration total number routine meeting current member attend attend attend attend attend attend attend sir jonathan symonds emma walmsley julie brown elizabeth mckee anderson dr hal barron charles bancroft dr anne beal wendy becker october dr harry dietz dr jesse goodman urs rohner dr vishal sikka retire member iain mackay number additional meeting director serve year number bracket number meeting director eligible attend detail committee member skill experience include biography page high attendance record schedule board committee meeting director serve set january urs rohner reach year service step board agm plan continue demonstrate characteristic independence expect board carry role board dr vishal sikka join board july year board unable attend board meeting preexist external board commitment contribute fully board work meet regularly chair provide input board committee material inputte technology ai discussion audit risk committee spend time chief digital technology officer team year sharing expertise perspective frc uk corporate governance code financial experience member audit risk committee financial industry experience detail find accordance frc code board determine biography page charle bancroft recent relevant financial experience agree appropriate compliance statement qualification background audit committee board please report financial expert define sarbanesoxley act alignment provision frc code determine independent mean security exchange act amended board please report consistently apply principle frc code set page corporate governance report copy code available frc website wwwfrcorguk board appointment policy nonexecutive director expect devote time necessary performance duty director require attend minimum schedule board committee meeting recognise rare occasion possible explain attendance table special allowance give year board membership calendar align board director external appointment govern boardapprove policy consider external appointment help board glt member widen expertise knowledge perform role effectively propose new nonexecutive director appointment board approval board consider demand individual time appoint board individual require disclose significant commitment indication time involve subsequently additional prospective external appointment serve board director consider approve board note nature role type organisation time commitment potential conflict arise company secretary maintain register commitment potential conflict board satisfied give director interest sufficient time carry role gsk executive nonexecutive director undertake maximum listedcompany directorship respectively strategic report governance remuneration financial statement investor information gsk annual report ahead board oversight board carry responsibility annual programme meeting board seek optimise effectiveness set annual meeting programme focus priority agree year support delivery company short medium longterm strategy board committee programme work set complement avoid unnecessary duplication year board receive paper presentation actively discuss progress management people material discussion help board effective decision contribute oversight business performance ensure good governance key area board consider highlight area focus board work include building oversee gsk pure biopharma business delivery performance include momentum set approve board priority pure biopharma company discuss scrutinise strategic plan gsk assess potential upgrade longerterm outlook scrutinising update rd strategy progress progression company pipeline discuss gsk overall commercial strategy particular china discuss endtoend business opportunity impact ai advanced technology performance patient ahead oversee fundamental commercial execution costbase management capital allocation pipeline culture include receive regular report ceo cfo cso include assessment delivery performance target strengthen receive update rd strategy approach pipeline progress fundamental assess product area strategy report vaccine speciality care include hiv oncology general medicine value creation review gsk capital allocation priority ensure investment growth deliver improved return shareholder evaluate business development transaction acquisition strategic partnership party include bellus health zhifei hansoh aiolos bio arrowhead pharmaceuticals janssen pharmaceuticals scrutinise group financial performance shareholder value creation development investor relation roadmap review zantac litigation strategy approve monetisation retain share haleon post demerger consumer healthcare business enhance oversee culture embed esg core include esg leadership assess esg performance review plan lowcarbon ventolin include clinical nonclinical datum available support regulatory submission approve esg performance report oversight company pricing access policy principle review stakeholder perception research regular board programme governance include corporate review quarterly financial result dividend proposal earning guidance investor material result announcement governance annual report form f receive related report external auditor oversight set annual budget forwardlooke threeyear plan longrange forecast conduct annual review enterprise risk responsibility framework enterprisewide risk undertake annual board evaluation implement agree outcome receive report board committee work review continue evolve board governance architecture evaluate ceo performance set objective review culture talent succession plan annually engage gsk stakeholder people gather understand view company activity operation culture review employee pulse survey result receive report wide corporate governance regulatory development company secretary report approve company modern slavery statement gender pay gap position strategic report governance remuneration financial statement investor information gsk annual report ahead board oversight continue board performance board committee evaluation review board committee focus potential board evaluate performance opportunity support gsk momentum pure committee year biopharma company help remove duplication support delivery board priority identify evaluation normally carry externally addition committee review committee member year recent external evaluation facilitate tenure expertise diversity jan hall business advisory company connection gsk committee consider operate effectively follow enhancement agree board committee evaluation conduct internally company secretary corporate responsibility committee wide remit perform consideration give provide questionnaire board member additional route identify potential emerge issue draw response theme response committee area responsibility review discuss outcome recommendation addition committee continue seek external committee chair perspective provide challenge science committee work effectively opportunity follow discussion committee board enhance effectiveness consider particular identify area focus improvement committee programme focus rd board committee set tech strategy capacity undertake deep dive action point specific area rd activity input early new project explored consideration discussion follow action nomination corporate governance committee point improve performance agree work effectively successor dr jesse goodman key priorities board focus programme seek ahead retirement board meeting year ahead committee undertake review board committee architecture membership ensure give fundamental importance culture board remain aligned board priority wish ensure fully embody gsk culture audit risk committee consider effective undertake culture training provide work appropriately streamline material review employee committee good progress continue additional opportunity increase informal engagement area opportunity year ahead committee board management continue focus tech cyber security use ai removal unnecessary duplication board remuneration committee operate effectively committee work continue programme aim despite challenge environment focus simplify paper create time deeply determine right business imperative discussion meeting gsk remuneration policy ensure globally competitive reward delivery outperformance chair evaluation senior independent director sid carry chair evaluation seek feedback chair performance director individually collectively review conclude chair leading board appropriately effectively chair sid discuss result review strategic report governance remuneration financial statement investor information gsk annual report continuous engagement key decision prioritise continuous engagement stakeholder rightly high expectation ongoing basis encourage report company dynamic operating environment present board experience relevant material challenge opportunity board aim sure engage people commercially successful balanced align meeting stakeholder expectation uphold wellestablished strong engagement mechanism reputation maintain licence operate building employee describe page trust engage brief stakeholder board monitor regularly key governance view sure identify respond channel help board understand people expectation effectively appropriately think engage main stakeholder group include regular board update chief people officer patient shareholder consumer customer people ceo culture talent company cover page strategic feedback annual employee engagement survey report include question engagement confidence patient people stakeholder heart inclusivity culture people ambitious patient range pulse survey differentsize employee group accountable outcome commit right help check sentiment quick frequent thing culture describe page basis provide valuable insight impact major strategic report initiative event communication direct engagement board influence importance different stakeholder group vary depend matter consider certain workforce engagement company demerger stakeholder interest conflict meaning board review formal workforce engagement board need balanced judgement arrangement decide specific workforce engagement director model apply continuous stakeholder engagement feedback help alternative arrangement method set identify emerge issue enable decision frc code context relevant important give new gsk board recently refresh term principal board committees glt undertake tenure half independent nonexecutive engagement board behalf accord remit director serve year give mean build detailed understanding gsk renew purpose focus global biopharma action plan affect affect stakeholder company consider important adopt collective insight share board board engagement model agree particular board receive briefing stakeholder effective approach ensure new board member meet perspective work corporate responsibility employee hear view committee discuss page new model operate board member regularly receive direct inperson reception local employee ceo board report board site visit include wavre belgium specific external stakeholder insight report provide global vaccine hubs boston global strategic insight base analysis key development headquarters brentford achievement risk affect reputation chair site visit include wavre singapore perception external stakeholder vaccine manufacture site philadelphia regular investor relation report summarise investor commercial site perception chair attendance management meeting include regular corporate governance litigation regulatory china commercial employee commercial core update leadership team uk china regional general manager commercial talent saudi arabia general board learn stakeholder view management team engagement feedback event quarterly investor chair corporate responsibility committee chair result call annual general meeting employee survey convene attend ongoing meeting leader report board workforce engagement activity company employee resource group talk expert present board committee meeting chair experience gsk think dei agenda hold regular investor checkin meeting sid ambition progress sharing suggestion charlie bancroft join available individual enhance dei agenda meeting investor utilise variety bespoke engagement enable broad open dialogue facilitate opportunity board member gain wide hand engagement discussion ned stakeholder view annual strategy meet people individually small group glt yearly review strategy budget encompass perspective strategy purpose planning process include review specific ahead culture dei aspect company policy strategy addition board member encourage meet individually employee shareholder key stakeholder induction strategic report governance remuneration financial statement investor information gsk annual report continuous engagement key decision continue engage shareholder annual governance meeting board aim directly engage directly year hybrid meeting hold central london accountable institutional investor private retail institutional shareholder key investment industry body shareholder way include regular proxy advisory firm invite representative communication annual governance meeting annual institutional shareholder proxy adviser attend general meeting work investor relation event comprise approximately company share team chair jonathan symond company register secretary victoria whyte sid charlie bancroft meet new format interactive point contact shareholder possible begin jon share investor board quarter ceo emma walmsley cfo julie brown priority focus charlie result presentation institutional investor analyst provide reflection year jon charlie non media webcast regularly join executive director hold informal open discussion cso chief commercial officer cco ceo viiv issue shareholder mind help foster able provide investor detailed insight rich dialogue specific area responsibility key theme cover include regular meeting ongoing board change succession planning arrangement active dialogue institutional shareholder work challenge board year company performance plan objective company current future momentum excellent ceo engagement represent company execution key priority share register harness digital technology talent drive current previous cfo engagement ahead purpose comprise register positive sign influence culture cso engagement represent register ambitious patient accountable impact cco engagement represent register right thing ceo viiv engagement register meet new format receive chair maintain consistent dialogue shareholder shareholder feedback share board include fund portfolio manager regularly annual general meeting engage governance esg professional please hold company hybrid agm date publication annual report jon sofitel heathrow shareholder join hold individual engagement range meeting person shareholder join virtually institutional shareholder approximately lumi platform watch listen update chair company share register enable gain current ceo vote shareholder able ask question understand shareholder view insight perspective meet person virtually propose company discuss continual evolution resolution approve shareholder majority aspect board governance performance oversight range succession hybrid agm year hold new venue royal year chair ceo rest board key glt lancaster hotel central london locate close member focus communicate strong ongoing new global headquarters detail performance gsk global biopharma business successful launch arexvy world rsv vaccine progress pipeline core therapy area infectious disease hiv respiratoryimmunologyand oncology strategic report governance remuneration financial statement investor information gsk annual report continuous engagement key decision continue section statement board member require law promote success company benefit shareholder wide stakeholder include employee supplier society statement meet requirement set section section cza company act act summarise director address matter set section f act perform duty board consider statement focus risk opportunity strategically important gsk consistent group size complexity allow properly understand potential effect decision make stakeholder detail engagement main stakeholder group include patient shareholder consumer customer employee organisation summarise generally page strategic report board continuous engagement company shareholder people particular set section page corporate governance architecture process summarise page board seeks consider relevant matter make decision especially continue drive performance momentum gsk future longterm result likely consequence decision long term challenge economic political landscape director propose choice highlight relevant stakeholder recognise criticality investing pipeline vaccine impact proposal consideration positive medicine prevent disease meeting change andor negative director relevant unmet healthcare need support gsk purpose factor consideration decisionmake process ahead strategy ultimately longterm success papersinformation relevant duty normally submit sustainability gsk time gsk work ceo cfo chief scientific officer chief commercial government regulator industry partner ensure officer president corporate development president global medicine vaccine reach patient scale bring affair glt member andor direct report value patient need payer input challenge decision awareness director director appreciate assess consequence matter consider director include longterm decision environment multifacete finely balanced invariably involve trade pipeline progression review compete stakeholder interest budget planning support decisionmake director provide business development deal papersinformation minimum describe longterm proposal consideration comment capital allocation priority fit withstrengthen impact business commercial vaccine general med specialty review strategy budget threeyear plan relevant dividend policy align ahead ambition outlook esg ambition include area esg focus director apprise success risk factor appropriate alternative consider rationale specific detail ahead business model disclosure page b workforce interest people director understand people core matter consider director include ahead ambition help power purpose culture progress deliver strategy seek create oversee environment gsk outstanding people thrive talent pipeline positive employee experience critical attract retain diversity equity inclusion ambition motivate good people ethnicity gender pay gap datum trend report papersinformation relevant duty normally submit board chief people officer head reward employee engagement practice feedback input challenge decision awareness director health safety risk pay fairness benefit performance choice workplace environment specific detail culture people diversity equity inclusion engage people disclosure page strategic report governance remuneration financial statement investor information gsk annual report continuous engagement key decision continue c business relationship importance develop group business relationship supplier customer patient place gsk heart purpose matter consider director include culture ambitious patient accountable access healthcare impact right thing ethical standard supplier key stakeholder include government ngo healthcare authority healthcare global health health security professional rd joint venture partner affiliate company help research develop manufacture regulate human right provide access distribute medicine vaccine modern slavery act statement product patient need product governance key imperative director custodian responsible business ensure company develop scientific patient engagement monitor relationship partnership ultimately supplier payment policy serve patient line code conduct supplier expect meet antibribery corruption thirdparty risk management programme labour right standard comply standard work party policy quality health safety environment explore detail help foster good specific detail responsible business relation supplier offer preferential payment term disclosure page designate small supplier uk papersinformation relevant duty normally submit ceo cfo president global supply chain chief commercial officer chief scientific officer president global affairs andor direct report input challenge decision awareness director community environment impact group operation community environment environment principal esg focus area esg papersinformation relevant duty normally submit embed strategy fundamental success president global affairs president global supply ahead disease help ensure longterm success chief people officer andor direct report input director recognise responsible business need challenge decision awareness director consider esg impact extend matter consider director include lab patient take action climate nature community investment donation policy manufacturing site key role contribution net zero nature positive healthy planet environmental clinical trial diversity planning enrolment sustainability fundamental global supply chain diversity equity inclusion strategy strategy supplier action turn help gsk achieve environmental goal climate nature embody environment net zero nature positive goal gsk sustainable procurement programme year operation see supplier action carbon environment health safety risk power heat transport water waste sustainable emerge climate environmental legislativeregulatory deforestationfree source material support review environmental sustainability goal specific detail responsible business director believe company reflective climate naturerelate financial disclosure page support diversity local community serve strengthen early stem education investment support longterm diverse talent pool increase positive impact volunteering activity community invest plan improve natural habitat protect biodiversity improve soil water quality near manufacture site strategic report governance remuneration financial statement investor information gsk annual report continuous engagement key decision continue e reputation desire maintain reputation high standard business conduct responsible company gsk seek force good matter consider director include ambitious target positive impact health audit assurance plan people society planet company manage risk effectively take action thing wrong seek respect code conduct human right director periodically review continue corporate financial statement appropriateness framework underpin high standard business code conduct include corporate governance regulatory update range policy standard architecture corporate governance arrangement enterprise risk assessment papersinformation relevant duty normally submit esg ambition include area esg focus ceo cfo general counsel chief commercial officer emerge esg legislativeregulatory review president global affairs chief people officer chief digital technology officer chief compliance officer company internal control risk effectiveness review secretary head audit assurance input challenge speak internal investigation decision awareness director specific detail responsible business corporate governance architecture disclosure page separate esg performance report f fairness shareholder aim act fairly member group director seek act fairly interest matter consider director include shareholder major retail shareholder alike annual general meeting regular constructive dialogue shareholder communicate strategy performance receive investor annual governance meeting view perspective promote investor confidence ensure capital market day meet management event continue access capital inform director decisionmake strategic matter group individual director shareholder meeting director navigate weigh range shareholder opinion arrive decision support longterm investor analyst perception survey success company investor relation plan papersinformation relevant duty normally submit remuneration policy proposal ceo cfo president global affairs head investor relation company secretary input challenge specific detail shareholder engagement decision awareness director shareholder information disclosure page strategic report governance remuneration financial statement investor information gsk annual report continuous engagement key decision continue key decision decisionmake board focus gsk priority pure biopharma company strong momentum big ambition whilst balance interest stakeholder select example key decision take board january drive purpose momentum strategy include stakeholder group decision boardcommittee regard stakeholder interest section duty consider upgrade ambition june gsk articulated shareholder outlook period stakeholder patient growth give gsk improve performance strong momentum focus employees biopharma company board audit risk committee agree investor board consider update investor expectation appropriate duty upgrade new longterm result longterm ambition gsk january follow thorough review gsk publish new upgrade outlook workforce fairness invest market sale grow adjust profit shareholder business future deliver cagr basis deliver sale relationship attractive return billion represent increase billion versus estimate give shareholder mark sale acceleration provide clear visibility shareholder people key stakeholder build block future growth company progressive dividend board recognise importance dividend shareholder december stakeholder policy audit risk committee board consider gsk progressive investor patient dividend policy well apply line agree capital allocation workforce board audit risk priority group investment strategy growth alongside duty committee consider sustainability dividend longterm result application progressive dividend policy line workforce business capital allocation priority result increase dividend p q q p relationship reputation p year p expect dividend p fairness shareholder capital allocation board approve update capital allocation framework priority stakeholder patient framework invest business focusse development pipeline employee organic rd portfolio target business development investor board consider achieve increase focus roi investment duty update capital allocation longterm result framework good support ultimately board determine update framework continue workforce fairness growth sustainable support invest growth deliver sustainable return shareholder shareholder business return shareholder underpin strong balance sheet consistent gsk strategic relationship priority support company commitment deliver longterm profitable growth business development board support science committee commercial review stakeholder patient late stage asset review business development opportunitie employee science committee year leading conclude transaction include investor consider scientific duty merit business development opportunitie licence agreement hansoh pharma antibodydrug conjugate longterm result relevant late potential solid tumour indication support work workforce business stage asset commercial develop cancer treatment relationship review prior board agreement chongqe zhifei biological product copromote shingrix review approval china significantly extend availability vaccine support patient access acquisition bellus health aiolos bio expand strengthen gsk respiratory portfolio deal consider context potential help gsk deliver transformational medicine patient drive growth accelerate pipeline strategic report governance remuneration financial statement investor information gsk annual report continuous engagement key decision continue stakeholder group decision boardcommittee regard stakeholder interest section duty consider artificial intelligence board review provide feedback strategy integrate stakeholder patient workforce culture responsibly scale ai business accelerate pipeline amplify employee performance drive productivity duty board consider longterm result approach impact board recognise significant potential ai particularly context workforce adopt ai endto interpret dataset develop medicine high probability success business relationship end basis business support audit risk committee board consider associated risk ai describe page board approve establishment ai governance council cochaire general counsel cdto help manage risk group close attention pay impact adopt ai workforce include wellbee gain enable increase efficiency benefit upskille building ai capability lowcarbon ventolin year corporate responsibility committee endorse board stakeholder patient strategy review approve plan progress transition meter dose employee inhal newgeneration lowcarbon inhaler significantly contribute gsk investor corporate responsibility carbon reduction target phase iii trial begin duty committee board successful programme potential reduce greenhouse gas emission longterm result review plan use inhaler approximately workforce business progression phase relationships development low carbon ventolin programme board corporate responsibility committee carefully consider need patient rely ventolin complexity clinical development process investment require new manufacturing facility successful programme lead regulatory submission support health asthma copd patient make significant positive impact gsk transition environmentally sustainable future strategic report governance remuneration financial statement investor information gsk annual report board committee report discuss management step need help corporate responsibility committee report leverage leadership position conjunction support expertise science committee include grow dr anne beal business development strategy improve pathogen surveillance capability give amr urgent public threat corporate responsibility committee stakeholder increasingly interested gsk approach please present report second chair agree appropriate include amr corporate responsibility committee committee esg performance rating metric time year gsk operate global environment biopharma company renew purpose unite science carbon reduction plan strong case make technology talent ahead disease transition lowcarbon inhaler salbutamol essential deliver purpose company need consider esg rescuereliever medicine gsk ventolin salbutamol impact committee oversee meter dose inhaler mdi million patient esg focus area address material globally use inhaler high global warming business issue matter stakeholder potential gwp current propellent account half work programme activity year gsk carbon footprint management update committee committee focus ask management fundamental develop propose plan transition inhaler question concern nextgeneration lowcarbon propellant successful significantly contribute gsk carbon reduction target company perform make develop lowcarbon inhaler impact esg area embed company complex involve clinical nonclinical programme strategy establish new manufacturing facility support sustainable performance long examine key consideration term growth invest lowcarbon transition programme improvement identify reduce greenhouse gas emission inhaler implement endorse management rd mdi transition programme investment case board submit readout support undertake number esg performance late early clinical datum receive deepdive evaluate support board decision november progress phase iii trial trial successful access lead regulatory submission committee review progress company aim nature plan review committee receive update improve health billion people current performance company nature positive ensure access vaccine medicine include goal achieve reduce reach billion people lowermiddle income country company environmental impact water waste llmic particular discuss material biodiversity investing protect flexible tailor operating model drive access restore nature committee satisfy nature llmic depend need goal target remain appropriate industry lead work partner right capability note standard assess verify geographical footprint deliver intervention company nature approach continue strengthen include donation affordable supply licensing pleased gsk actively help shape sure people access vaccine medicine environment source competitive advantage science need base target network nature sbtn set science base target nature framework validate company invest billion year global health rd nature target similar regulatory approach pipeline contribute build resilient health system previously adopt climatebase target give relative global health security maturity nature positive programme company please select group company antimicrobial resistance amr committee review globally target validation process accredit external amr landscape trend major threat nature target sbtn methodology finalise globally consider company holistic innovative additionally gsk commit disclose investment approach address amr threat arrangement taskforce naturerelate pleased note approach result large financial disclosure framework annual report relevant amr vaccine rd pipeline industry diversity equity inclusion delivery people dei aspiration committee hear chief people officer cpo progress company workstreams drive increase leadership diversity build diverse talent pipeline foster inclusive culture please excellent progress date discuss challenge opportunity maintain future progress area strategic report governance remuneration financial statement investor information gsk annual report board committee report continue clinical trial diversity chief scientific officer cso science committee report outline approach broaden clinical trial diversity connect patient impact committee strongly agree company clinical trial dr hal dietz accessible inclusive ensure clinical development science committee programme reflect diversity patient population impact disease study include limited pleased present report chair science age race ethnicity sex gender noted committee committee activity importance reflect epidemiological profile join committee january succeed census profile benchmark plan dr jesse goodman chair january appropriate patient representation work community group build trust awareness participation jesse chair committee create clinical trial seven year ago outstanding contribution define implement committee role remain esg performance rating important member committee offer vital insight esg performance rating rating help integrate esg work delivery strategy allow measure committee key activity split verify progress make second year important area rating committee continues oversee evolution sure meet expectation pipeline review monitor gsk pipeline key stakeholder business development undertake technical review discuss management rationale remove assurance underlie science potential business esg metric relate access scrutinise development transaction new amr metric formulated review set scientific deepdive discuss analyse key sure suitably stretch strategically scientific technology theme drive company relevant metric joined cpo cso discuss rd strategy status dei metric measure need progress performance metric pipeline progress separately committee keep inform work committee continue monitor progress lead cfo assure datum underlie esg metric rd cso dr tony wood provide regular update rating oversee audit risk progress company therapeutic area committee infectious disease hiv respiratoryimmunology oncology monitor evaluate company progress particular pipeline highlight launch metric rating half year arexvy gsk worldfirst rsv vaccine old adult recommend board publishing final track esg year vaccine gain approval eu japan performance rating alongside esg disclosure country arexvy marked turning point annual report esg performance report effort reduce burden rsv respiratory virus evade prevention therapeutic advance detail strategic report year herald wave vaccine innovation esg performance report available gsk gskcom oncology jemperli combination chemotherapy dr anne beal receive approval eu new frontline corporate responsibility committee chair treatment option decade patient dmmrmsih february primary advanced recurrent endometrial cancer approval reinforce potential jemperli redefine cancer treatment backbone immunooncology therapy number key regulatory milestone achieve year shingrix vaccine shingle approve people risk japan positive datum efficacy trial china apretude longacte preventative treatment hiv approve hiv prevention option europe ojjaaraomjjara approve eu uk treatment newly diagnose previously treat myelofibrosis patient anaemia gonorrhoea vaccine candidate receive fda fasttrack designation strategic report governance remuneration financial statement investor information gsk annual report board committee report continue committee please progress deepdive innovative science accelerate pipeline year term investment latestage pipeline drive growth year committee continue undertake rigorous decisionmake early stage pipeline scientific deepdive highly innovative maximise potential impact patient technology currently explore cso team deepdive undertake include limited rd leadership change liver disease oligonucleotide strategy continue accelerate pipeline rely attract gsk expertise infectious disease immunology human good people foster culture ambitious genetic drive research chronic hepatitis b patient accountable impact right new datum present bepirovirsen improve thing committee please rd understand heterogeneous nature hepatitis b leadership change year include create infection insight bclear btogether phase dedicated research unit vaccine infectious disease iib trial bepirovirsen help gsk progress respiratory immunology oncology hiv research comprehensive functional cure people live chronic operate global specialist hiv company viiv hepatitis b common cause chronic liver disease healthcare deepdive oligonucleotidebase therapeutic change mean company well focus core strategy position gsk achieve leadership field therapeutic area easily identify target oligonucleotide unique ability address wide range good outcome patient support new genomic target therapeutic area team single research technology organisation mean offer enormous potential help patient bring platform data group integrate disease historically difficult treat technology effectively gsk workflow company collaboration wave life sciences initiate business development transaction bring wave prismtm platform gsk demerger cso team work hard expertise genetic genomic progress accelerate business development complement gsk organic preclinical programme collaboration grant gsk pipeline call committee devote nearly twice exclusive licence wave preclinical programme treat time meeting critically vet business alpha antitrypsin deficiency complement gsk development proposal transaction compare clinicalphase oligonucleotide include bepirovirsen year committee change transaction review committee year chair change include committee composition work underway bellus health acquisition bellus latestage nomination corporate governance committee refresh biopharmaceutical company work well life board scientific expertise include successor dr jesse patient suffer refractory chronic cough rcc goodman retire board look acquisition provide gsk access camlipixant forward provide update year potential bestinclass treatment phase iii development dr hal dietz firstline treatment rcc acquisition align gsk science committee chair expertise prioritisation respiratory medicine february hansoh pharma exclusive licence agreement antibodydrug conjugate hs bestinclass potential ovarian endometrial cancer hs promise initial clinical activity lung cancer potential address unmet medical need broad solid tumour indication aiolos bio acquisition aiolos closed february add aio gsk respiratory biologics portfolio aio phase iiready longacting antibody redefine standard care asthma patient dose month potential expand company reach broad range asthma patient arrowhead pharmaceutical janssen pharmaceuticals transfer exclusive worldwide right development commercialisation investigational therapeutic treat chronic hepatitis b gsk plan evaluate drug sequential regiman bepirovirsen gsk investigational antisense oligonucleotide treatment chronic hepatitis b transaction potential redefine treatment paradigm chronic hepatitis b enable patient achieve functional cure committee confident transaction strong scientific justification look forward seeing develop year strategic report governance remuneration financial statement investor information gsk annual report board committee report continue nomination corporate governance board glt diversity committee report commit diversity board committee gsk commit equal opportunity jonathan symond employee level company board management seek support encourage diverse nomination corporate governance committee inclusive culture company please present fifth report chair effective board include range balance skill nomination corporate governance committee experience knowledge diversity ethnicity committee gender sexual orientation professional socialeconomic evolving board pipeline talent background disability age independence individual prepare challenge collaboratively corporate governance statement discuss mix complement diversity personal board important board appointment process attribute include character intellect judgement honesty undertake recently julie brown new cfo appoint courage september join board wendy becker new remuneration committee chair designate committee responsible develop measurable appoint joined board second half objective line relevant regulatory good practice transition process underway enable wendy succeed urs target monitor progress rohner remuneration committee chair close implement board diversity policy policy include agm appointment tailor biopharma gender ethnicity diversity target apply company board committee minimum seek align policy objective financial conduct authority fca ftse committee seeks follow good practice search woman leader review parker review diversity target make appointment recommend board regulatory good practice target ensure agree criterion role appropriate diverse consistent public dei aspiration currently interview panel consider comprehensive diverse meet exceed policy objective regulatory longlist candidate shortlist candidate interview good practice target show assess choose criterion diligence undertaken committee make final board glt diversity datum collection recommendation executive search firm appoint year diversity datum gather directly self accord company procurement policy base identify basis follow expertise relative role board member questionnaire committee engage search firm signatorie voluntary code conduct executive search firm glt member individual election hold gsk hr database gender diversity good practice diversity datum publish follow section report committee work number executive search firm december date publication provide additional consultancy service continue oversee develop pipeline direct company korn ferry general recruitment executive search report glt gender ethnically diverse assessment service hrrelate service egon backgrounds zehnder executive search assessment coach service specific senior executive russell reynolds executive detail gsk representation woman ethnically search service diverse leader cover diversity global workforce please progress dei committee review potential conflict interest commitment include gender ethnicity illustrate judge appropriate safeguard esg performance report gskcom good progress conflict look forward report committee boost introduce dei measure continue work progress evolve board annual bonus arrangement executive year report director glt members committee continue review diverse talent sir jonathan symond succession pipeline development plan key nomination corporate governance committee chair management role successor year february undertake deepdive emerge senior talent glt identify people exceed expectation exceptionally talented potential glt role future include review strategic approach talent development planning board seeks meet individual employee reception board engagement opportunity strategic report governance remuneration financial statement investor information gsk annual report board committee report continue diversity equity inclusion ethnicity gender female composition current post agm l ethnically diverse l currenthistoric l white l expect target female representation board datum gsk annual report publish quarter year current female representation include allfemale executive board run ftse company expect rise urs rohner retires board board glt diversity objective status objective performance board position hold woman meet director woman senior board position ceo cfo sid andor chair end exceed ceo cfo glt position hold woman exceed board director ethnically diverse exceed director glt member ethnically diverse end meet glt member fca uk list rule diversity report number senior position board percentage number board percentage ceo cfo sid number executive executive member board chair management management gender identity sex man woman specifiedpreferre ethnic background white british white include minority white group mixedmultiple ethnic group asianasian british blackafricancaribbeanblack british ethnic group include arab specifiedpreferre strategic report governance remuneration financial statement investor information gsk annual report board committee report continue audit risk committee report technology datum privacy ethic rapidly evolve principal risk committee oversight number privacy law charle bancroft regulation base eu general data protection audit risk committee regulation increase number territory world consequently committee interested pleased present report chair understand regulatory approach adopt audit risk committee committee big market include india china follow page aim share insight activity affect gsk operation include rd undertake overseen committee year operation gsk year focus global biopharma committee receive regular report robust company committee review key operational feature integrate governance framework gsk operate monitor risk governance platform underpin purpose govern use datum generally gsk framework unite science technology talent ahead disease specialist governance board include representative please report progress member relevant internal function framework committee expand remit oversee review esg data augment team legal assurance compliance function expertise advise global digital committee continue primary oversight privacy cyber security matter zantac litigation regular legally privileged update committee discuss tenet new enhance review relate accounting disclosure flexible datum privacy model introduce expect communication requirement committee review comprise global privacy principle standardise global current indicative timeline case report summarise control meet eu standards reward key matter board awareness input decision flexibility adopt different standard local law continue defend claim bring vigorously base incompatible gsk standardised global control provide science meet gsk global privacy principle base work committee inspect gsk detail measure take year mitigate continue exhibit strong compliance culture risk describe consistent tone engagement run organisation financial reporting information cyber security principal risk gsk control framework remain robust require area remains stand agenda item fundamental change year discuss schedule meeting science chief digital technology officer cdto chief information security officer ciso chief compliance strategic vaccine partnership china q officer cco present update information cyber company enter exclusive agreement chongqe security assessment status associate zhifei biological products ltd zhifei copromote shingrix key risk indicator china support accelerate market penetration innovative vaccine committee scrutinise cdto skill experience especially relate arrangement conclude significant cyber security set ciso spend time resource devote diligence career building lead technology team arrangement key control introduce ensure functional area include cyber security infrastructure compliance expectation met mitigate risk digital communication healthcare company responsible establish cyber security function committee satisfy ongoing governance haleon plc prior demerger framework monthly review monitor arrangement appropriate experienced compliance cco focus ensure consistent cohesive personnel allocate support partnership approach information cyber security operate aspect business enterprise risk management chief patient officer new role chief patient officer cco responsible risk analytic monitoring establish begin committee organisation previous experience create assess control governance arrangement dedicated global risk office combine enterprise risk new role chief patient officer primary role provide management reporting activity gsk medical leadership overarch gsk asset disease strategy chief patient officer report chief year committee review progress commercial officer ensure patient treat gsk year update multiyear cyber security plan product benefit robust compliant scientific information plan benchmarke national institute line commitment patient standard technology cyber security framework nist csf end help validate company satisfied key area medical ethic capability improve committee examine result safety execution clinical trial clear line internal nist assessment undertake jointly escalation chief medical officer enhance tech audit assurance function build company internal control framework independent assessment committee review schedule business monitoring protocol external nist review specialist independent cyber expert look forward provide update result independent review report year strategic report governance remuneration financial statement investor information gsk annual report board committee report continue committee closely follow esg data assurance development finalisation introduction security committee oversaw creation implementation q exchange commission sec new cyber security rule rule new dedicated esg datum assurance hub effective end satisfied finance organisation formally establish consistent company foreign private issuer take necessary approach governance process control governance step ensure compliance develop improve assurance esg data requirement support company performance key esg metric committee assess adequacy gsk insurance risk corporate responsibility committee behalf coverage arrangement annually include information board continues oversee esg strategy performance cyber security risk insurance risk programme assessment report review communicate committee recommendation hub initial focus environmental datum later board implementation process capability develop hub look social agenda cyber security training glt governance area soon committee include cyber security simulation exercises learning oversee development implementation technology wide workforce discuss mandatory training solution automate information gathering supplement new joiner regular phishingsimulation exercise level process control standard surround esg performance datum highlight previously relevant cyber security expertise board colleague dr vishal sikka bring deliberation look forward committee continue review look strengthen oversight area upcoming regulation affect future esg run bespoke cyber incident training session assurance reporting obligation director cyberrelate experience include highlight hub horizonscanne activity board biography page particular committee discuss initial result ongoing impact assessment underway corporate detail measure take year sustainability report directive directive mitigate risk describe partially effective reporting year artificial intelligence ai rapid advancement ai fully effective consolidated reporting level gsk particular generative technology potential application aware reporting arrangement reflect company present significant opportunity drive publish sec climate regulation expect innovation growth productivity effective financial year accelerate purpose end board review internal control framework opportunity scale use ai potential competitive advantage balanced awareness board recognise obligation present fair balanced lack harmonisation new emerge regulation understandable assessment gsk current position govern ethical responsible use ai new trend prospect accountable evaluating approving impact risk profile research practice scientific effectiveness gsk internal control include financial patient engagement data ethic privacy operational compliance control risk management information cyber security principal risk process future impact gsk value chain ensure reliability financial reporting development monitor closely compliance law regulations internal management committee control framework comprehensive enterprisewide risk end board approve establishment ai management model support board identify governance council council cochaire general evaluate manage group principal emerge risk counsel cdto comprise crossfunctional expert require frc code framework design particular council assess business activity manage risk gsk achieve business objective current risk environment internal control fitforpurpose framework complement corporate framework importantly council fully connected key culture speak process ensure risk datum management board data ethic privacy associate business activity actively information cyber security please report effectively control line agree risk appetite council approve implement suite write believe gsk framework provide reasonable absolute standard control adopt new ai tool training assurance material misstatement loss tailor developer procurer user ai board mandate group risk oversight committee auditor share goal leverage compliance council rocc senior leader support technology appropriate particularly interested committee oversee risk management internal control discuss auditor use ai deliver activity provide business framework risk increase effectiveness efficiency audit management escalation significant risk risk keen well understand opportunity gsk use management compliance board rmcbs scalable aienabled innovation improve speed group promote tone establish risk performance tracking detection capability culture ensure effective oversight internal control key stay ahead increasingly sophisticated risk management process threat group party area continue focus strategic report governance remuneration financial statement investor information gsk annual report board committee report continue principal risk assign risk owner draw committee receive regular report principal risk senior management accountable managing owner compliance aa area significant risk principal risk oversight glt member include group relate internal control report assess set implement risk mitigation plan risk owner internal control environment principal risk area report quarterly respective risk management approach include enhancement strengthen control progress rocc appropriate board consider report committee report annually committee compliance function assist rocc board effectiveness gsk internal control rmcbs compliance responsible advance enterprise authority delegate committee wide risk management develop riskbase board conduct robust assessment group principal ethically sound work practice actively promote risk assessment line frc code include ethical behaviour enable employee operate line consideration nature extent risk board culture comply applicable law willing achieve gsk strategic objective regulation board committee oversee effectiveness audit assurance aa function provide independent internal control environment risk management assurance senior management board process group year effectiveness risk management groupwide line approval date annual report agree assurance plan help senior management board meet oversight advisory responsibility detail review group risk management fulfil gsk strategic objective build trust patient approach discuss risk management section stakeholder aa dual reporting line cfo strategic report page committee management principal risk explain principal risk uncertaintie page group viability discuss strategic report strategic report governance remuneration financial statement investor information gsk annual report board committee report continue significant issue relate financial statement consider gsk quarterly financial result announcement financial result annual report committee review significant issue management judgement determine result review management paper set key area risk action take quantify effect relevant issue judgement management appropriate accounting require address issue financial statement significant issue consider relation financial statement year end december set follow table summary financial outcomes appropriate committee external auditor discuss significant issue address committee year area particular audit focus describe independent auditor report page significant issue consider committee relation financial statement issue address committee go concern basis preparation committee consider outcome management halfyearly yearend financial statement review current forecast net debt position financing facility option available group committee consider management review impact current economic environment climate change follow consideration assessment include stress testing viability scenario sources liquidity funding forecast estimate committee confirm application go concern basis preparation financial statement continue appropriate revenue recognition include return committee review management approach time recognition rebate rar accrual revenue accrual customer return rebate rar accrual commercial operation billion december committee review basis accrual concurred management judgement amount involved full description process operate commercial operation determine level accrual necessary set critical accounting policy page provision legal matter include committee receive detailed report actual potential litigation investigation group internal external legal counsel include zantac litigation commercial practice number detailed update investigation group commercial practice management outlined level provision correspond disclosure consider necessary respect potential adverse litigation outcome area possible determine provision necessary december provision legal matter billion note financial statement provision detail provision uncertain tax position committee consider current tax dispute area potential risk concur management judgement level tax contingency require december tax payable liability billion include provision uncertain tax position recognise group balance sheet impairment intangible asset committee review management process review testing goodwill intangible asset potential impairment committee accept management judgement intangible asset require writing result impairment loss million note financial statement intangible asset detail valuation contingent consideration committee consider management judgement necessary relation viiv healthcare increase liability pay contingent consideration primarily result update exchange rate assumption increase sale forecast unwind discount cash payment nearly billion year december group balance sheet include contingent consideration liability billion relation viiv healthcare note financial statement contingent consideration liability detail viiv healthcare option committee review agree accounting pfizer option concur management judgement valuation option billion december strategic report governance remuneration financial statement investor information gsk annual report board committee report continue effectiveness quality external audit auditor reappointment process external auditor committee commit make sure gsk receive external auditor appointment highquality effective external audit evaluate tender maydecember deloitte performance prior make recommendation reappointment early transition year committee review effectiveness performance shareholder approval current criterion agree management auditor beginning audit annual report fyear end december detailed criterion judge deloitte effectiveness new lead audit engagement partner external auditor available gskcom base audit approach strategy ensure highquality audit tender require effect regulation independent audit effective partnership value money committee monitor engagement external contractual similar obligation restrict stakeholder relevant area oversight include group choice external auditor frc securities exchange commission audit partner rotation seek ensure deloitte deliver smooth thorough efficiently execute audit external auditor require rotate audit engagement consider partner gsk year overall quality audit previous audit partner step march independence deloitte audit gsk financial statement conclude deloitte show appropriate level challenge robust review process committee scepticism work cfo new audit partner select committee approve appointment effect deloitte length tenure take account start financial year assess independence objectivity give commence role auditor committee satisfied deloitte manage orderly handover consider effectively assume role auditor new audit engagement partner resulted committee consider feedback external seamless transition maintenance high level audit audit survey committee member quality effectiveness report year financial management team corporate business unit level survey cover audit tender effectiveness auditor challenge committee consider company comply mandatory audit process audit integrity deloitte committee responsibility provision competition transparency report management market authority statutory audit service order committee auditor effective use technology deloitte continue maintain independence clarity auditor communication way work objectivity committee remain satisfied quality audit team leadership performance gsk intend tender external skill experience audit team auditor contract end current require period year identify consider good committee chair regularly meet independently interest shareholder committee mindful audit partner meet auditor privately appointment new cfo gsk audit partner end committee meeting discuss progress deloitte financial year helpful appropriate mitigate risk overfamiliarity company auditor review feedback note area improvement implement audit team committee satisfied effectiveness auditor external audit process auditor independence qualification objectivity expertise resource agree recommend board deloitte reappointment agm free influence party strategic report governance remuneration financial statement investor information gsk annual report board committee report continue nonaudit services audit service comparison management operate presumption accountancy firm ordinarily provide nonaudit services gsk external auditor skill experience suitable supplier nonaudit support auditrelated matter tax service good interest company line gsks nonaudit service policy committee ensure auditor objectivity independence safeguard review preapprove external auditor provision service company policy complie frc revise ethical standard sarbanesoxley act observe follow core l audit service policy feature engage external auditor nonaudit services l assurance services gsk nonaudit services policy key feature fee payable deloitte nonaudit service relate consumer healthcare demerger million process nonaudit service million set annual report competitive tender financial service provider annual report respectively fee line group procurement process million pay auditor respect gsk pension scheme skill experience external auditor suitable supplier fee pay company auditor associate safeguard adequate safeguard establish set detail give note objectivity independence group audit threaten compromise financial statement operate profit fee cap total fee payable nonaudit services committee consider level nonaudit service exceed annual audit fee special incur annual review deloitte independence circumstance clear advantage set previous satisfied auditor auditor undertaking additional work continue independent exercise objectivity prohibition gsk policy include whitelist permit nonaudit service line relevant regulation service list prohibit fair balanced understandable assessment preapproval nonaudit service require preapproval set need annual report fair balanced table ensure service approve understandable key compliance requirement consistent gsk nonaudit policy permissible company financial statement ensure gsk annual service process ensure service fall report meet requirement wellestablished scope service permit preapproved document process govern coordination review committee represent delegation groupwide contribution publication run parallel authority preapproval process follow external auditor value preapprover committee receive summary management approach committee chair cfo gsk annual report ensure meet requirement frcs code enable committee board group financial controller confirm gsk annual report fair balanced understandable provide necessary designate group information shareholder assess company position financial controller performance business model strategy code conduct report line number wellestablishe policy include new code conduct available gskcom detail confidential speak line report investigate unlawful conduct charles bancroft audit risk committee chair february strategic report governance remuneration financial statement investor information gsk annual report remuneration report committee chair annual statement dear shareholder longterm incentive lti awards behalf remuneration committee please grant performance share plan present remuneration report include psp award vest base performance end annual statement explain committee work year award vest measure annual report remuneration summary vest pipeline progress measure remuneration policy approve shareholder vest innovation sale measure agm available page respectively cash flow measure vest annual report gskcom context remuneration outcome remain disappointed achieve vest outlined early report gsk deliver strong relative tsr measure reflect adverse performance sale adjust operate profit share price reaction zantac litigation period adjust eps grow doubledigit level year recognise relative concern exclude covid solution strong pipeline strength company pipeline confident progress major product approval include progress make develop portfolio world rsv vaccine arexvy improve longerterm outlook growth increasingly reflect gsk valuation overall company deliver step change performance commitment previously summary incentive outcome shareholder follow review contextual factor include previous payout committee believe outcome second year operation company new appropriately reflect performance round remuneration policy fundamental consider experience stakeholder include architecture gsk postseparation ensure build shareholder employee performance culture generate sustain delivery shareholder value incentive award relation accordance remuneration policy confirm policy well link executive remuneration delivery follow careful review committee deem outperformance annual bonus opportunity necessary exercise discretion significantly reduce target performance increase exceptional outperformance new remuneration policy implementation scheme increase bonus opportunity annual bonus lti increase potential cash reward executive incremental award deliver form share defer committee determine change year bonus lti measure total sale growth adjust operate profit growth target exclude annual bonus commercial benefit covid solution delivery committee review bonus annual bonus measure continue base outcomes ceo cfo annual total sale growth term financial measure company deliver sale growth adjust operate profit growth annual adjust operating profit growth exclude covid solution significantly high guidance company provide personal performance strategic operational start year market expectation strongly measure support delivery gsk growth outlook period esg diversity equity inclusion dei psp measure remain strong performance lead overall payout financial element bonus salary relative tsr target set consideration analyst consensus total sale growth year committee comfortable payout representative strong performance adjust operate profit growth year committee review performance non pipeline progress financial measure previously disclose esg environment composite scorecard executive delivery specific individual strategic operational measure performance target calibrate consider number internal external reference point particular performance combine overall payout analyst consensus challenge metric maximum salary ceo input science corporate responsibility salary deliver deferred share committee relevant committee salary cfo salary proration satisfied target set suitably stretch period employ salary deliver deferred share salary committee note increase agree wide workforce uk careful consideration include review market ceo cfos competitive positioning agree receive salary increase strategic report governance remuneration financial statement investor information gsk annual report committee chair annual statement continue workforce fairness thank set executive pay important committee like opportunity thank fellow good understanding group wide workforce committee member shareholder support approach pay emphasis fairness equity engagement tenure committee chair end annual basis meet senior human welcome feedback look forward receive resource leader company understand support report annual general meeting perspective pay gsk remuneration arrangement wide workforce globally year fifth annual meeting hold detail important urs rohner check give remuneration committee chair february board change announce september julie brown joined board cfo point iain mackay step board detail join leave arrangement transition describe year report remuneration committee chair succession finally retire nonexecutive director gsk agm final report chair committee delight welcome wendy becker join committee october wendy work smooth transition handover succeed committee chair wealth experience chair remuneration committee look forward chair committee lead policy review committee planning undertake review effectiveness remuneration arrangement advance schedule policy renewal agm wendy jonathan symond chair look forward engage investor ensure clear perspective work update remuneration policy strategic report governance remuneration financial statement investor information gsk annual report remuneration glance total remuneration emma walmsley ceo pay performance annual bonus outcome financial measure target deliver total sale growth adjust operate profit growth overall strategic operational esg nonfinancial measure measure dei emma walmsley exceed meet julie brown exceed meet annual bonus delivery ceo cfo overall bonus overall bonus salary salary julie brown cfo l share defer year service employment l cash april psp outcome adjust free relative tsr cash flow overall vest detail cfo join arrangement l fix pay salary benefit pension pipeline progress innovation sale l performance pay annual bonus vest ltis l vest l lapse remuneration implementation base salary increase uk employee executive director benefit pension change pay performance annual ltis bonus lti measure remain follow alignment strategy bonus psp total sale growth line sale growth ambition adjust operate profit growth line adjust operate profit growth ambition strategic operational individual accountability delivery strategy public ambition emphasis innovation reward acceleration strengthen pipeline pipeline relative total shareholder return alignment shareholder nature climate ambition esg ambition dei priority exclude covid solution strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration total remuneration audit fix pay pay performance salary lti awards total pension annual bonus psp award vest remuneration benefit read page page follow section provide detail element total remuneration committee implement company shareholderapprove remuneration policy year term fix performance pay total remuneration audit emma walmsley ceo julie brown cfo iain mackay cfo fix pay salary benefit pension total fix pay pay performance annual bonus vest psp lti awards total pay performance total remuneration represent sum pay julie brown cfo buyout arrangement relation leave burberry set annual report set buyout arrangement stage year period committee seek ensure compensate likeforlike basis far possible fulfilment arrangement cfo purchase share june defer annual bonus plan dabp mandatory dabp bonus deferral set annual bonus bonus payment iain mackay represent bonus earn respect period january detail bonus pay respect remainder year find leave director section bonus payment julie brown represent bonus earn respect period december bonus period employment show psp vest total remuneration figure ceo include vest topup award vest final actual value receive update bring total value million previously report million psp vest ceo figure value base vest price february share price february date grant vested amount executive director value attributable share price appreciation performance period committee exercise discretion relation vest award share price change psp vest value cfo unreduced illustrative award vest january accordance term executive senior management recoupment policy recoupment policy award remain subject twoyear hold period start original vest date award february actual value receive update annual report detail cfos leave arrangement set leave director section ceo cfo contribute maximum month share save plan buy share share reward plan respectively detail hm revenue customs hmrc approve allemployee plan set malus clawback committee specific circumstance line state principle apply malusclawback determine appropriate follow consideration committee recovery sum pay clawback reduction outstanding award vest level malus apply respect ceo cfo cfo strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue total remuneration audit continue fix pay audit salary committee aware sensitivity stakeholder level pay set reviewing salary consider average increase award employee executive director multipli effect increase base salary total remuneration opportunity committee consider wide economic context individual performance market positioning increase award table set base salary increase agree executive director compare increase uk workforce salary change effective date uk employee april emma walmsley january julie brown julie brown salary announcement appointment september set line predecessor give extensive experience cfo salary join increase reflect increase award uk employee ceo early benefit benefit table provide analysis total benefit gross tax receive executive director emma walmsley uk remuneration reporting regulation require benefit available employee company add executive director total benefit item deem tax authority taxable businessrelate service benefit include employee benefit total benefit businessrelate service provide employee assist enable carry role tax authority julie brown deem taxable benefit individual benefit available employee business expense company meet tax businessrelate service arise item show gross tax total benefit pension january pension arrangement executive director align wide workforce receive gsk pension contribution cash supplement base salary matching contribution salary march salary rest table show breakdown pension value include total remuneration calculate set uk large mediumsize company group account report regulation amend remuneration regulation emma walmsley julie brown pension remuneration value uk define contribution employer cash contribution pension strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue pay performance audit annual bonus adjust strategic total sale esg operate profit operational growth dei annual bonus growth measure l financial measure l nonfinancial measure annual bonus performance follow table show annual bonus earn compare bonus opportunity bonus bonus opportunity outcome pay share target maximum salary maximum dabp bonus salary salary bonus salary cash award emma walmsley julie brown detail mandatory deferral executive director dabp bonus set detail iain mackay bonus arrangement follow retirement company julie brown bonus prorate reflect period employ table provide detail bonus executive director financial measure total sale growth adjust operate profit growth target set follow consideration analyst consensus internal budget threshold maximum performance target growth respectively total sale growth adjust operate profit growth target outcome purpose annual bonus calculation base cer exclude commercial benefit covid solution overview performance financial performance measure gsk deliver strong performance sale adjust operating profit adjust ep grow double digit level year exclude covid solution significantly high guidance provide start year strongly support delivery gsk growth outlook period deliver fullyear report group sale billion aer cer exclude covid solution vaccine growth aer cer arexvy sale billion launch q specialty growth aer cer exclude covid solution adjust group operating profit cer growth exclude covid solution drive high sale support prioritise increase investment rd new product launch adjust eps p aer cer exclude covid solution ahead update guidance strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue pay performance audit continue strategic operational measure committee receive consider performance assessment report executive director show extent achievement individual personal strategic operational measure agree committee support delivery strategic commitment financial element annual bonus committee satisfied scale executive director achievement year excellent achievement focus pipeline commercial execution continue evolution culture achievement performance assessment emma walmsley innovation deliver pipeline progression target major product approval rsv prevention hiv exceed prevention oncology deliver innovation sale successful launch include arexvy new product launch contribute billion sale upgrade longterm outlook sale profit outlook sale adjust operate profit growth cagr exclude covid solution sale outlook increase billion cer average rate performance deliver financial plan exceed guidance set sale exclude covid exceed solution adjust operating profit positive impact exclude covid solution adjust eps grow positive impact exclude covid solution cer group sale billion trust sector leader sp global corporate sustainability assessment exceed access global health million people low income country reach access partnership malaria vaccine roll country global health pipeline asset progress environmental sustainability progress kpi include progression low carbon ventolin inhaler programme phase iii development diversity equity inclusion aspiration gender diversity uk ethnicity aspiration vp achieve culture annual survey employee engagement report increase exceed committee determine ceo clearly exceed individual objective maximum attribute overall bonus julie brown demonstrate deep review pipeline forecasting support upgrade longterm outlook exceed financial design new investor engagement programme include development investor relation leadership roadmap communication longterm outlook cost discipline deep review capital allocation pipeline value unlock support investment organic rd exceed cash flow business development maximise return shareholder management initiate work drive pl efficiency focus sga operating margin improvement demonstrate successfully integrate gsk establish strong partnership working ceo member meet strong glt notable output support rd commercial organisation culture leadership committee determined cfo clearly meet individual objective maximum attribute overall bonus esg dei aspiration emma walmsley julie brown payout level enterprise target meet directorate target meet nil enterprise target meet directorate target personal directorate target meet target enterprise directorate target meet maximum outcome achieve maximum payout maximum payout overview performance dei aspiration esg dei measure reinforce delivery commitment create diverse equitable inclusive workplace broader dei commitment set effort meet aspirational target diversity senior leadership committee agree interim annual aspirational target include global gender representation uk race ethnicity representation aspiration enterprise level ceo directorate level cfo internal governance team audit performance aspiration committee delivery interim aspiration meet year end gsk enterprise performance gender representation ethnicity uk ethnicity vp employee population julie brown directorate meet aspiration strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue pay performance audit continue vest psp lti awards pipeline innovation adjust free relative total progress sale cash flow shareholder return total vested lti overview performance line committee agree principle actual performance measure carefully review adjustment appropriate ensure vest outcome reflect genuine underlie business performance deliver line culture value committee deem necessary exercise discretion relation vest award share price change overall psp award vest target set performance period significant progress achieve accelerate delivery pipeline near vest achieve innovation sale reflect increase performance trelegy nucala dovato benlysta period strong performance evidence vest adjust free cash flow pipeline progress element disappointingly nilveste relative tsr percentage award value vest rounded number presentational purpose psp outcome outcome vest level performance measure relative weighting performance target outcome maximum award pipeline progress target strengthen pipeline progression high quality asset pivotal trial achievement regulatory approval major market point allocate achievement equally weight element threshold maximum measure pivotal trial start point major regulatory approval milestone point innovation sale recognise importance launch new product successfully billion driving performance key commercial success measure aggregate threeyear sale new innovative product launch year performance period precede year ie innovation sale billion vest maximum threshold adjust free line company agree principle afcf figure include billion cash flow afcf adjustment number material distort item include legal settlement exchange rate movement special pension contribution revise target billion vest maximum threshold revise target adjust annual report note relative tsr tsr ranking comparator rank th group company vest maximum st nd rd th th threshold median th th median vest threshold fall company relative tsr comparator group set total vest respect psp award afcf measure target threshold associate vest scale psp award adjust restate annual report net overall impact increase revise target billion billion psp award adjustment take account revise timing restructuring payment link future ready programme strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue pay performance audit continue psp vest value vest share grant vested emma walmsley number share vest value represent vest include dividend reinvestment performance period base vest price february psp award dr hal barron vest adjust time work performance period include dividend reinvestment share vest value million share sell tax hold year term recoupment policy committee aware guidance investor body potential executive benefit arise share award grant time stock market fall onset covid march remuneration policy contain sufficient flexibility reduce vest award require reduction require respect award grant february make determination committee consider share price time february award final quarter time previous award february whilst upward downward movement gsk share price period take point consideration committee satisfied risk windfall gain lti grant dabp award respect deferral bonus psp award set dabp award psp award face value face value total number award award level number award bonus defer share base salary share emma walmsley julie brown iain mackay face value dabp award calculate base share price closing price february day grant nilcost option executive director performance condition attach dabp award reflect mandatory threeyear deferral respect annual bonus face value psp award calculate base share price emma walmsley julie brown closing price february april respectively day respective grant unreduce psp award julie brown grant conjunction join arrangement detail annual report conditional share base performance measure iain mackay receive psp award retirement company performance period psp award january december awards vest maximum threshold performance director remuneration report detail measure target awards historical vest lti plan follow table summarise lti vest performance measure gsk year relative tsr adjust free cash flow innovation sale previously rd new product pipeline progress business diversification total vested allemployee share plan executive director participate hmrc approve allemployee share plan company share save share reward plan wide uk workforce participant share save plan save month year option buy gsk share discount share price start saving contract participant share reward plan contribute month purchase gsk share company match oneforone basis malus clawback policy exist policy malus clawback provide remuneration policy report annual report available gskcom committee review disclose recoupment committee exercise malus clawback disclosure matter subject public report misconduct fully resolve legally permissible disclose unduly prejudice company shareholder line disclosure guideline matter report administrative amendment malus clawback section remuneration policy describe annual report approve shareholders agm committee adopt additional clawback policy accordance securities exchange commission new clawback rule effective november detail exist policy recruitment remuneration loss office termination payment refer remuneration policy report page annual report available gskcom strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue pay performance audit continued pay performance annual bonus performance measure change operation annual bonus plan detail policy refer page annual report bonus opportunity salary target maximum emma walmsley julie brown equivalent salary defer portion excess defer weighting performance measure weight performance measure adjust operating profit strategic operational esg diversity equity total sale growth growth measure inclusion emma walmsley julie brown inevitably target link directly financial strategic plan commercially sensitive committee consider appropriate disclose annual bonus target year result competitive harm detail performance target usual disclose retrospective basis annual report lti award table provide detail mandatory deferral dabp annual bonus payment associate award grant share award performance condition hold year regardless continue employment award grant psp dabp award psp award bonus defer number face value face value award share salary share award base salary number share emma walmsley julie brown strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue pay performance audit continued lti performance measure measure weighting award remain unchanged award measure weight innovation pipeline progress performance relative tsr total sale growth adjust operate profit growth trust esg environment innovation performance pipeline progress measure seek reward acceleration relative tsr continue measure gsk strengthen pipeline base equally global pharmaceutical comparator group weighted element key asset indication measure total sale growth adjust operate profit growth threeyear performance period measure recognise importance commercial ambition target total sale growth adjust point allocate successful asset submeasure operating profit growth commercially sensitive base forecast commercial value peak year sale time grant end performance period submeasures award vest follow trust pivotal trial start esg environment measure base climate nature goal target award focuses mainly phase iii registrational trial start focus nature goal relate water waste material include phase ii start reduction biodiversity impact climate goal incorporate scope emission reduction target carbon performance level point payout offset industrialisation availability green threshold nil ventolin threshold achieve vest target measure achieve end climate nature maximum vest target measure achieve end major regulatory approval vest measure meet target performance level point payout vest measure threshold nil climate nature exceed threshold target maximum pipeline progress measure commercially sensitive time grant end performance period provide disclosure achieve strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue director pay wider set internal context comparison remuneration structure employee executive director element wide workforce executive director pay salary market competitiveness base salary company assess local market level competitiveness role keep regular review increase reflect change scope individual role responsibility experience executive director follow performance review increase base salary consider line market practice average increase wide employee population comparator tool agree increase executive director committee mindful multipli effect individual total remuneration benefit company seek provide appropriate benefit pension package align competitive pension market practice country company operate employee executive director base annual exception sale force participate separate arrangement wide workforce bonus participate plan base performance business financial measure structure reflect priority specific business area plan design reward employee collective contribution business achievement separate mechanism place recognise outstanding individual performance address performance executive director participate plan follow bonus salary pay cash share defer year bonus earn excess maximum salary deliver fully share defer year clawback andor malus provision apply lti plan senior vice president svp vice president vp employee participate performance share plan executive director clawback andor malus provision apply svp vp employee director manager glt receive annual share value plan award restrict share share ukbased employee participate hmrc approve share save share reward employee share ownership plan dilution limit award plan incorporate dilution limit consistent guideline publish investment association limit roll tenyear period plan roll tenyear period executive share plan grant senior executive estimate dilution exist award year december follow gsk employee share plan executive share plan strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue director pay wide set continue ceo wide employee pay ratio low quartile median upper quartile financial year p p p gsk continue use option methodology robust statistically accurate way calculate ratio option available remuneration regulation pay ratio high influence company strong performance deliver increase bonus ceo vest high previous year improvement gsk share price award grant vested pay ratio calculate actual earning ceo uk employee ceo total single figure remuneration million million detailed total remuneration uk fulltime equivalent employee december calculate line single figure methodology reflect actual earning receive exclude business expense produce percentile calculation option remuneration regulation business expense exclude reimburse employee sufficiently substantial value significantly impact ratio table show salary total pay benefit percentile p p p salary total pay benefit committee believe median pay ratio consistent company pay reward progression policy base salarie employee include executive director set reference range factor include market practice experience performance role relative importance spend pay table show total employee pay dividend pay figure table reflect payment shareholder year impact movement exchange rate set page cash dividend change declare respect million million decrease note financial total employee pay statement detail dividend pay year total employee pay base employee average number people employ note financial statement detail share repurchase company strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue director pay wide set continue external context target ceo total remuneration position comparator group review ceo remuneration committee european crossindustry comparator group primary comparator group european crossindustry committee primary comparator group ceo cfo comparator group reference pay global global pharmaceutical comparator group secondary pharmaceutical comparator group group ceo measure relative tsr performance european crossindustry comparator group roche holding ag linde deutsche telekom novartis sanofi kere lvmh astrazeneca heineken anheuserbusch inbev diageo basf unilever siemens vinci sap christian dior adida loreal inditex bayer novo nordisk bat safran airbus volkswagen reckitt benckiser remuneration include salary expect value incentive base global pharmaceutical comparator group committee agree benchmarke methodology france sanofi abbvie historic ceo remuneration amgen switzerland bristolmyers squibb emma walmsley novartis eli lilly roche holdings johnson johnson merck co reo mta ul n eration u ak strazeneca pfizer maximum abbvie amgen include remuneration benchmarke annual bonus include relative tsr performance comparator group award vest lti tsr performance graph award follow graph set performance company sir andrew witty relative ftse index global pharmaceutical performance comparator group tenyear period total remuneration december index select comparison purpose reflect primary index gsk maximum constituent industry gsk operate annual bonus award vest lti awards emma walmsley total remuneration include pay period january march ceo sir andrew witty receive prorata payment lieu variable bonus opportunity accordance remuneration policy psp dabp awards sir andrew witty grant vest april accordance term recoupment policy strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue remuneration governance committee role membership principal proxy advisory firm consult regularly detail available incorporate invite annual governance meeting reference report chair ceo chief people send engagement letter committee company officer head reward group financial controller chair company secretary assisted committee year agm voting adviser committee detail voting level respect remuneration independent willis tower watson plc wtw arrangement set adviser wtw member remuneration consultant vote group operate code conduct executive remuneration consulting uk total vote total vote total vote withhold cast billion million access wwwremunerationconsultantsgroupcom agm appoint december follow tender process remuneration report advice provide committee comfortable wtw amendment engagement partner team provide remuneration policy remuneration advice committee agm connection company director impair independence remuneration report fee charge time material basis remuneration policy month conflict wtw provide market datum hr consulting interest service company committee regularly review arrangement potential conflict appropriate ensure safeguard place statement consideration shareholder view committee engage regular dialogue shareholder hold regular meeting gsk large investor discuss feedback remuneration policy practice governance matter ongoing engagement detail extensive consultation committee company chair remuneration matter prior agm vote continue engagement shareholder set shareholder engagement investor share capital event date participation represent meeting hold prior january april investors agm meeting hold investor agm february publication annual report annual governance meeting invitation november investor attendance december investor strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue remuneration governance continue committee focus item discuss remuneration policy prepare agree propose administrative amendment remuneration policy continue engagement shareholder review consider shareholder proxy advisor feedback fix pay consider executive director glt performance benchmarke competitiveness gsk comparator group review glt company secretary salary recommendation executive director salary review recommendation review company chair fee pay performance annual bonus executive director glt bonus recommendation set executive director bonus objective lti plan consider lti performance outcomes award vest ceo executive director glt confirm lti grant executive director glt governance remuneration consideration committee programme area focus committee evaluation annual review term reference approve remuneration report confirm group budget remuneration purpose consider agm remuneration report feedback external remuneration environment performance target disclosure incentive plan agree committee key message annual governance meeting committee chair consult employee representative wide workforce pay practice pay generally leave director support cfo succession transition process announce september set annual report stepping board iain mackay continue receive remuneration leave gsk december line current remuneration policy base salary increase whilst serve executive director receive total benefit comprise benefit available employee businessrelate service value pension total comprise uk define contribution employer cash contribution explanation employee end remain eligible receive bonus executive bonus plan base delivery measure describe review committee determine total year comprise cash deliver gsk share defer year dabp plan bonus value respect period serve executive director eligible receive psp award give leave gsk vest exist lti award accordance recoupment policy regard psp award ordinary share vest january award share inclusive dividend vest accordance performance describe illustrative unreduced value award disclose single figure table value time vest update annual report executive service contract end december require satisfy postemployment share ownership requirement set payment audit past director loss office payment past director loss office payment strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue nonexecutive director fee company aim provide chair nonexecutive director fee competitive pay company equivalent size complexity subject limit contain article association nonexecutive directors fee nonexecutive director fee apply set table fee annum chair fee standard ned annual fee supplemental fee chair audit risk committee senior independent director scientific medical expert chair remuneration corporate responsibility science committee appoint workforce engagement director science committee member undertake significant additional responsibility behalf gsk follow review approval committee end determine chair fee increase effect january chair ceo recommend board approve increase nonexecutive director standard annual fee effect january line increase award wide uk workforce total fee audit audit table set value fee benefit receive nonexecutive director form cash share ad nonexecutive director fee pay currency sterling convert average exchange rate review time time average exchange rate update nonexecutive director fee convert dollar exchange rate benefit comprise gross cash value travel subsistence cost incur normal course business relation attendance board committee meeting fulfil role fix fee fix fee nonexecutive director emolument audit cash sharesad benefit total pay cash sharesad benefit total pay sir jonathan symonds elizabeth anderson charles bancroft dr hal barron dr anne beal wendy becker dr hal dietz dr jesse goodman urs rohner dr vishal sikka nonexecutive director section remuneration policy agm shareholder approve administrative amendment nonexecutive director section remuneration policy allow notional share ad previously allocate nonexecutive director plan deliver chair nonexecutive director time committee board consider appropriate applicable tax withholding chair mr rohner notional share release agm expect nonexecutive director holding release follow company agm company expect significant change fee structure chair nonexecutive director remainder remuneration policy period strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue director interest share audit executive director interest share interest executive director company office person closely associate pca show table december date retirement unvested share plan interest subject total director interest beneficial interest subject performance performance december february date retirement share share option share emma walmsley julie brown iain mackay director hold vested unexercised option total director interest include beneficial interest unvested share plan interest subject performance emma walmsley balance february include share award psp dabp vest february sell satisfy tax liability vest amount relevant share award psp dabp iain mackay vest january accordance term recoupment policy executive director shareholding sor outline beneficial interest include share hold executive director pcas emma walmsley julie brown include share share respectively purchase share reward plan unvested share subject performance represent psp share vest subject additional twoyear hold period unvested option subject performance represent bonus deferral dabp award nilcost option describe note figure exclude option option hold emma walmsley julie brown respectively share save plan unvested share subject performance represent unvested psp award iain mackay retire board dabp table show bonus deferral subsequent reinvestment dividend dabp amount represent gross share balance prior sale share satisfy tax liability vest december dabp bonus deferral february date retirement january emma walmsley julie brown iain mackay follow table set detail nilcost option exercise executive director number share date market price gain exercise date grant option exercise grant price exercise emma walmsley iain mackay nilcost option award dabp represent bonus defer executive director record remuneration annual bonus total remuneration table number share option include initial award reinveste dividend accrue date exercise executive director share ownership requirement sor audit align interest executive director shareholder require build maintain significant holding share gsk time executive director require continue satisfy sor hold sor month leave gsk sor month share subject performance condition exclude sor calculation end performance period vest share include extent performance condition meet value holding calculate posttax basis iain mackay exceed sor date retirement board continue maintain sor value holding salary sor february december salary emma walmsley julie brown strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue director interest share audit continued nonexecutive director interest share interest nonexecutive director office person closely associate pca show table prior ned share allocation plan total director interest number sharesad beneficial dividend elect ned sor interest reinveste allocate february february december december december january year end year share sir jonathan symond meet wendy becker progress urs rohner meet ad elizabeth anderson progress charles bancroft meet dr hal barron meet dr anne beal progress dr hal dietz progress dr jesse goodman meet vishal sikka meet ned share ownership requirement july company operate minimum nonexecutive director share ownership requirement ned sor time standard ned annual fee chair fee maintain retirement board chair nonexecutive director transition previous ned share allocation plan ne plan purchase share adss market net fee spend minimum net fee purchase gsk share adss market total director interest include beneficial interest notional sharesad receive fee previously operate ned plan dividend receive notional sharesad prior ned plan year january convert notional sharesad january dr hal barron include psp award vest february total interest dr barron reduce december follow vest psp dabp award grant executive capacity cso detail vest level psp show dabp vest relate deferral share annual bonus addition vest share sell meet executive tax liability detail transition cso non executive director give annual report beneficial interest include sharesad hold nonexecutive director pcas notional sharesad allocate year ned plan relate dividend reinveste year strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue percentage change remuneration director percentage change percentage change percentage change percentage change salary salary salary salary fee benefit bonus fee benefit bonus fee benefit bonus fee benefit bonus uk employee executive director emma walmsley julie brown nonexecutive director sir jonathan symonds elizabeth mckee anderson charles bancroft dr hal barron dr anne beal wendy becker dr hal dietz dr jesse goodman urs rohner dr vishal sikka retire executive director iain mackay table provide accordance schedule company director remuneration policy director remuneration report regulation uk employee population consider relevant comparison closely reflect economic environment encounter executive director percentage change calculate base total remuneration table executive director total fee table nonexecutive director information executive director salary benefit find dr hal barron transition nonexecutive director role august fee nonexecutive director include fee receive cash form share ad director senior management information provide compensation interest director senior management group group purpose group define executive nonexecutive director member glt company secretary financial year follow table set aggregate remuneration group period serve capacity remuneration total compensation pay aggregate increase accrue pension benefit net inflation aggregate payment define contribution scheme member group award share ad company lti plan set table align interest senior management shareholder executive director glt member require build maintain significant holding share gsk time glt member require hold share equivalent multiple time base salary continue satisfy share ownership requirement minimum month leave gsk award dividend reinvestment award award share ad share ad performance share plan defer investment award share value plan notional share ad executive director eligible receive defer investment award participate share value plan strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue director senior management continue february group pcas follow interest share ad company interest award lti plan describe note financial statement employee share scheme page interest february share ad own unexercised option defer annual bonus plan performance share plan defer investment award share value plan notional share executive director eligible receive defer investment award participate share value plan executive director external appointment company recognise executive director invited nonexecutive director company appointment broaden knowledge experience benefit company executive director entitle retain fee receive appointment emma walmsley independent nonexecutive director microsoft corporation year whilst iain mackay director gsk independent nonexecutive director national grid plc service contract letter appointment table set date executive director service contract available company register office gskcom date contract effective date expiry date emma walmsley julie brown na nonexecutive director letter appointment available view company register office nonexecutive director expect serve board end agm follow anniversary appointment provide elect subsequently reelect annually subject mutual agreement serve year term depend need board remuneration policy continue reflect provision uk corporate governance code code company remuneration policy approve gsk annual general meeting operate intended term company performance quantum approval policy available gskcom investor section administrative amendment approve shareholder gsk annual general meeting describe annual report clarity simplicity remuneration arrangement executive director set clear simple way risk operate deferral postvesting hold arrangement addition operate malus clawback provision committee discretion adjust award outcome predictability proportionality policy define maximum limit total annual bonus longterm incentive opportunity payout element link fulfilment performance condition support company publicly state ambition strategy alignment culture gsk purpose strategy culture continue directly reflect performance condition set annual bonus longterm incentive strategic report governance remuneration financial statement investor information gsk annual report operation scope remuneration policy remuneration policy policy set page ii policy come effect provide term annual report available governance payment consistent shareholderapprove section gskcom intend policy gsk remuneration policy force time agree executive nonexecutive director operate period iii time relevant individual director year date approval company company opinion committee annual general meeting payment consideration individual committee write policy principally relation director company purpose payment remuneration arrangement executive director whilst include committee satisfy awards variable take account possible recruitment replacement remuneration relation award share ad additional executive director operation term payment agree time award policy committee intend policy operate grant period set entirety performance share plan psp award subject term consideration seek change policy period psp plan rule award grant believe appropriate longterm committee adjust amend award success company consultation shareholder accordance provision plan rule includes seek shareholder approval general meeting make adjustment reflect oneoff corporate event committee reserve right remuneration change company capital structure payment andor payment loss office include committee minor amendment exercise discretion available connection policy regulatory exchange control tax administrative payment notwithstanding line purpose account change legislation policy term payment agree obtain shareholder approval amendment agm date company shareholderapprove director remuneration policy come effect basis preparation annual report remuneration prepare accordance company act large mediumsize company group account report amendment regulation regulation accordance regulation follow part annual report remuneration subject audit total remuneration figure executive director include detail element remuneration salary benefit pension annual bonus longterm incentive award non executive director fee emolument receive year director interest share include interest gsk share plan payment past director payment loss office share ownership requirement holding opinion thereon express remain section annual report remuneration subject audit page refer audit section annual report remuneration approve board director sign behalf urs rohner remuneration committee chair february strategic report governance remuneration financial statement investor information gsk annual report director report director power independent advice gsk director power determine uk legislation company agree procedure director article association contain rule independent legal andor financial advice company appointment replacement provide director expense deem necessary appoint ordinary resolution member indemnification director resolution board appoint board director retire annual general meeting qualify party indemnity provision define elect shareholder company act force benefit director director hold office article provide director require seek approval signature annual report reelection annually annual general meeting accordance frc code change control essential contract director cease director contract arrangement individually fundamental ability business bankrupt operate effectively company party cease director virtue company act material agreement effect altered article terminate change control follow takeover bid suffer mental physical ill health board resolve agreement director shall cease director provide compensation loss office employment result miss director meeting continuous period takeover provision company share month permission board resolve plan cause option award grant plan shall cease director vest takeover prohibit director law detail termination provision executive director resign offer resign board accept offer service contract give version company require resign board remuneration policy available gskcom director conflict interest investor section director duty company act content director report avoid situation direct indirect conflict interest possible conflict purpose uk company act director company article provide general power board report gsk plc year end december authorise conflict comprise board review new potential actual conflict director report record company secretary director count quorum authorisation actual section page potential conflict nomination corporate governance corporate governance report committee review register potential conflict employee engagement annual basis board subsequently approve director statement responsibility continue basis director responsible inform company secretary new actual investor information potential conflict arise change strategic report set matter require circumstance affect authorisation previously disclose director report consider give provide authorisation director strategic importance absolve statutory duty promote success company actual conflict arise postauthorisation strategic report board choose exclude director receipt relevant information participation debate section page suspend director board resort require risk management objective policy director resign nomination corporate governance committee likely future development company review register potential conflict authorisation research development activity register potential conflict january committee business relationship report board conflict appropriately authorise process authorisation continued diversity operate effectively committee recommend provision information consultation approval register potential conflict board employee subsequently approve describe note carbon emission financial statement relate party transaction end financial year director person closely section statement associate material interest contract significance group company article prohibit director voting resolution concern appointment term termination appointment strategic report governance remuneration financial statement investor information gsk annual report director report continue follow information incorporate director report location annual report interest capitalise financial statement note particular important postbalance financial statement sheet event company note subsidiary publication unaudited financial group financial review information detail longterm incentive remuneration report scheme waiver emolument director applicable waiver future emolument directornot applicable non preemptive issue equity cash applicable non preemptive issue equity cash applicable unlisted major subsidiary undertaking parent company participation place applicable list subsidiary provision service control applicable shareholder shareholder waiver dividend financial statement note shareholder waiver future dividend financial statement note agreement control shareholder applicable director report draw present accordance reliance english company law liability director connection report shall subject limitation restriction provide law approve board director february sign behalf sir jonathan symonds chair february gsk annual report financial statement section director statement responsibilitie independent auditor report financial statement note financial statement financial statement gsk plc prepare uk gaap strategic report governance remuneration financial statement investor information gsk annual report director statement responsibilitie director responsible prepare annual report director responsible keep adequate accounting remuneration report group parent company record sufficient explain company financial statement accordance applicable law transaction disclose reasonable accuracy regulation time financial position group enable ensure group financial statement uk company law require director prepare financial remuneration report comply company act statement financial year director require responsible safeguarding asset prepare group consolidated financial statement group take reasonable step prevention accordance ukadopte international accounting detection fraud irregularity standard conformity requirement company act international financial reporting group financial statement year end standard ifrs issue international accounting december comprise principal statement standard board iasb director elect prepare support note set financial statement parent company financial statement accordance page report parent company financial united kingdom accounting standard applicable law statement year end december comprise united kingdom generally accept accounting practice balance sheet statement change equity financial reporting standard reduce disclosure year end december support note framework company law director set page approve financial statement satisfied responsibility auditor relation financial true fair view state affair group statement set independent auditor report profit loss period prepare financial page statement director require financial statement year end december select suitable accounting policy apply include annual report publish print consistently form available website director judgement accounting estimate responsible maintenance integrity corporate reasonable prudent financial information include company website state group financial statement comply ifrs legislation united kingdom govern preparation issue iasb conformity dissemination financial statement differ requirement company act legislation jurisdiction state regard parent company financial statement applicable uk accounting standard current director name function follow subject material departure disclose list corporate governance section annual explain parent company financial statement report confirm good knowledge group financial statement prepare prepare financial statement go concern basis accordance applicable set accounting standard inappropriate presume group conformity requirement company act parent company continue business true fair view asset liability prepare group financial statement international financial position profit group accounting standard require director properly select strategic report risk section annual report apply accounting policy present information include represent management report include fair accounting policy manner provide relevant review development performance business reliable comparable understandable information provide position company group take additional disclosure compliance specific description principal risk requirement ifrs standard insufficient enable user uncertainty face understand impact particular transaction annual report financial statement take event condition entity financial position fair balanced understandable provide financial performance assessment information necessary shareholder assess company ability continue go concern company position performance business model strategy strategic report governance remuneration financial statement investor information gsk annual report director statement responsibility continue disclosure information auditor uk corporate governance code director office date annual report board consider gsk plc apply principle confirm complie provision uk corporate governance code maintain financial reporting council far aware relevant audit describe corporate governance section page information company auditor unaware board consider annual report take take step ought fair balanced understandable provide take director aware information necessary shareholder assess relevant audit information establish group position performance business model company auditor aware information strategy confirmation give interpret require financial conduct authority list rule accordance provision section company auditor consider director statement act compliance relation point uk corporate going concern basis governance code specify review page page contain information annual report performance group financial position cash flow net annual report year end december debt position borrowing facility climate relate risk comprise report director remuneration information include treasury risk management report financial statement additional information policy exposure market credit risk hedge investor approve board director activity give note financial instrument relate sign behalf disclosure financial statement assess principal risk matter consider connection viability statement director consider appropriate adopt go concern basis accounting prepare financial statement sir jonathan symond internal control chair february board audit risk committee review assessment risk internal control framework operate gsk consider effectiveness system internal control operation group year cover annual report date approval board director detail review internal control set governance report strategic report governance remuneration financial statement investor information gsk annual report independent auditor report member gsk plc report audit financial statement opinion basis opinion opinion conduct audit accordance international standard audit uk isas uk applicable law financial statement gsk plc parent company responsibility standard describe subsidiary group true fair view auditor responsibility audit financial state group parent company affair statement section report december group profit year end independent group parent company group financial statement properly prepare accordance ethical requirement relevant accordance united kingdom adopt international audit financial statement uk include accounting standard international financial reporting financial reporting council frc ethical standard standard ifrss issue international accounting apply list public interest entity fulfil standard board iasb ethical responsibility accordance parent company financial statement requirement confirm provide non properly prepared accordance united kingdom audit service prohibit frc ethical standard generally accept accounting practice include frs group parent company note audit risk reduce disclosure framework committee report corporate governance section financial statement prepare accordance annual report disclosure provide requirement company act note fee payable group auditor audit financial statement comprise believe audit evidence obtain sufficient appropriate provide basis opinion group consolidate balance sheet december summary audit approach consolidated income statement year end key audit matter consolidate statement comprehensive income year end key audit matter identify current year consolidated statement change equity year end valuation viiv healthcare shionogi contingent consideration liability consolidated cash flow statement year end valuation return rebate rar accrual valuation intangible asset note financial statement include material accounting policy information valuation uncertain tax position include transfer pricing parent company valuation contingent liability significant legal proceeding balance sheet december statement change equity year end materiality materiality group financial notes l financial statement include statement million million material accounting policy information determine basis statutory profit tax adjust profit tax revenue net cash flow financial reporting framework apply operation preparation group financial statement applicable law united kingdom adopt international accounting standard scope ifrss issue iasb financial reporting follow component subject audit procedure framework apply preparation assessment effectiveness internal parent company financial statement applicable law control financial reporting belgium canada china united kingdom accounting standard include frs france germany italy japan united kingdom reduce disclosure framework united kingdom generally united states accept accounting practice audit scope address group revenue group profit tax group total asset significant change approach remove key audit matter relate consumer healthcare demerger system impact financial report strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue conclusion relate go concern key audit matter audit financial statement conclude key audit matter matter professional director use go concern basis accounting judgement significance audit preparation financial statement appropriate financial statement current period include significant assess risk material misstatement evaluation director assessment group fraud identify matter include parent company ability continue adopt go great effect overall audit concern basis accounting include strategy allocation resource audit direct effort engagement team enquiry group director management assumption go concern model include matter address context audit potential impact climate change financial statement form opinion evaluate group exist access source financial statement provide financing include undrawn commit bank facility separate opinion matter include impact change interest rate remove key audit matter consumer profitability healthcare demerger key audit matter follow read analyst report industry datum external completion demerger prior year key audit information include understand macroeconomic matter relate system impact financial reporting environment determine provide corroborative follow remediation control deficiency relate contradictory evidence relation assumption governance operation infrastructure privilege access compare forecast sale recent historical financial management prior year information test underlie datum generate prepare forecast scenario determine adequate support assumption underlie forecast evaluate group disclosure go concern requirement ias base work perform identify material uncertainty relate event condition individually collectively cast significant doubt group parent company ability continue go concern period month financial statement authorise issue relation reporting group apply uk corporate governance code material add draw attention relation director statement financial statement director consider appropriate adopt go concern basis accounting responsibility responsibilitie director respect go concern describe relevant section report strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation viiv healthcare shionogi contingent audit procedure perform consideration liability perform follow audit procedure group complete number significant transaction relate primarily sale forecast result recognition material contingent test control key input assumption consideration liability key source estimation valuation contingent consideration uncertainty significant liability viiv liability include review control sale forecast healthcare shionogi contingent consideration liability viiv treatment product portfolio value viiv ccl ccl obtain group assessment key input group complete acquisition remain assumption sale forecast challenge interest shionogiviiv healthcare joint venture reasonableness include enquiry key completion group recognise contingent individual senior leadership team commercial consideration liability fair value expect future strategy team key personnel involve budgeting payment shionogi december forecasting process inspection support liability value million evidence challenge volume assumption group identify viiv ccl key audit matter estimate sale forecast involve benchmarke significant estimate assumption relate sale forecast market share datum external data forecast valuing viiv ccl sensitivity total prescription volume new patient prescription valuation input significant relate volume order assess source contradictory sale forecast united state certain product evidence treatment prevention portfolio forecast challenge reasonableness pricing assumption base assessment expect launch date group compare forecast return pipeline asset ability shift market practice rebate rate product current rate prescriber behaviour longacte injectable assess forecast return rebate treatment drug regimen size longacte comparable product consider expect change prevention market subsequent sale volume payer policy incremental challenge forecasting sale associate consider result clinical study undertake recently launch product lack historical actual year group key competitor order assess datum sale forecast require significant audit effort corroborative contradictory perform appropriate audit procedure challenge assumption product portfolio sale forecast evaluate reasonableness forecast contingent consideration liability include viiv ccl benchmarke group sale forecast disclose key source estimation uncertainty note include report analyst consider sale group financial statement disclosure forecast total viiv basis individual provide note matter discuss audit product basis assess identify contradictory risk committee report corporate governance datum section annual report valuation specialist assess reasonableness overall valuation methodology include benchmarke discount rate testing valuation model mechanical accuracy key observation communicate audit risk committee sale forecast valuation reasonable line relevant support information satisfy sale forecast appropriately reflect trend overall hiv treatment prevention market include impact competition healthcare reform predict shift longacte injectable product approach value viiv ccl consistent prior period overall satisfied valuation liability reasonable consistent ifrs strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation return rebate rar accrual audit procedure perform group sell customer perform follow audit procedure commercial government mandate contract relate estimate rar accrual reimbursement arrangement include rebate test key control estimation rar accrual chargeback right return certain pharmaceutical include control associate forecasting product revenue recognition reflect grosstonet utilisation rate process monthend accrual review sale adjustment adjustment know control return rebate rar accrual source challenge assumption selection utilisation rate significant estimation uncertainty material focus certain product conclude impact report revenue accrual sensitive assumption commercial business million rar challenge include comparison historical utilisation rate deduction gross revenue million consideration historical accuracy assessment result net revenue million balance sheet market change impact competition new accrual december commercial business product launch change government legislation amount million macroeconomic factor appropriately reflect rar accrual significant payer channel referred supplement substantive analytical procedure buy group rar accrual relate manage develop independent expectation accrual healthcare organisation medicaid ryan white medicare balance key segment base historical claim receive adjusted reflect market change main cause significant estimation uncertainty period include assessment time lag initial point sale claim receipt utilisation rate portion total sale compare independent expectation record payer channel estimate evaluate appropriateness year end accrual recording accrual utilisation assumption position challenge key assumption derive consider historical accuracy estimate accrual give influence market demand evaluate forecast assumption factor outside control group appropriately update selection case time lag point sale point actual rebate claim differed accrue exact rebate amount know group evaluated appropriateness completeness receipt claim payer channel long periodend adjustment liability time lag result great accrue period ongoing review estimate accrual great level estimation uncertainty estimate periodend accrual perform audit procedure actual rebate payment year agree relevant level estimation uncertainty impact contract assess rebate payment line significant shift channel mix drive change contractual term competitive landscape include competitor generic key observation communicate audit risk product launch change government legislation committee macroeconomic factor focus utilisation assumption product deem level satisfied estimate liability rar accrual estimation uncertainty significant yearend appropriate observe level prudence estimate assess focus periodend adjustment independent expectation accordance rar accrual adjustment reflect update requirement ifrs revenue contract initial assumption include forecasted rar customer limit risk significant reversal revenue rate view present great opportunity fraud revenue recognition notwithstanding existence internal control commercial operation return rebate disclose key source estimation uncertainty note group financial statement disclosure provide note matter discuss audit risk committee report corporate governance section annual report strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation intangible asset audit procedure perform december group hold million perform follow audit procedure intangible asset include license patent trademark forecast sale pricing volume growth rate trade name exclude goodwill computer probability technical regulatory success profit margin software include million intangible asset level discount rate assessment acquire acquisition bellus health valuation intangible asset acquire year group acquisition bellus health intangible asset indevelopment available tested review control key input assumption use test annually impairment valuation intangible asset control irrespective indication impairment exist encompass review valuation model contain number assumption probability technical carrying individual intangible asset regulatory success launch date plus revenue cashgenerating unit intangible asset belong cost assumption exceed recoverable impairment occur inquire key individual corporate recoverability intangible asset derive certain development team commercial forecasting lead key assumption estimate future trading performance personnel involve asset research development create significant estimation uncertainty process outcome inquiry evaluate underlying assumption include forecast sale pricing group evidence support key assumption volume growth rate probability technical overall sale forecast peak year sale include regulatory success ongoing clinical trial include anticipate market share volume uptake alongside assumption time cash flow determined price point require foreseeable competitive anticipated launch year peak year sale subsequent sale landscape growth rate probability regulatory erosion generic product competition profit margin technical success margin level addition impact uncertainty drive evaluate key input assumption apply ongoing global macroeconomic volatility valuation estimate sale profit margin forecast include intangible asset affect discount rate benchmarking forecast external market datum assumption group include independent market research therapeutic area price point price growth rate anticipate impairment charge million competitor market landscape currently time record primarily impairment forecast regulatory approval plus assessment cessation research development dictate negative source contradictory evidence clinical trial readout lack commercial attractiveness compare forecast sale profit margin level identify valuation intangible asset key plan datum asset asset internal forecast approve audit matter inherent judgement involve gsk leadership team board director estimate future cash flow auditing assumption indevelopment intangible asset forecast estimate require extensive audit effort challenge launch year period evaluate reasonableness forecast management assess historical accuracy sale forecast judgement perform retrospective review market asset business disclosure relate intangible asset include engage fair valuation specialist assess acquire business combination include reasonableness discount rate valuation note note group financial statement methodology apply perform mechanical matter discuss audit risk committee report accuracy check corporate governance section annual report consider event transaction occur balance sheet date reporting date affect conclusion reach carry value asset associate disclosure key observation communicate audit risk committee intangible asset acquire period bellus health business acquisition conclude assumption underpin fair value intangible asset reflect purchase price allocation reasonable accordance ifrs intangible asset indevelopment subject impairment review conclude judgement management reasonable accordance ifrs strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation uncertain tax position include transfer pricing audit procedure perform group operate numerous jurisdiction support tax specialist assess open tax transfer pricing matter exposure uk appropriateness uncertain tax provision focus overseas tax authority rise uncertain tax jurisdiction group great potential position wide range possible outcome exposure high level judgement require provision contingency certain judgement respect perform follow audit procedure estimate tax exposure contingency require test key control preparation review report order assess adequacy tax provision judgmental tax balance transaction include complex result consideration require provision uncertain tax provision multiple tax law regulation assess assumption judgements december group record provision require determine range possible outcome million respect uncertain tax position recognition measurement provision uncertain tax position compliance requirement ifric valuation uncertain tax position disclose key source uncertainty income tax treatment estimation uncertainty note group financial involve transfer pricing specialist evaluate statement disclosure include note transfer pricing methodology group associate matter discuss audit risk committee report approach provision recognition measurement corporate governance section annual report consider evidence actual result recent tax authority audits enquiry thirdparty tax advice obtain group tax specialist knowledge market practice relevant jurisdiction key observation communicate audit risk committee satisfied estimate relation uncertain tax position relate disclosure accordance ifrs work conclude consistent approach apply estimate uncertain tax provision appropriate accordance ifric strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation contingent liability significant legal audit procedure perform proceeding perform follow audit procedure group operate environment subject test group control completeness significant legal administrative proceeding include provision robustness provision product liability intellectual property tax antitrust consumer requirement ias appropriateness judgements fraud governmental regulation determine good estimate completeness group currently expose number regulatory accuracy datum process litigation matter group provision matter evaluate assessment provision associate million december matter disclose probability potential outcome accordance contingent liability criterion recognise ias provision ias provision contingent liability contingent asset meet include zantac litigation evaluate methodology datum significant describe note judgement assumption valuation provision appropriate context applicable significant judgement require group determine financial reporting framework ias provision contingent liability contingent asset particular relation zantac inquire inspect correspondence litigation group internal external counsel assess litigation matter evaluate group significant judgement outcome result probable outflow assumption particularly outcome litigation uncertain subject additional court proceeding provision actual expect trial outcome settlement evaluate group conclusion determination reliable estimate supportive contradictory evidence amount obligation requirement ias particularly respect nature extent contingent liability zantac litigation underlie significant estimation uncertainty disclose read board minute settlement agreement contingent liability significant legal proceeding evaluate management approach respect disclose note respectively key audit matter litigation agree term condition discuss corporate governance section arrangement payment evaluate provision annual report record requirement additional provision respect zantac litigation inspect evidence present relevant scientific study outcome product liability litigation jurisdiction alongside entitys assessment possible outcome ongoing trial expectation trial ahead schedule future trial evaluate disclosure financial statement appropriately reflect fact critical accounting judgement key observation communicate audit risk committee satisfied estimation provision contingent liability disclosure consistent requirement ias strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue application materiality set performance materiality level low materiality define materiality magnitude misstatement reduce probability aggregate uncorrected financial statement make probable economic undetected misstatement exceed materiality decision reasonably knowledgeable person financial statement group parent company change influence use materiality planning performance materiality set group parent scope audit work evaluate result materiality respectively audit work determine performance materiality consider factor base professional judgement determine include materiality financial statement follow risk assessment include assessment group parent company overall control environment consider group financial statement financial statement appropriate rely control number business materiality million million process million million basis determine benchmark materiality past experience audit indicate low determine materiality consider determined number correct uncorrected misstatement materiality metric investor total asset identify prior period reader financial benchmark cap agree audit risk committee statement particular report committee audit difference excess consider statutory profit group materiality tax adjust profit materiality million million difference tax revenue net cash flow represent threshold view warrant reporting qualitative operation total asset ground report audit risk committee disclosure matter identify assess overall professional judgement presentation financial statement determine materiality million materiality compare benchmark metric metric statutory profit tax adjust profit tax revenue net cash inflow operating activity reconciliation statutory profit tax adjust profit tax detail adjust item section strategic report rationale give importance strength metric investor balance sheet benchmark reader financial key measure apply statement conclude financial health statutory profit tax important primary benchmark shareholder adjust profit tax primary concern revenue net cash inflow parent company operating activity payment support dividend benchmark benchmark total asset component materiality appropriate metric allocate inscope component range current year million million materiality million increase reflect million size scale nature parent company account balance audit purpose consolidated financial statement low component materiality strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue audit scope execution structure approach audit reflect audit work perform global share service centre group organise ensure audit effective significant group operational process risk focus cover financial reporting undertake share service centre group audit team include senior individual central control common system group responsible global process coordinate enable deploy utilise technology datum analytic audit work share service centre utilise live breadth group enable detailed global project management platform structure enable understand flow transaction enable focus develop good understanding endtoend risk assessment design target audit testing process support material account balance class procedure transaction disclosure group financial embed technology audit improve quality statement evaluate effectiveness internal effectiveness include area plan control financial reporting process scope project management risk control assessment consider implication remainder audit substantive testing report insight management work audit risk committee pilot use audit work execute component level individual legal artificial intelligence power tool continue invest entity follow component subject audit use technology audit procedure assessment effectiveness internal control financial reporting belgium canada audit approach summarise follow china france germany italy japan united kingdom area enable obtain evidence require form united states group audit team active opinion group parent company financial dialogue audit component audit statement team responsible audit work direction risk assessment audit planning group level risk supervision group audit team include assessment procedure consider factor determine work plan perform impact climate change wide macroeconomic accordance overall group audit strategy environment account balance disclosure requirement group audit instruction company practice datum analytical tool allow component supervise work scrutinise large transactional datum set unusual trend component senior group audit team member visit characteristic outlier transaction flow support belgium usa uk china share service identification audit risk example analyse rar centre audits malaysia poland satisfy datum product payment channel identify product oversight supervision appropriate high value total rebate deduction perform review audit working paper increase recognise significant difference rebate frequency length review depend rate offer payer qualitative factor significance risk component continue impact brand section valuation return attend plan clearance meeting component rebates rar accrual data analytic audit procedure undertake group level determine product region valuation parent company addition perform viiv healthcare shionogi contingent consideration liability audit work group parent company financial sensitive assumption section statement include limited consolidation valuation viiv healthcare shionogi contingent group result preparation financial consideration liability appoint partner statement certain disclosure director group audit team lead global audit operate remuneration report litigation provision exposure segment commercial operation research addition entity level oversight control relevant development addition partner responsible financial reporting component legal entity component legal entity audits country annual revenue great total segment partner meet regularly senior segment group revenue include audit scope management understand strategy performance component legal entity cover audit scope matter arise year subject analytical procedure confirm impact financial reporting addition hold significant risk material misstatement regular meeting member internal audit aggregate financial information internal legal counsel global ethic compliance team understand work review report internal control testing approach test enhance risk assessment effectiveness internal control financial reporting inscope entity entity level control group level common system allow relevant control test centrally component utilise automate control test tool leverage support testing control automate business control able place reliance control plan audit scope address group revenue group profit tax group total asset strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue impact climate change audit consultation climate change specialist climate change potential impact group conduct detailed risk assessment procedure number way set strategic report page scope balance transaction determine risk annual report note page material misstatement financial statement financial statement group apply expect impact climate change commit net zero greenhouse gas emission understand business group value chain challenge appropriateness group assessment planning audit consider potential potential impact climate change impact impact climate change group business financial statement include area financial statement intangible asset seek understand group identification assessment impact climate change assessment potential impact climate change challenge group assessment go concern risk influence group strategy implication include consider potential impact future financial statement performance availability financing group assessment focus impact audit procedure require read frequent extreme weather condition water scarcity change consider disclosure consider political landscape medium focus materially inconsistent financial statement propensity cause change consumer market knowledge obtain audit identify behaviour volatility cost availability material material inconsistency result procedure resource impact future financial performance asset valuation strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue information information comprise information include identify material inconsistency apparent material annual report financial statement misstatement require determine give auditor report thereon director responsible rise material misstatement financial statement information contain annual report base work perform conclude material misstatement opinion financial statement cover information require report fact information extent explicitly state report express form assurance summarise work relation area conclusion thereon information include area specifically require report responsibility read information consider information materially inconsistent financial statement knowledge obtain course audit appears materially misstate matter specifically require report responsibility report principal risk viability statement set corporate governance statement section material report add review confirmation description light knowledge draw attention respect matter gather audit consider director process support statement challenging key judgement estimate consideration historical forecasting accuracy evaluate macroeconomic assumption consider statement align relevant provision code director remuneration report set opinion matter prescribe report director remuneration report company act section opinion audit properly prepare disclosure specify director remuneration report company act audit prepared accordance company act strategic report director report set opinion matter prescribe report consistent audit financial statement company act section opinion prepare accordance applicable legal requirement base work undertake course report identify material misstatement report audit information report consistent light knowledge understanding group audit financial statement parent company environment obtain course audit prepare accordance applicable legal requirement reference provide limited assurance accordance international standard assurance engagement isae isae select metric strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue report information responsibility report alternative performance measure apm opinion apm measure define generally accept accounting practice gaap typically include financial use calculation disclosure apm statement annual report group use apm consistent group publish definition adjust profit free cash flow constant currency growth rate policy report financial performance use apm group report result consistent guideline produce esma review assess calculation report frc metric assess consistency group publish definition appropriate balance use policy item statutory metric apm clear consider assess use apm definition reconciliation apm group report result consistent guideline produce financial reporting regulator european security market authority esma guideline use apm frc alternative performance measure thematic review publish october consider appropriate balance use statutory metric apm addition clear definition reconciliation apm financial reporting provide dividend distribution policy opinion dividend policy appropriately consider dividend policy transparent dividend disclose dividend pay consistent pay consistent policy outline strategic report policy responsibility director auditor responsibility audit financial statement explain fully director responsibilitie statement director responsible preparation objective obtain reasonable assurance financial statement satisfy financial statement free true fair view internal control director material misstatement fraud error determine necessary enable preparation financial issue auditor report include opinion reasonable statement free material misstatement assurance high level assurance guarantee fraud error audit conduct accordance isa uk detect material misstatement exist prepare financial statement director misstatement arise fraud error consider responsible assess group parent company material individually aggregate ability continue go concern disclose applicable reasonably expect influence economic decision matter related going concern go concern user take basis financial statement basis accounting director intend liquidate group parent company cease description responsibility audit operation realistic alternative financial statement locate frc website wwwfrcorgukauditorsresponsibilitie description form auditor report strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue audit response risk identify extent audit consider capable detecting irregularity include fraud result perform identify valuation return rebate accrual key audit matter relate potential risk fraud key audit matter irregularity include fraud instance noncompliance section report explain matter detail law regulation design procedure line describe specific procedure response key audit responsibility outline detect material matter common audits isas uk misstatement respect irregularity include fraud require perform specific procedure respond risk extent procedure capable detect management override irregularity include fraud detail addition procedure respond risk identify assess potential risk relate identify include follow irregularity identify assess risk material misstatement review financial statement disclosure test respect irregularity include fraud noncompliance support documentation assess compliance law regulation consider follow provision relevant law regulation describe direct effect financial statement nature industry sector control environment enquire senior leadership team audit risk business performance include design committee inhouse external legal counsel group remuneration policy key driver director concern actual potential litigation claim remuneration bonus level performance target perform analytical procedure identify unusual result enquirie senior leadership team internal unexpected relationship indicate risk material audit audit risk committee include obtain misstatement fraud review support documentation concern read minute meeting charge group policy procedure relate governance review internal audit report identify evaluate comply law correspondence regulator regulation aware instance address risk fraud management override noncompliance control test appropriateness journal entry detect respond risk fraud adjustment assess judgement knowledge actual suspect alleged make accounting estimate indicative potential fraud bias evaluate business rationale significant internal control establish mitigate risk relate transaction unusual outside normal course fraud noncompliance law regulation business matter discuss engagement team communicate relevant identify law regulation include significant component audit team involve potential fraud risk engagement team member relevant internal specialist include tax valuation significant component audit team remain alert pension industry specialist indication fraud noncompliance law fraud occur financial statement regulation audit potential indicator fraud report legal regulatory obtain understand legal regulatory framework group operate focus provision requirement law regulation direct effect determination material amount disclosure opinion matter prescribe financial statement key law regulation company act consider context include provision uk company act pension legislation tax legislation opinion director remuneration report consider key law regulation audit properly prepare accordance fundamental effect operation group include company act good clinical practice fda regulations general datum protection requirement antibribery corruption policy opinion base work undertake course foreign corrupt practice act audit information give strategic report director report financial year financial statement prepare consistent financial statement strategic report director report prepared accordance applicable legal requirement light knowledge understanding group parent company environment obtain course audit identify material misstatement strategic report director report strategic report governance remuneration financial statement investor information gsk annual report independent auditor report continue report audit financial statement continue director remuneration corporate governance statement company act require report list rule require review director statement opinion certain disclosure director remuneration relation go concern longerterm viability director remuneration corporate governance statement relate group report audit agreement accounting compliance provision uk corporate record return governance code specify review report respect matter base work undertake audit matter require conclude follow element corporate governance statement materially consistent address financial statement knowledge obtain audit auditor tenure follow recommendation audit risk committee director statement regard appropriateness effect january appoint adopt go concern basis accounting board director audit financial statement year material uncertainty identify set end december subsequent financial period director explanation assessment group period total uninterrupted engagement firm prospect period assessment cover year period appropriate set director statement fair balanced consistency audit report additional report understandable annual report set audit risk committee board confirmation carry robust audit opinion consistent additional report assessment emerge principal risk set audit risk committee require provide page accordance isa uk section annual report describe review effectiveness risk management internal control use report system set page section describe work audit risk report solely parent company member committee set body accordance chapter company act audit work undertake matter require report state parent company member exception matter require state auditor report purpose full extent permit law adequacy explanation receive accounting accept assume responsibility record parent company parent company member body audit work report opinion company act require report form opinion require financial conduct authority fca disclosure receive information explanation guidance transparency rule dtr rdtr r require audit financial statement form electronic adequate accounting record keep format annual financial report file national storage parent company return adequate audit mechanism fca accordance dtr rdtr receive branch visit r auditor report provide assurance parent company financial statement electronic format annual financial report agreement accounting record return prepare compliance dtr rdtr r report respect matter parent company pass resolution accordance section company act senior statutory auditor state deloitte llp statutory auditor london united kingdom february strategic report governance remuneration financial statement investor information gsk annual report consolidated income statement year end december note turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operate profit finance income finance expense share tax profitloss associate joint venture profitloss disposal interest associate joint ventures profit taxation taxation profit taxation continue operation profit taxation discontinue operation gainslosse demerger remeasurement discontinue operation distribute shareholder demerger profit taxation discontinue operation total profit taxation year profit attributable noncontrolle interest continue operation profit attributable shareholder continue operation profit attributable noncontrolle interest discontinue operation profit attributable shareholder discontinue operation total profit attributable noncontrolle interest total profit attributable shareholder basic earning share penny continue operation p p p basic earning share penny discontinue operation p p total basic earning share penny p p p dilute earning share penny continue operation p p p dilute earning share penny discontinue operation p p total diluted earning share penny p p p consolidate statement comprehensive income year end december note total profit year comprehensive incomeexpense year item reclassified subsequently continue operation income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary associate fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement item reclassify continue operation income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment fair value movement cash flow hedge remeasurement gainslosse define benefit plan tax remeasurement lossesgain define benefit plan comprehensive income expense year continue operation comprehensive income year discontinue operation total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year strategic report governance remuneration financial statement investor information gsk annual report consolidate balance sheet december note noncurrent asset property plant equipment right use asset goodwill intangible asset investment associate joint venture investment defer tax asset noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument current equity investment liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing contingent consideration liability trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing corporation tax payable deferred tax liability pension postemployment benefit provision contingent consideration liability noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity financial statement page approve board february sign behalf sir jonathan symonds chair strategic report governance remuneration financial statement investor information gsk annual report consolidate statement change equity year end december shareholder equity share share retain noncontrolle total capital premium earning reserve total interest equity december profit year comprehensive incomeexpense year total comprehensive incomeexpense year distribution noncontrolle interest contribution noncontrolle interest dividend shareholder share issue realise tax profit disposal equity investment share associates joint venture realise profit disposal equity investment writedown share hold esop trust sharebase incentive plan transaction noncontrolle interest tax sharebase incentive plan december profit year comprehensive incomeexpense year total comprehensive incomeexpense year distribution noncontrolle interest noncash distribution noncontrolle interest contribution noncontrolle interest change noncontrolle interest deconsolidation subsidiary dividend shareholder noncash dividend shareholder realise tax loss disposal liquidation equity investment share associates joint venture realise profit disposal equity investment share issue writedown share hold esop trust share acquire esop trust sharebase incentive plan tax sharebase incentive plan hedge gain taxation transfer nonfinancial asset december profit year comprehensive incomeexpense year total comprehensive incomeexpense year distribution noncontrolle interest contribution noncontrolle interest dividend shareholder realise tax loss disposal liquidation equity investment share associates joint venture realise profit disposal equity investment share issue writedown share hold esop trust share acquire esop trust sharebase incentive plan hedge gainloss taxation transfer nonfinancial asset tax sharebase incentive plan december analysis reserve present note movement equity strategic report governance remuneration financial statement investor information gsk annual report consolidate cash flow statement year end december note cash flow operating activity profit taxation continue operation year adjustment reconcile profit tax operating cash flow cash generate operation attributable continue operation taxation pay net cash inflowoutflow continue operating activity cash generate operation attributable discontinued operation taxation pay discontinued operation net operating cash flow attributable discontinued operation total net cash inflowoutflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment increasedecrease liquid investment purchase business net cash acquire proceed sale equity investment contingent consideration pay disposal business investment associate joint venture proceed disposal associate joint venture interest receive dividend distribution investment dividend associate joint venture net cash inflowoutflow continue investing activity net invest cash flow attributable discontinued operation total net cash inflowoutflow investing activity cash flow financing activity issue share capital repayment longterm loan issue longterm note repayment shortterm loan net increase inrepayment shortterm loan repayment lease liability interest pay dividend pay shareholder distribution noncontrolle interest contribution noncontrolle interest finance item net cash inflowoutflow continue financing activity net financing cash flow attributable discontinued operation total net cash inflowoutflow financing activity increasedecrease cash bank overdraft cash bank overdraft begin year exchange adjustment increasedecrease cash bank overdraft year cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft strategic report governance remuneration financial statement investor information gsk annual report note financial statement presentation financial statement description business prepare consolidated financial statement group consider impact physical transitional gsk global biopharma group prevent treat climate change risk plan mitigate disease vaccine specialty general medicine gsk current valuation asset liability focus science immune system use particularly context risk identify task force new platform datum technology invest core climaterelate financial disclosure tcfd therapeutic area infectious disease hiv respiratory immunology oncology group believe material impact judgement estimate relation climaterelate risk compliance applicable law ifrs result valuation asset liability financial statement prepare accordance significantly impact december ukadopted international accounting standard group review recoverable value property plant conformity requirement company act equipment inventory goodwill intangible asset international financial reporting standard issue material balance impact climaterelate iasb risk group transition plan mitigate risk composition financial statement climaterelate risk identify relate meter dose inhaler mdi group address risk consolidated financial statement draw sterling transition lowercarbon propellant transition functional currency gsk plc accordance ifrs expect material impact recoverable accounting presentation financial statement comprise estimate useful life relate property plant consolidated income statement equipment note property plant equipment detail consolidate statement comprehensive income consolidate balance sheet whilst currently significant mediumterm impact consolidate statement change equity expect group aware everchanging risk consolidated cash flow statement attach climate change continue assess impact note financial statement judgement estimate preparation consolidated financial statement composition group parent company financial statement list subsidiary associate opinion director principally affect profit net financial statement parent company gsk plc asset group give note principal group prepare accordance uk gaap uk companies accounting presentation company balance sheet present accounting policy give financial period page financial statement cover financial year january december comparative figure financial year january december appropriate january december accounting principle policy financial statement prepare historical cost convention modify revaluation certain item state accounting policy go concern basis financial statement prepare accordance group accounting policy approve board describe note accounting principle policy information application accounting policy include area estimation judgement give note critical accounting judgement key source estimation uncertainty preparation financial statement conformity generally accept accounting principle require management estimate assumption affect report amount asset liability disclosure contingent asset liability date financial statement report amount revenue expense report period actual result differ estimate strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue accounting principle policy consolidation payment relate original estimate fair value contingent consideration acquisition consolidated financial statement include report investing activity cash flow statement asset liability result cash flow payment relate increase company subsidiary include esop trust liability acquisition date report operating group share result net asset associate cash flow joint venture consideration transfer non group share asset liability revenue expense control interest exceed fair value net asset joint operation liability contingent liability acquire excess record goodwill cost effecting acquisition financial statement entity consolidate charge income statement period december year incur entity group power direct goodwill capitalise separate item case relevant activity affect return group subsidiary cost investment case generally control financial operating joint venture associate goodwill denominate policy account subsidiary currency operation acquire group ability exercise joint control cost acquisition group interest right net asset entity entity net asset acquire difference recognise directly account joint venture group ability income statement exercise joint control arrangement right specify asset obligation specify liability equity subsidiary acquire non arrangement arrangement account joint control interest recognise fair value operation group ability exercise noncontrolle interest share net asset significant influence entity account subsidiary casebycase basis change group associate result asset liability associate ownership percentage subsidiary account joint venture incorporate consolidated equity financial statement equity method accounting asset liability revenue expense joint operation foreign currency translation include consolidated financial statement foreign currency transaction book functional accordance group right obligation interest currency group company exchange rate ruling acquire entity consolidated date group date transaction foreign currency monetary asset acquire control interest sell deconsolidate liability retranslate functional currency rate date control cease exchange rule balance sheet date exchange transaction balance subsidiary eliminate difference include income statement profit tax take sale subsidiary consolidation asset liability include related product sell customer outside group goodwill overseas subsidiary associate joint venture relevant proportion profit transaction joint venture translate sterling rate exchange rule joint operation associate defer balance sheet date result cash flow overseas product sell party transaction non subsidiary associate joint venture translate control interest record directly equity defer tax sterling average rate exchange relief unrealise intragroup profit account extent consider recoverable exchange adjustment arise open net asset profit year retain overseas subsidiary business combination associate joint venture translate sterling business combination account acquisition exchange difference arise related foreign currency accounting method identifiable asset liability borrowings hedge group net investment contingent liability acquire measure fair value operation take separate component equity acquisition date consideration transfer measure retain earning fair value include fair value contingent translate sterling asset liability result consideration cash flow overseas subsidiary associate joint fair value contingent consideration liability venture report currency hyperinflationary reassess balance sheet date change economy adjustment material reflect recognise income statement payment contingent current price level loss net monetary asset charge consideration reduce balance sheet liability result consolidated income statement record income statement strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue accounting principle policy continue revenue operating income royalty income gsk enter development marketing collaboration turnover outlicence group compound product group receive revenue supply good external party contract rise fix variable customer order receive majority contract consideration upfront payment development milestone gsk enter relate sale order contain single salesbased milestone royalty performance obligation delivery pharmaceutical vaccine product average duration sale order income dependent achievement development month milestone recognise highly probable significant reversal cumulative revenue product revenue recognise control good recognise occur usually relate pass customer point control pass event occur salesbase milestone income recognise determined customer arrangement generally highly probable sale threshold reach occur delivery customer salesbase royalty licence intellectual property product revenue represent net invoice value include fix recognise relevant product sale occur variable consideration variable consideration arise sale good result discount allowance give revenue time recognition revenue accrual estimate future return rebate revenue payment customer expect recognise highly probable significant year impact material reversal cumulative revenue recognise consideration discount appropriate discount rate occur methodology assumption estimate value add tax sale taxis exclude rebate return monitor adjust regularly revenue light contractual legal obligation historical trend past experience project market condition estimate expenditure associate return rebate revisit expenditure recognise respect good service report date resolve revenue receive supply accordance contractual term adjust accordingly refer note critical provision obligation exist future liability accounting judgement key source estimation respect past event uncertainty detail rebate discount obligation reliably estimate manufacturing startup allowance cost validation achievement normal group enter collaborative agreement typically production expense incur pharmaceutical biotechnology company advertising promotion expenditure charge develop produce market drug candidate vaccine income statement incur qualify joint arrangement gsk control commercialisation activity group shipment cost intercompany transfer charge cost recognise turnover cost sale gross basis profit sale distribution cost sale customer include sharing amount royalty counterparty sell general administration expenditure record cost sale cost sale include net restructuring cost recognise provide recovery cost million cost million appropriate respect direct expenditure business cost million profit sharing arrangement reorganisation plan sufficiently detail royalty counterparty counterparty advance appropriate communication control commercialisation activity record sale affect undertaken group principal customer contract instead record share gross profit copromotion software service saas configuration cost expense income net basis turnover nature co incur software configure promotion activity group record cost control saas provider sale commercial operation turnover include copromotion research development revenue million million million reimbursement counterparty research development expenditure charge collaboration agreement sell general income statement period incur administration research development cost development expenditure capitalise criterion record net respective line consolidated income recognise asset meet usually regulatory filing statement major market approval consider highly probable property plant equipment research development capitalise depreciated accordance group policy strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue accounting principle policy continue legal dispute employee share plan provision anticipate settlement cost legal incentive form share provide employee dispute group outflow share option share award scheme resource consider probable reliable estimate fair value option award calculate likely outcome respect product liability grant date blackschole option pricing model claim relate certain product provision charge income statement relevant vest sufficient history claim settlement enable period management reliable estimate provision require cover assert unasserted claim group provide finance esop trust purchase company share meet obligation provide share certain case incur report ibnr actuarial employee exercise option award cost run technique determine estimate addition esop trust charge income statement provision legal expense arise claim receive dispute share hold esop trust deduct reserve transfer reserve group involved legal proceeding retain earning vest period relate share respect possible meaningfully assess option award reflect ultimate proceed receivable outcome result probable outflow employee exercise quantify reliably estimate liability case appropriate disclosure case include property plant equipment provision property plant equipment ppe state cost cost associate claim group purchase construction provision depreciation party charge income statement impairment financing cost capitalise cost incur qualifying asset construction pension postemployment benefit depreciation calculate write cost residual value ppe exclude freehold land straightline cost provide pension define benefit scheme basis expect useful life residual value live calculate project unit credit method review appropriate adjust annually spread period benefit expect normal expect useful life major category ppe derive employee service consistent advice qualified actuary pension obligation measure present value freehold building year estimate future cash flow discount rate reflect leasehold land building lease term year yield highquality corporate bond pension scheme asset plant machinery year measure fair value balance sheet date equipment vehicle year cost postemployment liability calculate similar way define benefit pension scheme spread disposal ppe cost relate accumulate period benefit expect derive depreciation impairment remove financial employee service accordance advice statement net proceed take qualified actuary income statement service cost provide retirement benefit employee lease year cost curtailment charge operating profit year group recognise right use asset lease actuarial gain loss effect change arrangement lessee shortterm actuarial assumption recognise statement lease define lease lease term month comprehensive income year arise lease low value asset right use asset own party lease agreement capitalise group contribution define contribution plan inception lease recognise consolidated charge income statement incur balance sheet correspond liability lessor recognise lease obligation short longterm borrowing carry subsequently increase reflect interest lease liability reduce lease payment calculate discount lease liability lease annual payment million implicit rate lease available incremental borrowing rate lease specific adjustment available lease annual payment million incremental borrowing rate incremental borrowing rate rate interest gsk able borrow similar term similar security fund necessary obtain similar asset similar market strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue accounting principle policy continue finance cost charge income statement contingent milestone payment recognise point produce constant periodic rate charge remain contingent event probable development balance obligation accounting period cost incur group associate acquire licence patent knowhow marketing right write variable rent lease liability right income statement incur criterion use asset payment charge income recognition internally generate intangible asset meet statement incur lease rental cost shortterm usually regulatory filing major lowvalue lease capitalise charge market approval consider highly probable income statement incur acquire process rd market product value nonlease component account separately independently fair value business acquire lease component plant equipment lease party value substantial separately account land building vehicle long term asset contractual lease legal nature sell separately rest modification reassessment lease obligation occur business acquire lease liability right use asset remeasure cost acquire develop computer software right use asset title expect pass gsk internal use internet site external use capitalise point future depreciate basis consistent intangible fix asset software site support similar own asset case right use asset significant business system expenditure lead depreciate short useful life asset creation durable asset control group erp lease term system software amortise seven year computer software year straight goodwill line basis goodwill state cost impairment goodwill deem impairment noncurrent asset indefinite useful life test impairment annually carry value noncurrent asset review impairment standalone basis large fair value interest acquire entitys cash generating unit indication asset asset liabilitie contingent liability exceed impair additionally goodwill intangible asset consideration pay excess recognise immediately available use test impairment gain income statement annually provision impairment charge income intangible asset statement year concern intangible asset state cost provision impairment goodwill reverse impairment loss amortisation impairment noncurrent asset reverse change estimate determine recoverable amount licence patent knowhow marketing right separately extent revise recoverable amount acquire acquire business combination exceed carry value exist net amortise estimate useful life generally depreciation amortisation impairment exceed year straightline basis time recognise available use estimate useful life determine amortisation charge account patent investment associate joint venture live exclusivity period applicable value joint operation obtain period nonexclusivity pharmaceutical intangible asset depend characteristic competitive investment associate joint venture carry environment estimate longterm profit asset consolidated balance sheet group share net book value amortise asset date acquisition postacquisition exclusivity period straightline basis remain retain profit loss comprehensive income book value amortise nonexclusivity period goodwill arise acquisition group year straightline basis vaccine intangible asset recognise asset liability revenue expense joint cost usually amortise exclusivity period plus operation accordance right obligation year year exclusivity period grant inventory straightline basis asset life review appropriate adjust annually inventory include financial statement low cost include raw material direct labour direct cost relate production overhead net realisable value cost generally determine basis pre launch inventory hold asset high probability regulatory approval product point provision carrying value reduce recoverable provision reverse point high probability regulatory approval determine strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue accounting principle policy continue financial instrument trade receivable trade receivable measure accordance financial asset business model portfolio trade receivables financial asset measure amortise cost fair value hold group portfolio business comprehensive income fvtoci fair value model ifrs collect contractual cash flow profit loss fvtpl measurement basis factoring agreement place measure determine reference business model amortise cost sell contractual cash flow manage financial asset contractual cash flow trade receivable sell factoring agreement characteristic financial asset financial asset measure fvtpl collect sell trade receivables month expect credit loss ecl contractual cash flow trade receivable sell allowance record initial recognition factoring arrangement measure fvtoci trade subsequent evidence significant increase credit risk receivables measure amortise cost carry asset allowance increase reflect lifetime original invoice allowance expect credit ecl realistic prospect recovery asset loss write expect credit loss calculate accordance expect credit loss recognise income statement simplify approach permit ifrs provision financial asset measure amortise cost fair matrix apply lifetime historical credit loss experience value comprehensive income apart equity trade receivables expect credit loss rate vary investment depend extent settlement trade receivables overdue adjust current equity investment appropriate reflect current economic condition current equity investment comprise equity investment estimate future condition purpose determine group hold intention sell sell credit loss rate customer classify grouping short term acquire intention similar loss pattern key driver loss rate measure fvtpl initially record fair value nature business unit location type remeasure subsequent reporting date fair value customer unrealise gain loss recognise income statement dividend income recognise income trade receivable determined reasonable statement group right receive payment expectation recovery write firstly establish purchase sale current equity investment expect credit loss allowance available account trade date income statement investment subsequent recovery amount previously provide write credit income statement longterm investment comprise equity investment investment receivable discount effect material limited life fund group elect designate majority equity investment measure fvtoci cash cash equivalent initially record fair value plus transaction cost cash hold deposit account measure amortise cost remeasure subsequent reporting date fair value investment money market fund hold fair value unrealised gain loss recognise profit loss fund fail solely payment comprehensive income disposal equity investment principal interest sppi test gain loss defer comprehensive income transfer directly retain borrowing earning borrowing initially record proceed investment limited life fund measure fvtpl receive net transaction cost borrowing subsequently initially record fair value remeasure carry amortise cost difference subsequent reporting date fair value unrealised gain proceed net transaction cost loss recognise income statement redemption recognise charge income statement period relevant borrowing dividend equity investment distribution fund recognise income statement group right derivative financial instrument receive payment establish derivative financial instrument manage exposure market risk principal derivative instrument gsk purchase sale investment account foreign currency swap interest rate swap foreign trade date exchange forward contract option group hold issue derivative financial instrument trade speculative purpose derivative financial asset liability include derivative embed host contract separate host contract measure fair value change fair value derivative instrument qualify hedge accounting recognise immediately income statement strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue accounting principle policy continue hedge accounting defer tax asset liability recognise temporary difference arise initial recognition derivative designate hedge instrument goodwill initial recognition asset classify inception hedge relationship cash flow liability transaction business combination hedge net investment hedge fair value hedge affect account taxable profit loss change fair value derivative designate cash flow unrecognised defer tax asset reassess hedge recognise comprehensive income reporting date recognise extent extent hedge effective accumulate probable future taxable profit allow cash flow hedge reserve ineffective portion recognise defer tax asset recover profit loss immediately amount defer cash flow uncertain tax position identify management hedge reserve reclassify income statement judgement probable outcome hedge item affect profit loss hedge forecast assume relevant tax authority knowledge transaction purchase nonfinancial asset situation assess economic outflow defer cash flow hedge reserve transfer directly probable arise provision good estimate equity include carrying value recognise liability estimate liability gsk apply risk nonfinancial asset base approach take account appropriate net investment hedge account similar way probability group able obtain cash flow hedge reclassify income compensatory adjustment international tax treaty statement hedge item affect profit loss estimate account specific circumstance dispute relevant external advice change fair value derivative designate fair value hedge record income statement discount change fair value hedge asset liability time value money material balance taxation discount current value appropriate discount rate unwind discount record finance income current tax provide amount expect pay finance expense apply tax rate enact substantively enact balance sheet date tax charge asset liability hold sale distribution period recognise income statement statement discontinue operation comprehensive income directly equity accord accounting treatment relate transaction disposal group classify held sale distribution defer tax provide temporary difference arise carrying recover principally sale tax basis asset liability carry distribution shareholder continue amount financial statement defer tax asset use available sale distribution present recognise extent probable future taxable condition sale distribution consider highly profit available temporary difference probable asset hold asset hold sale distribution utilise defer tax provide temporary measure low carrying fair value difference arise investment subsidiary associate cost sell distribute noncurrent asset include joint venture time reversal asset hold sale distribution depreciate temporary difference control probable amortise asset liability classify held sale temporary difference reverse foreseeable distribution present current asset current liability future defer tax provide rate tax separately asset liability balance enact substantively enact balance sheet sheet date defer tax asset liability offset discontinued operation component group legally enforceable right offset current tax asset dispose distribute classified hold sale current tax liability relate income taxis distribution represent separate major line levy tax authority company business result discontinue operation present subsidiary intend settle current tax asset liability separately consolidated income statement net basis consolidate statement comprehensive income consolidate statement cash flow comparative restate consistent basis strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue critical accounting judgement key source estimation uncertainty prepare financial statement management require revenue recognise highly probable judgement item significant reversal cumulative revenue recognise financial statement estimate recognise occur turnover recognise assumption affect amount asset liability year performance obligation satisfy previous revenue expense report financial statement period set note turnover segment information actual amount result differ estimate indication level sensitivity estimate follow consider critical accounting future event cause assumption judgement key source estimation uncertainty accrual base change materially affect turnover future result group report group turnover million taxation million tax charge year million estimate million december current tax payable million million noncurrent corporation tax payable gross turnover reduce rebate discount allowance million million current tax recoverable product return give expect give vary million million product arrangement buy group arrangement purchase organisation dependent judgement estimate submission claim time initial recognition group open tax issue number revenue sale accrual time sale authority management make judgement estimate rebate discount allowance payable return sufficient information able reliable estimate base available market information outcome dispute insufficient information historical experience available provision sale pharmaceutical vaccine product sufficient information available estimate potential tax complex arrangement rebate discount allowance liability gsk apply riskbased approach take turnover commercial operation product account appropriate probability group million million recording able obtain compensatory adjustment deduction million million rebate international tax treaty estimate account allowance return discount december specific circumstance dispute relevant external total accrual amount million advice inherently judgemental change million nature accrual practicable substantially time dispute progress new meaningful sensitivity estimate large volume fact emerge variable contribute overall rebate chargeback return revenue accrual december group recognise provision million respect uncertain tax position significant variability final outcome million number uncertain tax position hold group apply constraint measure variable number jurisdiction relate element revenue revenue recognise practicable meaningful sensitivity estimate suitably cautious objective constraint uncertain tax position individually material group ensure highly probable significant reversal revenue occur uncertainty resolve factor affect tax charge future year set constraint apply make suitably cautious estimate note taxation gsk continue believe input assumption estimate variable adequate provision liability likely arise open consideration amount estimate assessment open issue exist ultimate liability fully reflect final outcome amount subject matter vary amount provide change dependent thing type dependent outcome negotiation relevant buying group product sale mix constraint apply tax authority necessary litigation proceeding recognise revenue mean risk material downward adjustment revenue financial year low level accrual rebate return review adjust regularly light contractual legal obligation historical trend past experience project market condition market condition evaluate wholesaler thirdparty analysis market research datum internally generate information reasonably possible significant adjustment month recognise additional revenue actual outcome well cautious constrain estimate strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue critical accounting judgement key source estimation uncertainty continue legal dispute pension postemployment benefit legal cost year million million judgement december provision legal dispute surplus define benefit scheme arise amount million million potential surplus arise commit future judgement contribution right trustee prevent group obtain refund surplus future consider management make judgement sufficient determine necessary restrict information able reliable estimate likely surplus recognise uk scheme surplus outcome dispute legal expense uk scheme combine surplus arise claim group insufficient information million december million available provision disclosure claim recognise pension surplus totalling million give spread country million estimate provision account specific country gsk judgement amount circumstance dispute relevant external advice meet requirement recoverability inherently judgemental change substantially estimate time dispute progress new fact emerge detail status uncertainty involve significant cost provide pension postemployment unresolved dispute set note legal proceeding benefit assess basis assumption select management assumption include future earning company director take legal advice pension increase discount rate expect longterm rate establish provision take account relevant return asset mortality rate disclose note fact circumstance matter accordance pension postemployment benefit accounting requirement respect product liability claim relate certain product sufficient history discount rate derive aa rate corporate bond yield claim settlement enable management country deep market corporate reliable estimate provision require cover unasserted bond government bond yield sensitivity claim analysis provide note pension post employment benefit reduction discount rate group involved legal proceeding lead increase net pension deficit respect possible meaningfully assess approximately million increase annual outcome result probable outflow pension cost approximately million similarly quantify reliably estimate liability case increase discount rate lead decrease appropriate disclosure case provide net pension deficit approximately million provision contingent liability decrease annual pension cost approximately quantify million ultimate liability legal claim vary amount reduction discount rate lead provide dependent outcome litigation increase net pension deficit approximately proceeding investigation possible settlement million increase annual pension cost negotiation position change time approximately million similarly increase assurance loss result discount rate lead decrease net pension outcome legal proceeding exceed deficit approximately million decrease provision report group financial annual pension cost approximately million selection statement material different assumption affect future result group contingent consideration income statement charge contingent consideration million million december liability contingent consideration amount million million million million related acquisition shionogiviiv healthcare joint venture estimate contingent consideration include consideration payable business combination record fair value date acquisition fair value generally base riskadjuste future cash flow discount appropriate posttax discount rate fair value review regular basis change reflect income statement note contingent consideration liability strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue new accounting requirement international tax reform pillar model rule amendment amendment ias adoption ifrs insurance contract amendment group adopt amendment ias certain ifrs accounting standard year end introduce response oecds bep pillar december material impact rule include result financial position group mandatory temporary exception recognition certain amendment ifrs accounting standard disclosure defer taxis arise jurisdictional interpretation publish mandatory implementation pillar model rule december report period disclosure requirement affect entity help user adopt early group amendment financial statement well understand entitys interpretation expect material impact exposure pillar income taxis arise result financial position group future reporting legislation period gsk apply mandatory exception amendment ias statement cash flow ifrs recognise defer tax impact information financial instrument disclosure supplier finance impact pillar model framework include arrangement require additional disclosure information impact effective tax rate set note group supplier finance arrangement disclosure taxation requirement apply annual reporting period begin january interim period end december exchange rate group use average exchange rate prevail period translate result cash flow overseas subsidiary joint venture associate sterling period end rate translate net asset entity currency influence translation relevant exchange rate average rate period end rate euro euro yen yen strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue turnover segment information operating segment report base financial information provide chief executive officer responsibility gsk leadership team glt gsk report segment commercial operation total rd member glt responsible segment originally gsk report result segment pharmaceutical pharmaceutical rd vaccine consumer healthcare report operating segment change demerger consumer healthcare operate segment reportable comparative information retrospectively revise consistent basis change reportable segment rd investment essential sustainability business segment report commercial operating profit exclude allocation globally fund rd total rd segment responsibility chief scientific officer report separate segment operating cost segment include rd activity specialty medicine include hiv vaccine include rd sell general administrative sga cost relate regulatory function group management reporting process allocate intragroup profit product sale segment sale record profit analysis present basis turnover segment commercial operation product sale report product group vaccine specialty medicine general medicine commercial operation shingle meningitis rsv influenza establish vaccine pandemic vaccine vaccine hiv respiratoryimmunology oncology pandemic specialty medicine respiratory general medicine general medicine total commercial operation strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue turnover segment information continue sale wholesaler million million million million million million million million million respectively allocate finalcustomer discount wholesaler revenue recognise year performance obligation satisfy previous period total million million include million million impact turnover arise change prior year estimate rar return rebate accrual million million milestone income million million royalty income recognise current year segment profit commercial operation research development segment profit corporate unallocated cost reconcile item segment profit operating profit total operating profit finance income finance cost gainloss disposal interest associate share aftertax profitslosse associate joint venture profit taxation continue operation taxation profit taxation year continue operation reconcile item segment profit operating profit comprise item specifically allocate segment profit include impairment amortisation intangible asset major restructuring cost include impairment tangible asset computer software transactionrelate adjustment relate significant acquisition proceed cost disposal product business significant legal charge expense settlement litigation government investigation operate income royalty income item refer detail reconcile item segment profit operating profit analysis adjust item group financial review depreciation amortisation segment commercial operation research development segment depreciation amortisation corporate unallocated depreciation amortisation reconcile item segment depreciation amortisation total depreciation amortisation total depreciation amortisation strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue turnover segment information continue ppe intangible asset goodwill impairment segment commercial operation research development segment impairment corporate unallocated impairment reconcile item segment impairment total impairment total impairment ppe intangible asset impairment reversal segment commercial operation research development segment impairment reversal corporate unallocated impairment reversal reconcile item segment impairment reversal total impairment reversal total impairment reversal net operating asset segment commercial operation research development segment net operating asset corporate unallocated net operating asset net operating asset net debt investment associate joint venture current equity investment derivative financial instrument current defer taxation asset hold sale exclude cash cash equivalent net asset commercial operation segment include shionogiviiv healthcare contingent consideration liability million million pfizer option million million geographical information uk regard group country domicile turnover location customer uk rest world external turnover noncurrent asset location subsidiary uk belgium rest world noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivables country individually material external revenue noncurrent asset strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue operating incomeexpense upfront settlement income fair value remeasurement equity investment disposal business asset fair value remeasurement contingent consideration recognise business combination remeasurement viiv healthcare option liability preferential dividend fair value adjustment derivative financial instrument income february viiv healthcare reach agreement gilead sciences inc gilead settle global patent infringement litigation relate commercialisation gilead biktarvy concern viiv healthcare patent relate dolutegravir antiretroviral medication medicine treat human immunodeficiency virus hiv term global settlement licensing agreement gilead upfront payment billion million viiv healthcare february addition gilead pay royalty future sale biktarvy respect bictegravir component future bictegravircontaine product sell royalty payable gilead viiv healthcare february expiry viiv healthcare patent october record royalty income income statement fair value remeasurement equity investment include loss million remeasurement group retain investment haleon plc detail note current equity investment disposal business asset primarily include milestone income disposal business asset include milestone income reversal provision long require disposal business asset include net gain disposal right royalty stream cabozantinib net gain disposal cephalosporin antibiotic brand sandoz fair value remeasurement contingent consideration recognise business combination include net charge million relate acquisition shionogiviiv healthcare joint venture million net credit payable novartis relate vaccine acquisition fair value movement relate hedging contract charge million relate contingent consideration acquisition affinivax primarily relate unwind discount income primarily include net income dividend relate investment include million dividend receive retain investment haleon plc strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal depreciation right use asset impairment right use asset amortisation intangible asset impairment intangible asset net reversal impairment tangible intangible asset hold sale net reversal net foreign exchange gainslosse inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory shortterm lease charge lowvalue lease charge variable lease payment fees payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration net foreign exchange gainslosse include net gain million million loss million gain arise recycling exchange liquidation disposal overseas subsidiary recycle exchange disposal overseas associate nil nil recycling exchange disposal overseas subsidiary include recycle exchange disposal consumer healthcare subsidiary report profit taxation demerger discontinue operation include operate profit major restructuring charge million million million note major restructuring cost fee payable company auditor associate audit parent company consolidate financial statement include attestation sarbanesoxley act audit company subsidiary total audit service auditrelated assurance service total audit service auditrelate assurance service assurance service provide auditor relate agree procedure assurance service outside statutory audit requirement audit related assurance service include nil million million report accountant work perform preparation consumer healthcare demerger addition fee pay auditor respect gsk pension scheme audit strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance cost sharebase incentive plan analyse follow share value plan performance share plan share option plan cash settle plan average number person employ group include director year number number number manufacturing sell general administration research development total continue operation discontinue operation total note consumer healthcare divest july show discontinued operation table average monthly number group employee exclude temporary contract staff number group employee end financial year give financial record compensation director senior management member glt aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan information remuneration director give section annual report remuneration label audit page strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue major restructuring cost pharmaceutical sector highly regulate manufacture operation supply chain long lifecycle business mean restructure programme particularly involve rationalisation closure manufacturing rd site likely year complete major restructuring cost relate specific boardapprove major restructuring programme include integration cost follow material acquisition structural significant scale cost individual relate project exceed million january board approve separation preparation programme prepare separation gsk company programme largely complete acquisition sierra oncology july affinivax august board approve major restructure programme integration significant acquisition design integrate achieve synergies june gsk acquire bellus health inc total restructuring cost million million million incur follow area restructure cost separation gsk company continue transformation central function include gsk technology platform interface deliver great digital synergy simplification application staff reduction integration acquisition analysis cost charge operating profit programme follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise noncash chargescredit cash cost provision reversal million reflect provision release mainly relate separation preparation programme asset impairment million noncash charge million principally comprise fix asset writedown manufacture administrative facility accelerate depreciation asset life shorten supply chain manufacturing network result major restructuring programme charge settle cash include site closure cost consultancy project management cost analysis major restructuring charge programme follow cash noncash total separation preparation programme significant acquisition legacy program cash noncash total separation preparation programme significant acquisition legacy program analysis major restructuring charge income statement line follow cost sale sell general administration research development strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue finance income finance income arise financial asset measure amortise cost financial asset measure fair value profit loss net gain arise forward element forward contract net investment hedge relationship finance income finance expense finance expense arise financial liability amortise cost net loss arise financial instrument mandatorily measure fair value profit loss retranslation loan reclassification hedge comprehensive income unwind discount provision finance expense arise lease liability finance expense strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue associate joint venture group share aftertax profit loss associate joint venture set share aftertax lossesprofit associate share aftertax loss joint ventures year group dispose investment joint venture nil consideration release relate commitment future capital contribution result net million profit disposal group agreed innoviva inc sell share innoviva innoviva million follow disposal december december december group hold significant individual associate summarise income statement information respect innoviva set result innoviva include summarise income statement information represent estimate earning innoviva relevant period base publicly available information figure include share innovivas turnover profit total comprehensive income date disposal turnover profit taxation total comprehensive income aggregate financial information respect gsk share associate undertaking joint venture set share aftertax loss share comprehensive incomeexpense share total comprehensive incomeexpense group sale associate joint venture nil nil nil refer balance sheet information note investment associate joint venture strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue taxation group tax charge sum total current defer tax expense taxation charge base profit year uk current year charge rest world current year charge chargecredit respect prior period current taxation defer taxation gsk corporate income tax payment globally billion billion million million uk corporation tax pay hmrc amount corporate income tax include business taxis bear gsk year defer tax credit period reflect current year loss offset taxable profit future period probable release defer tax liability relate primarily unwind defer tax liability intangible asset follow table reconcile tax charge calculate uk statutory rate group profit tax actual tax charge year reconciliation taxation group profit profit tax uk statutory rate taxation difference overseas taxation rate benefit intellectual property incentive rd credit permanent difference disposal acquisition transfer permanent difference reassessment prior year current tax estimate reassessment prior year defer tax estimate change tax rate tax chargetax rate global biopharmaceutical company substantial business employment presence country world impact difference overseas taxation rate arise profit earn country tax rate high uk statutory rate significant belgium japan adverse impact offset benefit intellectual property incentive uk patent box belgian innovation income deduction regime provide reduce rate corporation tax profit earn qualifying patent claim incentive manner intend relevant statutory regulatory framework permanent difference disposals acquisition transfer include tax internal restructuring simplify group structure group tax rate influence update estimate prior period tax liability follow closure open issue tax authority jurisdiction change tax rate cumulative impact item reduction tax rate change tax rate include credit relation enactment increase headline rate uk corporate income tax effective future tax charge effective tax rate affect factor acquisition disposal restructuring location research development activity tax regime reform resolution open matter continue bring tax affair date world uk government substantively enact legislation introduce global minimum corporate income tax rate effect line organisation economic cooperation development oecd pillar model framework anticipate rule restrict ability benefit innovation incentive uk belgium patent box regime consequently underlie effective tax rate forecast increase strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue taxation continue tax item charge equity statement comprehensive income current taxation sharebase payment define benefit plan fair value movement cash flow hedge fair value movement equity investment defer taxation sharebase payment define benefit plan fair value movement cash flow hedge fair value movement equity investment total chargecredit equity statement comprehensive income item charge statement comprehensive income tax share base payment issue relate taxation integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket line current oecd guideline base transfer pricing policy arm length principle support transfer price economic analysis report different tax authority seek attribute profit activity undertake jurisdiction potentially result double taxation group open item jurisdiction concern matter deductibility particular expense tax treatment certain business transaction gsk apply risk base approach determine transaction likely subject challenge probability group able obtain compensatory adjustment international tax treaty calculation group total tax charge necessarily involve degree estimation judgement respect certain item tax treatment finally determine resolution reach relevant tax authority appropriate formal legal process december group recognise provision million respect uncertain tax position million net increase recognise provision drive reassessment estimate agreement number open issue tax authority jurisdiction amount related discontinued operation whilst ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate group continue consider appropriate provision period open agree tax authority provision defer tax liability million december million respect taxation payable remittance profit certain overseas subsidiary whilst aggregate unremitte profit balance sheet date approximately billion billion majority unremitted profit subject tax include withhold tax repatriation uk legislation relate company distribution provide exemption tax overseas profit subject certain exception defer tax provide temporary difference million million arise unremitted profit management ability control future reversal consider reversal probable strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue taxation continue movement defer tax asset liability pension share accelerate intra post option net capital intangible contingent group employment tax award temporary allowance asset consideration profit benefit loss scheme difference total january exchange adjustment creditcharge income statement creditcharge statement comprehensive income acquisitionsdisposal rd credit utilisation transfer asset saledistribution december exchange adjustment creditcharge income statement creditcharge statement comprehensive income acquisitionsdisposal rd credit utilisation december defer tax liability relation intangible asset predominately relate temporary difference arising result historic business combination acquisition year predominantly relate bellus health note acquisition disposal group continue recognise defer tax asset future obligation respect contingent consideration amount payable minority shareholder payment tax deductible point time payment deferred tax asset recognise intragroup profit arise intercompany inventory eliminate consolidated account intragroup profit eliminate individual entity tax return temporary difference arise reverse point time inventory sell externally defer tax asset million million recognise tax loss relate trading loss defer tax asset recognise extent group longrange forecast indicate sufficient future taxable profit available utilise asset net temporary difference include accrue expense tax deduction available pay basis defer tax asset liability recognise balance sheet follow defer tax asset defer tax liability unrecognised unrecognised defer tax defer tax tax loss asset tax loss asset unrecognised tax loss trading loss expire year year available indefinitely december capital loss expire available indefinitely december defer tax asset recognise probable future taxable profit available utilise loss strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue earning share pence pence pence basic earning share continue operation basic earning share discontinue operation total basic earning share dilute earning share continue operation dilute earning share discontinue operation total diluted earning share basic earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust future exercise share option share awards treasury share trustee waive right cash dividend gsk share hold esop trust diluted earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option award dilute dividend dividend total dividend total dividend total share dividend share dividend share dividend paidpayable penny pay penny pay pence interim july july july second interim october october october interim january january january fourth interim april april april total estimate fourth interim dividend disclose annual report million million dividend ultimately pay ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend demerger consumer healthcare effect gsk declare interim dividend specie haleon plc share fair value distribution million amount recognise year follow cash dividend shareholder dividend specie shareholders haleon plc share note strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition business combination addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold saledistribution cost december exchange adjustment addition business combination addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold saledistribution cost december depreciation january exchange adjustment charge year disposal writeoff transfer asset hold saledistribution depreciation december exchange adjustment charge year disposal writeoff transfer asset hold saledistribution reclassification depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold saledistribution impairment december exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold saledistribution reclassification impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue property plant equipment continue weight average interest rate capitalise borrowing cost year disposal writeoff year include number asset nil net book value long use business impairment loss principally arise decision rationalise facility calculate base fair value cost disposal fair value cost disposal valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate specific segment country currency risk asset continue group generally assess associate cash generating unit value use basis value use calculation posttax cash flow include impact future uncommitted restructuring plan improvement impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pre tax discount rate approximately net impairment reversal credit cost sale million net impairment loss million rd million net impairment loss million net impairment loss charge sga million million charging impairment loss million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition give rise original impairment deem long apply million impairment reversal credit cost sale million impairment reversal credit rd expense million impairment reversal credit sga impairment reversal million credit cost sale million million computer software reclassify asset construction intangible asset ready use group assess qualitative quantitative impact climate relate risk asset recoverable amount conclude material impairment december million capitalise property plant equipment transition lowercarbon propellant right use asset land plant building equipment vehicle total net book value january exchange adjustment addition business combination addition depreciation transfer asset hold saledistribution disposal impairment net book value december exchange adjustment addition business combination addition depreciation transfer asset hold saledistribution disposal impairment reclassification net book value december group enter commitment lease contract commence note commitment analysis lease liability set note net debt strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue goodwill cost january exchange adjustment addition business combination note movement note transfer asset hold saledistribution cost december net book value january net book value december goodwill allocate group segment follow commercial operation total rd net book value december recoverable amount cash generating unit assess fair value cost disposal model fair value cost disposal calculate discount cash flow approach posttax discount rate apply project risk adjust posttax cash flow terminal value discount rate base group wacc cash generating unit integrate operation large part group discount rate adjust appropriate specific segment country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy rd segment evaluate arm length pricing model assumption detail relate discount cash flow model impairment test follow valuation basis fair value cost disposal key assumption sale growth rate profit margin terminal growth rate discount rate taxation rate determination assumption growth rate internal forecast base internal external market information margin reflect past experience adjust expect change terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc adjust appropriate taxation rate base appropriate rate jurisdiction period specific project cash flow year terminal growth rate discount rate terminal growth rate discount rate commercial operation pa pa rd pa pa commercial operations pa pa rd pa pa terminal growth rate exceed longterm project growth rate relevant market reflect impact future generic competition account new product launch goodwill monitor impairment segmental level valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill group assess qualitative quantitative impact climate relate risk asset recoverable amount conclude material impairment strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue intangible asset computer licence patent indefinite life software amortise brand brand total cost january exchange adjustment capitalise development cost addition business combination addition disposal asset writeoff transfer asset hold saledistribution reclassification cost december exchange adjustment capitalise development cost addition business combination addition disposal asset writeoff transfer asset hold saledistribution reclassification cost december amortisation january exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december exchange adjustment charge year disposal asset writeoff transfer asset hold saledistribution reclassification amortisation december impairment january exchange adjustment impairment loss transfer asset hold saledistribution reversal impairment disposal asset writeoff impairment december exchange adjustment impairment loss transfer asset hold saledistribution reversal impairment disposal asset writeoff impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weight average interest rate capitalise borrowing cost year net book value computer software include million million internally generate cost carry value december intangible asset impairment charge year follow impairment million million result appraisal gsk assumption relate inlicence collaboration agreement carry value december intangible asset impairment reversal charge year follow impairment reversal nil million million individual intangible asset account material impairment strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue intangible asset continue patent expiry date group significant asset relevant set page refer note accounting principle policy group accounting policy estimate useful life intangible asset exclusivity nonexclusivity period amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development licence patent amortise brand etc include large number acquire licence patent knowhow agreement marketing right market use development note acquisition disposal give detail addition business combination year book value large individual item follow tesaro asset meningitis portfolio momelotinib camlipixant affinivax asset dolutegravir include cabotegravir iteos asset alector asset benlysta shingrix okairos bms asset curevac asset spero rsv relvarbreoanoro stiefel trade wave life science ucb arrowhead dt fluarixflulaval vir asset announcement december gsk wave life sciences ltd enter strategic collaboration january advance oligonucleotide therapeutic focus novel genetic target june gsk complete acquisition bellus health inc latestage biopharmaceutical company acquisition provide gsk access camlipixant refer note acquisition disposal group consider reasonably possible change key assumption cause recoverable intangible asset disclose fall carry value group assess qualitative quantitative impact climate relate risk asset recoverable amount conclude material impairment strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue investment associate joint venture joint joint ventures associates total ventures associates total january exchange adjustment addition disposal distribution receive net fair value movement comprehensive income impairment interest associate profitloss tax recognise consolidated income statement december year group dispose investment joint venture nil consideration refer income statement information note associate joint venture current equity investment investment investment measure measure fvtpl fvtpl current january addition net fair value movement profit loss disposal settlement exchange adjustment december current equity investment represent haleon plc share hold demerger consumer healthcare share hold trading measure fair value profit loss fvtpl base haleon plc share price change fair value present operating incomeexpense continue operation group investment haleon plc end december hold glaxo group limited gsk scottish limited partnership gsk scottish limited partnership nil gsk scottish limited partnership nil esop trust nil strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue investment investment investment designate investment designate investment measure measured measured measured fvtoci fvtpl fvtoci fvtpl noncurrent january exchange adjustment addition net fair value movement comprehensive income net fair value movement profit loss hold sale disposal december noncurrent investment comprise noncurrent equity investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument recent financing round discount cash flow underlie net asset net fair value movement include impact exchange loss million comprehensive income nil profit loss gain million comprehensive income nil profit loss investment include list investment million million gsk elect designate majority equity investment measure fair value comprehensive income fvtoci significant investment hold december crispr therapeutics ag fair value december million million vir biotechnologyinc fair value december million million fair value investment nimbus therapeutic llc disclose significant investment december million december million investment include equity stake company gsk research collaboration company provide access biotechnology development potential interest disposal equity investment measure fvtoci accumulate fair value movement reclassify fair value reserve retain earning investment measure fvtoci fair value million million dispose year cumulative loss investment tax million gain million certain investment investment fund limited live investment acquire intention sell measure fair value profit loss fvtpl significant investment hold december sr capital fund ib lp fair value december million million noncurrent asset amount receivable insurance contract pension scheme surplus receivables amount receivable insurance contract hold cash surrender value movement profit loss receivables million million million million classified financial asset million million classify fair value profit loss remain balance million million expect credit loss allowance immaterial december receivable include million relate carbonbase nature removal project million strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue inventory raw material consumable work progress finish good tcfd climaterelate risk identify affect meter dose inhaler mdi impact recoverable value associate inventory hold year end trade receivable trade receivables net loss allowance accrue income prepayment interest receivable employee loan advance receivables trade receivable balance nil associate joint venture significant component receivables comprise receivables indirect taxis million million significant balance receivables royalty receivable million million receivable collaboration partner nil million loss allowance trade receivables january exchange adjustment charge year transfer asset hold sale subsequent recovery amount provide utilise december total trade receivables balance million million consider credit impair million million expect credit loss allowance apply purchase originated credit impair receivables million million million million classified financial asset nil nil classify hold fair value profit loss december expect credit loss allowance million million recognise respect financial asset release expect credit loss allowance million nil report profit loss year discussion credit risk practice refer note financial instrument relate disclosure strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue cash cash equivalent cash bank hand cash equivalent cash cash equivalent include million million available general use restriction apply subsidiary hold restriction include exchange control taxis repatriation million transfer asset hold sale relate consumer healthcare demerge year note acquisition disposal asset hold sale property plant equipment noncurrent asset disposal group transfer asset hold sale expect carry amount recover principally disposal sale consider highly probable hold low carrying fair value cost sell strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue trade payable trade payable wage salary social security viiv healthcare option payable defer income customer return rebate accrual accrual trade payable include nil nil associate joint ventures group provide limited supplier financing arrangement certain supplier amount involve december material revenue recognise year include deferred income january million million customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer fully describe group financial review december customer return rebate accrual include million million respect commercial operation accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual amount pay change arrangement future event cause assumption accrual base change affect future result group pfizer option shareholding viiv healthcare currently exercisable pfizer request ipo viiv healthcare time gsk consent ipo offering complete month pfizer require gsk acquire shareholding liability option hold gross redemption basis derive internal valuation viiv healthcare business utilise discount forecast future cash flow multiplesbase methodology table show indicative basis income statement balance sheet sensitivity pfizer option reasonably possible change key assumption increasedecrease financial liability lossgain income statement increase sale forecast increase sale forecast decrease sale forecast decrease sale forecast basis point increase discount rate basis point increase discount rate basis point decrease discount rate basis point decrease discount rate cent appreciation dollar cent appreciation dollar cent depreciation dollar cent depreciation dollar cent appreciation euro cent appreciation euro cent depreciation euro cent depreciation euro sale forecast viiv healthcare sale respect viiv healthcare option accrual include interest accrue financial liability amortise cost million million explanation accounting viiv healthcare set strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing commercial paper bank loan overdraft euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange euro medium term note london stock exchange lease liability longterm borrowing medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note london stock exchange euro medium term note london stock exchange medium note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange longterm borrowing lease liability net debt strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue net debt continue current asset liquid investment classify financial asset amortise cost december include treasury note government bond effective interest rate liquid investment december approximately approximately liquid investment balance december earn interest float rate million million liquid investment balance december earn interest fix rate million nil balance report cash cash equivalent original maturity month effective interest rate cash cash equivalent december approximately approximately cash cash equivalent december earn interest float fix rate amount million million respectively million noninterest bearing holding amount million million gsk policy credit quality cash cash equivalent set note financial instrument relate disclosure shortterm borrowing gsk billion billion commercial paper programme million million issue december million million gsk billion euro commercial paper programme million million issue december million million gsk billion threeyear commit facility billion billion day commit facility threeyear commit facility agree february extend year august september day commit facility agree september facility undrawn december weight average interest rate commercial paper borrowing december weight average interest rate current bank loan overdraft december average effective preswap interest rate note classify shortterm december longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year bilateral buyback outstanding sterling note gsk repurchase euro medium term note euro medium term note average effective preswap interest rate note issue december approximately approximately longterm borrowing repayable year carry interest effective rate repayment date range effective rate exclude impact oneoff premium associate early repayment sterling note pledge asset group hold pledge investment treasury note par value million million million million security irrevocable letter credit issue group behalf respect group selfinsurance activity provision respect selfinsurance include provision legal dispute discuss note provision lease liability maturity analysis discount lease liability recognise group balance sheet follow rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total lease liability strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue pension postemployment benefit pension postemployment cost uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service pension cost define benefit scheme accounting purpose calculate project unit credit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year remeasurement movement year recognise statement comprehensive income discount rate derive aa rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest government bond uk mortality rate determine adjust sap standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line cmi projection longterm rate improvement year male female mortality rate calculate pri white collar table adjust reflect recent experience rate project mp allow future improvement life expectancy strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue pension postemployment benefit continue average life expectancy assume individual age project apply individual age follow uk male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment physical asset allocation strategy uk plan returnseeke asset liabilitymatche assets buyin insurance contract purchase cover substantially obligation uk plan december value insurance contract million million asset allocation plan currently set return seek asset liabilitymatche asset pension plan expose risk arise estimate market value plan asset decline investment return reduce estimate value plan liability increase line agree mix returnseeke asset generate future return liabilitymatche asset well match future pension obligation group define overall longterm investment strategy plan investment broad range asset main market risk asset hedge portfolio credit risk interest rate longterm inflation equitie property currency bank counterparty risk plan liability series future cash flow relatively long duration ias basis cash flow sensitive change expect longterm inflation rate discount rate aa corporate bond yield curve increase long term inflation correspond increase liability increase discount rate correspond decrease liabilitie interest rate risk credit rate risk partially hedge target base accounting measure plan liability uk plan interest rate inflation hedge strategy place target base economic measure plan liability climaterelate impact environmental social governance esg consideration financially material regard expect return risk implication incorporation consideration investment policy subject local regulation fiduciary obligation uk define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent uk employee entitle join define contribution scheme addition group operate number postretirement healthcare scheme principal uk define benefit plan close future accrual effective march result post closure accrue benefit active participant revalue line inflation rpi legacy glaxo wellcome plan cpi legacy smithkline beecham plan subject relevant cap arrangement capped pay increase april define benefit plan employee transfer define contribution plan define benefit plan participant active april receive define pension contribution cash balance pension plan close future accrual january group apply follow financial assumption assess define benefit liability uk rest world pa pa pa pa pa pa pa pa pa rate increase future earning na na na na na discount rate expect pension increase na na na cash balance creditconversion rate na na na inflation rate sensitivity analysis detail effect change assumption provide analysis provide reflect assumption change material impact result group strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit uk rest world group group amount charge operating profit current service cost past service cost net interest cost gain settlement expense remeasurement gainslosse record statement comprehensive income postretirement pension benefit uk rest world group group amount charge operating profit current service cost past service costcredit net interest incomecost gain settlement expense remeasurement gainslosse record statement comprehensive income postretirement pension benefit uk rest world group group amount charge operating profit current service cost past service costcredit net interest incomecost gain settlement expense remeasurement gainslosse record statement comprehensive income amount include past service cost uk include million million million augmentation cost arise major restructuring programme strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue pension postemployment benefit continue summarise balance sheet presentation group define benefit pension scheme postretirement benefit set table recognise noncurrent asset pension scheme surplus recognise pension postemployment benefit pension scheme deficit postretirement benefit event plan windup gsk believe uk pension scheme rule provide company right refund surplus asset follow settlement plan liability result net surplus uk define benefit pension scheme recognise fair value asset liability uk define benefit pension scheme aggregate datum define benefit pension scheme group follow uk rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract liabilitiesasset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset multiasset fund comprise investment pool investment vehicle invest range asset class increase diversification growth portfolio value fund asset class quote market price million million liabilitiesasset category comprise cash mark market value derivative position indexlinke gilt hold uk repo programme include government bond relate loan million december million million deduct asset strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue pension postemployment benefit continue uk rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract liabilitiesasset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset uk rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract liabilitiesasset fair value asset asset ceiling restriction present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue pension postemployment benefit continue postretirement pension benefit uk rest world group group movement fair value asset asset january exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution transfer asset hold saledistribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution transfer asset hold saledistribution benefit pay asset december final instalment cash funding technical provision deficit million identify december pension scheme valuation gsk uk pension scheme pay march gsk transfer gsk consumer healthcare holdings limited gskchh c ordinary share represent aggregate gsk interest gskchh scottish limited partnership slp provide funding mechanism separate gsk uk define benefit pension scheme step relate demerger separation slp transfer applicable portion gskchh c ordinary share haleon plc haleon consideration share haleon time demerger slp hold share represent total issue share capital haleon contribution collateralise creation scottish limited partnership slp principal uk define benefit pension scheme benefit current glaxo welcome employee benefit current smithkline beecham employee interest slp time demerger scottish limited partnership general partner limited partner gsk scottish limited partnership gsk gp ltd gsk lp ltd berkeley square pension trustee company ltd acting behalf gsk pension scheme cease limited partner effective june gsk scottish limited partnership gsk gp ltd gsk lp ltd berkeley square pension trustee company ltd acting behalf gsk pension fund cease limited partner effective june gsk scottish limited partnership gsk gp ltd gsk lp ltd smithkline beecham pension plan trustee ltd acting behalf smithkline beecham pension plan cease limited partner effective june strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue pension postemployment benefit continue pension scheme slp interest receive distribution slp regard net proceed sale haleon share dividend income haleon share equal agree threshold proceed threshold million increase million notional interest payment fully fund cash funding technical provision deficit pension scheme show december valuation december total cash contribution total million million million proceed threshold leave outstanding uk pension scheme cash contribution include million distribution dividend haleon share slp scheme gsk uk pension scheme exit slp partnership june receipt proceed threshold notional interest remain economic interest slp hold gsk lp ltd own subsidiary gsk plc gsk control general partner slp employer contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit postretirement pension benefit uk rest world group group movement define benefit obligation obligation january exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution transfer asset hold saledistribution benefit pay obligation december exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution transfer asset hold saledistribution benefit pay obligation december strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue pension postemployment benefit continue define benefit pension obligation analyse follow fund unfunded liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade december postretirement healthcare scheme obligation million million million postretirement benefit unfunded movement net define benefit liability follow january exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement return plan asset exclude amount include interest lossgain change demographic assumption gainloss change financial assumption experience lossgain employer contribution transfer asset hold saledistribution expense december remeasurement include postretirement benefit detailed gain change demographic assumption gainloss change financial assumption experience gain define benefit pension obligation analyse membership category follow active retire defer postretirement benefit obligation analyse membership category follow active retired defer weight average duration define benefit obligation follow year year year pension benefit postretirement benefit strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue pension postemployment benefit continue sensitivity analysis effect change assumption benefit obligation annual define benefit pension post retirement cost detailed information determine take account duration liability overall profile plan membership increase decrease discount rate decreaseincrease annual pension cost increasedecrease annual postretirement benefit cost decreaseincrease pension obligation decreaseincrease postretirement benefit obligation increase decrease decreaseincrease annual pension cost increasedecrease annual postretirement benefit cost decreaseincrease pension obligation decreaseincrease postretirement benefit obligation increase decrease inflation rate increasedecrease annual pension cost increasedecrease pension obligation increase decrease increasedecrease annual pension cost increasedecrease pension obligation year increase life expectancy increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation increase rate future healthcare inflation increase annual postretirement benefit cost increase postretirement benefit obligation strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue provision legal major employee restructure relate dispute programme provision provision total january exchange adjustment charge year reverse unused unwind discount utilise transfer asset hold saledistribution addition business combination reclassification movement transfer pension obligation december settle year settle year december legal dispute nature group business number matter subject negotiation litigation group involve substantial number legal year litigation proceeding include dispute include notification possible claim set appeal procedure year reach resolution note legal proceeding provision legal outofcourt settlement discussion dispute include amount relate product liability antitrust protract indemnify dispute result provision charge government investigation contract termination self correspond receivable insurance group potential settlement discussion number group involved significant legal dispute amount provide base proceeding respect possible current assessment progress dispute meaningfully assess outcome result estimate million provide probable outflow quantify reliably estimate liability december settle year result ultimate resolution discussion legal issue note legal proceeding proceeding case group provide appropriate disclosure case provision major restructuring programme group major restructure net charge year million include reversal programme separation preparation programme estimate insurance recovery primarily relate focused prepare separation gsk provision product liability case commercial dispute company largely complete plus significant government investigation acquisition programme focus integration recent acquisition discount provision million million discount calculate riskadjusted restructure provision primarily include severance cost project cash flow riskfree rate return management formal decision eliminate certain position communicate group respect product liability claim relate certain product employee affect appropriate consultation procedure provision sufficient history claim complete appropriate provision staff settlement enable management reliable severance payment pay immediately estimate provision require cover unasserted claim determine probability outflow cash discount provision increase million ultimate liability matter vary amount increase million provide dependent outcome litigation pension augmentation include million relate proceeding investigation possible settlement define benefit plan arise staff redundancy show negotiation note pension postemployment benefit group position change time assurance loss result outcome legal proceeding exceed material provision report group financial account strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue provision continue employee relate provision give nature provision amount likely settle year employee relate provision include obligation certain medical benefit disabled employee spouse provision include provision provision onerous contract december provision benefit insurance provision number provision include amount million million employee vehicle insurance regulatory matter benefit reflect variety provision severance cost jubilee awards longservice benefit contingent consideration liability consideration certain acquisition include amount contingent future event development milestone sale performance group provide fair value contingent consideration follow shionogiviiv novartis healthcare affinivax vaccine total january remeasurement income statement cash payment operate cash flow cash payment invest activity december remeasurement income statement exchange movement reserve initial recognition business combination cash payment operate cash flow cash payment invest activity december remeasurement income statement exchange movement reserve cash payment operate cash flow cash payment invest activity december contingent consideration payable december million million expect pay year consideration payable acquisition shionogiviiv healthcare joint venture affinivax novartis vaccine business expect pay number year result total estimate liability discount present value show shionogiviiv healthcare contingent consideration liability discount affinivax contingent consideration liability discount novartis vaccine contingent consideration liability discount commercialise product pipeline asset shionogiviiv healthcare novartis vaccine contingent consideration liability calculate principally base forecast sale performance specify product live product affinivax contingent consideration base potential milestone payment billion billion pay certain paediatric clinical development milestone achieve strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue contingent consideration liability continue table show indicative basis income statement balance sheet sensitivity reasonably possible change key input valuation contingent consideration liability shionogiviiv novartis shionogiviiv novartis increasedecrease financial liability lossgain healthcare affinivax vaccines healthcare affinivax vaccines income statement increase sale forecast na na increase sale forecast na na decrease sale forecast na na decrease sale forecast na na increase discount rate increase discount rate decrease discount rate decrease discount rate cent appreciation dollar cent appreciation dollar cent depreciation dollar cent depreciation dollar cent appreciation euro na na cent appreciation euro na na cent depreciation euro na na cent depreciation euro na na increase probability milestone success na na decrease probability milestone success na na sale forecast viiv healthcare sale respect shionogiviiv healthcare contingent consideration explanation accounting viiv healthcare set noncurrent liability accrual defer income payable payable include number employeerelate liability include employee saving plan contingent liability december contingent liability gsk present obligation result past event comprise guarantee item arise normal course business amount million million december million million financial asset pledge collateral contingent liability provision outcome tax legal dispute probable group suffer outflow fund possible reliable estimate outflow possible meaningfully assess outcome result probable outflow quantify reliably estimate liability provision record description significant legal dispute group party set note legal proceeding strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment pension postretirement benefit interest loan future finance charge lease lease contract commence commitment relate intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount disclose riskadjuste discount increase intangible asset commitment mainly attributable new rd collaboration include collaboration wave life sciences usa inc shanghai hansoh biomedical co ltd gsk reach agreement trustee uk pension scheme additional contribution million eliminate pension deficit identify december actuarial funding valuation prior consumer healthcare demerger gsk agree collateralise commitment accelerate fund additional contribution refer note pension postemployment benefit december nil million additional contribution unpaid include total commitment million relate nature base carbon removal project support gsk net zero nature positive goal million relate transition lowercarbon propellant table exclude amount capitalise financial statement year end strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue share capital share premium account share consolidation follow completion consumer healthcare business demerger july gsk plc ordinary share consolidate maintain share price comparability demerger consolidation approve gsk shareholder general meeting hold july shareholder receive new ordinary share nominal value pence exist ordinary share nominal value pence earning share dilute earning share adjust earning share dividend share retrospectively adjust reflect share consolidation period present year ordinary share p preshare consolidation share ordinary share p postshare consolidation premium number share capital issue fully pay january issue employee share scheme ordinary share acquire esop trust december impact share consolidation issue employee share scheme ordinary share acquire esop trust december issue employee share scheme ordinary share acquire esop trust december december issue share capital share hold esop trust share hold future exercise share option share award share hold executive supplemental saving plan share hold treasury share share free issue issue share fully pay share authorise issue nominal carry market value share hold esop trust disclose note employee share scheme movement equity retain earning reserve amount million december million million million million million relate associate joint venture cumulative translation exchange equity follow net translation exchange include non total retain fair value control translation earning reserve interests exchange january exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary associate december exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary associate movement attributable continue operation movement attributable discontinue operation december exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary associate december include million reclassification consolidated income statement net exchange gain relate demerger consumer healthcare business strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue movement equity continue analysis comprehensive income equity category follow non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal subsidiary associate fair value movement cash flow hedge tax fair value movement cash flow hedge reclassification cash flow hedge income item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement define benefit plan tax remeasurement define benefit plan fair value movement cash flow hedge total comprehensive expenseincome year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal subsidiary associate fair value movement cash flow hedge tax fair value movement cash flow hedge reclassification cash flow hedge income item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement define benefit plan tax remeasurement define benefit plan fair value movement cash flow hedge comprehensive expenseincome year continue operation comprehensive expenseincome year discontinue operation total comprehensive expenseincome year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal subsidiary associate fair value movement cash flow hedge tax fair value movement cash flow hedge reclassification cash flow hedge income statement item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement loss define benefit plan tax remeasurement define benefit plan comprehensive expenseincome year strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue movement equity continue information net investment hedge provide note financial instrument relate disclosure analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserves total january exchange adjustment transfer income expense year impairment equity investment transfer retain earning year disposal equity investment net fair value movement year december exchange adjustment transfer retain earning year disposal equity investment balance derecognise demerger net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december exchange adjustment transfer retain earning year disposal equity investment reclassification cash flow hedge income statement hedging gainloss transfer nonfinancial asset net fair value movement year include tax ordinary share acquire esop trust writedown share hold esop trust december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million noncontrolling interest total noncontrolle interest includes follow individually material noncontrolle interest noncontrolle interest individually material viiv healthcare gsk hold viiv healthcare subgroup give rise material noncontrolle interest summarise financial information available late practicable date respect viiv healthcare subgroup follow turnover profit taxation comprehensive incomeexpense total comprehensive income noncurrent asset current asset total asset current liability noncurrent liability total liability net liability strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue noncontrolle interest continue net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity increasedecrease cash bank overdraft year financial information relate viiv healthcare group standalone basis impact grouprelate adjustment primarily relate recognition preferential dividend profit taxation million million million state charge preferential dividend payable gsk pfizer charge million million million remeasurement contingent consideration payable consideration expect pay number year follow amount attributable viiv healthcare group include gsk financial statement share profit year attributable noncontrolle interest dividend pay noncontrolle interest noncontrolle interest consolidate balance sheet relate party transaction december loan million nil index venture loan million nil medicxi venture lp remain gsk cash distribution receive investment medicxi venture lp million medicxi venture lp million december qura therapeutics llc liquidate investment associate commitment future contribution derecognise balance sheet immaterial gain million recognise group significant relate party transaction reasonably expect influence decision user financial statement aggregate compensation director glt give note employee cost strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give business acquisition june gsk complete acquisition bellus health inc bellus effect plan arrangement arrangement pursuant canada business corporation act arrangement approve bellus shareholder june completion gsk acquire outstanding common share bellus common share cash represent total equity value billion billion acquisition provide gsk access camlipixant potential bestinclass highly selective px antagonist currently phase iii development firstline treatment adult patient refractory chronic cough rcc total net asset acquire intangible asset noncurrent equity investment right use asset trade receivables investment hold current asset cash cash equivalent lease liability trade payable defer tax liability noncontrolle interest goodwill total consideration provisional value identifiable asset liability acquire affinivax inc business combination update finalisation fair value intangible asset result increase intellectual property million decrease goodwill million decrease defer tax million amount recognise december restate basis materiality business disposal gsk complete material business disposal associate joint venture gsk complete material investment disposal associate joint venture year cash flow business business acquisition disposal cash consideration pay receive net defer consideration pay transaction cost cash cash equivalent acquireddiveste cash outflowinflow strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue acquisition disposal continue business acquisition july gsk complete acquisition sierra oncology inc californiabase latestage biopharmaceutical company focus target therapy treatment rare form cancer billion billion main asset momelotinib target medical need myelofibrosis patient anaemia total transaction cost million august gsk complete acquisition affinivax inc clinicalstage biopharmaceutical company base cambridge boston massachusetts focus pneumococcal vaccine candidate consideration acquisition comprise upfront payment billion billion adjust work capital acquire pay close potential milestone payment billion billion pay achievement certain paediatric clinical development milestone estimate fair value contingent consideration payable million value provisional subject change total transaction cost million sale arise sierra oncology affinivax business include group turnover revenue expect regulatory approval receive acquire asset gsk continue support ongoing development acquire asset consequently asset loss make regulatory approval asset receive development asset integrate group exist rd activity impracticable quantify development cost impact total profit taxation period end december goodwill million million sierra oncology million affinivax expect deductible tax purpose recognise goodwill represent workforce place specific synergy available gsk business combination goodwill allocate group commercial operation rd segment refer note goodwill allocation methodology sierra oncology affinivax total net asset acquire intangible asset property plant equipment right use asset inventory trade receivables cash cash equivalent lease liability trade payable taxation goodwill total total cash fair value contingent consideration november gsk sign agreement buy noncontrolle interest glaxo saudi arabia ltd sar million million pay strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue acquisition disposal continue demerger consumer healthcare business july gsk plc separate consumer healthcare business gsk group form haleon independent list company separation effect way demerger gsk hold consumer healthcare business gsk shareholder follow demerger haleon hold aggregate gsk shareholder hold gsk include share receive gsk consolidated esop trust hold certain scottish limited partnership slp set provide collateral funding mechanism pursuant gsk provide additional funding gsk uk define benefit pension scheme note pension postemployment benefit aggregate ownership gsk include ownership esop trust slp demerger measure fair value change profit loss pfizer hold haleon demerger ifric distribution noncash asset owner liability equity distribution measure fair value asset distribute dividend appropriately authorise long entity discretion liability equity movement associate gain distribution recognise q demerger distribution authorise occur asset distribute ownership consumer healthcare business net carrying value consumer healthcare business consolidate financial statement include retain net attributable noncontrolle interest approximately billion end june gsk billion share shareholder loan q advance preseparation dividend eliminate consolidated financial statement asset distribute reduced consumer healthcare transaction july principally include preseparation dividend declare settle end q july dividend include billion billion attributable gsk dividend fund consumer healthcare debt partially onlent q dividend billion billion attributable gsk available cash balance fair value ownership consumer healthcare business distribute billion measure reference quote average haleon share price day trade fair value measure observable input consider representative fair value distribution date gain distribution fair value book value attributable net asset consumer healthcare business billion record income statement additional gain billion remeasure retain book value fair value billion fair value methodology distribute share gain distribution remeasurement retain stake demerger present discontinue operation future gain loss retain stake haleon recognise continue operation addition reclassification group share cumulative exchange difference arise translation foreign currency net asset divest subsidiary offset net investment hedge reserve income statement billion total gain demerger consumer healthcare billion transaction present profit discontinue operation fair value consumer healthcare business distribute fair value retain ownership haleon plc total fair value carry net asset liability distributedderecognise carrying noncontrolle interest derecognise gain demerger exchange movement transaction cost reclassification exchange movement net investment hedge movement disposal overseas subsidiary total gain demerger consumer healthcare consumer healthcare present discontinue operation june disclose interim financial statement consolidated income statement consolidate cash flow statement distinguish discontinue operation continue operation comparative figure restate consistent basis financial information relate operation consumer healthcare period set follow include financial information july financial information differ purpose basis preparation historical financial information interim financial information include haleon prospectus publish haleon march result whilst set financial information similar certain difference accounting disclosure ifrs strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue acquisition disposal continue total result turnover expense profit tax taxation tax rate lossprofit taxation discontinue operation consumer healthcare gainslosse demerger remeasurement discontinue operation distribute shareholder demerger profit taxation demerger discontinue operation noncontrolle interest discontinue operation earning attributable shareholder discontinue operation earning share discontinue operation p p business disposal material business disposal business business business disposal disposal acquisition demerger cash flow cash consideration net defer consideration pay cash cash equivalent divestedacquire transaction cost pay cash outflowinflow cash consideration business acquisition include million relate business acquisition activity business acquisition gsk complete material business acquisition business disposal gsk number business disposal net cash consideration receive year million profit disposal business year million calculate follow total consideration cash consideration include currency forwards purchase adjustment defer consideration total net asset sell property plant equipment cash cash equivalent net asset total cost deal cost reclassification exchange comprehensive income gain disposal strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue acquisition disposal continue associate joint venture gsk agree innoviva inc innoviva sell approximately million share common stock innoviva innoviva price share raise gross proceed approximately million follow settlement transaction gsk long hold innoviva stock detail note investment associate joint venture cash flow associate joint business venture disposal disposal cash consideration receive net defer consideration pay transaction cost cash cash equivalent divestedacquire cash outflowinflow adjustment reconcile total profit tax operating cash flow total profit tax continue operation tax profit share aftertax profitslosse associate joint venture finance expense net finance income depreciation amortisation intangible asset impairment asset write profit sale business profit sale intangible asset profitloss sale investment associate profit sale equity investment change work capital decreaseincrease inventory increase trade receivables increasedecrease trade payable increasedecrease receivables contingent consideration pay note noncash increase contingent consideration liability increasedecrease payable decrease pension provision sharebase incentive plan fair value adjustment operate cash flow continue operation operate cash flow discontinue operation total cash generate operation strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue reconciliation net cash flow movement net debt net debt begin year adjust decrease cash bank overdraft decrease liquid investment issue longterm loan repayment shortterm note repayment ofincrease shortterm loan repayment longterm loan repayment lease liability investmentsdebt subsidiary undertaking acquire exchange adjustment noncash movement decreaseincrease net debt continue operation decreaseincrease net debt discontinue operation total net debt end year january interest change reclass december exchange expense fair value ification cash flow analysis change net debt liquid investment cash cash equivalent overdraft debt year commercial paper europeanu mtn bank facility lease liability debt year europeanu mtn bank facility lease liability net debt interest payable derivative financial instrument total liability finance activity exclude cash cash equivalent overdraft liquid investment strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue reconciliation net cash flow movement net debt continue january interest change reclass december exchange expense fair value ification demerger cash flow analysis change net debt liquid investment cash cash equivalent overdraft liquid investment attribute continue operation liquid investment attribute discontinued operation debt year commercial paper europeanu mtn bank facility lease liability debt year attribute continue operation debt year attribute discontinued operation debt year europeanu mtn bank facility lease liability debt year attribute continue operation debt year attribute discontinued operation net debt interest payable derivative financial instrument total liability finance activity exclude cash cash equivalent overdraft liquid investment information significant change net debt note net debt strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure objective gsk treasury activity minimise net gsk access shortterm finance billion cost financial operation reduce volatility benefit billion commercial paper programme million earning cash flow gsk use variety financial million issue december instrument finance operation derivative financial million million gsk access shortterm instrument manage market risk operation finance billion euro commercial paper programme derivative principally comprise foreign exchange forward million million issue december contract swap swap borrowing million million gsk billion liquid asset currency require group purpose year billion billion day commit facility interest rate swap manage exposure commit facility undrawn december financial risk change interest rate financial gsk consider level commit facility adequate instrument reduce uncertainty foreign currency give current liquidity requirement transaction interest payment gsk billion euro medium term note programme derivative exclusively hedge purpose relation december billion note issue underlie business activity trade programme group billion billion speculative instrument note issue december shelf registration gsk borrowing mature date capital management gsk financial strategy support group strategic priority option own pfizer viiv healthcare exercisable regularly review board gsk manage review liquidity requirement gsk consider sufficient capital structure group appropriate mix financing option available option debt equity exercise capital structure group consist net debt market risk billion note net debt total equity include item relate noncontrolle interest billion interest rate risk management consolidate statement change equity gsk objective minimise effective net interest cost total capital include provide noncontrolle balance mix debt fix float rate time interest billion group main interest rate risk arise borrowing group continue manage financial policy credit investment float rate refinance mature profile particularly target rating aa fix rate debt change interest rate affect cycle group longterm credit future cash flow fair value financial instrument rate standard poor stable outlook policy interest rate risk management limit net moodys investor service moodys stable outlook float rate debt specific cap review agree group shortterm credit rating p standard annually board poor moodys respectively majority debt issue fix interest rate liquidity risk management change float rate interest significantly gsk policy borrow centrally order meet anticipated affect group net interest charge shortterm borrowing funding requirement strategy diversify liquidity include bank facility expose risk future source range facility maintain broad access change market interest rate majority cash financial market day gsk sweep cash liquid investment number global subsidiary central treasury account foreign exchange risk management liquidity management purpose gsk utilise physical group objective minimise exposure overseas notional cash pool arrangement appropriate location operating subsidiary transaction risk match local currency notional cash pool liquidity draw currency income local currency cost possible foreign currency balance provide local funding foreign currency transaction exposure arise external central liquidity require balance actively internal trade flow selectively hedge gsk internal manage maintain appropriate level balance trading transaction match centrally intercompany notional pool arrangement settle payment term manage reduce foreign currency risk currency gross cash overdraft balance report possible gsk manage cash surplus borrow december gsk billion borrowing requirement subsidiary company centrally forward repayable year hold billion cash contract hedge future repayment originate cash equivalent liquid investment billion currency hold centrally order reduce foreign currency translation exposure group seek denominate borrowing currency principal asset cash flow primarily denominate dollar euro sterling borrowing swap currency require strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue borrowing denominate swap foreign currency change estimation technique match investment overseas group asset significant assumption current reporting treat hedge relevant asset forward period assess loss allowance financial asset contract major currency reduce exposure amortise cost fvtoci adoption ifrs group investment overseas asset net start report period investment hedge section note detail treasuryrelate credit risk credit risk gsk set global counterparty limit gsk banking credit risk risk counterparty default investment counterpartie base longterm credit contractual obligation result financial loss group rating moodys standard poor usage arise cash cash equivalent favourable limit actively monitor derivative financial instrument hold bank financial gsk actively manage exposure credit risk reduce institution credit exposure wholesale retail surplus cash balance possible gsk customer include outstanding receivables strategy regionalise cash management concentrate group consider maximum credit risk december cash centrally possible table set million december million credit exposure counterpartie rate liquid total group financial asset investment cash cash equivalent derivative exception investment comprise equity gross asset position derivative contract investment bear equity risk credit risk consider purpose table isda detail group total financial asset agreement risk net position december gsk great concentration credit risk counterparty table e set group billion wholesaler billion financial asset liability offset basis wholesaler information group credit risk exposure respect large wholesaler customer strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue december million million cash categorise hold unrated subinvestment grade rate counterpartie low bbbbaa exposure concentrate overseas bank local cash management investment purpose include million saudi arabia saudi british bank million halk bank uk million nigeria hold united bank africa zenith bank access bank stanbic ibtc bank million brazil hold banco bradesco itau unibanco banco brasil caixa economica federal million banco de la produccion ecuador million bank balance deposit hold bbbbaa rate counterpartie million hold bbbbaa rate counterpartie include balance deposit million state bank india india bank local investment purpose gsk measure expect credit loss cash cash equivalent function individual counterparty credit rating associate month default rate expect credit loss cash cash equivalent thirdparty financial derivative deem immaterial loss experience credit rating assign standard poor moodys respectively opinion rating agency differ gsk assign low rating counterparty local rating agency fitch datum source available rating convert global rating equivalent standard poor moodys publish conversion table credit rating form basis assessment expect credit loss treasuryrelate balance hold amortise cost bank balance deposit government security bbba aaaaaa aaaa aa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security party financial derivative total bbba aaaaaa aaaa aa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security party financial derivative total gsk centrally manage cash reserve amount billion concentration trade receivables reflective standard december available month market practice pharmaceutical sector include billion cash manage group viiv significant portion sale wholesaler healthcare own subsidiary group invest disclose note turnover segment information centrally manage liquid asset bank deposit aaaaaa gsk assessment limited credit risk associate rate treasury treasury repo money market fund customer aaaaaa rate liquidity fund group credit risk monitoring activity relate wholesale retail credit risk wholesaler include review quarterly financial information standard poor credit rating development outside customer account gsk internal risk rating establishment periodic group trade receivable balance review credit limit line pharmaceutical company new customer subject credit vetting process group sell product small number wholesaler exist customer subject review annually addition hospital pharmacie physician vetting process subsequent review involve obtain group sale large wholesaler amount information include customer status government approximately sale private sector entity audit financial statement credit bureau commercial operation business report debt rating agency eg moodys standard poor december group trade receivable report payment performance history trade reference wholesaler total million industry credit group bank reference total trade receivables million group expose concentration credit risk respect wholesaler encounter financial difficulty materially adversely affect group financial result strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue trade receivables consist amount large number follow method assumption measure customer spread diverse industry fair value significant financial instrument carry fair geographical area ongoing credit evaluation perform value balance sheet financial condition account receivable investment equity investment trade active appropriate credit insurance purchase factoring market determine reference relevant stock arrangement place exchange quote bid price equity investment information obtain proportional level determine reference current market value exposure consider information evaluate similar instrument recent financing round discount quantitatively ie credit score qualitatively ie cash flow underlie net asset judgement conjunction customer credit trade receivables carry fair value base invoice requirement determine credit limit interest rate swap foreign exchange forward contract trade receivables group customer segment swap option base present value similar loss pattern assess credit risk contractual cash flow option valuation model receivables financial asset assess individually market source datum exchange rate interest rate historical forwardlooke information consider balance sheet date determine appropriate expect credit loss allowance cash equivalent carry fair value base net asset group believe credit risk provision value fund require excess allowance expect credit loss contingent consideration business acquisition note trade receivables divestment base present value expect future credit enhancement cash flow group use credit enhancement include factoring follow method assumption estimate credit insurance minimise credit risk trade fair value significant financial instrument receivables group december million measure fair value balance sheet million trade receivables insure order receivables payable include option carry protect receivables loss credit risk amortise cost approximate carry default insolvency bankruptcy liquid investment approximate carry group entity assess credit risk private cash cash equivalent carry amortise cost customer determine credit insurance require approximate carry longterm loan base quote market price level factoring arrangement manage locally entity fair value measurement case european mitigate risk arise large credit risk medium term note approximate carry concentration factoring arrangement nonrecourse case fix rate borrowing float rate bank fair value financial asset liability loan exclude lease liability shortterm loan overdraft commercial paper approximate carry short table present carry amount maturity instrument fair value group financial asset liability exclude lease liability december december fair value financial asset liability include price receive sell asset pay transfer liability orderly transaction market participant measurement date strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue carry fair carry fair value value value value note financial asset measure amortise cost noncurrent asset b trade receivables b liquid investment cash cash equivalent financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables ab financial asset mandatorily measure fair value profit loss fvtpl current equity investment investment noncurrent assets ab trade receivables ab hold trading derivative designate ade effective hedging relationship cash cash equivalent derivative designate effective hedging instrument fair value ade movements comprehensive income total financial asset financial liability measure amortise cost borrowing exclude obligation lease liability bond designate hedge relationship bond bank loan overdraft commercial paper designate hedge relationship commercial paper borrowing total borrowing exclude lease liability f trade payable c provision c noncurrent liability c financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability ac hold trading derivative designate ade effective hedging relationship derivative designate effective hedging instrument fair value ade movements comprehensive income total financial liability exclude lease liability net financial asset financial liability exclude lease liability valuation methodology measure fair value table describe categorise trade receivables noncurrent asset trade payable provision contingent consideration liability noncurrent liability reconcile relevant note page strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue fair value investment gsk share december employee share ownership plan esop trust hold gsk share carry value million million market value million million base quote market price share hold esop trust satisfy future exercise option award employee incentive scheme carry value low cost expect proceed share recognise deduction reserve december gsk hold treasury share cost million million deduct retain earning financial instrument hold fair value follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level investment classify level table comprise equity investment unlisted entity group enter research collaboration investment provide access biotechnology development potential interest level level level total december financial asset fair value financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl current equity investment investment noncurrent asset trade receivable hold trading derivative designate effective hedge relationship cash cash equivalent derivative designate effective hedging instrument fair value movement oci financial liability fair value financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedging relationship derivative designate effective hedging instrument fair value movement oci level level level total december financial asset fair value financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl current equity investment investment noncurrent asset trade receivable hold trading derivative designate effective hedge relationship cash cash equivalent derivative designate effective hedging instrument fair value movement oci financial liability fair value financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedging relationship derivative designate effective hedging instrument fair value movement oci strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue movement year financial instrument measure level valuation method present january exchange adjustment net loss recognise income statement net loss gain recognise comprehensive income contingent consideration relate business acquisition period settlement contingent consideration liability addition disposal settlement transfer level december total net loss million million attributable level financial instrument recognise income statement million million respect financial instrument hold end year report operating incomeexpense charge million million arise remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture remeasurement gain million million loss arise remeasurement contingent consideration payable acquisition novartis vaccine business acquisition affinivax result additon million contingent consideration level financial liability charge million million arise remeasurement contingent consideration liability year transfer million level financial instrument year transfer level financial instrument movement arise translation overseas net asset consolidation group account record exchange adjustment net gain loss include impact exchange movement financial liability measure level valuation method december include million million respect contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year vary line future performance specify product movement certain foreign currency million million respect contingent consideration acquisition novartis vaccine business consideration expect pay number year vary line future performance specify product achievement certain milestone target movement certain foreign currency result acquisition affinivax contingent consideration payable million million recognise december consideration expect pay number year vary line achievement certain development milestone movement usdgbp exchange rate sensitivity analysis balance provide note contingent consideration liability b trade receivables noncurrent asset scope ifrs follow table reconcile financial instrument trade receivables noncurrent asset fall scope ifrs relevant balance sheet amount financial asset predominantly noninterest earn non financial instrument include tax receivables pension surplus balance prepayment outside scope ifrs non non amortise financial financial amortise financial financial fvtpl fvtoci cost instrument instrument total fvtpl fvtoci cost instrument instrument total trade receivable note noncurrent asset note trade receivables include trade receivables million million group portfolio business model ifrs million million measure fvtpl hold sell contractual cash flow receivable sell factoring arrangement million million measure fvtoci hold collect sell contractual cash flow receivables sell factoring agreement million million measure amortise cost hold collect contractual cash flow factor agreement place strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue c trade payable provision contingent consideration liability non current liability scope ifrs follow table reconcile financial instrument trade payable provision contingent consideration liability noncurrent liability fall scope ifrs relevant balance sheet amount financial liability predominantly noninterest bear nonfinancial instrument include payment account tax social security payable provision arise contractual obligation deliver cash financial asset outside scope ifrs non non amortise financial financial amortise financial financial fvtpl cost instrument instrument total fvtpl cost instrument instrument total trade payable note provision note contingent consideration liability note noncurrent liability note derivative financial instrument hedge programme derivative economic hedging purpose speculative investment classify hold trading designate effective hedging instrument present current asset liability expected settle month end reporting period classified noncurrent group follow derivative financial instrument fair value fair value asset liability asset liabilitie current cash flow hedge foreign exchange contract net principal million million net investment hedge foreign exchange contract net principal million million derivative designate effective hedging instrument current foreign exchange contract net principal million million embed derivative derivative classify hold trading total derivative instrument strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue fair value hedge december december group designate fair value hedge net investment hedge december certain foreign exchange contract designate net investment hedge respect foreign currency translation risk arise consolidation group net investment european euro american usd singaporean sgd canadian cad japanese jpy foreign operation show table carry value bond include million million designate hedging instrument net investment hedge cash flow hedge group enter forward foreign exchange contract designate cash flow hedge enter hedge foreign exchange exposure arise cash flow euro denominate coupon payment relate note issue group european medium term note programme hedge foreign currency payment acquisition collaboration licensing arrangement group manage cash flow interest rate risk floatingtofixed interest rate swap addition group carry balance reserve arise prehedge fluctuation longterm interest rate pricing bond issue prior year current year balance reclassify finance cost life bond foreign exchange risk current year group designate certain foreign exchange forward contract swap cash flow net investment hedge foreign exchange derivative financial asset liability present line derivative financial instrument asset liability consolidate balance sheet follow table detail foreign exchange forward contract swap outstanding end report period information relate hedge item hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessment ensure economic relationship exist hedge item hedging instrument group enter hedge relationship critical term hedge instrument match exactly term hedge item qualitative assessment effectiveness perform change circumstance affect term hedge item critical term long match exactly critical term hedge instrument group use hypothetical derivative method assess effectiveness main source hedge ineffectiveness hedging relationship effect counterparty group credit risk fair value foreign exchange forward contract swap reflect fair value hedge item attributable change foreign exchange rate source ineffectiveness emerge hedging relationship ineffectiveness record cash flow hedge nil ineffectiveness record net investment hedge nil periodic change value calculate average foreign net notional carry hedge exchange rate currency value value ineffectiveness hedge instrument cash flow hedge foreign exchange contract buy foreign currency month usd month month usd sell foreign currency month eur strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue periodic change value calculate average foreign net notional carry hedge exchange rate currency value value ineffectiveness hedging instrument net investment hedge foreign exchange contract sell foreign currency month eur jpy usd month cad sgd borrowing month eur month month jpy eur cumulative balance cash balance cash flow hedge periodic change value flow hedge reserveforeign reserve arise hedge calculate hedge currency translation reserve relationships hedge ineffectiveness continue hedgesaccounting long apply hedge item cash flow hedge variability cash flow highly probable forecast transaction net investment hedge net investment foreign operation periodic change value calculate average foreign net notional carry hedge exchange rate currency value value ineffectiveness hedge instrument cash flow hedge foreign exchange contract buy foreign currency month usd month eur month eur sell foreign currency month eur strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue periodic change value calculate average foreign net notional carry hedge exchange rate currency value value ineffectiveness hedging instrument net investment hedge foreign exchange contract sell foreign currency month eur jpy month month cad sgd borrowing month eur month eur month eur cumulative balance cash balance cash flow hedge periodic change value flow hedge reserveforeign reserve arise hedge calculate hedge currency translation reserve relationships hedge ineffectiveness continue hedgesaccounting long apply hedge item cash flow hedge variability cash flow highly probable forecast transaction variability cash flow foreign exchange exposure arise euro denominate coupon payment relate debt issue net investment hedge net investment foreign operation nil million balance cash flow hedge reserve arise hedging relationships hedge accounting long apply follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss reclassify balance sheet hedge line item line item future cash profit loss line item hedge hedge profit flow balance gainslosse ineffectiveness loss long hedge item reclassification hedge sheet recognise recognise hedge expect affect adjustment item affect reclassification reserve profit loss ineffectiveness occur profit loss include balance sheet adjustment include include cash flow hedge variability cash flow finance finance intangible highly probable forecast income income asset transaction expense expense variability cash flow finance finance foreign exchange exposure income income arise euro denominate expense expense coupon payment relate debt issue net investment hedge net investment foreign finance operation income income expense expense strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue reclassify profit loss reclassify balance sheet hedge line item future cash line item line item hedge hedge profit flow profit loss balance gainslosse ineffectiveness loss long hedge item hedge sheet recognise recognise hedge expect affect reclassification item affect reclassification reserve profit loss ineffectiveness occur profit loss adjustment balance sheet adjustment include include include cash flow hedge variability cash flow finance intangible highly probable forecast income asset transaction expense variability cash flow finance finance foreign exchange exposure income income arise euro denominate expense expense coupon payment relate debt issue net investment hedge net investment foreign finance discontinue operation income operation expense reclassify consolidated income statement demerger consumer healthcare business interest rate risk group manage cash flow interest rate risk floatingtofixed interest rate swap quarterly interval difference fix contract rate float rate interest amount calculate reference agree notional principal amount exchange swap outstanding december december impact financial statement interest rate swap interest rate risk element future debt issuance manage enter forward start interest rate swap effectively lock interest rate debt advance close time issue debt result gain loss hold cash flow hedge reserve reclassify income statement interest payment debt impact income statement forward start interest rate swap forward start interest rate contract exchange float interest fix interest designate cash flow hedge hedge interest variability interest cash flow associate future fix rate debt interest rate swap interest rate swap contract asset liability present applicable line derivative financial instrument asset liability consolidate balance sheet million million balance cash flow hedge reserve arise hedge relationships hedge accounting long apply follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss line item line item profit hedge future profit loss hedge hedge loss cash flow gainslosse ineffectiveness hedge long hedge item reclassification recognise recognisedineffectiveness expect affect adjustment reserve profit loss include occur profit loss include cash flow hedge prehedge longterm interest rate finance finance mature past income income expense expense strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue reclassify profit loss line item line item profit hedge future profit loss hedge hedge loss cash flow gainslosse ineffectiveness hedge long hedge item reclassification recognise recognise ineffectiveness expect affect adjustment reserve profit loss include occur profit loss include cash flow hedge prehedge longterm interest rate mature past finance finance income income expense expense e offset financial asset liability financial asset liability offset net report balance sheet legally enforceable right offset recognise amount intention settle net basis realise asset settle liability simultaneously arrangement meet criterion offset allow related amount offset certain circumstance bankruptcy termination contract follow table set financial asset liability offset subject enforceable master netting arrangement similar agreement offset december december column net show impact group balance sheet offset right exercise gross gross net financial relate financial financial asset amount asset liability liability set liability asset set balance sheet balance sheet net december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument gross gross financial financial net financial relate asset liability asset amount net liability asset offset liability offset balance december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument amount meet criterion offset balance sheet settle net certain circumstance principally relate derivative transaction isda international swap derivative association agreement party option settle amount net basis event default party presently legally enforceable right offset amount offset balance sheet present separately table strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue f debt interest rate repricing table follow table set exposure group interest rate debt include commercial paper maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing lease liability total debt total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue g sensitivity analysis table illustrate estimate impact income statement equity result hypothetical market movement foreign exchange interest rate relation group financial instrument range variable choose sensitivity analysis reflect management view change reasonably possible oneyear period foreign exchange sensitivity group operate internationally primarily expose foreign exchange risk relation sterling movement dollar euro japanese yen foreign exchange risk arise translation financial asset liability functional currency entity hold base group net financial asset liability december weaken strengthen sterling currency variable hold constant illustrate table table exclude financial instrument expose group foreign exchange risk risk fully hedge financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent appreciation dollar cent appreciation euro cent appreciation euro yen appreciation yen yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent depreciation dollar cent depreciation dollar cent depreciation euro cent depreciation euro yen depreciation yen yen depreciation yen equity impact show foreign exchange sensitivity relate derivative nonderivative financial instrument hedge group net investment european euro foreign operation cash flow hedge foreign exchange exposure arise euro denominate coupon payment relate note issue group european medium term note programme increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent appreciation dollar cent appreciation euro cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent depreciation dollar cent depreciation dollar cent depreciation euro cent depreciation euro strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue table present group sensitivity weakening strengthen sterle relevant currency base composition net debt show note net debt adjust effect foreign exchange derivative net debt affect future foreign currency cash flow increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent appreciation dollar cent appreciation dollar cent appreciation euro cent appreciation euro yen appreciation yen yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent depreciation dollar cent depreciation dollar cent depreciation euro cent depreciation euro yen depreciation yen yen depreciation yen interest rate sensitivity group expose interest rate risk outstanding borrowing investment change interest rate affect future cash flow fair value financial instrument majority debt issue fix interest rate change float rate interest significantly affect group net interest charge majority cash liquid investment earn float rate interest table hypothetically show group sensitivity change interest rate relation sterling dollar euro float rate financial asset liability basis point basis point movement eur usd sterling interest rate deem material effect equity basis point basis point decrease eur usd sterling interest rate equal opposite impact show increasedecrease increasedecrease income income income statement impact interest rate movement basis point increase sterling interest rate basis point increase sterling interest rate basis point increase dollar interest rate basis point increase dollar interest rate basis point increase euro interest rate basis point increase euro interest rate strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue financial instrument relate disclosure continue h contractual cash flow nonderivative financial liability derivative instrument follow table provide analysis anticipate contractual cash flow include interest payable group non derivative financial liability undiscounte basis purpose table debt define class borrowing lease liability interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december finance trade payable charge interest lease lease liability debt debt liability liabilitie net debt total december year year year year year year great year gross contractual cash flow finance trade payable charge interest lease lease liability debt debt liability liabilitie net debt total december year year year year year year great year gross contractual cash flow table provide analysis anticipate contractual cash flow group derivative instrument exclude equity option rise cash flow embed derivative material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument gross cash inflow gross cash outflow gross cash inflow gross cash outflow foreign exchange forward foreign exchange forward foreign exchange forward foreign exchange forward contract swap contract swap contract swap contract swap year gross contractual cash flow strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue employee share scheme gsk operate employee share scheme include share value plan award grant employee acquire share ad gsk plc cost threeyear vest period performance share plan award grant employee acquire share ad gsk plc cost subject achievement group specify performance target grant restrict share award replace grant option employee cost scheme readily equate potential gain employee group operate saving relate share option scheme option grant employee acquire share gsk plc discount price grant restrict share award normally exercisable end threeyear vest performance period award normally grant employee acquire share ad gsk plc circumstance settle cash grant savingsrelate share option scheme normally exercisable year save accordance uk practice majority option savingsrelate share option scheme grant price market price ruling date grant option historical share option scheme grant market price ruling date grant total charge sharebase incentive plan million million million million million million arise share value plan note employee cost detail gsk share award scheme share value plan share value plan share award grant certain employee cost award vest half year performance criterion attach fair value award determine base closing share price day grant deduct expect future dividend yield duration award share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december performance share plan performance share plan share award grant director senior executive cost percentage award vest base performance group define measurement period dividend reinveste period award grant performance condition base measure threeyear performance period adjust free cash flow tsr rd new product performance pipeline progress award grant performance condition base measure threeyear performance period tsr pipeline progress profit measure sale measure esg environment fair value award determine base closing share price day grant tsr performance element adjust likelihood condition meet assess time grant award million share weight fair value million ad weight fair value december outstanding award million share million ad strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue employee share scheme continue share option savingsrelate option purpose value savingsrelated option arrive sharebased payment charge blackschole option pricing model assumption model follow grant grant grant riskfree interest rate dividend yield volatility expect life year year year savingsrelate option grant price include discount savingsrelate option outstanding share save plan share option scheme weight number exercise price december range exercise price option outstanding year end weight average market price exercise year weight average remain contractual life year option million share grant year savingsrelate share option scheme weight average fair value december million savingsrelate share option exercisable change effective exercise price outstanding option year employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share gsk plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share finance provide group way loan contribution cost run esop trust charge income statement share hold esop trust deduct reserve amortise value proceed receivable employee exercise transfer retain earning trustee waive right dividend share hold esop trust december share hold esop trust hold future exercise share option share award share hold executive supplemental saving plan share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue principal group company follow represent principal subsidiary country incorporation group december equity share capital entity show percentage column company incorporate principal country operation state england scotland glaxo group limited gsk scottish limited partnership glaxo operation uk limit glaxo wellcome uk limit glaxosmithkline capital plc affinivax inc glaxosmithkline export limited corixa corporation glaxosmithkline finance plc glaxosmithkline capital inc glaxosmithkline holdings limiteda glaxosmithkline holdings americas inc glaxosmithkline ihc limited glaxosmithkline llc glaxosmithkline intellectual property limited gsk equity investment limited glaxosmithkline intellectual property limited human genome sciences inc glaxosmithkline intellectual property limited stiefel laboratories inc glaxosmithkline intellectual property development limit tesaro inc glaxosmithkline intellectual property limited viiv healthcare company glaxosmithkline research development limited glaxosmithkline service unlimiteda glaxosmithkline uk limit glaxo saudi arabia limit saudi arabia glaxosmithkline trading limit glaxo wellcome manufacturing pte ltd singapore setfirst limited glaxosmithkline thailand limited thailand smithkline beecham limited glaxosmithkline australia pty ltd australia viiv healthcare finance limited glaxosmithkline brasil limitada brazil viiv healthcare uk limited glaxosmithkline far east bv taiwan viiv healthcare uk limited glaxosmithkline ilaclari sanayi ticaret turkey glaxosmithkline inc canada europe glaxosmithkline kk japan glaxosmithkline ag switzerland glaxosmithkline korea limited republic korea glaxo wellcome production sas france glaxosmithkline limited hong kong glaxosmithkline bv netherlands glaxosmithkline mexico sa de cv mexico glaxosmithkline biological sa belgium glaxosmithkline pakistan limited pakistan glaxosmithkline gmbh co kg germany glaxosmithkline pharmaceuticals limited india glaxosmithkline manufacturing spa italy gsk enterprise management co ltd china glaxosmithkline pharma gmbh austria gsk pharma vietnam company limited vietnam glaxosmithkline pharmaceuticals sa belgium d biomedical corporation quebec canada glaxosmithkline sa spain viiv healthcare kk japan glaxosmithkline spa italy viiv healthcare ulc canada glaxosmithkline single member aebe greece glaxosmithkline trading services limited republic irelandb gsk capital bv netherlandsb gsk service sp z oo poland gsk vaccines gmbh germany gsk vaccines srl italy jsc glaxosmithkline trading russia laboratoire glaxosmithkline france laboratorios viiv healthcare sl spain viiv healthcare gmbh germany viiv healthcare srl italy viiv healthcare sas france directly hold whollyowne subsidiary gsk plc b tax resident uk subsidiarie associate list principally affect figure group financial statement glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline finance plc gsk capital bv glaxosmithkline llc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline finance plc gsk capital bv glaxosmithkline llc page complete list subsidiary undertaking associate joint venture form financial statement strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue legal proceeding group involve significant legal administrative december teva file petition rehear en proceeding principally product liability intellectual property banc court grant tevas petition rehear tax antitrust consumer fraud governmental investigation threemember panel issue original decision significant matter tax matter august original panel issue rehear opinion describe group make provision majority reinstate jurys damages award proceeding regular basis summarise note million gsk favour accounting principle policy note teva file petition rehear en banc provision note describe disclosure reject court appeal federal circuit proceeding provision legal expense february july teva file petition writ incur provision relate legal claim charge certiorari supreme court united states seek sell general administration cost group overturn federal court decision believe information seek plaintiff supreme court deny tevas request certain issue remain known meaningful respect legal resolve district court party await proceeding number factor include scheduling status conference limit stage proceeding entitlement party appeal decision clarity theory liability dolutegravir proceeding damage govern law tivicaytriumeq december group aggregate provision legal september viiv healthcare receive paragraph iv dispute include tax matter describe note letter lupin relate tivicay mg dosage oral taxation million assurance suspension challenge crystal form patent loss result outcome legal november viiv healthcare file suit lupin proceeding materially exceed district court district delaware march provision report group financial statement party reach settlement conclude matter happen material adverse impact result operation group report period juluca judgements incur settlement enter june cipla send viiv healthcare paragraph iv letter relate juluca july viiv healthcare intellectual property file suit cipla federal court delaware march party reach settlement conclude intellectual property claim include challenge validity matter enforceability group patent product process assertion noninfringement rsv patent loss case result loss patent june pfizer inc file suit london high court protection product issue consequence challenge validity request revocation gsk loss significant decrease sale european patent relate rsv vaccine technology product materially affect future result operation correspond invalidity suit additional patent group file district court hague netherlands coreg january frenchspeaking enterprise court brussels belgium march matter gsk initiate suit teva induce gsk counterclaim pfizer rsv vaccine infringe gsk infringement patent relate use carvedilol patent august gsk file patent infringement suit coreg decrease mortality cause congestive heart pfizer united states district court district failure june case proceed jury trial delaware allege infringement gsk patent district court district delaware jury return pfizer rsv vaccine abrysvo gsk patent verdict gsk favour award gsk lose profit add litigation november reasonable royalty total award million march trial judge rule posttrial motion file trial uk action take place june decision teva find substantial evidence trial expect end q netherlands support jury find induce infringement overturn separate firstinstance hearing schedule jury award gsk appeal october hold january second schedule divide panel court appeal federal circuit march belgium trial merit expect q reverse district court rule reinstate jury award instance decision likely q trial date gsk favour set gsk seek monetary compensation pfizer pfizer infringe sale abrysvo gsk sale arexvy issue litigation strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue legal proceeding continue product liability gsk name defendant approximately plaintiff state jurisdiction plaintiff group currently defendant number product approximately plaintiff file delaware liability lawsuit delaware plaintiffs allege cancer cancer pursue plaintiff mdl proceeding avandia delaware court hold general causation hear pende class action file admissibility expert testimony cancer plaintiff thirdparty payer assert claim racketeer decide pursue breast colorectal kidney prostate influence corrupt organization act rico state pancreatic lung bladder liver esophageal stomach consumer protection law december circuit january court appeal reverse summary judgement grant favour group remand thirdparty payer case california zantac litigation case jccp jccp district court discovery complete class court issue sargon rule case schedule trial certification summary judgment briefing goetz court find plaintiff expert causation complete hear certain daubert motion relate opinion admissible present jury expert hold february gsk request oral ruling apply goetz case affect argument class certification schedule state court case june gsk reach confidential settlement goetz case october gsk announce reach confidential settlement zantac cantlayharper case remain breast group contact regulatory cancer bellwether case california february gsk authority detection nnitrosodimethylamine announce reach confidential settlement ndma zantac ranitidine product base information browne case file california state court case available time correspondence regulator set begin trial february dismiss group decision suspend release distribution settlement reflect gsk desire avoid distraction relate supply dose form zantac market pende protract litigation gsk admit liability outcome ongoing test investigation settlement continue vigorously defend base precautionary action group decision initiate fact science zantac case voluntary pharmacyretail level recall zantac product case schedule trial jccp boyd colorectal globally court set sargon hear february trial date april additional bellwether case jccp april european medicine agency ema set trial q q recommend suspension ranitidine medicine follow publication emas recommendation company multiple trial state court set date communicate decision reenter market include illinois texas florida fda request manufacturer withdraw ranitidine case valadez colorectal schedule trial product market april additional case illinois trial date case texas florida group name defendant approximately firm trial date trial expect occur personal injury case file federal zantac multidistrict litigation mdl court proceeding southern district florida mdl plaintiff originally identify different outside propose class action pende type cancer wish pursue plaintiff subsequently gsk ontario quebec canada class drop cancer proceed bladder action israel canada certification hearing hold esophageal stomach liver pancreatic cancer october british columbia propose class action plaintiff state court continue pursue claim class action proceed certification designate cancer december court presiding hearing class action sought certify national class federal mdl proceeding grant defendant daubert court dismiss propose class action motion find plaintiff expert causation opinion manufacturer defendant appeal zantac cause cancer issue decision abandon ontario action mdl liver bladder pancreatic esophageal stomach discontinue approximately individual unreliable inadmissible expert causation action file canada opinion mdl court grant summary judgment gsk give complex ownership marketing zantac brand defendant mdl court find prescription overthecounter otc medicine scientist outside litigation conclude year numerous claim involve defendant result ranitidine cause cancer plaintiff scientist defendant serve include litigation systemically utilize unreliable methodology group notice potential indemnification claim fail use consistent objective sciencebase standard possible liability connect particularly zantac otc evenhanded evaluation datum ruling effectively give current stage proceeding group dismiss approximately file case mdl meaningfully assess liability bind claim census registry meaningfully assess liability party relevant approximately plaintiff include plaintiff indemnification provision file case registry claimant appeal mdl decision eleventh circuit court appeal plaintiff brief april follow court daubert decision enter final order dismiss medical monitoring consumer class action base reasoning daubert hold plaintiff file notice appeal medical monitoring consumer class action case strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue legal proceeding continue addition march department justice korea fair trade commission kftc commence doj send group notice civil investigation proceeding matter kftc hearing take open allegation false claim act violation place july gsk korea find violation group relate zantac june doj serve applicable fair trade law kftc impose fine civil investigative demand cid group formalise krw million approximately request document group continue cooperate electronic health record subpoena doj cid day new mexico attorney general file lawsuit multiple defendant march group receive subpoena include group allege violation state consumer united states attorney office western district protection false advertising statute claim virginia working united states department justice civil division seek document relate group november mayor city baltimore file electronic health record programme group cooperate action group allege zantac increase risk enquiry cancer andor cause cancer baltimore patient group fail warn conceal risk fact senate help enquiry expert discovery ongoing court set trial date group receive letter date january june majority member senate health education labor pension help committee initiate investigation zofran pricing inhaler treatment asthma group defendant product liability case copd letter similar letter receive number involve zofran pende multidistrict litigation mdl pharmaceutical company request information proceeding district massachusetts case allege pricing research treatment respiratory disease child suffer birth defect mother patent business practice group cooperate ingestion zofran andor generic ondansetron pregnancy enquiry relate nausea vomit plaintiff assert group sell zofran know unsafe pregnant woman fail orange book challenge warn risk illegally market zofran offlabel november federal trade commission ftc use pregnant woman write group identify patent challenge fda orange book list dispute june mdl court grant group motion process reserve right action number summary judgment federal preemption ground court company contact ftc citing find fda fully inform relevant safety total patent patent listing challenge information zofran repeatedly reject ftc group ask fda remove patent attempt add birth defect warning label time orange book respect certain product court grant judgment group case pende group position patent properly list mdl approximately case close mdl time list decision generic competition proceeding plaintiff appeal decision january impact previous listing delist patents united states court appeal circuit remain valid enforceable subsequent ftcs affirm district court decision favour group challenge group receive letter senator elizabeth remain state court case propose class warren congresswoman pramila jayapal senator actions canada currently active amy klobuchar senator tammy baldwin reiterate ftc position request information sale marketing regulation group orange bookliste patent group response group marketing promotion pharmaceutical fda challenge process group cooperate vaccine product subject certain governmental enquiry investigation private lawsuit bring litigant antitrustcompetition theory law certain governmental action private lawsuit gsk korea proceeding fair trade law bring group allege violation competition august gsk korea indict koreas antitrust law monopoly regulation fair trade law relation lamictal government tender hpv cervarix pcv synflorix vaccine prosecutor allege gsk purport class direct purchaser file suit korea action employee district court district new jersey allege interfere tender process national group teva pharmaceuticals unlawfully conspire delay immunisation programme straw bidder generic competition lamictal result overcharge purchaser enter allegedly anticompetitive gsk korea employee charge reverse payment settlement resolve patent infringement individual capacity prosecutor relation litigation separate count accuse group monopolising matter number wholesaler codefendant market proceeding february court render guilty verdict respect defendant gsk korea fine december trial judge grant plaintiff class krw million approximately appeal certification motion certify class direct purchaser proceeding ongoing group file rule f motion court appeal circuit challenge class certification decision april court appeal vacate low court grant class certification remand issue low court analysis strategic report governance remuneration financial statement investor information gsk annual report note financial statement continue legal proceeding continue october district court hear argument zejula royalty dispute plaintiff renew motion class certification remand october tesaro inc wholly own subsidiary april district court deny plaintiff motion gsk enter worldwide patent license agreement class certification putative direct purchaser class leave astrazeneca uk limit relate niraparib later potential class brandonly purchaser plaintiff move approve zejula supplement expert report seek additional discovery support addition certain generic purchaser astrazeneca file lawsuit tesaro january district court deny plaintiff motion high court england wale allege tesaro fail supplement expert report seek additional discovery pay royalty license agreement hold issue generic purchaser tesaro counterclaimed base calculated decided deny court rule decertification overpayment trial hold week march party conduct briefing class certification judgment enter group april ruling remain brandonly purchaser plaintiff seek current use zejula generate royaltybeare sale add small category purchaser word license agreement june court appeal england wale grant february district court deny plaintiff renew group request permission appeal april class certification motion series followon complaint judgment appeal hear january file district court eastern district february court appeal rule group favour pennsylvania group allege purchaser case overturn trial court judgment determine consolidate previously pende case zejula sale use fall license patent district new jersey discovery ongoing deem royaltybeare appropriate quantum royalty commercial corporate accord court appeal judgment subject proceeding group involve certain contractual andor commercial dispute post balance sheet event acquisition aiolos bio inc january gsk announce enter agreement acquire aiolos bio inc aiolos clinical stage biopharmaceutical company focus address unmet treatment need patient certain respiratory inflammatory condition upfront payment billion million certain successbase regulatory milestone payment addition gsk responsible successbase milestone payment tiere royalty owe jiangsu hengrui pharmaceuticals co ltd hengrui transaction subject customary condition include applicable regulatory agency clearance hart scottrodino act subsequently close february give time closure transaction gsk expect disclose provisional accounting acquisition q result announcement disposal share haleon plc january gsk complete sale million share haleon plc equivalent haleon plcs issue share capital price penny share raise gross proceed million follow sale gsk hold approximately million ordinary share haleon plc represent issue share capital haleon plc strategic report governance remuneration financial statement investor information gsk annual report company balance sheet uk gaap include frs reduce disclosure framework december note fix asset investment e current asset trade receivables f cash bank total current asset trade payable g total current liability net current asset total asset current liability provision liability h noncurrent liability net asset capital reserve share capital j share premium account j reserve k retain earning january profitloss year ordinary share issue share optionaward scheme treasury share transfer esop trust dividend specie dividend pay shareholder k equity shareholder fund financial statement page approve board february sign behalf sir jonathan symonds chair gsk plc register number company statement change equity year end december share share premium retain total capital account reserve earning equity january profit total comprehensive income attributable shareholder treasury share transfer esop trust dividend shareholder note dividend specie note share issue employee share scheme december profit total comprehensive income attributable shareholder treasury share transfer esop trust dividend shareholder note share issue employee share scheme december strategic report governance remuneration financial statement investor information gsk annual report note company balance sheet uk gaap include frs reduce disclosure framework presentation financial statement key accounting judgement estimate description business key accounting judgement estimate require current year gsk plc parent company gsk major global biopharma group prevent treat disease b accounting policy vaccine specialty general medicine gsk focus foreign currency transaction science immune system use new platform datum technology invest core therapeutic area foreign currency transaction record exchange infectious disease hiv respiratoryimmunology oncology rate ruling date transaction foreign currency asset liability translate rate exchange rule preparation financial statement balance sheet date financial statement prepare dividend pay receive historical cost convention modify include revaluation certain financial instrument go dividend pay receive include financial concern basis prepare accordance financial statement period relate dividend report standard reduce disclosure framework actually pay receive uk accounting presentation company act expenditure december comparative figure december expenditure recognise respect good service receive supply accordance contractual term permit section company act provision obligation exist future liability income statement company present respect past event annual report obligation reliably estimate company include group financial statement investments subsidiary company gsk plc publicly available investment subsidiary company hold cost follow exemption requirement ifrs provision impairment include capital apply preparation financial statement contribution relation movement contingent accordance frs consideration paragraph b ifrs sharebase impairment investment payment carry value investment review impairment ifrs financial instrument disclosure indication investment paragraph ifrs fair value measurement impair assessment method compare paragraph ias presentation financial statement carry value investment share net comparative information requirement respect asset value investment share paragraph iv ia valuation subsidiary base expect discount cash paragraph f b flow impairment charge recognise income ia presentation financial statement statement year concern ias statement cash flow asset hold saledistribution paragraph ias accounting policy change noncurrent asset hold disposaldemerg accounting estimate error available immediate disposaldemerger present paragraph ias relate party disclosure condition disposaldemerg highly probable requirement ia disclose related party expect complete year date transaction enter member classification asset measure low group carry value fair value cost disposal accounting convention standard trade receivable balance sheet prepare historical cost trade receivables carry amortise cost convention complie applicable uk accounting allowance expect credit loss expect credit loss standard calculate accordance approach permit ifrs accounting principle policy majority balance trade receivables amount owe group undertaking preparation balance sheet conformity company apply general approach calculate generally accept accounting principle require expect credit loss receivable determined non management estimate assumption affect collectable write firstly expect credit report amount asset liability disclosure loss allowance available statement contingent asset liability date balance comprehensive income subsequent recovery amount sheet actual amount differ estimate previously provide credit statement balance sheet prepare accordance comprehensive income long term receivables discount company accounting policy approve board effect material describe note b policy consistently sharebase payment apply state company issue share employee behalf subsidiary company cash consideration strategic report governance remuneration financial statement investor information gsk annual report note company balance sheet uk gaap include frs reduce disclosure framework treasury share defer tax measure average tax rate expect apply period temporary purchase price pay treasury share include difference expect realise settle defer tax retain earning treasury share transfer liability asset discount esop trust fair market price date transfer cash consideration proceed equal financial guarantee purchase price pay company share liability relate guarantee issue company proceed treat realise loss proceed exceed behalf subsidiary initially recognise fair value purchase price excess purchase price subsequently measure higher transfer share premium account purchase price pay company share determine use expect credit loss ecl measure general weight average price method approach taxation initially record appropriate current tax provide amount expect pay accumulate amortisation apply tax rate enact substantively c operating profit enact balance sheet date fee relate audit defer tax provide liability method company charge operate profit temporary difference arise tax basis asset liability carry amount financial statement defer tax asset recognise extent consider recoverable future taxable profit dividend director declare interim dividend result dividend year penny detail note dividend group financial statement demerger consumer healthcare business implement gsk declare interim dividend july follow dividend specie haleon plc share distribute external shareholder dividend specie haleon plc share distribute esop trust e fix asset investment share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited shares glaxosmithkline mercury limited share gsk lp limited capital contribution relate sharebased payment contribution relate contingent consideration strategic report governance remuneration financial statement investor information gsk annual report note company balance sheet uk gaap include frs reduce disclosure framework f trade receivables amount year debtor amount owe group undertaking amount year amount owe group undertaking amount owe group undertaking year primarily include account balance gsk finance plc unsecured repayable demand interest receive sonia rate annum sonia rate director consider carry amount owe group undertaking approximate fair value provision expect credit loss recognise counterparty access sufficient fund asset fulfil future obligation amount owe group undertaking past increase credit risk experience initial recognition movement amount owe group undertaking period reflect note f g primarily reflect receipt dividend income subsidiary utilisation company current account fund payment interim dividend g trade payable amount year creditor contingent consideration payable corporation tax amount owe group undertaking company guarantee debt issue certain subsidiary company receive annual fee subsidiary aggregate company outstanding guarantee billion debt instrument billion financial guarantee contract liability million million include creditor amount subsidiary company relation guarantee fee recover life bond disclose trade receivable note f h provision liability january charge year utilise december provision relate number legal dispute company currently involve noncurrent liability contingent consideration payable contingent consideration relate payable acquisition novartis vaccine portfolio current year liability include trade payable detail note contingent consideration liability group financial statement strategic report governance remuneration financial statement investor information gsk annual report note company balance sheet uk gaap include frs reduce disclosure framework j share capital share premium account share premium ordinary share account number share capital issue fully pay january impact share consolidation issue employee share scheme ordinary share acquire esop trust december issue employee share scheme ordinary share acquire esop trust december december issue share capital share hold esop trust hold future exercise share option share award share hold executive supplemental saving plan share hold treasury share share free issue issue share fully pay share authorise issue nominal carry market value share hold esop trust disclose note employee share scheme k retain earning reserve profit gsk plc year million million dividend pay million million include consumer healthcare business demerger dividend million effect million treasury share transfer subsidiary company million retain earning december stand million million million consider company available distribution million dividend shareholder pay reserve company consider available distribution december amount million million reserve include capital redemption reserve reserve reflect historical contribution share company issue satisfy share option award grant employee subsidiary company l group company page complete list subsidiary associate joint venture significant shareholding form financial statement gsk annual report investor information section commercial operation turnover year record product development pipeline product competition intellectual property principal risk uncertainty share capital control dividend financial calendar annual general meeting tax information shareholder shareholder service contact law regulation group company glossary term strategic report governance remuneration financial statement investor information gsk annual report financial record commercial operation turnover therapeutic area total europe international growth growth growth growth cer cer cer cer shingles shingrix meningitis bexsero menveo rsv arexvy influenza fluarixflulaval establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccine ex covid pandemic vaccine pandemic adjuvant vaccine hiv dolutegravir product tivicay triumeq juluca dovato rukobia cabenuva apretude respiratoryimmunology nucala benlysta oncology zejula blenrep jemperli ojjaara specialty medicine ex covid pandemic xevudy specialty medicine respiratory arnuity ellipta anoro ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair trelegy ellipta ventolin respiratory general medicine dermatology augmentin avodart lamictal general medicine total commercial operation strategic report governance remuneration financial statement investor information gsk annual report financial record continue commercial operation turnover therapeutic area total europe international growth growth growth growth cer cer cer cer shingles shingrix meningitis bexsero menveo influenza fluarixflulaval establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccine ex covid pandemic vaccine pandemic adjuvant vaccine hiv dolutegravir product tivicay triumeq juluca dovato rukobia cabenuva apretude respiratoryimmunology nucala benlysta oncology zejula blenrep jemperli specialty medicine ex covid pandemic xevudy specialty medicine respiratory arnuity ellipta anoro ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair trelegy ellipta ventolin respiratory general medicine dermatology augmentin avodart lamictal general medicine total commercial operation strategic report governance remuneration financial statement investor information gsk annual report financial record continue threeyear select financial datum record financial performance provide analysed accordance current reporting practice information include select financial datum number employee adjust result prepare accordance international accounting standard conformity requirement company act ifrs issue international accounting standard board group turnover geographic region europe international group turnover product group vaccine specialty medicine general medicine vaccine turnover shingle meningitis rsv influenza establish vaccine pandemic vaccine specialty medicine turnover hiv respiratoryimmunology oncology pandemic general medicine respiratory general medicine financial result total turnover profit taxation continue operation profit taxation discontinue operation gainslosse demerger remeasurement discontinue operation distribute shareholder demerger profit taxation discontinue operation profit taxation year pence pence pence basic earning share continue operation p p p basic earning share discontinue operation p p total basic earning share p p p dilute earning share continue operation p p p dilute earning share discontinue operation p p total diluted earning share p p p strategic report governance remuneration financial statement investor information gsk annual report financial record continue threeyear select financial datum continue financial result adjust turnover continue operating profit continue profit taxation continue profit taxation reconciliation total adjust operating profit year summarise follow total continue operate profit intangible asset amortisation intangible asset impairment major restructuring transactionrelate item divestment significant legal item adjust continue operate profit reconciliation total adjust earning share year summarise follow pence pence pence total continue earning share p p p intangible asset amortisation p p p intangible asset impairment p p p major restructuring p p p transactionrelate item p p p divestment significant legal item p p p adjust continue earning share p p p return capital employ nm return capital employ calculated total profit taxation percentage average net asset year restate return capital employ calculate meaningful nm average net asset year include consumer healthcare demerge july balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity noncontrolle interest total equity number employee europe international manufacturing sell administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis strategic report governance remuneration financial statement investor information gsk annual report pipeline product competition pharmaceutical vaccine product development pipeline key inlicense alliance relationship party approve viiv healthcare global specialist hiv company gsk submit pfizer inc shionogi limited shareholders responsible phase evaluation clinical pharmacology usually conduct volunteer develop deliver hiv medicine phase ii determination dose initial evaluation efficacy conduct bla biological licence application small number patient maa marketing authorisation application europe large comparative study compound versus placebo andor establish phase iii nda new drug application treatment patient establish clinical benefit safety maa ndabla regulatory review milestone show table achieve future filing date include list achieve regulatory review milestone compound mechanism actionvaccine type indication phase maa ndabla oncology ojjaaraomjjara jak jak acvr inhibitor myelofibrosis approve ajan asep momelotinib jemperli antiprogramme cell death protein dmmrmsih l endometrial cancer approve adec ajul dostarlimab receptor pd antibody l endometrial cancer combination iii zejula niraparib perioperative dmmrmsih colon cancer iii nonsmall cell lung cancer ii neoadjuvant dmmrmsih rectal cancer ii zejula poly adpribose polymerase parp l maintenance ovarian cancer combination iii niraparib inhibitor jemperli dostarlimab l maintenance non small cell lung cancer iii nsclc combination pembrolizumab iii blenrep adc target bcell maturation l multiple myeloma combination iii belantamab antigen pomalyst dexamethasone mafodotin l multiple myeloma combination iii velcade dexamethasone multiple myeloma combination anti ii cancer treatment platform study l multiple myeloma combination velcade revlimid dexamethasone cobolimab antitcell immunoglobulin mucin nonsmall cell lung cancer combination iii domain tim antibody jemperli dostarlimab docetaxel belrestotug antitigit nonsmall cell lung cancer combination ii jemperli platform study squamous cell carcinoma head neck ii combination jemperli gsk platform study antipvrig cancer anticd cancer xmt sting agonist adc cancer wholly own mersana therapeutic belantamab bcell maturation antigen binder multiple myeloma dna polymerase theta inhibitor cancer adc target bh gynecologic malignancy hiv apretude hiv integrase strand transfer inhibitor hiv preexposure prophylaxis approve asep adec cabotegravir longacte hiv infection hiv broadly neutralise antibody hiv infection ii hiv maturation inhibitor hiv infection ii hiv capsid protein inhibitor hiv infection ii hiv capsid protein inhibitor hiv infection ii hiv integrase inhibitor hiv infection ii brand name appear italic trade mark own license gsk group company footnote nonregistrational gsk exclusive global license option codevelop commercialize candidate strategic report governance remuneration financial statement investor information gsk annual report pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound mechanism actionvaccine type indication phase maa ndabla infectious disease arexvy recombinant protein adjuvante respiratory syncytial virus prophylaxis adult approve ajun amay rsv vaccine vaccine year old respiratory syncytial virus prophylaxis old registration sjan sdec adult population year age gepotidacin triazaacenaphthylene bacterial type ii uncomplicated urinary tract infection uuti iii topoisomerase inhibitor urogenital gonorrhea gc iii bepirovirsen hbv antisense oligonucleotide chronic hepatitis b virus infection iii bexsero vaccine recombinant protein outer prevention invasive disease cause n iii membrance vesicle vaccine meninigitidis serogroup b individual month age old recombinant protein outer prevention invasive disease cause n iii man abcwy vaccine membrance vesicle glycoconjugate meninigitidis serogroups abcw vaccine adolescent years age tebipenem pivoxil antibacterial carbapenem complicated urinary tract infection cuti iii ibrexafungerp antifungal glucan synthase inhibitor invasive candidiasis iii ganfeborole leucyl trna synthetase inhibitor tuberculosis ii alpibectir ethionamide booster tuberculosis ii recombinant protein adjuvante malaria prophylaxis plasmodium falciparum ii malaria fractional vaccine dose generalize modules membrane shigella diarrhea prophylaxis ii antigen gmma vaccine primeboost viral vector co treatment chronic hepatitis b infections ii therapeutic hbv sequentially administrate aim functional cure controlling adjuvante recombinant protein resolve clinical sequelae infection reduce need treatment recombinant protein outer prevention invasive disease cause n ii man abcwy nd membrance vesicle conjugate meninigitidis serogroup abcw gen vaccine adolescent child week age old live attenuate vaccine active immunization prevention ii varicella new strain varicella individual month age old sanfetrinem cilexetil serine beta lactamase inhibitor tuberculosis ii recombinant proteinadjuvante active immunization girl woman boys ii hpvas vaccine man year prevention cancer genital wart precancerous dysplastic lesion girl boy cause human papillomavirus hpv target immunotherapy viral vector treatment chronic hepatitis b virus infection ii chbv aso combo adjuvante recombinant protein individual year decompensate direct act antiviral gsk cirrhosis bepirovirsen map pneumococcal valent paed prevention pneumonia invasive ii pneumococcal disease cause streptococcus pneumoniae serotype include vaccine child aged week year map pneumococcal valent prevention pneumonia invasive ii pneumococcal disease cause streptococcus pneumoniae serotype include vaccine adult aged year old live attenuate vaccine active immunization prevention ii mmrv new strain measle mump rubella varicella child month year age brand name appear italic trade mark own license gsk group company strategic report governance remuneration financial statement investor information gsk annual report pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound mechanism actionvaccine type indication phase maa ndabla infectious disease continue recombinant subunit adjuvante cytomegalovirus cmv infection prophylaxis ii cmv vaccine female year age mrna vaccine active immunization prevention ii mrna seasonal flu influenza disease adult year old mrna vaccine active immunization prevent covid ii mrna covid disease cause sarscov individual year old recombinant proteinadjuvante treatment suppression recurrent ii therapeutic hsv genital herpe adult aged year old bivalent generalize module invasive nontyphoidal salmonella ii int typhimurium membrane antigen gmma vaccine enteritidis bivalent generalize module invasive nontyphoidal salmonella typhoid ii int typhimurium membrane antigen gmma vaccine fever enteritidis typhoid conjugate vaccine tcv typhi generalize module membrane active immunization prevention ii gonorrhoea antigen gmma vaccine gonorrhea infection individual aged year daplusiran hepatitis b virustargete sirna chronic hepatitis b virus infection ii tomligisiran sequential combination fimh antagonist uncomplicate urinary tract infection uuti crk inhibitor visceral leishmaniasis proteasome inhibitor visceral leishmaniasis mtb cholesterol dependent inhibitor tuberculosis pik beta inhibitor viral copd exacerbation bivalent typhoid paratyphoid salmonella typhoid paratyphoid enteric salmonella typhoid conjugate fever paratyphoid papdpapd inhibitor chronic hepatitis b virus infection tlr agonist chronic hepatitis b virus infection p falciparum cell inhibitor malaria p falciparum cell inhibitor malaria brand name appear italic trade mark own license gsk group company footnote transition activity underway enable progression partner strategic report governance remuneration financial statement investor information gsk annual report pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound mechanism actionvaccine type indication phase maa ndabla immunology respiratory nucala mepolizumab antiil copd iii depemokimab antiil longacting asthma iii chronic rhinosinusitis nasal polyps iii crswnp eosinophilic granulomatosis polyangiitis iii egpa hypereosinophilic syndrome s iii latozinemab antisortilin monoclonal antibody frontotemporal dementia ftd iii heterozygous mutation progranulin gene amyotrophic lateral sclerosis al ii frontotemporal dementia ftd ii mutation corf gene camlipixant px receptor antagonist refractory chronic cough iii ventolin low carbon beta adrenergic receptor agonist asthma iii version meter dose inhaler benlysta belimumab antib lymphocyte stimulator systemic sclerosis associate interstitial lung ii monoclonal antibody disease anticcl osteoarthritis pain ii diabetic peripheral neuropathic pain ii al antisortilin monoclonal antibody alzheimer disease ii antiil atopic dermatitis ii antiil autoimmune disease transglutaminase tg inhibitor pulmonary fibrosis rnaedite oligonucleotide alpha antitrypsin deficiency antiil copd interferon pathway modulator systemic lupus erythematosus opportunity drive jesduvroq prolyl hydroxylase inhibitor anaemia chronic kidney disease approve afeb daprodustat linerixibat ileal bile acid transporter ibat cholestatic pruritus pbc primary biliary iii inhibitor cholangitis hsdb silencer nonalcoholic steatohepatitis nash ii dnmt inhibitor sickle cell disease brand name appear italic trade mark own license gsk group company footnote phase iii start expect strategic report governance remuneration financial statement investor information gsk annual report pipeline product competition continue pharmaceutical product competition intellectual property major patent expiry date product compound indication competitor brand eu respiratory anoro ellipta umeclidinium bromide copd spioltostiolto respimat vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair bevespi aerosphere device device brimica genuair avamysveramyst fluticasone furoate allergic rhinitis dymista xhance expired expire nasonex fluticasone gx nucala mepolizumab asthma crswnp egpa fasenra expire expire s relvarbreo ellipta fluticasone furoate asthma copd symbicort foster vilanterol trifenatate budesonideformoterol nce nce generic fluticasone propionatesalmeterol device device generic beclomethasone formoterol generics atectura seretideadvair salmeterol xinafoate asthma copd symbicort foster expire expire fluticasone propionate budesonideformoterol diskus device diskus device generic fluticasone expire propionatesalmeterol hfadevice hfadevice generics beclomethasone formoterol generic atectura trelegy ellipta fluticasone furoate copd asthma breztri aerosphere trimbow vilanterol trifenatate nce nce umeclidinium bromide device device ventolin salbutamol sulphate asthma copd salbutamolsaba generics expire symbicort reliever prn hfadevice hfadevice marti airsupra xevudy sotrovimab early treatment covid regencov bamlanivimab etesevimab evusheld central nervous system lamictal lamotrigine epilepsy bipolar disorder vimpat trokendi xr expire expire inovelon keppra generics keppra levetiracetam epilepsy briviact vimpat lamictal na na depakene depacon generics cardiovascular urogenital avodart duodart dutasteride benign prostatic hyperplasia generic finasteride alpha expire expire dutasteride tamsulosin bph blocker antibacterial augmentin amoxicillin trihydrate common bacterial infection generic oral na expire potassium clavulanate cephalosporin cefuroxime axetil cefixime cefpodoxime cefdinir cephalexin oral macrolide azithromycin clarithromycin state patent expiry date relate late expire new molecular entity patent relevant territory appropriate patent expiry date include grant patent term extension grant supplementary protection certificate multiple country eu uk paediatric exclusivity period additional exclusivitie example regulatory data protection type patent exist list table regulatory data protection expire eu prn use require mart maintenance reliever therapy strategic report governance remuneration financial statement investor information gsk annual report pipeline product competition continue pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brand eu dermatology dermovate clobetasol propionate inflammatory skin condition generic topical market expire betnovate betamethasone valerate corticosteroid like cutivate fluticasone propionate mometasone furoate eumovate clobetasone butyrate methylprednisolone aceponate hydrocortisone oncology zejula niraparib ovarian cancer lynparza rubraca blenrep belantamab mafodotin relapsedrefractory multiple abecma carvykti tecvayli myeloma talvey elrexfio jemperli dostarlimab dmmrmsih recurrent keytruda imfinzilynparza advance endometrial cancer dmmr solid tumour ojjaaraomjjara momelotinib myelofibrosis patient jakafi inrebic vonjo anemia immunoinflammation benlysta benlysta belimumab systemic lupus lupkynis saphnelo sc iv erythematosus lupus nephritis renal jesduvroq duvroq daprodustat anaemia chronic kidney evrenzo roxadustat approve disease vadadustat eu hiv apretude cabotegravir hiv prevention descovy truvada cabenuvavocabria cabotegravir rilpivirine hivaids descovy genvoya odefsey rekambys biktarvy rukobia fostemsavir hivaids trogarzo sunlenca dovato dolutegravir lamivudine hivaids descovy genvoya odefsey biktarvy juluca dolutegravir rilpivirine hivaids descovy genvoya odefsey biktarvy triumeq dolutegravir lamivudine hivaids descovy genvoya odefsey abacavir biktarvy tivicay dolutegravir hivaid isentress prezista symtuza reyataz biktarvy state patent expiry date relate late expire new molecular entity patent relevant territory appropriate patent expiry date include grant patent term extension grant supplementary protection certificate multiple country eu uk paediatric exclusivity period additional exclusivitie example regulatory data protection type patent exist list table strategic report governance remuneration financial statement investor information gsk annual report pipeline product competition continue vaccine product competition intellectual property major patent expiry date product compound indication competitor brand eu arexvy respiratory syncytial virus respiratory syncytial virus abrysvo vaccine vaccination bexsero meningococcal groupb meningitis group b trumenba vaccine prophylaxis boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expire expire pertussis pertussis booster vaccination infanrix hexa diphtheria tetanus pertussis prophylaxis pentacel pediacel pentaxim expire expire pediarix polio hepatitis b diphtheria tetanus pertussis pentavac haemophilus influenzae type polio hepatitis b hexaxim hexyon b eu haemophilus influenzae type vaxeli b eu cervarix hpv virus like human papilloma virus gardasil silgard market expired particle vlps type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza intenza flumist qiv expire expire antigen virus subtype prophylaxis vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza vaxigrip mutagrip expire expired antigen virus subtype prophylaxis fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c meningitis group c w nimenrix menquadfi w conjugate prophylaxis vaccine priorix priorix live attenuate mmr measle mumps rubella mmr ii mmrvaxpro expire expired tetraa varilrix varicella mmrv chickenpox prophylaxis proquad varivax vaccine rotarix human rotavirus rix rotavirus prophylaxis rotateq expire expire strain synflorix conjugate pneumococcal prophylaxis invasive prevenar prevnar note market polysaccharide disease pneumonia acute otitis medium shingrix zoster vaccine herpe zoster zostavax recombinant adjuvante shingle state patent expiry date relate late expire new molecular entity patent relevant territory appropriate patent expiry date include grant patent term extension grant supplementary protection certificate multiple country eu uk paediatric exclusivity period additional exclusivitie example regulatory data protection type patent exist list table strategic report governance remuneration financial statement investor information gsk annual report principal risk uncertainty outline principal risk uncertaintie relevant litigation government investigation relate gsk business financial condition operation provision unfavourable outcome affect performance ability achieve objective increase related cost insurance premium risk believe cause actual materially adversely affect financial result result differ materially expect historical result detail status uncertainty operate biopharmaceutical sector carry significant unresolved dispute potential litigation set inherent risk uncertainty affect business note legal proceedingson comply broad range law regulation detail risk management framework apply research development manufacturing identify principal risk find page test approval distribution sale marketing incorporate section risk relate pharmaceutical vaccine product affect cost environmental social governance esg product development time require reach market level principal risk include environmental sustainability likelihood successfully uninterrupted climate change manage focus area basis describe esg performance report additional information climaterelate risk management rule regulation change government interpretation climaterelate financial disclosure page policy evolve business activity develop nature particular risk alter change regulatory uk regulation require description principal risk regime substantial alteration failure uncertainty explanation comply applicable law regulation materially manage mitigated description adversely affect financial result principal risk summary impact manage risk business list similarly global business expose litigation order significance consistent principal government investigation include product liability litigation risk detailed page patent antitrust litigation sale marketing litigation patient safety risk definition context risk gsk include party fail accountable safeguarding patient clinical trial appropriately collect assess follow report human safety participant receive medicine vaccine information include adverse event potential source development market harm unforeseen gsk potentially fails appropriately act relevant event unfavorably shift benefitrisk profile finding affect benefitrisk profile medicine probable occurrence event fully discount vaccine timely manner mitigate risk robust safety evaluation product risk management activity risk impact chief medical officer single point accountability gsk tolerate unfavourable benefittorisk profile benefitrisk decisionmake crossfunctional safety patient use product important review team continually assess new safety efficacy consequence ineffective pharmacovigilance potential information gsk product life cycle harm patient maintain robust process global safety board leadership chief medical manage human safety information conduct timely safety officer head global safety review product safety signal detection ensure appropriate measure establish milestone situation place manage risk patient gsk intend fully potential impact benefitrisk profile comply pharmacovigilance relevant regulation worldwide noncompliance result inspection finding operate complex restrictive regulatory scrutiny civil criminal sanction pharmacovigilance regulatory environment temporary permanent loss product marketing complicate variable requirement regulatory authorisation regularly review respond patient agency regulatory complexity illustrate safety risk limit potential reputational damage loss instance regulatory agency take decision safety trust patient healthcare provider productrelate medicine vaccine base externally available datum litigation loss shareholder confidence accessible marketing authorisation holder trend inhibit ability timely decision appropriate action relation safety product confirm refute conclusion assert external party potential extend regulatory agency nextgeneration digital health datum hold technology company datum custodian inaccessible industry andor regulatory agency strategic report governance remuneration financial statement investor information gsk annual report principal risk uncertainty continue patient safety continue source information trigger take additional step strengthen increase report relate product andor adverse event safeguard patient enhance execution medium coverage social medium government health pharmacovigilance operational activity add risk authority etc ineffective management patient safety risk management benefitrisk expertise global safety result reputational damage loss trust organisation enhance ability define risk patient healthcare provider decline shareholder management strategy evolve portfolio confidence increase volume product complex risk minimisation measure require related litigation include classaction lawsuit follow new system well enable regularly face gsk industry general track implementation effectiveness risk management plan transition simplified mitigating action efficient approach collect follow report chief medical officer accountable patient safety human safety information include adverse event enterprise risk human safety matter collaboration potential source continue build capability head global safety crossenterprise safety gsk staff hold accountability pharmacovigilance governance board oversee implementation control quality management system process framework include risk management global safety embed simplify process manage board ensure address human safety proactively pharmacovigilance agreement safety clause product lifecycle global policy gsk party include strategic partner management human safety information require employee immediately report issue relate safety product party risk management framework support identify training party encounter human safety information product quality risk definition mitigating action risk gsk party potentially fail ensure align extensive global network quality appropriate control governance quality compliance professional sitelevel senior management development commercial product place business unit provide oversight assist compliance industry practice regulation delivery quality performance operational manufacturing distribution activity term gsk compliance deliver management oversight product license support regulatory activity meet hierarchy quality council global head quality risk impact expand quality management system good manufacturing practice audit quality assurance oversight failure ensure product quality farreache programme rd ensure mitigate potential implication patient safety cause product launch delay product quality risk endtoend process drug shortage product recall regulatory legal implement riskbase approach assess financial consequence materially manage party supplier provide material adversely affect gsk reputation financial result finish product include monitor party lab context independently check good expect contract manufacturer product comply external environment product quality remain gsk standard regularly conduct audits provide challenging increase supplier merger supply assurance use key risk indicator support risk network create challenge influence quality management activity provide leadership team standard rapid advancement use digital quality council integrate assessment product technology artificial intelligence machine quality performance learn aiml evolve regulatory framework introduce opportunity modernisation potential continue actively manage impact product quality adequately control deployment plan align new annex guidance need adopt adapt new update guidance manufacture sterile medicinal product context emerge threat cyberattack datum global equipment component supply chain constraint breach industry risk integrity product effecting industry increasingly apply advanced quality datum audit trail additionally gradual digital technology insight drive scientific excellence divergence regulatory expectation inspection enhance modernise development manufacture particularly health authority present challenge testing product protect datum actively site prepare inspection retain expertise contribute industry advocacy influence thinking biopharma deep capability support digital regulatory framework advance technology progression potential challenge highly support patient safety benefit access competitive environment strategic report governance remuneration financial statement investor information gsk annual report principal risk uncertainty continue product quality continue collaboratively work pharma company continue adapt procedure evolve industry trade association respond question expectation topic work mitigation plan ema complete safety evaluation use alongside regular engagement regulator time titanium dioxide medicine identify potential ensure inspection readiness market serve substitute work industry monitor emerge risk factor regulatory intelligence guidance nitrosamine financial control report risk definition lead double taxation profit tax country complexity tax regulation mean risk gsk fail comply current tax law fail occasionally disagree tax authority report accurate financial information compliance technical interpretation particular area tax law tax accounting standard applicable legislation incur charge include financial statement well estimate significant loss treasury activity tax liability pende audits tax authority expect risk impact continue focus tax reform drive initiative oecd ec address tax challenge arise noncompliance exist new financial new esg digitalisation economy report disclosure requirement change recognition income expense expose gsk domestic initiative world litigation regulatory action materially result significant change establish tax principle adversely affect financial result failure comply increase tax authority dispute regardless merit change substance application law govern outcome costly divert management attention transfer pricing dividend tax credit intellectual property adversely impact reputation relationship key materially adversely affect financial result stakeholder law regulation order measure failure comply applicable law regulation restrict dealing certain country government result gsk investigate relevant government government official entity individual use agency authority andor legal proceeding financial institution movement fund government investigation litigation mitigating action unpredictable regardless outcome costly require significant management attention damage date late development financial reputation inconsistent application treasury policy report requirement review update regulator transactional settlement error counterparty default work external auditor legal advisor lead significant loss perform respond emerge risk financial result review approve regional management context review gsk group financial controller chief require law jurisdiction publicly financial officer cfo allow financial controller disclose financial result event cfo assess evolution business time materially affect group financial result regulator evaluate performance plan significant judgement routinely review financial statement list company review confirm senior management integrate compliance new revise exist accounting technical organisational transformation newly acquire regulatory requirement believe comply activity external risk risk assessment apply appropriate regulatory requirement concern financial appropriate control review statement disclosure material information include maintain control environment design identify transaction relate business restructuring material error financial reporting disclosure acquisition divestiture subject standardised global financial reporting operating model investigation potential noncompliance accounting design operating effectiveness key financial reporting disclosure requirement lead restatement control regularly review management test previously report result significant penalty external party location treasury group deal daily high value transaction standard model apply minimum standard set control foreign exchange cash management transaction review management monitor transaction involve market volatility counterparty risk independently give assurance control key group effective tax rate reflect location activity financial reporting disclosure process operating value generate determine jurisdiction effectively global finance risk management control profit arise applicable tax rate frmc group provide extra support significant higher low uk statutory rate transformation system deployment management reflect regime encourage innovation investment structural reorganisation add operational resource rd provide tax incentive change adapt programme timeline ensure process control affect gsk tax rate addition worldwide nature maintain significant change disclosure operation mean crossborder supply routes committee reporting board review gsk quarterly necessary ensure supply medicine vaccine result annual report result conflict claim tax authority profit tax individual country strategic report governance remuneration financial statement investor information gsk annual report principal risk uncertainty continue financial control report continue year consultation legal advisor relevant provide pragmatic constructive disclosure committee determine necessary business input tax policy maker directly disclose publicly information group stock industry trade body include advocate reform exchange announcement treasury management group support economic growth job creation need meet regularly ensure liquidity interest rate patient key stakeholder tax affairs counterparty foreign currency transaction foreign currency manage global basis team tax professional lead translation risk manage line prudent global head tax work closely business approach detailed risk strategy policy adopt daytoday basis global tax team suitably qualified board counterparty exposure subject define limit role perform support training need approve board credit rating individual provide date technical advice line counterpartie responsibility submit tax return accord statutory time limit engage proactively tax authority ensure middle office treasury monitor management tax affair current enter continuous audit counterparty risk line agree policy oversight programme advance pricing agreement corporate compliance officer operate independently appropriate arrangement provide longterm certainty treasury detail mitigation treasury risk tax authority gsk tax treatment find page manage tax risk robust business base disclosure relevant fact seek internal policy process train compliance resolve difference interpretation tax legislation programme maintain open constructive relationship tax authority cooperative manner exceptional case tax authority worldwide monitor government debate resolve dispute formal proceeding tax policy key jurisdiction understand potential future change tax law share inform point view legal matter risk definition supportive aspect external environment include increase focus corporate transparency advance risk gsk party potentially fail comply technology use data analytic provide certain legal requirement development supply well platform streamline process detect potential commercialisation product operation business issue specifically relation requirement competition law antibribery corruption sanction failure meet mitigation action compliance legal standard particular area group general counsel oversee accountable lead increase scrutiny enforcement legal matter principal risk enterprise antibribery government agency corruption competition law sanction control risk impact framework programme design ensure compliance applicable law regulation build code failure mitigate legal risk expose gsk associate culture business standard monitor adapt person governmental investigation regulatory action evolve regulation business activity civil criminal liability compromise gsk ability programme include senior leader commitment set supply product certain government contract tone addition failure manage legal risk substantial implication gsk reputation credibility senior control framework base globally recognise leader erode investor confidence governance accept principle include global policy write risk management future performance standard control govern business activity consequential negative impact share performance rise risk mandate enhance control include lead imposition significant financial penalty diligence requirement sanction screen specific imposition additional reporting obligation highrisk activity interaction government official business development transaction context engagement party overall environment antibribery corruption regularly provide antibribery corruption competition competition law sanction export control remain law sanction training employee relevant challenging continue strong enforcement complementary worker party accordance appetite bribery investigation prosecution role responsibility risk face include particular focus conduct multinational company aspect key risk annual mandatory training operate focus sanction export control reinforce workforce clear expectation competition law enforcement increase acceptable behaviour sanction perspective see penalty violation levy company number different industry leverage datum analytic use information merger control see increase intervention great monitoring assurance activity key risk indicator divergence decision policy enforcement agency investigation speak channel identify specific area financial penalty hand type case intervention drive continuous improvement significant enhancement control investigate allegation noncompliance disciplinary action require permit locally strategic report governance remuneration financial statement investor information gsk annual report principal risk uncertainty continue legal matter continue dedicated team responsible implementation continuously assess monitor understand risk evolution risk framework programme anti exposure relate risk include money launder risk bribery corruption competition law sanction actively consider implement improvement risk framework programme base internal external learning consider complexity geographic breadth risk commercial practice risk definition financially new productsindication carry uncertainty future success product development costly risk gsk party potentially engage lengthy uncertain carry potential failure commercial activity fail comply law regulation stage successful product development face industry code internal control requirement challenge launch competitor product risk impact pricing strategy render asset competitive support product innovation continue focus failure engage activity consistent letter inperson virtual engagement constant focus spirit law industry regulation group patient approve medicine requirement relate sale promotion medicine vaccine obligation provide important information vaccine appropriate interaction healthcare healthcare community way professional hcp organisation patient responsible legal ethical manner legitimate transparent transfer value pricing competition antitrust regulation commercial appropriate product promotion ensure hcp access practice include trade channel activity business information need patient consumer tender materially adversely affect ability fact medicine vaccine require deliver strategy longterm priority additionally product prescribe recommend result incomplete awareness riskbenefit profile manner provide healthcare benefit commit product possibly suboptimal treatment patient ethical responsible commercialisation product consumer governmental investigation regulatory action support purpose improve quality human life legal proceeding bring group governmental ahead disease private plaintiff result government mitigating action sanction criminal andor financial penalty practice find misaligned culture evolve policy standard incrementally result reputational harm dilute trust establish ensure commercial activity undertake external stakeholder conduct behalf execute establish governance train employee relevant information context focus interactive learning element behavioural science commercial activity worldwide conform operate highly regulated extremely competitive high ethical regulatory industry standard local biopharma industry peer significant standard differ global one apply product innovation technical advance intensify price stringent standard acquire company joint competition additional external factor include access venture partner differ global standard remediate limitation customer macroeconomic inflationary legacy policy implement revision align dynamic pricing pressure market achieve business continue use internal control framework strategic objective continue develop commercially support assessment management risk viable new product sustain reliable supply deliver additional use exist product address need patient consumer hcp payer strategic report governance remuneration financial statement investor information gsk annual report principal risk uncertainty continue commercial practice continue business unit risk management compliance board allow fairmarket value payment gsk manage risk global incountry business activity expert practitioner speak innovative medicine oversee commercial activity monitor vaccine restrict period product lifecycle programme promotional material activity new competitive datum publish support review approve accord policy embed global endtoend expert engagement standard conduct accordance local law process roll healthcare organisation hco process regulation requirement seek ensure create new standard operating procedure tender material activity fairly represent group product update external expert engagement operating procedure service necessary event misconduct strengthen interactive digital medium channel discipline employee include termination control identification channel contract appliedenforced gsk senior leader contract party monitor channel recoupment policy continue evolve incentive gsk drive consistent way working efficiency programme sale representative well recognise strengthen control automation use datum reward individual effort nearly market cap permit report payment individual hcp variable pay element representative compensation commitment transparency responsible evaluated basis individual sale target disclosure scientific patient engagement risk definition mitigating action risk gsk party potentially fail engage chief medical officer cmo oversee nonpromotional externally gain insight educate communicate scientific patient engagement spe enterprise risk science medicine associate disease area owner gsk code practice key internal policy provide grant donation legitimate transparent nonpromotional engagement activity activity include manner compliant law regulation industry code scientific interaction support medical education advice internal control requirement seek gathering insight unmet need patient scientific communication research disease risk impact awareness healthcare support service patient support control place risk result real perceive program disguise promotion include offlabel prior process simplification continued global process authorisation promotion real perceive provision owner accountable endtoend process medical advice lead reputational damage assign simplified process seek advice content competitor complaint regulatory inspection subsequent approval medical information medical education corrective action civil litigation accountability include comprehensive oversight fully appropriately engage externally bring process creation appropriate internal control patient benefit advance science innovation framework continuous evaluation process deliver strategy risk reduce trust improvement necessary public patient healthcare professional payer regulator spe material activity review approve government accord policy standard additional control context review spe content implement continue ensure content nonpromotional accurate fair objective scientific patient engagement diverse non balanced perceive promotion promotional activity direct healthcare professional patient payer external stakeholder engagement modernise digital approach hcp aim improve patient care exchange provision embed framework interaction patient knowledge use product relate disease patient organisation develop policy healthcare scientific patient engagement external stakeholder support service patient support programme apply group vital gsk researchbase biopharma internal principle activitie internal framework company ambitious patient advance science software medical device establish include medicine expert panel provide business owner multi disciplinary advice crossbusiness unit spe risk council expect activity scientifically sound accurate oversee spe activity review monitor audit datum conduct ethically transparently compliant spe network review maturity internal applicable code law regulation control framework spe process continuously industry local code law regulation improve internal control system network identify apply privacy datum integrity mean measure emerge risk early support staff conduct activity risktake root sound ethical consideration compliance gsk culture policy local law principlesbase decisionmake training communication regulation build effective risk management monitoring activity key manage risk management monitoring system enable appropriate engagement strategic report governance remuneration financial statement investor information gsk annual report principal risk uncertaintie continue data ethic privacy risk definition mitigating action risk gsk party potentially fail ethically general counsel gsk enterprise risk owner ero collect use reuse artificial intelligence datum analytic chair digital privacy governance board automation secure share destroy personal information oversee gsk overall data ethic privacy operating model accordance law regulation internal control gsk business area appoint risk owner requirement accountable overseeing privacy risk support privacy leader business country local risk impact datum privacy law require appointment datum protection noncompliance datum privacy law globally lead officer dpo gsk appointment include harm individual gsk damage trust eu dpo result gsk focus technology datadriven gsk individual community business partner science use aiml evolve global datum strategy government authority country increase ero appoint head digital privacy enforcement power datum protection authority cybersecurity head dpc daytoday allow impose significant fine restrict crossborder accountability designing implement control data flow temporarily ban datum process new framework national law enable individual bring collective legal action company gsk fail follow head dpc lead global crossfunctional core team datum privacy law digital privacyqualifie attorney compliance professional support network privacy leader context business unitsfunction privacy contact locally wide datum protection privacy legislation diverse limited legal compliance team gsk global data ethic global harmonisation simplification make challenging privacy framework base eu general data protection multinational standardise approach compliance regulation deploy market base factor government enforce compliance datum protection include robustness local privacy legislation establish privacy law rigorously data protection authority gsk footprint approach focus datum protection privacy country deploy proportionate regulator differ region country control framework set minimum privacy standard create challenge global organisation seek irrespective applicable legislation implement single harmonise global privacy programme core team responsible increase volume datum process advance operate improve centralised global data ethic technology result great focus datum privacy control framework governance ethical use personal information continuously assess provide relevant compliance datum privacy law company proportionate control aid nondeploye market seek foster innovation artificial intelligence monitor new change law adapt privacy new technology face evolve decision global framework accordingly policymaker well promote trust system avoid unintended outcome harmful impact deploy comprehensive training programme drive great awareness accountability manage personal additionally number emerge law concern information entire organisation localisation datum restriction international transfer legal regulatory expertise emerge technology datum security change exist framework include artificial intelligence machine learning gsk previously rely increase trend datum sovereignty affect ability drive medical innovation ensure key gsk privacy network role sufficient effectively operate internationally training experience carry role effectively continuously improve process issue identification global regulator eu uk china report handle monitor core team process introduce legislation use work business ensure build privacy control artificial intelligence machine learning aiml exist new business initiative ensure continue considerable uncertainty final meet accountability obligation accordance version propose law global data protection privacy law strategic report governance remuneration financial statement investor information gsk annual report principal risk uncertainty continue research practice risk definition use wide variety biological material discovery research development asset commit risk gsk party potentially fail ensure research compliant term condition adequately conduct ethical credible preclinical license agreement authorisation acquire clinical research collaborate research activity compliant use transfer biological material technology law regulation internal control requirement convention biological diversity cbd nagoya risk impact protocol international community establish global framework regulate access use genetic resource potential impact risk include harm human nonhuman origin research development support subject reputational damage failure obtain necessary equitable access fairness principle access regulatory approval product governmental benefit sharing ab outlined cbd nagoya investigation legal proceeding bring gsk protocol recognise importance appropriate governmental private plaintiff product liability suit effective proportionate implementation measure claim damage loss revenue inadequate patent national regional level protection inability supply product regulatory action fine penalty loss product authorisation mitigating action poor datum integrity governance compromise gsk research practice risk oversee enterprise rd effort negatively impact reputation framework seeks strengthen governance rd materially adversely affect financial result leadership research practice enterprise risk damage trust patient customer owner management risk take pragmatic approach context information sharing streamline risk identification escalation ensure ownership risk mitigation stay research involve animal raise ethical concern business case research involve animal way investigate effect potential new medicine living establish office animal welfare ethic body human animal research provide critical strategy risk oawesr lead chief veterinary information cause mechanism disease officer oversee ensure humane remain vital research continually responsible care use animal conduct ethical seek way minimise use animal review independent scientific review animal study research development testing comply advocate application nonanimal alternative regulatory requirement reduce impact oawesr provide framework animal welfare animal human subject research critical assess governance define provide oversight animal care demonstrate safety efficacy use programme promote replacement refinement investigational product evaluate product reduction animal use research conduct quality approve assessment manage programme diligence external animal research research include clinical trial healthy volunteer patient adhere regulation high ethical medical ensuring implement maintain proper data governance scientific standard disclose result research control remain important priority especially externally regardless reflect positively scientific strategy evolve advantage breadth negatively product scientific community datum example genomic artificial intelligence learn outcome research work machine learn aiml focus build datum human biological sample fundamental integrity privacy usage control internal control discovery development safety monitoring product framework quality assurance team conduct audits provide independent business monitor internal control commit manage human biological sample rd organisation maintain control prepublication accordance relevant law regulation ethical procedure guard public disclosure patent principle manner respect interest sample application file addition lack datum donor data pivotal rd strategy integrity prepare patent application datum information maximise use datum serve patient govern lead loss patent protection legal expert datum accordance relevant law regulation contractual collaborate rd support review process new obligation expectation culture data ethic patent application rd organisation collaborate privacy information cyber security datum integrity legal expert development asset essential account relevant thirdparty patent right strategic report governance remuneration financial statement investor information gsk annual report principal risk uncertainty continue environment health safety ehs risk definition function leader ensure ehs control framework implement effectively respective business area risk gsk party potentially fail ensure compliant applicable law regulation appropriate control governance organisation adequately resource maintain communicate asset facility infrastructure business activity include monitor employee qualified contractor act execution hazardous activity handle hazardous behalf gsk personally responsible ensure material release substance harmful environment follow applicable local standard operating procedure disrupt supply harm employee party riskbase proactive approach articulate global ehs environment policy detailed global ehs standard risk impact audit operation ensure compliance ensure hazards appropriately control design failure manage ehs risk lead significant harm facility equipment system rigorous procedure people environment community apply correctly effective barrier place protect operate fine inability meet stakeholder expectation employee health safety regulatory requirement litigation regulatory action damage company reputation materially refresh rebrande life save rule adversely affect financial result gsk global initiative embed rule daily operation safety leadership experience training context continue gsk incident knowledge enhance gsk subject health safety environmental law learning build strong collaborative safety culture jurisdiction law impose duty protect contractor safety assessment deploy people environment community support external expert review current gsk contractor operate management improve driver safety safe car enhance training mitigating action gsk leadership team responsible ehs governance risk oversight ensure effective control framework inplace inuse manage ehs risk impact legal compliance issue business include assign responsibility senior manager provide maintain control ensure tiere monitoring governance process place business unit information cyber security risk definition context risk gsk party potentially fail ensure external environment continue extremely appropriate control governance identify protect challenge make hard pace increasingly detect respond recover cyber incident sophisticate cyber security threat factor include increase unauthorised access disclosure theft unavailability geopolitical conflict digital nationalism rise frequency corruption gsk information key system technology severity datum breach grow capability infrastructure accordance applicable law regulation sophistication cyber threat actor additional tool like industry standard internal control requirement generative ai propagate attack gsk business relie operate highly connect information network internal risk impact external system hold confidential research failure adequately protect information system development manufacture commercial workforce cyber security threat cause harm patient financial datum mean system information workforce customer disruption business andor loss continue target cyber security commercial strategic advantage regulatory sanction threat actor acceleration use digital datum damage reputation analytic aiml cloud computing capability drive gsk pipeline performance productivity require continuously adapt strengthen control defensive capability strategic report governance remuneration financial statement investor information gsk annual report principal risk uncertainty continue information cyber security continue gsk rely thirdparty contractor partner information cyber security governance supplier face similar cyber security threat chief digital technology officer cdto lead emphasise focus party risk management digital technology function include ciso additionally hybrid working environment create large cyber security office cdto enterprise risk owner complex attack surface cyber security threat actor information cyber security principal risk responsible exploit employee access company resource manage report risk enterprise risk plan location device new threat vulnerability plan include description risk context arise assessment risk appetite treat risk mitigating action action need manage line corporate internal control framework ciso responsible risk manage cyber security risk coordination organisation develop use corporate enterprise risk management internal overseeing implementation control monitor control framework manage oversee information report enterprise risk plan board cyber security principal risk follow corporate audit risk committee oversee cyber security risk risk governance hierarchy risk report escalation oversight compliance council help audit risk chief information security officer ciso head cyber committee oversee cyber security risk security office responsible identify put strategy address ciso report cyber security place control measure help gsk mitigate manage risk year cdto risk oversight cyber security risk include actively monitor compliance council audit risk committee initiate remediation action respond cyber reporting cover external insight key risk indicator security intelligence threat include ongoing management action update implement enterprise investment people process technology improve risk plan progress cyber maturity programme ability prevent detect respond recover escalation cyber security office analyse potential cyber cyber security incident monitor risk key risk security incident support internal expert give indicator include tolerance threshold report monthly update ciso ciso escalate cyber incident business quarterly governance channel potential material impact chief compliance officer cdto turn escalate gsk thirdparty security risk management leadership team company secretary trigger review programme assess cyber security risk select disclosure committee determine materiality board party like external partner supplier material cyber security incident subsequently escalate use widely accept standard framework benchmark board audit risk committee internal environment control help define security objective desire security outcome cyber security awareness training readiness standard framework evolve response cyber security awareness training programme dynamic threat environment rely external include phishe simulation monthly awareness campaign framework include mandatory annual refresher employee new hire national institute standard technology nist highrisk role run quarterly phishe simulation test cyber security framework measure overall cyber relate remedial training offer optional training readiness maturity annual global event effort aim increase cyber international organisation standardisation iso security awareness foster culture security general information technology control everyone responsibility run periodic crisis simulation sarbanesoxley sox assessment internal control exercise target function test response cyber security incident draw thirdparty consultant expertise process assess identify manage cyber security risk compliance governmental cyber security year cyber security maturity programme design regulation reduce risk datum compromise improve cyber security office guide general counsel security posture ability detect protect work stay abreast emerge government regulation respond recover malicious cyber activity trend compliance expectation cyber security create ai governance council include ciso new regulatory guidance available include assess manage information security risk adopt securities exchange commission rule cyber scale ai gsk security relate disclosure respond remedial compliancerelate action strategic report governance remuneration financial statement investor information gsk annual report principal risk uncertainty continue supply continuity risk definition supply chain imperative focus accelerate innovation use technology datum transform way risk gsk party potentially fail deliver manufacture supply medicine vaccine drive continuous supply compliant finished product respond competitive advantage longterm strategic effectively crisis incident timely manner recover partnership rd focus talent skill need sustain critical supply operation future addressing skill new technology risk impact modality bring vaccine medicine supply chain global supply chain recognise important continuity supply organisation leverage benefit highly skilled product patient rely supply disruption workforce continual business monitoring place assess lead sectorwide risk spread industrial relation product shortage product recall challenge arise global cost living pressure keep patient supply medicine priority regulatory intervention reputational harm mitigating activity lose sale revenue risk management consequently need sophisticated endtoend supply chain medicine vaccine supply chain set ensure management robust crisis management business sustainable global supply gsk internal control framework continuity plan place respond drive approach risk management context design identify emerge new risk support clear decision make risk oversight manage hierarchy operate supply chain continually evolve highly risk management compliance board assure risk regulated environment single set global mitigation include identify new emerge threat regulation govern manufacture distribution medicine adhere requirement inventory management market licence sell manufacture product supply chain governance committee medicine rely internal quality management system vaccine closely monitor inventory status delivery internal control framework ensure maintain licence product core commercial cycle link supply chain operate complex endtoend supply chain involve forecast commercial ambition design party supplier active pharmaceutical ingredient reduce risk demand fluctuation manage temporary api manufacturer raw material supplier shortage supply periodically review node party logistic provider contract engineering firm supply chain ensure hold adequate safety stock whilst integrate risk management source balance work capital particular emphasis day day business process emphasis mitigate supply risk associate medicallycritical high party oversight external factor continue challenge supply revenue product new product launch example continuity difficulty source bioscience dual source key product apis use monthly material ease year performance management process supply chain monitor business activity highlight adverse trend supply new constraint party sterile manufacturing operation budget workforce capability capacity increase global competition contract manufacturing operation continue operate global business continuity supply chain rapidly change geopolitical environment crisis management business continuity plan place increase nationalism friction china supply chain include authorise response create divergence global supply strategy recovery strategy key area responsibility clear react design supply route derisk source communication route regularly use business continuity decision use business continuity planning mitigate plan manage potential supply disruption maintain supply continuity eg dual source material manufacturing site crisis management plan place adapt supply route meet regulatory expectation plan test annually ensure maintenance commercial late stage clinical supply chain core skill crisis management strategic report governance remuneration financial statement investor information gsk annual report shareholder information share capital control detail issue share capital number share article association right holder vote hold treasury december find note respect company share financial statement share capital share premium account interest vote right ordinary share list london stock exchange lse quote new york stock exchange state far company aware nyse form american depositary share ad person significant direct indirect holding ad represent ordinary share detail list debt company information provide company pursuant list refer note financial fca disclosure guidance transparency rule dtr statement net debt publish regulatory information service company website gskcom holder ordinary share ad entitle receive dividend declare copy company company receive notification accordance annual report elect entitle attend dtr follow notifiable interest voting right speak appoint proxy exercise voting right general company issue share capital meeting company december february restriction transfer limitation percentage percentage hold ordinary share ad requirement total total obtain approval prior transfer ordinary share vote voting voting voting ad carry special right regard control right right right right company restriction vote right major blackrock inc shareholders voting right share dodge cox shareholder know arrangement percentage total voting right date notification financial right hold person holder company share know agreement restriction share comprise indirect interest ordinary share transfer vote right hold qualify financial instrument contract difference share acquire group employee share plan comprise indirect interest ordinary share rank equally share issue special ad right trustee employee share ownership plan trust waive right dividend share hold company acquire disposed interest trust share period review demerger haleon share consolidation share buyback programme report previously july company complete board authorise issue allot ordinary demerger consumer healthcare business share article company article association group detail find wwwgskcomengb power article authority company haleoncmdtodemergerarchive july purchase share subject shareholder shareholder receive new gsk plc share nominal value authority seek annual basis annual pence gsk plc share nominal general meeting agm share purchase value penny company cancel hold treasury share group reduce share hold haleon plc satisfy share option grant group employee course financial year end december share plan information find note current equity programme cover purchase share cancellation investment january group reduce hold treasury share accordance authority shareholding gsk hold approximately million renew shareholder agm ordinary share haleon plc represent company authorise purchase maximum issue share capital haleon information find million share note post balance sheet event determine specific share repurchase level company exchange control limitation consider development free cash flow year affect holder treasury share purchase detail share purchase cancel hold treasury share certain economic sanction force subsequently transfer treasury satisfy award time time currently applicable law group employee share plan disclose note decree regulation force uk restrict import financial statement share capital share premium export capital restrict remittance dividend account company confirm currently payment holder company share intend market purchase company nonresident uk continue review potential future share buyback similarly certain economic sanction line usual annual cycle subject return force time time limitation relate rating criterion nonresident uk english law company market capitalisation share price trend year end market capitalisation base share issue exclude december treasury share gsk december billion date gsk th large company market capitalisation ftse index share price january december increasedecrease high year low year table set middle market closing price companys share price decrease compare decrease ftse index year middle market closing share price february ku strategic report governance remuneration financial statement investor information gsk annual report shareholder information continue share capital control continue jan jan jan uk share price uk share price nature trading market follow table set period indicate high low middle market closing price company ordinary share lse ad nyse ordinary share ad uk share share high low high low february january december november october september quarter end december quarter end september quarter end june quarter end march quarter end december quarter end september quarter end june quarter end march year end december year end december year end december february strategic report governance remuneration financial statement investor information gsk annual report shareholder information continue analysis shareholding december number total total account account share number share hold share hold institutional corporate holder individual corporate body guaranty nominee limit adr programme hold treasury share gsk jp morgan chase bank na depositary company american depositary receipt adr programme company ad list nyse ordinary share represent company adr programme manage depositary register guaranty nominee limit february guaranty nominee limit hold ordinary share represent issue share capital exclude treasury share february number holder ordinary share holding ordinary share number register holder ad holding ad certain ordinary share ad hold broker nominee result number holder record register holder representative number beneficial holder residence beneficial holder dividend company pay dividend quarterly continue return adjusted share consolidation prior year cash shareholder dividend policy dividend adjust remain essential component total shareholder return q ordinary dividend receivable ad holder calculate base exchange rate april cumulative gsk recognise importance dividend shareholder dividend receivable ad holder q q q june gsk investor update gsk set progressive dividend policy implement expect dividend p ordinary share guide percent payout ratio detail dividend declare amount investment cycle dividend policy total expect cash payment date give note financial statement distribution respective dividend payout ratio gsk dividend remain unchanged dividend calendar dividend share exdividend ad ex quarter date dividend date record date payment date table set dividend share ad year dividend ad translate q february february february april dollars applicable exchange rate q july year pence q august august august october q november november november january q february february february april annual fee ad ad quarter charge depositary amount show dividend pay ad annual fee charge dividend declare pay respect p share q p share q p share q dividend p share declare q strategic report governance remuneration financial statement investor information gsk annual report shareholder information continue financial calendar event date result announcement quarter result announcement result announcement issue lse available annual general meeting news service send security quarter result announcement july exchange commission sec nyse issue medium available website quarter result announcement october preliminaryquarter result announcement february financial report annual report publication februarymarch company publish annual report annual report distribution march available website date publication shareholder elect receive notification email information company include share ad publication annual report register price available website gskcom information wwwshareviewcouk elect receive print available website constitute annual copy annual report contact registrar equiniti report limited stock exchange announcement notification copy previous annual report available website provide shareholder service receive automatic print copy obtain registrar email notification publish stock exchange contact detail announcement receive email notification sign announcement gskcom investor section annual general meeting annual general meeting agm hold pm uk ad holder wish attend meeting electronically time wednesday royal lancaster refer agm notice detail request proxy london lancaster terrace london w ty appointment depositary jp morgan chase bank na broadcast live join electronically enable attend ask question vote electronically business transact meeting agm company principal forum communication private shareholder addition formal agm ad holder remind instruct business presentation ceo depositary way share represent performance group future development ad vote complete return opportunity question ask board voting card provide depositary share chair board committee available vote question relate role document display detail access agm electronically article association company director attend person ask question vote find service contract applicable letter appointment notice annual general meeting agm notice director company subsidiary available website gskcom letter relate severance term pension march arrangement available inspection company investor hold share nominee service register office available inspection arrange service appoint proxy agm respect shareholding attend vote meeting electronically strategic report governance remuneration financial statement investor information gsk annual report shareholder information continue tax information shareholder summary certain uk tax federal income tax inheritance tax consequence holder share ad citizen individual ukdomicile shareholder uk set complete analysis liable uk inheritance tax transfer share ad possible tax consequence purchase ownership exposure uk inheritance tax charge typically occur sale security intend general guide death asset owner transfer share holder advise consult adviser respect commercial sale seven year death remain tax consequence purchase ownership sale relevant inheritance tax exposure death share ad consequence state local tax transfer trust arrangement lifetime rise law implication current ukus tax immediate inheritance tax charge convention tax charge value holder ad generally treat owner shareholder estate reduce result transfer underlie share purpose current ukus double way lifetime gift disposal market taxation convention relate income gain income tax value case bequ death tax charge convention estate gift taxis estate gift tax value share date shareholder convention purpose internal revenue code death exposure uk inheritance tax estate amend gift tax exist careful planning undertake uk shareholder understand opportunity utilise usuk estate gift double tax convention manage tax credit avoid summary apply uk resident shareholder double taxation hold share capital asset overall exposure dependent specific taxation dividend circumstance situation important note uk tax year uk resident individual tax charge arise jurisdiction bespoke advice entitle dividend tax allowance tailor individual personal circumstance dividend receive tax year free tax obtain tax professional dividend excess allowance tax stamp duty stamp duty reserve tax basic rate taxpayer high rate taxpayer additional rate taxpayer note april uk stamp duty andor stamp duty reserve tax sdrt dividend allowance reduce subject certain exemption payable transfer share rate round near uk resident shareholder corporation taxpayer case stamp duty consideration transfer note dividend payable ordinary share generally notwithstanding provide instrument execute entitle exemption corporation tax pursuance agreement give rise charge taxation capital gain sdrt instrument stamp year agreement include stamp exempt sdrt uk resident shareholder liable uk tax gain charge cancel sdrt disposal share ad pay repay list share transfer disposal individual uk tax year company connect transferor chargeable taxable capital gain accrue disposal share ad consideration deem market tax basic rate taxpayer value share transfer market value override allowable deduction individual taxable income apply nonliste share transfer company year exceed basic rate income tax banding note connect transferor consideration include follow use exemption available individual issue share taxpayer annual exempt shareholder corporation taxpayer entitle indexation summary apply shareholder citizen allowance apply reduce capital gain extent resident domestic corporation person gain arise inflation indexation allowance subject federal income tax net income reduce chargeable gain create allowable loss basis respect share ad hold share ad asset acquire january legislation capital asset resident uk uk tax purpose finance act freeze level indexation allowance hold share purpose trade profession give calculate company chargeable gain vocation carry uk branch value apply disposal asset agency december asset acquire january onwards legislation finance act remove summary address tax treatment indexation allowance disposal holder subject special tax rule bank tax exempt entity insurance company dealer security currency person hold share ad integrate investment include straddle comprise share ad position person directly indirectly constructively company stock vote value address tax treatment applicable result international income tax treaty strategic report governance remuneration financial statement investor information gsk annual report shareholder information continue tax information shareholder continue taxation dividend information report backup withholding gross dividend receive treat foreign dividend payment proceed sale share source dividend income tax purpose eligible ad pay certain usrelated financial dividend receive deduction allow corporation intermediary subject information reporting dividend ad payable dollar dividend subject backup withholding holder ordinary share payable sterling dividend pay corporation exempt recipient provide taxpayer sterling include income dollar identification number certifie loss exemption calculate reference exchange rate day occur nonus holder generally subject dividend receive holder subject certain information report backup withholding exception shortterm hedge position individual require provide certification nonus status eligible holder subject taxation maximum connection payment receive amount withhold federal rate plus applicable state local tax allow refund credit holder federal respect qualified dividend qualified dividend define income tax liability provide require information internal revenue service irs dividend furnish irs meet follow criterion estate gift taxis issue corporation corporation estate gift tax convention shareholder incorporate possession corporation generally subject uk inheritance tax eligible benefit comprehensive income tax treaty holder subject federal estate gift tax deem satisfactory publish irs stamp duty dividend type list irs dividend qualify uk stamp duty andor sdrt subject certain exemption payable transfer share ad custodian require dividend hold period meet depositary rate consideration share own day provide transfer sale value transfer hold period define day consideration period begin day exdividend date day stock trade dividend price stamp duty sdrt payable example stock exdividend date october transfer agreement transfer ad transfer share hold day period clearance service notwithstanding august november year order clearance service operator election count qualified dividend sa finance act broadly stamp dutysdrt charge arise transfer clearance dividend qualified subject taxation service transfer system federal graduate tax rate maximum rate change beneficial ownership attract charge type dividend automatically exclude qualified dividend meet requirement demerger share consolidation include limited summary certain uk tax consequence respect capital gain distribution demerger haleon plc consolidation dividends bank deposit company share capital relevant company shareholder resident case individual dividend hold corporation employee stock resident domicile uk uk tax purpose ownership plan esop citizen resident tax purpose set dividend pay taxexempt corporation circular relation demerger state local tax rate qualify nonqualified share consolidation publish june circular page dividend vary assess addition circular information federal tax rate communicate demerger share consolidation find gskcom demerger section taxation capital gain information tax base cost allocation assist uk generally holder subject uk capital gain tax shareholder apportion base cost gsk plc subject tax capital gain realise share haleon plc share uk capital gain tax purpose sale disposal share ad gain long follow demerger include work example term capital gain subject reduce rate taxation find tax section gskcom demerger section individual holder share ad hold year date share vestedrelease short term capital gain subject taxation rate longterm capital gain subject rate state local tax rate capital gain apply strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure shareholder service contact registrar company registrar equiniti limited aspect house spencer road lance bn da wwwshareviewcouk tel equiniti provide range service shareholder service offer participate dividend reinvestment plan alternative receive cash dividend drip election form term condition drip choose reinvest dividend buy gsk share information fee download wwwshareviewcouk request contact equiniti dividend payment direct dividend pay directly bank building dividend bank mandate form download bank account bank society account receive cash dividend wwwshareviewcouk request contact equiniti mandate provide equiniti bank building society account detail quick secure method payment dividend payment direct equiniti convert dividend local currency information overseas payment service bank account overseas send direct local bank account include information fee find shareholder overseas overseas payment service available approximately wwwshareviewcouk contact equiniti payment service country worldwide electronic communication shareholder elect receive electronic notification register wwwshareviewcouk company communication include annual report dividend payment dividend confirmation availability online vote general meeting time gsk publish shareholder document receive email contain link document relevant website shareview portfolio service enable create free online portfolio view register wwwshareviewcouk share balance movement update address dividend payment instruction register vote general meeting deduplication receive duplicate copy mailing contact equiniti publication mailing account contact equiniti arrange account merge convenience avoid waste unnecessary cost share deal service shareholder trade share hold certificate information share deal service include note market form corporate sponsor nominee online information fee find trading hour telephone postal dealing service provide wwwshareviewcoukdeale pm uk time equiniti financial service limit online transaction log monday friday exclude wwwshareviewcoukdeale public holiday england wale telephone transaction uk outside uk line open pm uk time monday friday exclude uk public holiday postal transaction request deal form corporate sponsor convenient way manage share application form request nominee account require share certificate service provide facility wwwshareviewcouk contact equiniti hold share nominee account sponsor company continue receive dividend payment attend vote company general meeting shareholder name appear publicly available share register service free join individual saving account equiniti financial service limit provide eqi flexible detail include information fee available isa isa hold gsk share wwweqicouk request call equiniti customer experience team line open pm uk time monday friday exclude uk public holiday line open pm uk time monday friday exclude public holiday england wale use country code dialling outside uk provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue shareholder service contact continue ad depositary share scam alert adr programme administer jpmorgan receive unsolicited telephone offering sell buy chase bank na share extra care caller highly organise financial scam regular correspondence eq shareowner service uk shareholder contact financial po box conduct authority wwwfcaorgukconsumer st paul mn consumer helpline delivery stock certificate overnight mail tel uk eq shareowner service tel outside uk centre pointe curve suite mendota height mn line open pm uk time monday friday uk public holiday pm saturday shareowneronlinecominformationalcontactus outside donate share save child depositary provide global invest direct direct ad gsk embark ambitious global partnership purchasesale dividend reinvestment plan ad holder save child share expertise resource detail enrol visit wwwadrcom aim find innovative way reduce number child helpline number obtain enrolment pack die preventable disease shareholder small number share value contact make uneconomical sell wish consider donate investor relation save child donate share aggregate investor relation contact follow sell behalf save child use fund raise help reach goal uk obtain share donation form contact registrar great west road equiniti manage donation sale uk share brentford middlesex tw gs save child free charge tel provision share deal detail intend invitation inducement engage investment activity advice share deal walnut street obtain stockbroker independent financial adviser philadelphia pa tel toll free tel outside gsk response center tel toll free tel outside strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue law regulation number provision law regulation apply section corporate responsibility company share quote nyse financial report form ad sarbanesoxley require ceo cfo complete nyse rule formal certification confirm general nyse rule permit company follow uk review annual report form f corporate governance practice instead apply base knowledge annual report form f provide explain significant variation contain material misstatement omission explanation contain form f access sec edgar database website base knowledge financial statement nyse rule require file annual interim write financial information fairly present material respect affirmation concern audit risk committee arc financial condition result operation cash flow statement significant difference corporate date period present annual governance report form f sarbanesoxley act responsible establish maintain disclosure control procedure ensure material follow number corporate accounting scandal information know evaluate congress pass sarbanesoxley act effectiveness control procedure year sarbanesoxley wideranging piece legislation end result evaluation contain concerned largely financial report corporate annual report form f governance responsible establish maintain internal recommend sec company establish control financial reporting provide reasonable disclosure committee committee report ceo assurance reliability financial reporting cfo arc chair company secretary preparation financial statement external purpose member consist senior manager finance legal accordance generally accept account corporate communication investor relation principle appropriate external legal counsel external disclose annual report form f auditor sponsor bank internal expert invite change internal control financial reporting attend disclosure committee meeting periodically period cover annual report form f committee responsibility consider materiality materially affect reasonably likely affect information timely basis determine disclosure materially company internal control financial information responsibility timely filing reporting report sec formal review annual report annual report form f committee disclose base recent evaluation meet time include purpose receive relevant internal control financial report external appropriate training auditor arc significant deficiency material weakness design operation internal control sarbanesoxley require annual report form f financial reporting reasonably likely affect contain statement member arc adversely company ability record process summarise audit committee financial expert define rule report financial information fraud regardless sarbanesoxley statement relevant member materiality involve person significant role arc charles bancroft include board committee company internal control financial reporting information area corporate governance report group carry evaluation supervision biography participation management include additional disclosure requirement arise section ceo cfo effectiveness design operation section sarbanesoxley respect disclosure control group disclosure control procedure procedure internal control financial reporting december inherent limitation effectiveness system disclosure control procedure include possibility human error circumvention override control procedure accordingly effective disclosure control procedure provide reasonable assurance achieve control objective strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue law regulation continue ceo cfo expect complete certification group export certain medicine iran sale non report conclusion effectiveness disclosure entity subsidiarie entity control procedure march follow distributor iran pursuant specific licence issue certification file sec group office foreign asset control annual report form f group regularly receive information section management annual report identity distributor downstream customer intermediary iran possible party internal control financial reporting include entity hospital pharmacy accordance requirement section own directly indirectly iranian government sarbanesoxley follow report provide person entity sanction connection terrorism management respect company internal control proliferation activity financial report define rule af df securities exchange act amend group regularly receive information exchange act identity distributor downstream customer intermediary establish proportion gross management responsible establish maintain revenue sale potentially attributable entity affiliate adequate internal control financial report iranian government party sanction group internal control financial reporting design disclosable activity result group reporting provide reasonable assurance reliability entire gross revenue million net profit financial reporting preparation financial million group sale iran statement external purpose accordance ifrs hospital medical facility lebanon management conduct evaluation effectiveness affiliate control hezbollah group internal control financial reporting base designate united states pursuant executive framework internal control integrate framework order group deal directly issue committee sponsor organisation hospital facility instead sell distributor treadway commission coso group unable establish proportion gross revenue change group internal control sale potentially attributable reportable activity result financial reporting materially group report entire gross revenue million affect reasonably likely materially affect net loss million group sale lebanon groups internal control financial reporting management assess effectiveness internal control financial reporting december addition section r exchange act law conclusion file group annual generally restrict dealing person dealing report form f subject jurisdiction certain country deloitte llp audit consolidated financial territory subject comprehensive sanction currently statement group year end december crimea cuba socalle donetsk people republic iran assess effectiveness group socalle luhansk people republic north korea syria internal control financial reporting auditing government venezuela standard public company accounting oversight country venezuela group engage board united states audit report file activity certain jurisdiction assess group form f applicable licence exemption section r exchange act believe group complie applicable sanction material respect law complex section r exchange act require issuer continue evolve rapidly specific disclosure annual report certain type dealing iran include transaction dealing governmentowne orcontrolle entity dealing entity sanction activity relate terrorism proliferation weapon mass destruction activity prohibit law involve person strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue donation political organisation political expenditure ensure consistent approach political contribution result definition cover legitimate business group global policy introduce activity ordinary sense consider political voluntarily stop corporate political contribution donation political expenditure design support political party independent election candidate period january december group political donation eu noneu notwithstanding policy organisation intend donation eu political party organisation incur eu political expenditure notwithstanding introduction policy accordance annually seek shareholder authorisation inadvertent federal election campaign act continue expenditure support employeeoperate political action committee pac facilitate voluntary political donation eligible authority precautionary measure ensure gsk employee company subsidiary inadvertently breach legislation pac control gsk decision amount recipient contribution govern pac board authorisation process expenditure director contribution pac year date agm hold follow participate eligible employee exercise legal right introduction political party election pool resource political contribution referendum act authority renew subject strict limitation law total annually donate political organisation gsk employee pac english law require prior shareholder approval political contribution eu political party independent election candidate eu political expenditure definition political donation political expenditure political organisation legislation broad particular definition eu political organisation extend body concern policy review law reform representation business community special interest group concern environment company subsidiary wish support strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company accordance section company act list subsidiary associate joint venture joint arrangement address register office effective percentage equity own december disclose state share capital disclose comprise ordinary share indirectly hold gsk plc percentage hold class share state state subsidiary company register office tax resident country incorporation security register address wholly own subsidiary canada inc common armandfrappi boulevard laval hv canada canada inc common milverton drive suite mississauga lr h canada alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny united kingdom adechsa gmbh ii ordinary co prv provide treuhandgesellschaft ag dorfstrasse baar switzerland affinivax inc common corporation service company little fall drive wilmington de united states allen hanburys limited ii ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary town planning way ilupeju lagos nigeria allen pharmazeutika gesellschaft mbh ordinary wienerbergstrae wien austria austria beecham group plc ordinary b great west road brentford middlesex tw gs england ordinary beecham pharmaceutical pte limited ordinary quality road jurong industrial estate jurong singapore beecham portuguesa quota rua dr antonio loureiro borge arquiparque miraflore produto farmaceutico e quimicos lda alge portugal beecham sa ordinary avenue fleming wavre belgium bellus health corp common corporation trust company corporation trust center orange street wilmington de united states bellus health inc common boulevard armand frappier laval qc hv canada biovesta ilalari ltd sti ii nominative bykdere caddesi levent plaza b blok levent istanbul turkey cascan gmbh co kg partnership capital prinzregentenplatz munich bavaria germany cellzome gmbh ordinary meyerhofstrasse heidelberg germany clarge pharmaceutical trustee limited ii ordinary great west road brentford middlesex tw gs england colleen corporation common corporation service company little fall drive wilmington de united states corixa corporation common corporation service company little fall drive wilmington de united states dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energia solar alternativa sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain duncan pharmaceuticals philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines etex farmaceutica ltda social capital av andrs bello costanera center torre piso providencia santiago chile glaxo group limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny united kingdom glaxo kabushiki kaisha ii ordinary akasaka minatoku tokyo japan glaxo new zealand pension plan trustee limited ordinary level e generator gridakl madden street wynyard quarter auckland new zealand glaxo operation uk limit ordinary great west road brentford middlesex tw gs england glaxo property bv ordinary van asch van wijckstraat h lp amersfoort netherlands glaxo saudi arabia limit ordinary po box area warehouse city stage al khomrah jeddah saudi arabia glaxo verwaltung gmbh ordinary prinzregentenplatz munich bavaria germany glaxo wellcome farmaceutica limitada ordinary rua dr antonio loureiro borge arquiparque miraflore alge portugal glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production ordinary rue franois jacob rueilmalmaison france strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxo wellcome vidhyasom limited liquidation ii ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgo spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxochem pte ltd iii ordinary rochester park singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal glaxosmithkline cambodia co ltd ordinary th floor dksh building preah monivong boulevard co sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room unit floor mid th east ring road chaoyang district beijing china glaxosmithkline china rd company limited equity f building huanke road pilot free trade zone shanghai china glaxosmithkline gsk srl ordinary str dr nicolae staicovici nr opera center ii etaj sector bucureti romania glaxosmithkline ireland limit ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline private limited ii ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada quota luanda bairro petrangol estrada de cacuaco n angola glaxosmithkline argentina sa ordinary tucumn piso buenos aire caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline australia pty ltd ordinary level johnston street abbotsford victoria australia glaxosmithkline bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands glaxosmithkline beteiligung gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biological kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biological sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biological sa ordinary rue de b rixensart belgium preference glaxosmithkline brasil limitada quotas estrada do banderiantes rio de janeiro brazil glaxosmithkline capital inc common wilmington trust sp services inc n market street th floor wilmington de united states glaxosmithkline china rd company limited equity f building huanke road pilot free trade zone shanghai china glaxosmithkline gsk srl ordinary str dr nicolae staicovici nr opera center ii etaj sector bucureti romania glaxosmithkline ireland limit ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline private limited ii ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada quota luanda bairro petrangol estrada de cacuaco n angola glaxosmithkline argentina sa ordinary tucumn piso buenos aire caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline australia pty ltd ordinary level johnston street abbotsford victoria australia glaxosmithkline bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands glaxosmithkline beteiligung gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biological kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biological sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biological sa ordinary rue de b rixensart belgium preference strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline brasil limitada quotas estrada do banderiantes rio de janeiro brazil glaxosmithkline capital inc common wilmington trust sp services inc n market street th floor wilmington de united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital av andrs bello torre piso providencia santiago regin metropolitana chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer hold bv ii ordinary van asch van wijckstraat h lp amersfoort netherlands glaxosmithkline doo beogradnovi beograd liquidationordinary milutin milankovic j novi beograd belgrade serbia glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline el salvador sa de cv ordinary municipio de san salvador departamento de san salvador el salvador glaxosmithkline eood ordinary nedelcho bonchev str sofia sofiya bulgaria glaxosmithkline export limit ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary van asch van wijckstraat h lp amersfoort netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala sa ordinary ra av zona torre citibank nivel guatemala city guatemala glaxosmithkline hold ordinary drammensveien oslo norway glaxosmithkline holdings americas inc common wilmington trust sp services inc north market street th floor wilmington delaware glaxosmithkline holding limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holding limit ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings pty ltd ordinary level johnston street abbotsford victoria australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limit ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithkline inc class common milverton drive suite mississauga lr h canada class c preference glaxosmithkline insurance ltd ordinary co trinity corporate services ltd trinity hall cedar avenue hamilton hamilton hm bermuda glaxosmithkline intellectual property limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny united kingdom glaxosmithkline intellectual property development limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny united kingdom glaxosmithkline intellectual property holding limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny b ordinary united kingdom glaxosmithkline intellectual property limit defer gsk medicine research centre gunnel wood road stevenage sg ny ordinary united kingdom glaxosmithkline intellectual property management limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny united kingdom glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline investments pty ltd ordinary level johnston street abbotsford victoria australia glaxosmithkline kk ordinary akasaka minatoku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline limit ordinary f tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline limited ii ordinary great west road brentford middlesex tw gs england glaxosmithkline llc llc interest corporation service company little fall drive wilmington de united states glaxosmithkline manufacture spa ordinary viale dellagricoltura verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou ham el glaza casablanca morocco glaxosmithkline medical healthcare product kft ordinary budap andrassy ut hungary glaxosmithkline mercury limit ordinary great west road brentford middlesex tw gs england strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline mexico sa de cv ordinary av real mayorazgo piso colonia xoco alcaldia benito jurez ordinary b ciudad de mexico mexico glaxosmithkline nz limit ordinary level e generator gridakl madden street wynyard quarter auckland new zealand glaxosmithkline oy ordinary porkkalankatu helsinki finland glaxosmithkline peru sa ordinary av vctor andrs belande n va principal n piso distrito de san isidro lima peru glaxosmithkline pharma ordinary vallensbk company house iii delta park dk valle denmark glaxosmithkline pharma gmbh ordinary wienerbergstrae wien austria austria glaxosmithkline pharmaceutical kenya limit ordinary po box likoni road nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary hz horizon penthouse powerhouse persiaran bandar utama bandar utama petale jaya selangor malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals costa rica sa ordinary autopista florencia del castillo kilmetro siete oficentro terracampus edificio uno cuarto piso san diego cartago costa rica glaxosmithkline pharmaceuticals sa ordinary avenue fleming wavre belgium glaxosmithkline pharmaceutical ukraine llc charter capital pavla tychyny avenue v kiev ukraine glaxosmithkline philippines inc ordinary rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common corporation service company puerto rico inc co rvm professional service llc reparto mendoza humacao puerto rico glaxosmithkline republica dominicana sa ordinary blue mall tower floor ave winston churchill santo domingo dominican republic glaxosmithkline research development limit ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline spa ordinary viale dellagricoltura verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline services gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline service unlimite ordinary great west road brentford middlesex tw gs england glaxosmithkline single member aebe ordinary kifissias avenue halandri athens greece glaxosmithkline sl llc llc interest corporation service company little fall drive wilmington de united states glaxosmithkline sl lp iiviii partnership great west road brentford middlesex tw gs england glaxosmithkline south africa pty limited ordinary flush meadow build campus sloane street bryanston south africa glaxosmithkline trading services limit iii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline tunisia sarl ordinary immeuble regus lot b centre urbain nord tunis tunisia glaxosmithkline uk limit ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa register provisory stock victor solio montevideo montevideo uruguay glaxosmithkline trading limit ordinary great west road brentford middlesex tw gs england glaxosmithkline venezuela ordinary calle altagracia edificio pg piso mezzanina torre torre sur urbanizacion sorokaima la trinidad caracas venezuela bolivarian republic glaxosmithkline vietnam limited liability company ii equity capital metropolitan dong khoi street district th floor unit ho chi minh city vietnam glycovaxyn ag liquidation common grabenstrasse schlieren switzerland prefer preferred b prefer c groupe glaxosmithkline ordinary rue franois jacob rueilmalmaison france gsk biopharma argentina sa nominative non tucumn piso buenos aire caaa argentina endorseable ordinary gsk scottish limited partnership viii partnership lothian road festival square edinburgh scotland eh wj united kingdom gsk scottish limited partnership viii partnership lothian road festival square edinburgh scotland eh wj united kingdom gsk scottish limited partnership viii partnership lothian road festival square edinburgh scotland eh wj united kingdom strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue gsk business service centre sdn bhd ordinary level quill jalan prof khoo kay kim petale jaya selangor malaysia gsk capital bv iiiv ordinary great west road brentford middlesex tw gs gsk capital kk ordinary akasaka minatoku tokyo japan gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk enterprise management co ltd ordinary floor lane huanke road zhongke road shanghai china gsk equity investment limited unit corporation service company interstate drive suite harrisburg pa united states gsk finance plc ordinary great west road brentford middlesex tw gs england gsk finance limit ordinary great west road brentford middlesex tw gs england gsk india global services private limited equity level luxor north tower bagmane capital business park outer ring road bangalore karnataka india gsk international hold finance bv ordinary van asch van wijckstraat h lp amersfoort netherlands gsk kazakhstan llp participation interest nursultan nazarbayev ave business center usko rd fl almaty kazakhstan gsk life sciences fze ordinary lb jebel ali freezone dubai united arab emirates gsk pharma india private limited equity battery house bhulabhai desai raod mumbai maharashtra india gsk pharma vietnam company limited charter capital unit th floor metropolitan tower dong khoi street ben nghe ward district ho chi minh vietnam gsk pharmaceutical trading sa ii ordinary buchar costache negri street opera center th floor discussion room district romania gsk psc poland sp z oo equal indivisible share ul grunwaldzka pozna pol gsk service sp z oo ordinary ul grunwaldzka poznan poland gsk vaccine bv ordinary hullenbergweg cl amsterdam netherlands gsk vaccine gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quota fiorentina siena italy gsk vaccines srl quota fiorentina siena italy gsk vaccines vertriebs gmbh ordinary rudolfdieselring holzkirchen germany human genome sciences inc common corporation service company little fall drive wilmington de united states d biomedical corporation quebec common boul du parc technologique qubec qubec gp r canada instituto luso farmaco limitada ii quota rua dr antonio loureiro borge arquiparque miraflore alge portugal interpharma dienstleistungen gmbh quota wienerbergstrae wien austria austria jj technologies lc ii llc interest corporation service company shockoe slip nd floor richmond va united states jsc glaxosmithkline trading ordinary leningradskiy prospect build floor premise xv room moscow russian federation laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerde algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerde algeria laboratoires paucourt ii ordinary rue franois jacob rueilmalmaison france laboratoire saintgermain ii ordinary rue franois jacob rueilmalmaison france laboratorios dermatologico darier sa de cv ordinary av real mayorazgo piso colonia xoco alcaldia benito jurez ordinary b ciudad de mexico mexico laboratorios farmaceuticos stiefel portugal ltda ii ordinary rua dr antonio loureiro borge arquiparque miraflore alge portugal laboratorios stiefel de venezuela sa ordinary calle altagracia edificio pg nivel mezzanina piso mezzanina local torre sur urbanizacion sorokaima la trinidad caracas venezuela bolivarian republic laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem bairro de bonsucesso municipality guarulhos sao paulo cep brazil laboratorios wellcome de portugal limitada ii quota rua dr antonio loureiro borge arquiparque miraflore alge portugal maxinutrition limited liquidation ordinary co bdo llp temple square temple street liverpool l rh pt glaxo wellcome indonesia class jl pulobuaran raya kaviii class b dd kws industri pulogadung jatinegara cakung jakarta timur indonesia setfirst limit ordinary great west road brentford middlesex tw gs england strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue sierra oncology australia pty ltd ordinary co maddock lawyer angel place level pitt street sydney australia sierra oncology canada ulc common suite west georgia street vancouver bc vb canada sitari pharma inc common corporation service company little fall drive wilmington de united states smith kline french portuguesa ordinary rua dr antonio loureiro borge arquiparque miraflore produto farmaceuticos lda ii alge portugal smithkline beecham bangladesh private limited ii ordinary housea roadgulshan dhaka bangladesh smithkline beecham cork limit ordinary riverwalk citywest business campus dublin ireland smithkline beecham egypt llc quota amoun street el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham legacy h limited ordinary great west road brentford middlesex tw gs england smithkline beecham limit ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limit ordinary great west road brentford middlesex tw gs england smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltung gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited ii ordinary flush meadow build campus sloane street bryanston south africa smithkline beecham pharmaceutical co common corporation service company little fall drive wilmington de united states smithkline beecham senior executive pension plan trustee ordinary great west road brentford middlesex tw gs england limited ii stiefel gmbh co kg partnership capital prinzregentenplatz munchen germany stiefel laboratory legacy ireland limited ordinary unit build avenue cork airport business park cork ireland stiefel laboratory pte limited ordinary pioneer sector singapore stiefel laboratories inc common corporation service company little fall drive wilmington de united states stiefel maroc sarl ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary level johnston street abbotsford victoria australia stiefel research australia pty ltd ordinary level johnston street abbotsford victoria australia stiefel west coast llc llc interest corporation service company little fall drive wilmington de united states strebor inc common corporation service company little fall drive wilmington de united states tesaro bio gmbh liquidation ordinary poststrasse zug switzerland tesaro bio netherlands bv ordinary joop geesinkweg ab amsterdamduivendrecht netherland tesaro development ltd ordinary clarendon house church street hamilton hm bermuda tesaro inc common corporation service company little fall drive wilmington de united states sydney ross co ii ordinary corporation service company princeton south corporate center suite charle ewing blvd ewe nj united states ucb pharma asia pacific sdn bhd ii ordinary th floor menara symphony jalan prof khoo kay kim seksyen petale jaya malaysia wellcome consumer healthcare limited ii ordinary great west road brentford middlesex tw gs england wellcome limited ordinary great west road brentford middlesex tw gs england effective security ownership register address subsidiary effective interest amoun pharmaceutical industry co sae monetary share el salam city po box cairo egypt biddle sawyer limited equity dr annie besant road mumbai india british pharma group limited guarantee great west road brentford middlesex tw gs england galvani bioelectronics inc common corporation service company little fall drive wilmington de united states galvani bioelectronic limited ordinary gsk medicine research centre gunnel wood road stevenage sg ny b ordinary united kingdom glaxo laboratories nigeria limited ii ordinary marine road apapa lago nigeria glaxoallenburys nigeria limited ii ordinary creek road apapa lagos pmb nigeria strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline consumer nigeria plc vi ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline pharmaceuticals limited equity dr annie besant road mumbai india glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt laboratorios viiv healthcare sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain modern pharma trading company llc quota amoun street po box el salam city cairo egypt phivco llc llc interest corporation service company little fall drive wilmington de united states phivco llc llc interest corporation service company little fall drive wilmington de united states smithkline beechambiome ooo participation interest leningradskiy prospect build floor premise xiv room moscow russian federation stiefel egypt llc ii quota amoun street po box el salam city cairo egypt viiv healthcare south africa proprietary ordinary flush meadow build campus sloane street bryanston limited south africa viiv healthcare bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands viiv healthcare company common corporation service company little fall drive wilmington de united states viiv healthcare finance limit ordinary great west road brentford middlesex tw gs england viiv healthcare finance limit ordinary great west road brentford middlesex tw gs england redeemable preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare kk ordinary akasaka minatoku tokyo japan viiv healthcare limited ordinary gsk medicine research centre gunnel wood road stevenage sg ny b ordinary united kingdom c ordinary preference ordinary defer e cumulative preference viiv healthcare pty ltd ordinary level johnston street abbotsford victoria australia viiv healthcare puerto rico llc llc interest corporation service company puerto rico inc co rvm professional service llc reparto mendoza humacao puerto rico viiv healthcare srl quota viale dellagricoltura verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary avenue fleming wavre belgium viiv healthcare trading llc ii participation interest leningradskiy prospect build floor premise xiv room moscow russian federation viiv healthcare trading service uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny united kingdom viiv healthcare uk limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny united kingdom viiv healthcare uk limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny united kingdom viiv healthcare uk limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny united kingdom viiv healthcare uk limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny united kingdom viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued viivhiv healthcare unipessoal lda quota rua dr antonio loureiro borge arquiparque miraflore alge portugal winster pharmaceutical limit ordinary association avenue ilupeju industrial estate lago po box nigeria effective security ownership register address associate glaxosmithkline landholde company inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines index ventures life vi jersey lp partnership interest esplanade st helier jersey je wg channel islands kurma biofund ii fcpr partnership interest rue royale th floor paris france longwood fund lp partnership interest prudential tower suite boylston street boston medicxi ventures lp partnership interest esplanade st helier jersey je wg channel island joint ventures chiron panacea vaccines private limited liquidation equity share th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india significant holding axon therapy inc common walsh avenue santa clara united states series preference alpheus medical inc series preference hopkin place north oakdale minnesota usa series preference global farm sa share mendoza ciudad autnoma de buenos aires argentina b shares c c shares shares longwood fund ii lp partnership interest prudential tower suite boylston street boston sanderle ventures vii lp partnership interest el camino real suite san mateo sr capital fund ib lp partnership interest corporation service company little fall drive city wilmington county new castle delaware sr capital opportunity fund lp partnership interest corporation service company little fall drive city wilmington county new castle delaware strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company continue follow uk register subsidiary advantage audit exemption set section company act period end december state undertaking list own directly indirectly gsk plc effective company security ownership register address number uk register subsidiary exempt audit burrough wellcome international limited ordinary great west road brentford middlesex tw gs england domantis limit ordinary gsk medicine research centre gunnel wood road stevenage sg ny united kingdom edinburgh pharmaceutical industry limited ii ordinary shewalton road irvine ayrshire ka ap united kingdom sc preference eskaylab limit ordinary great west road brentford middlesex tw gs england glaxo wellcome uk limit ordinary great west road brentford middlesex tw gs england glaxochem uk unlimite ordinary great west road brentford middlesex tw gs england ordinary b ordinary c glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england gsk gp limit iv share lothian road festival square edinburgh scotland eh sc b shares wj united kingdom gsk gp limit iv ordinary lothian road festival square edinburgh scotland eh sc wj united kingdom gsk lp limited iiv ordinary great west road brentford middlesex tw gs england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap united kingdom sc phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limit ordinary great west road brentford middlesex tw gs england smith kline french laboratory limit ordinary great west road brentford middlesex tw gs england smithkline beecham export limit ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative great west road brentford middlesex tw gs england nonredeemable ordinary smithkline beecham investment limit ordinary great west road brentford middlesex tw gs england smithkline beecham marketing technical service ordinary great west road brentford middlesex tw gs england limited smithkline beecham nominee limit ordinary great west road brentford middlesex tw gs england smithkline beecham overseas limit ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limit ordinary great west road brentford middlesex tw gs england stiefel laboratory uk ltd ordinary great west road brentford middlesex tw gs england tesaro uk limit ordinary great west road brentford middlesex tw gs england wellcome foundation limit ordinary great west road brentford middlesex tw gs england viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england accordance section c company act company guarantee debt liability uk subsidiary undertaking december total sum debt liabilitie million million key directly own gsk plc ii dormant entity iii tax resident uk iv exempt regulation partnership account regulation requirement deliver registrar financial statement qualify partnership entity member accordance company act v incorporate netherlands vi consolidated subsidiary accordance section company act ground dominant influence vii principal business address puerto rico viiiexempt provision regulation partnership account regulation accordance exemption note regulation regulation strategic report governance remuneration financial statement investor information gsk annual report glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr receipt evidence title ad gsk adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share call share capital ordinary share issue fully pay cer growth growth constant exchange rate company gsk plc currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan equity shareholder fund shareholder equity finance lease capital lease freehold ownership absolute right perpetuity group gsk plc subsidiary undertakings gsk gsk plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party ordinary share fully pay ordinary share capital company profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity gsk exercise control treasury share treasury stock turnover revenue uk corporate governance code require uk list authority company disclose annual report apply good practice corporate governance provision financial reporting council uk corporate governance code strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue index access major restructuring cost accounting principle policy movement equity acquisition disposal net debt adjustment reconcile total profit tax operate new accounting requirement cash flow nomination corporate governance committee report annual general meeting noncontrolle interest approach tax noncontrolle interest viiv healthcare asset hold sale nonexecutive director fee associate joint venture nonfinancial sustainability information statement audit risk committee report note financial statement business model operate profit cash cash equivalent intangible asset cash generation conversion investment ceo statement noncurrent asset chair statement noncurrent liabilitie chair governance statement operating incomeexpense climaterelate financial disclosure provision commitment culture people continuous engagement key decision external environment consolidate balance sheet longterm priority consolidated cash flow statement pension postemployment benefit consolidate income statement performance consolidate statement change equity pharmaceutical product competition intellectual consolidate statement comprehensive income property contingent consideration liability pipeline contingent liability post balance sheet event corporate governance presentation financial statement corporate responsibility committee report principal group company critical accounting judgement key source principal risk uncertaintie estimation uncertainty property plant equipment critical accounting policy reconciliation net cash flow movement net debt demerger consumer healthcare business registrar director senior management relate party transaction director interest share reliable supply director report remuneration committee chair annual statement director statement responsibility remuneration governance dividend remuneration report donation political organisation political reporting framework expenditure research development earning share responsible business employee cost right use asset employee share scheme risk management environment science committee report ethical standard section statement exchange rate share capital control finance expense share capital share premium account finance income share consolidation financial calendar shareholder information financial instrument relate disclosure shareholder service contact financial performance summary specialty medicine financial position resource task force climaterelate financial disclosure general medicine taxation glossary term tax information shareholder goodwill board group company threeyear select financial datum group financial review trade payable gsk leadership team trade receivables gsk plc parent company account uk gaap treasury policy independent auditor report trust innovation turnover segment information inventory law regulation investment associate joint venture datum responsibly investor relation vaccine key performance indicator vaccine product competition intellectual property legal proceeding viability statement gsk gsk plc incorporate glaxosmithkline brand name appear italic report trade mark own andor license gsk associated companies plc english public limited company trade mark property respective owner december form merger print sustainably uk pureprint carbonneutral company glaxo wellcome plc smithkline fsc chain custody iso certify environmental management system recycle dry waste beecham plc gsk acquire english print arena eco ew smooth wood free uncoated paper ecf company december fsc certification recycle fibre merger arrangement effective glaxosmithkline plc change gsk plc july gsk plc separate consumer healthcare business gsk group form haleon independent download pdfs list company annual report form f share list london stock esg performance report exchange new york stock exchange fullyear fourth quarter result gskcom cautionary statement forwardlooke assumption basis preparation relate assumption gsk update revenue operating statement guidance outlook profit operate margin cash flow outlook document group report publish guidance outlook expectation read revenue outlook margin expectation file furnish security exchange guidance outlook assumption dolutegravir loss exclusivity factor commission sec write information cautionary statement annual report divestment product exit announce date release oral statement public group q earning release material cost investment new product launch f l gou rot ou k ur ine pg b sy ct uo rr r eo em nn eb ene xth pa efl cf r awf ia oh r ne g l oor ro fu k oip n g c asa tst c e oo fn e ft ua n tti un r g efo iv erw e v ea nhrd te p cn ee ro r tiu il ni n ai n sg su mh e p tg ou ni ad sna adn b c f ooe ur f tr h e th ae g rn ord eo u cpu ot nhlo oao msk ms ic f dr eth e p l ra en la ge n nr lt e tnd od rel r r nu si uans ck lc ceha ese td ss smj u w fas oht e c ed h fa hrl hee ae r si psi sn k r ec tal bu d nad j dus el vs te ea oe b f ps mf eso ce er h np n ct ne tn lh eia n dl investor identify statement fact environment healthcare sector include potential future sale contribution blenrep relate strictly historical current fact exist possible additional governmental legislative exclude use word anticipate estimate expect regulatory reform different market intend project plan believe target competitive landscape group operate notwithstanding guidance outlook word term similar meaning connection delivery revenue financial benefit expectation uncertainty discussion future operate financial current portfolio development pipeline assumption guidance outlook expectation performance particular include statement restructure programme achieve include base assumption relate future action prospective product product guidance outline p wfp n tctp hi mcr io n tp e sv ta nia ln ettl g ses g ed af n u n lp ct odru io r f e u sp guc ne uctsr c lh af ts lm rrl ye ela e g ue bc lf le l g p aor rtr ts ir oc e e nes x eu srp dl e h nnn cg n lf e u ic ndu nir vhr gce ie c n ueo ot nn u ra dddtn c ea rn cee e thxh n epe es g ee c ra op ar ul n ta pii onn sngn pi sn rapg ose dsa r u u cs h tu e sm r n nep gt mo un ad ta e ea n r rs ic ia aw e l l e ia mnl nl eea rrs g rd u eo pv rp si tde ar ea nn ct qdi n u og sp itu ir opo npfi st ly r f b toall ts hi su e l n yd ek u rt e sa te om e n v e wa yr ir ea te hng g e v e e x n c aho sn n hg e e c bran set e os yn ua et ts l aoc ru r kbr e ren fec ey r market abuse regulation uk list rule disposal material litigation investigation cost notice limitation director liability disclosure transparency rule financial company save recognise english law conduct authority group undertake obligation provision change uk company act safe harbour limit update forwardlooke statement group shareholding viiv healthcare liability director respect statement result new information future event assumption assume material change omission director report reader consult additional disclosure healthcare environment unexpected significant strategic report remuneration report group document change price result government competitor english law director liable publish andor file sec reader action guidance factor divestment company party locate note disclosure product exit announce date report contain error result recklessness accordingly assurance give outlook know misstatement dishonest concealment particular expectation meet investor assumption gsk update revenue operating material fact liable page caution place undue reliance forward profit operate margin cash flow outlook inclusive comprise look statement revenue outlook margin expectation director report page inclusive comprise f f e cn aso h c pr uie tw soor ea e rr snr aat et cn h r tl u ftk h ao ek lc rr tn g ee ong r rbd e lu ut tiya sp nn c tc ce n ole uam r ddu te ia fh nn fi oe gn et ns r g sea mh r isr oo n ae su vm es e epu ris n ib tn cj le r lho ysc n st ff h r drw oao mh tla c c tr hhs nu p ur em r se enlp c tb ei e co e r oo f l r ae po v hv j pl e uu e rcn st ol ho te u pg e ah ds mr l sba v oan enir fs b il p hef en e aps na peo n l ia df pc n ee ei e sa sx le icc l p n rbl esu ibe e rs pt en di fv ode ft r f l oy tfii ot fu r osa rt lfs h ihr f os io esu om rm pr fu b ue di g et r rps lt uo h c oa gwe u sn erd r ee r nv enl ni dgv c ae ua vcr ln ar ay ind cto oe k c f r ny es u u th ot p p ir e r oa ea hr not cn ee e ted g lm r mi pc sgu r il inr te ne ase hp tcer ao ctr n not oit eo n n e p cir nnd ae di p n oap rno e r c lg w st ao te w r h c ohnh nec ot e ssto f eh p w w e r r e h l h p vi ac ioi da bn h r en ic tlh si ddl tu es biv hni se yv r e l seb l f uc l e bi cao e h e hnm n e sc l ad e br wr js ewe c n express imply forwardlooke statement underlie expectation website factor include limited assess purpose riskadjuste basis gsk website wwwgskcom give additional information discuss principal risk uncertainty describe material interruption group notwithstanding reference page annual report forward supply group product successful delivery annual report gsk website look statement behalf group ongoing plan integration restructuring plan information available website constitute speak date base material merger acquisition disposal annual report shall deem knowledge information available material business development transaction material incorporate reference director date report litigation investigation cost company save recognise provision number nonifrs measure report share repurchase company performance business measure define change shareholding viiv healthcare page reconciliation adjust result gsk assume premature loss exclusivity key total result set page product period information document constitute offer sell invitation buy share gsk plc invitation inducement engage investment activity past performance rely guide future performance annual report construe profit forecast unite science technology talent ahead disease head office register office gsk plc great west road brentford middlesex tw gs united kingdom tel register number